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Abstract 
Background 
Polymyalgia rheumatica (PMR) is a common inflammatory rheumatic disease 
that affects older people. It can cause stiffness, severe pain and significant 
impairment to daily activities. Glucocorticoids (GCs) remain the mainstay of 
treatment. Contemporary estimates of the incidence and prevalence are lacking, 
and no previous study has assessed treatment patterns at a population level. 
Patients with a diagnosis of PMR may have an increased risk of comorbidities 
such as vascular disease or cancer, and the effect of PMR on mortality is 
uncertain. 
 
Methods 
This thesis contained results from a series of observational studies of PMR. The 
data sources included the Clinical Practice Research Datalink, Hospital Episode 
Statistics and Office of National Statistics Death registration datasets. A range of 
outcomes was assessed, including incidence, prevalence, treatment, 
comorbidities, hospital admissions and mortality.  
 
Results 
This study estimated that, in patients aged over 40 years, the prevalence and 
incidence of PMR in the UK was 0.85% and 95.9 per 100,000 respectively. 
Median (IQR) continuous glucocorticoid (GC) treatment duration was 15.8 (7.9, 
 v 
 
31.2) months. However, around 25% of patients received more than four years 
total therapy. Patients with a diagnosis of PMR had a greater burden of comorbid 
disease compared to matched controls, and were more likely to be diagnosed 
with vascular, respiratory, renal, autoimmune, endocrine and psychiatric 
diseases. However, they were less likely to be diagnosed with cancer or 
dementia. Despite these differences, PMR had a neutral effect on all-cause 
mortality. 
 
Conclusions 
PMR is a common inflammatory rheumatological disease, affecting 1 in 120 
adults aged over 40 years. Incidence is stable. Management of PMR largely 
followed guidelines, but there was a subset of patients subject to prolonged GC 
therapy. Although, compared to matched controls, patients with PMR have a 
slightly different profile of comorbid disease, no difference in mortality was 
observed.  
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Context and organisation of this thesis 
In 2013 I completed my General Practice Vocational Training scheme and 
decided to try and find a role in primary care research.  
My first foray into academia was a position as a Clinical Teaching Fellow at 
Lancaster University. This job came with responsibilities such as the creation of 
teaching materials, written exam questions and objective structured clinical 
examination scenarios. Alongside this, my responsibilities included setting and 
marking special study modules. While this occupied part of my time, I continued 
to work as a salaried General Practitioner and concurrently undertook a two year 
part time taught MSc in Clinical Pharmacology and Therapeutics at Glasgow 
University. 
The experience and knowledge I gained from these roles enabled me to be 
successful in my application for a role as a Clinical Research Fellow at Keele 
University, which I commenced in August 2016. I chose this PhD topic as it fitted 
perfectly with my research interests of primary care, epidemiology, prescribing 
and musculoskeletal medicine. Furthermore, in my role as a GP, I have observed 
the effects of prolonged glucocorticoid prescribing and I was privileged to be able 
to dedicate time to investigate the treatment burden for which PMR is 
responsible. 
My thesis is organised as follows:   
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Chapter 1 INTRODUCTION  
1.1 Introduction to thesis 
Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic 
disease affecting people over the age of 50 and is most commonly seen in people 
of Northern European origin. (Michet and Matteson, 2008) Its impact on patients’ 
lives can be devastating if not treated, causing stiffness, severe pain, systemic 
illness and significant impairment to daily activities. (Helliwell et al., 2016) The 
aims of this thesis were to study the incidence, prevalence and management of, 
as well as the comorbidities associated with, PMR. These aims were met using 
a national database of primary care health records: the Clinical Practice Data 
Link (CPRD) 
This chapter provides an introduction to PMR, including the aetiology, 
pathophysiology, history, clinical features, investigations into, and management 
of, PMR. Finally, existing estimates of the incidence and prevalence of PMR will 
be described.  
 
1.2 Aetiology  
The cause of PMR is unknown, however studies suggest epidemiological and 
genetic factors may play a role. Familial aggregation of PMR, although rare, has 
been described. (Liozon and Ouattara, 2009) Complicating the problem of 
ascertaining the cause of PMR is the significant, and well documented, crossover 
between PMR and Giant Cell Arteritis (GCA). GCA is a chronic, systemic 
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vasculitis affecting large and medium sized arteries, (Borchers and Gershwin, 
2012) which classically presents with a new onset headache over the temporal 
or occipital areas; although it may localise elsewhere. (Salvarani, Cantini and 
Hunder, 2008) Around 40-60% of patients with GCA have symptoms of PMR at 
diagnosis, while 16-21% of patients with PMR will develop GCA during their 
disease course. (Salvarani, Cantini and Hunder, 2008) 
A number of studies have reported an association between PMR and certain 
genetic polymorphisms. These polymorphisms have been found in an area of the 
genome responsible for the coding of transcription factors of specific immune 
components involved in immune regulation. (Gonzalez-Gay et al., 1999) 
Alterations in this part of the genome lead to alterations in the expression of 
genes for interleukin 6, interleukin 1 receptor antagonist and intracellular 
adhesion molecule 1, and have been found to be associated with an increased 
risk of PMR disease onset or severity. (González-Gay et al., 2003; Boiardi et al., 
2006; Alvarez-Rodriguez et al., 2009) More recently, genetic associations 
between specific human leucocyte antigen-DR (HLA-DR) genotypes and GCA 
have been found, (Carmona et al., 2015) although the relationship of these 
molecules to PMR remains unclear. (González-Gay, Matteson and Castañeda, 
2017) So far it has not been possible to elucidate whether there are genetic, viral 
or cytokine features common to both conditions. (Cantini et al., 2004) 
Many of the studies which have assessed the degree to which genetics is 
responsible for PMR have only been able to utilise small (n<150) cohorts of 
patients and frequently use patients with a diagnosis of both PMR and GCA. This 
 3 
 
has so far diluted their ability to isolate specific polymorphisms which could be 
implicated in the development of pure PMR.  
 
1.3 Pathophysiology  
PMR is an inflammatory rheumatological disease. Key laboratory features of the 
disease are an elevation in acute phase proteins, such as CRP (C-reactive 
protein), PV (plasma viscosity), fibrinogen and ESR (erythrocyte sedimentation 
rate). (Dasgupta et al., 2012; McCarthy et al., 2013) Acute phase reactants are 
produced in the body in response to acute injury, infection, or other forms of 
inflammation. Medically, they can be used to identify when inflammation is 
present in the body and, by the magnitude of their elevation, the extent of the 
inflammation. (Ballantyne and Nambi, 2005)  
The location of the inflammation in PMR appears to be articular or periarticular. 
Imaging studies utilising a mixture of modalities, including ultrasound, magnetic 
resonance imaging (MRI) and fluorodeoxyglucose positron emission tomography 
(PET) scans, have demonstrated bursitis (inflammation of the bursa)  around the 
shoulder, hips and cervical spine (Salvarani et al., 1997, 2013; Frediani et al., 
2002; Blockmans et al., 2007) as well as synovitis (inflammation of the inner joint 
capsule) in the shoulders and hips. (Koski, 1992; Frediani et al., 2002) 
Histological analyses of tissue samples (for example, synovial membranes) taken 
from people with PMR generally show infiltration with macrophages and CD4 T-
cells on a background of chronic inflammation. (Meliconi et al., 1996) These cells, 
particularly macrophages, synthesise molecules such as interleukin 1 and 6 
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which, as previously discussed, are known to be increased in patients with PMR. 
(Dasgupta and Panayi 1990) Intriguingly, although myalgia is a cardinal symptom 
of PMR, muscle inflammation is not typically found. The presence of inflammation 
on muscle biopsy is indicative of polymyositis, a rare autoimmune disease 
causing proximal weakness, with raised muscle enzymes, and associations with 
interstitial lung disease. (Hopkinson, Shawe and Gumpel, 1991; Clark and 
Isenberg, 2018)   
Whether PMR can be regarded as an autoimmune (AD) or auto-inflammatory 
disease (AID) is also the subject of debate. (Floris et al., 2018) Autoimmune and 
auto-inflammatory diseases are regarded as opposite ends of an immunological 
disease spectrum. An auto-inflammatory disease involves aberrant activation of 
the innate immune system without autoantibody production or T lymphocyte 
activation. In comparison, autoimmune diseases involve an abnormal activation 
of the adaptive immune system. (Doria et al., 2012) PMR doesn’t easily fit in 
either end of this spectrum. For example, it has some characteristics in favour of 
classification as an auto-inflammatory disease such as the lack of specific 
autoantibodies; (Floris et al., 2018) however, in common with autoimmune 
diseases, PMR is strongly associated with female sex. (Smeeth, Cook and Hall, 
2006) Currently, the overall consensus is that PMR has more in common with 
auto-inflammatory rather than autoimmune diseases. (Floris et al., 2018)  
GCA, in contrast, is a chronic, idiopathic granulomatous vasculitis of the medium 
and large arteries. (Lensen et al., 2016) GCA is categorised as a systemic 
connective tissue disease, (World Health Organisation, 2016) within this group 
are other autoimmune conditions, such as systemic lupus erythematosus (SLE), 
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systemic sclerosis and dermatopolymyositis. GCA has previously been known by 
a number of names, for example temporal arteritis.  Although this name implies 
the condition exclusively affects the temporal artery, many patients are also found 
to have vasculitis of a number of large vessels, including the aorta, subclavian 
and vertebral arteries. (Bossert et al., 2011) Furthermore, the degree of 
inflammation can vary from florid accumulations of giant cells, to intermittent 
areas of non-granulomatous inflammation interspersed with normal vessel walls 
(‘skip lesions’). Giant cells are multinucleated masses produced by the fusion of 
many cells that can form granulomas, which are organised collections of 
epithelioid cells. (Stacy, Rizzo and Cestari, 2011) 
The clinical and laboratory findings in PMR share a number of features with GCA, 
such as female predominance, chronically raised levels of inflammation, 
specifically interleukin 6, (Weyand et al., 2000; Alvarez-Rodríguez et al., 2010) 
as well as a pronounced response to glucocorticoid (GC) therapy. Furthermore, 
it has been found that in patients with PMR, even without clinical features of GCA, 
temporal artery biopsies may show evidence of subclinical inflammation. 
(Weyand et al., 1994; Weyand and Goronzy, 2003) 
PMR and GCA are therefore chronic inflammatory conditions that commonly 
coexist. Laboratory findings of raised inflammation occur in both diseases and 
immunosuppressant therapy, in the form of glucocorticoids, work well in both 
diseases. However, the site of inflammation in each condition, and their 
pathophysiology, differ significantly. In spite of these differences, both of these 
conditions, and the link between them, were tentatively identified before the 
development of sophisticated laboratory tests or treatments. 
 6 
 
1.4 History of Polymyalgia Rheumatica 
Polymyalgia rheumatica was first described in medical literature in 1888 by Dr 
William Bruce. (Bruce, 1888) In this paper, five patients, who were all men, were 
described; each of them had severe muscle pain or stiffness after a period of 
exposure to cold temperatures. Four had shoulder girdle involvement, and in two 
there was peripheral joint swelling. Each patient exhibited a complete recovery 
over a period of up to two years, although some relapses were observed. 
True recovery from inflammatory rheumatological conditions was at the time 
unheralded due to the paucity of treatment options. The improvement of these 
patients was the more remarkable in view of their age, all were at least 60 and 
four were over 70 years. This, in part, helped Bruce reach the conclusion that he 
had found a novel condition. (Mowat, 1981) The name given to this ailment was 
senile rheumatic gout. 
This unusual collection of cases was found at a spa at Strathpeffer, 24 miles 
north-west of Inverness in the United Kingdom. Taking baths in natural springs 
in an attempt to cure medical ailments had been practised since ancient Greece. 
Bathing was recommended by physicians of the classical era such as 
Hippocrates, Asclepiades, Pliny the Elder and Galen. (van Tubergen and van der 
Linden, 2002) This practice, however, fell out of favour through the Dark and 
Middle Ages. From the Renaissance, and particularly the beginning of the 19th 
century, interest in bathing in natural springs as a treatment began to grow. 
Around the Victorian era, and for decades after, bathing in springs was 
recommended for many rheumatic diseases, although this was largely due to the 
absence of effective medical treatments. This meant an unusual concentration of 
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rarer rheumatological conditions could be found in spa towns, sometimes 
allowing identification and classification of new conditions. (Bird, 2008) 
After Bruce, no further observations about PMR were recorded until almost 
halfway through the twentieth century. Over a period of around twenty years, 
numerous studies were published with descriptions of patients with PMR and 
multiple attempts were made to name the condition and understand its 
pathophysiology. In 1945 Meulengracht described two patients with shoulder 
pain and stiffness and constitutional symptoms including fever and weight loss 
as well as a raised Erythrocyte Sedimentation Rate (ESR). Their symptoms 
gradually improved and the patients recovered. He proposed the term 
periarthrosis humeroscapularis. (Meulengracht E, 1945) 
Also, in 1945, Holst and Johansen reported a case series of 5 women who 
suffered limitation in shoulder movement alongside pain in the shoulders, arms 
and hips with an elevated ESR. Two of the patients had slight joint swelling and 
low grade fevers were noted in three patients. These symptoms and signs 
regressed after a year. At this time, the name given to the condition was peri-
extraarticular rheumatism. (Holst and Johansen, 1945) 
A presentation was made at the second European Congress of Rheumatology in 
Barcelona in 1951. In this presentation, the cases of 13 patients with the 
characteristic pattern of girdle pain and stiffness, raised inflammatory markers 
and subsequent regression of symptoms were discussed. (Kersley GD, 1951) 
The name chosen for the disorder at that point was myalgic syndrome of the aged 
with systemic reaction. This presentation also discussed the first use of 
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glucocorticoids as treatment for the condition and investigation findings, such as 
negative muscle biopsies. 
Later, in 1953, Forestier and Certonciny published observations of 25 patients 
seen in France aged between 45 and 79 who presented with pain in the shoulder 
and hip girdles, systemic symptoms and a raised ESR. (Forestier and Certonciny, 
1953) They noted there was no sign of joint swelling and that the symptoms 
resolved over a period of months. The name suggested in this case was pseudo-
polyarthrite rhizomélique. 
In the same year a larger cohort of 50 patients were discussed in detail by 
Bagratuni; each of them had developed what he termed anarthritic rheumatoid 
syndrome, and most improved with time, with only two progressing to frank 
rheumatoid arthritis. (Bagratuni, 1963) 
Finally, in 1957, Barber, a physician from Buxton in the United Kingdom (UK), 
described 12 patients with stiffness and pain, and noted further that the stiffness 
often occurred in the morning. He suggested the condition be named polymyalgia 
rheumatica. (Barber, 1957) Buxton, like Strathpeffer, is a spa town in the UK, and 
so it can be seen that even well into the twentieth century, rheumatology retained 
strong roots in these areas. 
Subsequently, editorials published in the British Medical Journal in 1957 (BMJ, 
1957) and the Lancet in 1961 (Lancet, 1961) increased general awareness of 
this condition and cemented the term polymyalgia rheumatica in the medical 
literature. It has been postulated that the reason PMR has been identified only 
relatively recently is simply that it is a disease of old age, and it is only in recent 
human history that life expectancy has lengthened to the extent that significant 
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numbers of patients are alive for sufficient time to develop PMR. (Dequeker, 
1981)  
 
1.5 History of PMR and GCA 
The identification of the link between GCA and PMR occurred around the same 
time as awareness of PMR was increasing. The first time the similarity between 
the symptoms of PMR and GCA was highlighted was during the second 
European Congress of Rheumatology in 1951. (Porsman, 1951) Following this, 
in 1960, Paulley and Hughes published a series of 71 patients with GCA. They 
noted 32 patients had symptoms of PMR and speculated whether PMR may be 
a symptom of GCA. (Paulley et al., 1960) 
In 1963, Alestig and Barr took temporal artery biopsies in patients with PMR who 
did not have temporal symptoms typical of GCA. Despite the fact that these 
patients did not have symptoms or signs of GCA, 7 of the sample of 10 had 
biopsies positive for arteritis. These findings were replicated in a study by Hamrin 
in 1964. (Hamrin, Jonsson and Landberg, 1964) By 1970 the link between PMR 
and GCA was well established in the medical literature, and the overall rate of 
positive temporal artery biopsy in PMR was thought to be around 10-20%. 
(Hunder, Disney and Ward, 1969)  
However, GCA as a condition was recognised long before PMR; in fact human 
records of people with GCA predate all medical literature. 
 
 10 
 
1.6 History of Giant Cell Arteritis 
The first evidence of GCA may have inadvertently been recorded in artworks 
dating from Antiquity. A carving found on the Egyptian tomb of Pa-Aton-Em-Eb, 
which was produced around 1350BC, shows a harpist with a prominent temporal 
artery as well as a closed eye, indicating potential blindness, who appears to be 
staring into space. (Appelboom T, 1990) 
 
Figure 1-1: Limestone scene from the Tomb Chapel 
of Paätenemheb, Sakkara. 1333-1307 B.C. 
 
 
Around two thousand years later, in 1000 AD, a well-known mediaeval 
ophthalmologist, in what is now modern Iraq, named Ali ibn Isa al-Kahhal, first 
recognised a relationship between an inflamed temporal artery, headache and 
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visual symptoms, and suggested excision of the artery as a potential treatment. 
(Hollenhorst et al., 1960) 
However, in Europe, the only evidence of GCA continued to be created by artists 
rather than recorded by physicians. For example, the painting below, which is 
now held in Bruges, of Canon Van der Paele and the Holy Virgin by Jan Van Eyck 
in 1436.  
Figure 1-2: Canon Van der Paele and the Holy 
Virgin (Eyck, 1434) 
 
 
In this painting it was observed that Canon Van der Paele had a prominent left 
temporal artery, loss of hair anterior to the ear on the same side and swelling of 
the left hand suggestive of peripheral oedema which can be associated with 
GCA. (Dequeker, 1981) 
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Another example of likely GCA in Renaissance art can be seen in Piero di 
Cosimo's 1505 portrait of Francesco Giamberti, which now hangs in 
Rijksmuseum, Amsterdam. In this, one of the typical signs of GCA, a torturous, 
inflamed temporal artery is again present. (Roth, 1969) 
 
Figure 1-3: Francesco Giamberti (Cosimo, 1485) 
 
 
In western medical literature, the first clinical description of GCA is credited to 
Jonathan Hutchinson who, in 1890, described a case of a gentleman who was 
almost 80 years of age with swollen and painful superficial temporal arteries. 
(Hutchinson, 1890)   
More than 40 years later, Horton published two cases of patients with fever, 
weakness, anaemia and painful, tender areas along the temporal vessels. 
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Included in the study were biopsy samples demonstrating inflammation. (Horton, 
Magath and Brown, 1932) Soon after, in 1934, the two cases were revisited and 
the symptoms of headache and jaw claudication were added to the description. 
(Horton, Magath and Brown, 1934) Following this, in 1937, Horton and Magath 
described a further series of patients aged between 55 and 75 years with 
headache, jaw ache, tender temporal arteries and fever. Biopsy of the temporal 
artery revealed an arteritis. Much later, Horton published examples of 
experiments carried out that ruled out an infectious aetiology, leading to the 
conclusion that GCA was an autoimmune condition. (Horton, 1979) Many of the 
early case series of patients with GCA included descriptions of musculoskeletal 
pain, (Horton, Magath and Brown, 1934; Gilmour, 1941) however, no specific link 
was made between PMR and GCA. 
The name given to describe this condition went through several iterations; initially 
Hutchison named it thrombotic arteritis of the aged. Horton used the term 
temporal arteritis; Kilbourne and Wolff then suggested cranial arteritis, as the 
temporal artery is not the only vessel involved. Others (Andersen, 1947; Schmidt, 
1995) advocated naming the condition Horton’s disease in homage to the person 
who first described it. However, the most common term now used to describe the 
condition, suggested by Gilmour, (Gilmour, 1941) is giant cell arteritis (GCA). 
This name arose because characteristically giant cells are found in temporal 
artery biopsies taken from patients with this condition. However, the 
nomenclature remains imperfect because, as discussed earlier, giant cells are 
only demonstrated in 50% or fewer of the histological samples taken from 
patients with GCA. (Murchison et al., 2012; Saedon et al., 2012)   
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GCA and PMR were therefore fully identified, defined and named as distinct 
clinical entities in medical literature, around 80 and 60 years ago respectively. In 
the years following this, knowledge of both conditions has increased and 
diagnostic processes have been refined in order to improve the reliability of 
identification and classification of patients who present with features suggestive 
of these conditions. 
 
1.7 Clinical features and diagnosis of PMR 
Clinically, most patients with PMR present to healthcare practitioners with acute 
or subacute onset of bilateral shoulder pain and stiffness. (Salvarani et al., 2002b; 
Salvarani, Cantini and Hunder, 2008) Other common symptoms include pain and 
stiffness in the upper arms, neck and hip girdle. This pain and stiffness often 
make completion of activities of daily living a challenge for patients, for example 
combing their hair or rising from a bed. (Mackie et al., 2015) This can also 
complicate the diagnostic process for clinicians as it may erroneously give the 
impression of muscle weakness, which is not typically a feature of PMR. (Michet 
and Matteson, 2008)  
Alongside these local symptoms and signs, PMR is associated with systemic 
features in up to 40% of patients. These include a low grade fever, depression, 
fatigue, anorexia and weight loss. (Chuang et al., 1982; Salvarani et al., 1987) 
Furthermore, in some cases of PMR, a mild synovitis in the shoulder and hip 
joints has been observed. (Koski, 1992; Frediani et al., 2002)  
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PMR is very rare in patients aged less than 50 years old. Its incidence increases 
with age and it has a mean age of onset of around 73 years. (Doran et al., 2002) 
The diagnosis of PMR is clinical and is made when a patient has a combination 
of the characteristic cluster of symptoms and laboratory tests showing raised 
inflammatory markers (invariably ESR or CRP). (Helliwell et al., 2018) As 
previously discussed, no specific autoantibody has been identified as occurring 
with PMR to aid in diagnosis, (Floris et al., 2018) nor does it have any other 
specific diagnostic clinical feature or laboratory test.   
This reliance on the clinical signs, and lack of a specific diagnostic marker, means 
the process of diagnosing a patient with PMR is somewhat more complex than 
otherwise anticipated. In the UK, most patients (71-84%) with PMR are 
diagnosed and managed in primary care. (Barraclough et al., 2008; Yates et al., 
2016) However, a recent survey of UK General Practitioners (GPs), found that 
many found making a diagnosis of PMR challenging. A number of different 
reasons were given for this, but two main themes predominated. The first was in 
cases where patients presented atypically, for example patients with a classical 
history but normal inflammatory markers. The second theme was around non-
specific presentations together with the wide range of differential diagnoses that 
are to be considered alongside PMR, compounded by the fact that multimorbidity 
is common among patients of the age group affected by PMR. (Helliwell et al., 
2018) 
In the absence of a specific diagnostic test, a number of clinical classification 
criteria have been created with the aim of increasing uniformity of diagnosis. The 
first to formally set criteria for PMR research was H A Bird et al. in 1979, followed 
 16 
 
by Jones and Hazleman (1981) and Chuang et al. (1982). A review of these 
criteria, published in 2005, suggested that the Bird and Chuang criteria had the 
greatest sensitivity in correctly classifying PMR. However, its authors also made 
clear that their results could be better described as a “test of homogeneity” and 
that their results may be “biased towards the study of “true” PMR rather than a 
clinical syndrome that might appear indistinguishable initially.”  (Bird et al., 2005) 
Following this review, a collaborative working group was formed by the European 
League Against Rheumatism (EULAR) and the American College of 
Rheumatology (ACR) to develop standardised classification criteria for PMR 
research. These criteria were published in 2012. (Dasgupta et al., 2012)  
The first limitation of these criteria is apparent in their name. Clinical classification 
criteria exist primarily to create well-defined, relatively homogenous cohorts for 
clinical research. (Aggarwal et al., 2016) This is compared to diagnostic criteria 
which are for use in routine clinical care to guide diagnosis of individual patients. 
(Aggarwal et al., 2016) Therefore, it is not recommended to use clinical 
classification criteria in day to day healthcare practice. 
The criteria are mainly based on clinical and simple laboratory findings, however 
they can also accommodate results from ultrasound imaging (table 1-1).  
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Table 1-1: Clinical classification criteria for PMR 
Criteria Points 
Clinical  
Morning stiffness duration >45 minutes 2 
Hip pain or limited range of motion 1 
Absence of RF* or ACPA* 2 
Absence of other joint pain 1 
Threshold for PMR classification  >3 points  / 6 
Ultrasound  
At least one shoulder with subdeltoid bursitis and/or biceps 
tenosynovitis and/or glenohumeral synovitis (either posterior or 
axillary) and at least one hip with synovitis and/or trochanteric 
bursitis 
1 
Both shoulders with subdeltoid bursitis, biceps tenosynovitis or 
glenohumeral synovitis 
1 
If ultrasound results included, threshold for PMR > 4 points / 8 
*RF (Rheumatoid factor) ACPA (anticitrullinated protein antibody) 
Adapted from: Dasgupta B, Cimmino MA, Maradit-Kremers H, et al 2012 provisional 
classification criteria for polymyalgia rheumatica: a European League Against 
Rheumatism/American College of Rheumatology collaborative initiative Annals of the 
Rheumatic Diseases 2012;71:484-492 (Dasgupta et al., 2012)  
 
These criteria reflect the typical symptoms of a patient with suspected PMR very 
well, and their sensitivity can be further enhanced through the use of ultrasound 
imaging, where available. Furthermore, by excluding patients with rheumatoid 
factor, there is a specific aim to reduce misdiagnosis of patients with rheumatoid 
arthritis, (RA) which can present with a polymyalgic onset. 
Rheumatoid arthritis is a chronic inflammatory disease which can cause cartilage 
and bone damage that classically presents with subacute onset of tender, 
swollen joints with morning stiffness and raised inflammatory markers. (Smolen, 
Aletaha and McInnes, 2016) Therefore RA is regarded as the prime differential 
diagnosis in patients with PMR, particularly in the presence of peripheral 
synovitis. (Cutolo, Cimmino and Sulli, 2009) The difficulty in differentiating 
between PMR and RA is compounded by the fact that both are particularly 
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responsive to treatment with glucocorticoids (GCs). A full list of differential 
diagnoses to consider with PMR is below (table 1-2). 
 
Table 1-2: Differential diagnosis of PMR 
Rheumatological 
diseases 
Rheumatoid arthritis 
Spondyloarthropathy 
Crystalline arthritis (calcium pyrophosphate disease and 
calcium hydroxyapatite disorders) 
Remitting seronegative symmetric synovitis with pitting 
oedema syndrome 
Connective tissue diseases 
Vasculitis (giant cell arteritis, antineutrophil cytoplasmic 
antibody-associated vasculitis) 
Inflammatory myopathies (dermatomyositis, 
polymyositis) 
Non-
inflammatory 
musculoskeletal 
disorders 
Rotator-cuff disease 
Adhesive capsulitis 
Degenerative joint disease 
Fibromyalgia 
Endocrinopathies Thyroid diseases 
Disorders of the parathyroid gland 
Infections Viral 
Bacterial sepsis, endocarditis, disc space infection, 
septic arthritis 
Mycobacterial—e.g. tuberculosis 
Malignant 
diseases 
Solid, haematological 
Miscellaneous 
disorders 
Parkinsonism 
Depression 
Hypovitaminosis D 
Drug-induced myopathy—e.g. from statins 
Reproduced from Kermani T, Warrington KW. Polymyalgia rheumatica. The Lancet 2013; 
381(9680), 63-72 (Kermani and Warrington, 2013) 
 
The difficulty in making a diagnosis is therefore due to two main factors, a lack of 
a specific diagnostic test for PMR and a very long list of plausible, common, and 
medically serious, differential diagnoses. One of the most frequently diagnosed 
differentials, RA, tends to present between the ages of 40-60, but it can be 
diagnosed at any age. (Allen, Carville and McKenna, 2018) Elderly-onset 
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rheumatoid arthritis (EORA), which is defined as rheumatoid arthritis that 
develops in patients aged 60 or over, (Wakura et al., 2016) confuses the 
diagnostic process still further. EORA therefore presents therefore at a similar 
age to PMR and its early symptomatology mirrors PMR. Furthermore, despite the 
requirement to exclude RA in order to diagnose PMR, studies have reported that 
many patients with an initial diagnosis of PMR later go on to develop RA and 
other related conditions, such as systemic lupus erythematosus (SLE) and 
spondyloarthropathies. (Dasgupta et al. 2008) 
The suggestion, implicit in the clinical classification criteria, that PMR and RA 
cannot coexist, is reinforced and extended in the most recent recommendations 
made by EULAR and ACR for the management of PMR. They suggest that prior 
to making a diagnosis of PMR, “clinical evaluation should be directed towards 
exclusion of relevant mimicking conditions (e.g. non-inflammatory, inflammatory 
(such as giant cell arteritis or rheumatoid arthritis), drug-induced, endocrine, 
infective and neoplastic)”. (Dejaco, Singh, Perel, et al., 2015)  
Therefore, the current recommended classification model defines PMR, perhaps 
inadvertently, as a diagnosis of exclusion. However, as previously discussed, 
PMR is a disease of older people. As such, patients with a diagnosis of PMR are 
as likely as others in this age group to have already developed, or go onto 
develop, one or more of these morbidities. The critical question then, is whether 
a diagnosis with one of these conditions should invalidate or supersede a 
diagnosis of PMR. To give an example, osteoarthritis, a condition which affects 
more than 40% of people aged over 80 years, (Litwic et al., 2013) is statistically 
likely to affect a large proportion of patients who have PMR. Should the presence 
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of osteoarthritis preclude a new, or rule out an existing, diagnosis of PMR? In 
order to answer these questions, it is necessary to define which comorbidities 
frequently coexist in patients with PMR.  
 
1.8 Comorbidities in PMR 
Comorbidities can be regarded, as per Feinstein’s description, as, “any distinct 
additional entity that has existed or may occur during the clinical course of a 
patient who has the index disease under study.” (Feinstein, 1970) There are three 
ways in which different diseases may be found in the same individual - chance, 
surveillance bias or causal association. (Valderas et al., 2009) For example, two 
common conditions may coexist due to chance, such as hypertension and 
asthma, simply because they are both very common. Surveillance bias may lead 
to comorbidities being diagnosed more often in patients with an index condition 
due to intensive follow up. (Haut and Pronovost, 2011) Finally, causation is where 
comorbidities are directly linked, for example a patient with hypertension who 
subsequently develops coronary artery disease, as the former is a risk for the 
latter. 
Multimorbidity is commonly defined as when a patient has two or more chronic 
medical conditions. (Wallace et al., 2015) Aging is an important predictor of 
multimorbidity; a recent Scottish study found the number of adults with two or 
more chronic conditions increased from 30.4% between 45-64 years, to 64.9% 
in those aged 65 to 84 and greater than 80% in those aged over 85. (Barnett et 
al., 2012) Therefore, patients with PMR, for whom the mean age of onset is 
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around 73 years (Doran et al., 2002) are demographically highly likely to have at 
least one comorbidity. A study of newly diagnosed cancer patients in the United 
States found the most common comorbidities in patients aged 65-73 were 
hypertension, diabetes mellitus, respiratory disease, previous solid tumour(s) 
and angina. (Piccirillo et al., 2008) Each of these conditions had a prevalence of 
greater than 10%.  
Therefore, some of the conditions which, according to current criteria, would 
preclude diagnosis of PMR are likely to be very common in the age group affected 
by PMR. The uncertainty around the general health of patients with PMR, and 
comorbidities that may coexist with it, present a challenge for healthcare 
practitioners who deal most with this condition, be they from primary or secondary 
care. (Helliwell et al., 2018) This lack of clarity around the diagnosis of PMR 
extends also to its management, which is considered in detail in the following 
section. 
 
1.9 Management of PMR 
PMR symptoms are effectively managed with gradually reducing glucocorticoid 
(GC) therapy, from moderate to low doses. (Buttgereit et al., 2016) Joint guidance 
released by the American College of Rheumatology (ACR) and the European 
League Against Rheumatism (EULAR) affirms that PMR should be treated in this 
way and that GC treatment for most patients should end by two years, and 
prescribing should be individualised to ensure the minimum effective duration 
and dose is prescribed. (Dejaco, Singh, Perel, et al., 2015) Some risk factors for 
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relapse or prolonged therapy, have been suggested, such as female sex, 
(Cimmino et al., 2006) high ESR (Barraclough et al., 2008) and peripheral 
inflammatory arthritis. (Salvarani et al., 1998) 
The initial GC dose to be prescribed is recommended to lie between 12.5mg and 
25mg prednisolone equivalent per day. A higher dose can be considered if the 
patient is thought to be at higher risk of relapse or a lower dose in those with risk 
factors for GC related side effects. (Dejaco, Singh, Perel, et al., 2015) 
Glucocorticoids are potent inhibitors of inflammatory processes. They act by 
either direct binding to glucocorticoid receptors or by interaction with transcription 
factors, and subsequently inhibit many molecules associated with inflammation, 
including cytokines, chemokines and arachidonic acid metabolites. (Van Der 
Velden, 1998)  
The guidelines also recommended strongly against the use of non-steroidal anti-
inflammatory drugs (NSAIDs) in PMR and do not make recommendations on the 
use of biologic treatments (which are commonly used in other rheumatological 
conditions) as trials into their effectiveness were ongoing at the time of 
publication. (Dejaco, Singh, Perel, et al., 2015) Two of these trials have published 
results subsequent to the guidelines being published. The first showed 
tocilizumab to be effective in a small (n=13) sample of patients with intractable 
PMR. (Izumi et al., 2015) However, the other trial (NCT01364389) was 
terminated early as the biologic agents were less effective in reducing disease 
activity than conventional GC therapy.  
The majority of cases of PMR in the United Kingdom are diagnosed and managed 
in primary care (71-84%). (Barraclough et al., 2008; Yates et al., 2016) 
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Guidelines suggest referral to secondary care should be considered where there 
is uncertainty regarding diagnosis, either because of an atypical presentation, 
high risk of therapy related side effects, prolonged or inadequate response to 
therapy, or relapses following cessation of treatment. (Dejaco, Singh, Perel, et 
al., 2015) 
Therefore, within the current guidelines, there is recognition that a proportion of 
patients experience symptom flare upon cessation, or even reduction, of GC 
therapy (a “symptom tail’). (Mackie et al., 2014) This has led to the suspicion that 
a significant number of patients are subject to GC treatment for more than two 
years following diagnosis. (Liew, Owen and Buchanan, 2018) Previous studies 
have shown that long-term GC treatment increases a person’s risk of a wide 
range of conditions, including hypertension, cardiovascular disease, type two 
diabetes, cataract, osteoporosis and proximal myopathy. (Oray et al., 2016) 
Therefore, although much is known of the aetiology, pathophysiology, history, 
clinical characteristics, and diagnosis and management of PMR, significant gaps 
in the body of knowledge remain. In order to ascertain the clinical importance of 
these gaps it is important to first establish what the existing estimates are of how 
many people are affected by PMR. 
 
1.10 Epidemiology of Polymyalgia Rheumatica  
In this section, a summary of the development, and current estimates, of the 
incidence and prevalence of PMR is presented. 
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Epidemiology is defined as “the study of the distribution and determinants of 
health related states or events (including disease), and the application of this 
study to the control of diseases and other health problems.” (World Health 
Organisation, 2017) In order to effectively allocate resources within a healthcare 
economy it is necessary to ascertain accurate estimates of the number of patients 
with different medical conditions. There are several ways to measure disease 
frequency, all of which must be related to the total population at risk of the 
disease. 
Incidence is defined as “the rate at which new cases occur in a population during 
a specified period”. (British Medical Journal, 2017) When a population is stable, 
incidence is expressed as below: (Tenny and Boktor, 2018) 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑛𝑒𝑤 𝑐𝑎𝑠𝑒𝑠
𝑇𝑜𝑡𝑎𝑙 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑎𝑡 𝑟𝑖𝑠𝑘 𝑥 𝑡𝑖𝑚𝑒𝑓𝑟𝑎𝑚𝑒
= 𝐼𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 (𝑐𝑎𝑠𝑒𝑠 𝑝𝑒𝑟𝑠𝑜𝑛𝑡𝑖𝑚𝑒⁄ ) 
Point prevalence is the “proportion of a population that are cases at a point in 
time”. Period prevalence is similar in that it measures the proportion of a 
population that has a disease but within a period of time, for example twelve 
months. (British Medical Journal, 2017) Therefore, this measure contrasts to 
incidence which measures only new cases within a specified period. 
Incidence and prevalence are inter-related. Each incident case of a disease is a 
prevalent case also, until resolution of the disease. Therefore, in the case of a 
condition such as PMR which has a relatively long duration, and does not pose 
a direct threat to life, even relatively low incident rates can cause high prevalence 
figures. This effect has been summarised as: 
𝑃𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒 = 𝐼𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 𝑥 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑑𝑢𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑑𝑖𝑠𝑒𝑎𝑠𝑒 
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Estimates have been calculated for both incidence and prevalence of PMR, and 
these will each be considered in turn. 
 
1.11 Incidence of Polymyalgia Rheumatica 
A number of studies have estimated the incidence of PMR to lie between 12 - 
113 per 100,000 person years. (Salvarani et al., 1991; Barraclough et al., 2008; 
Raheel et al., 2017) However, despite many patients being treated in primary 
care, much of the existing literature is based on secondary care hospital records, 
therefore the burden of disease may have been underestimated. The studies 
investigating the incidence of PMR are summarised in table 1-3. 
 
Table 1-3: Incidence of Polymyalgia Rheumatica 
Authors Country Population 
size 
Study 
Type 
Incidence rate 
per 100,000 
Barraclough et al. (2008) United Kingdom, 
Gloucestershire 
37,908 General 
Practice 
113* 
JT Gran and Myklebust 
(1997) 
Norway, Aust 
Auger 
97,314 Hospital 112.6* 
Smeeth, Cook, and Hall 
(2006) 
United Kingdom 17,830,028 + Database 84** 
Boesen and Sorensen 
(1987) 
Denmark, Ribe 214,700 Survey 68.3* 
Raheel et al. (2017) United States, 
Olmsted County 
109,555 Hospital 63.9* 
Schaufelberger, 
Bengtsson, and 
Andersson (1995) 
Goteborg, 
Sweden 
435,000 Hospital 49.7 
Elling, Olsson, and Elling 
(1997) 
Denmark 10,818 Database 41.3 
M A Gonzalez-Gay and 
Garcia-Porrua (1999) 
Spain, Lugo 250,000 Hospital 18.67* 
C Salvarani et al. (1991) Italy, Reggio 
Emilia 
169,950 Hospital 12.7* 
* = in patients > 50 years ** = in patients > 40 years + = total person years 
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The study with the largest sample size was from the UK by Smeeth, Cook, and 
Hall 2006. In this study they used the primary care database that was also used 
in this thesis, albeit an earlier version. Therefore, this study was a key comparator 
for the findings of this thesis, however the final year of data this study reported 
was 2001. They found one of the highest estimates of incidence rate of PMR 
compared to other studies, as well as a gradual trend towards an increase in the 
incidence rate over time. This study also found that the incidence rates in the UK 
were higher in the south of the UK compared to the north. This finding is the 
reverse of worldwide trends where the incidence of PMR has been found to 
increase at higher latitudes; with the lowest estimates of PMR incidence being 
found around in Southern Europe. (Carlo Salvarani et al., 1995; Gonzalez-Gay 
et al., 1999, 2009; Herlyn et al., 2014; Buttgereit et al., 2016) 
The study that found the highest incidence rate, 113 per 100,000 patients, was a 
study based in primary care from the south of England. (Hayward et al., 2014) 
This finding is consistent with Smeeth, Cook, and Hall 2006 who reported that 
there was a higher incidence in the south of England and Hayward et al’s study 
was also based in primary care. However, although the sample size is large, 
(n=37,908) the relative rarity of PMR meant that only 183 new diagnoses of PMR 
were seen over a ten-year study period. The rate reported in this paper was 
similar to that found in a study from Norway by Gran et al. 1997. This study was 
based in secondary care but also made a concerted effort to identify patients in 
primary care also. 
The most recent estimate of PMR incidence was reported to be 63.9 per 100,000 
by Raheel et al.   This study was the latest report from the Olmsted County cohort 
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of the Rochester Epidemiology Project. This is a long term project where 
epidemiological research has been carried out since 1966 on a population of 
people with linked healthcare records between all medical providers in a county 
in the United States. (St Sauver, Grossardt, Yawn, et al., 2012) The studied 
population has strong historic and genetic links to Northern European, and 
particularly Scandinavian, populations that may lead to higher incidences of PMR 
being found than might be expected.  
This project, in the duration of follow up and completeness of medical record 
linkage has many strengths. However, it has been suggested that the sample 
size may be too small to adequately characterise relatively infrequent conditions 
and that the ethnic and socio-economic characteristics of the population may 
mean that some racial and ethnic groups are under-represented. (St Sauver, 
Grossardt, Leibson, et al., 2012) 
In each of the incidence studies, where specifically reported, a strong association 
with PMR is found with increasing age and female sex, with a median age of 
diagnosis of between 70-75 years and a ratio of roughly two women developing 
PMR for every male. (Smeeth, Cook and Hall, 2006; Barraclough et al., 2008) 
This association between PMR and women is in contrast to the original 
description of PMR from 1888 (Bruce, 1888) where the case series consisted of 
five men. 
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1.12 Prevalence of Polymyalgia Rheumatica 
Existing research estimates the prevalence of PMR to lie between 0.1-2.3%. The 
denominator used in the prevalence estimates given vary but, as PMR affects 
older people more often, usually excludes patients aged either under 50 or 55 
years of age. In all but one study the prevalence was 1% or less (table 1-4). (C 
Salvarani et al., 1995; Eaton et al., 2010; Hayward et al., 2014) 
 
Table 1-4 Prevalence of Polymyalgia Rheumatica 
Authors Country Population 
size 
Study 
Type 
Prevalence 
(%)  
Yates et al. 
(2016) 
United Kingdom, 
East Anglia 
5,108 GP, survey 2.27* 
Hayward et al. 
(2014) 
United Kingdom, 
North Staffordshire 
13,831 GP, survey 1%** 
Bernatsky et al. 
(2009) 
Canada, Manitoba 1,100,000 Population Urban: 0.6  
Rural: 0.9 
Doran et al. 
(2002) 
United States, 
Olmsted County 
124,919 Hospital 0.7 
Manzo et al. 
(2009) 
Italy, Massa 
Lubrense 
12,186 GP survey 0.6** 
C Salvarani et al. 
(1995) 
United States, 
Olmsted County 
109,555 Hospital 0.6** 
Eaton et al. 
(2010) 
Denmark 5,506,574 Population 0.3 
Barrier, Billaud, 
and Magadur 
(1992) 
France, Loire 
Atlantique 
1,026,000 Survey 0.1 
Boesen and 
Sorensen (1987) 
Denmark, Ribe 214,700 Survey 0.1** 
* = patients >55 years ** = in patients > 50 years;  
 
The highest prevalence was reported by a study based in primary care in the 
United Kingdom. (Yates et al., 2016) It was based on a small sample of patients 
(n=5,108) registered with a General Practice in East Anglia, in the south of the 
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UK, which corresponds with Smeeth et al’s findings that PMR is more common 
in the south of the United Kingdom. (Smeeth, Cook and Hall, 2006)  
The second highest prevalence was found in another study from the UK but again 
had a relatively small (n=13,831) sample size. (Hayward et al., 2014) This study 
reported prevalence over a four-year period. It was based upon the results of 
questionnaires sent to patients at eight general practices. Potential diagnoses 
were corroborated by cross referencing with medical records to ensure that each 
patient had at least two prednisolone prescriptions issued. Survey response rate 
was reasonably high (69.3%) and checking for GC therapy provided reassurance 
in the accuracy of the PMR diagnosis. However, just over 30% of patients did not 
respond to the questionnaire. These patients may not have responded if they felt 
the issues the questionnaire addressed didn’t directly affect them, which could 
cause an overestimate of disease burden. Alternatively, if they had been too 
unwell to complete the questionnaire, this may lead to an underestimate. 
The other weakness with this study is it took place within a relatively small and 
culturally homogenous region of the UK. Studies which are based in relatively 
small regions are prone to generalisability issues when attempting to apply the 
results to a wider population. For example, in Staffordshire, where this study took 
place, the population is different when compared to the rest of the UK, being 
slightly older, less ethnically diverse and with lower education levels. (Office for 
National Statistics, 2011) A nationwide study would provide a more accurate 
estimation of prevalence but would be more time consuming and cost 
significantly more.  
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A number of studies from Canada, (Bernatsky et al., 2009) Italy (Manzo et al., 
2009) and the United States (C Salvarani et al., 1995; Doran et al., 2002) reported 
the prevalence of PMR to be between 0.6-0.9%. Of these, the prevalence of 0.6% 
reported by (Manzo et al., 2009) is perhaps the most surprising given the known 
predilection of PMR to affect northern, rather than southern, Europeans. This 
could be explained by the study design in which GPs were directly questioned, 
rather than only assessing medical records which would provide a more accurate 
estimate of disease burden in this region. 
The next highest prevalence was found in Manitoba, a province in Canada. 
(Bernatsky et al., 2009) This study used hospitalisation databases and physician 
billing as the data source and also found a notable difference between the rural 
and urban prevalence of PMR (0.9 to 0.6%). This could provoke debate as to 
whether there is an environmental or socio-economic aetiology. 
Of the three studies reporting the lowest prevalence estimates, two were 
published more than 25 years ago. (Boesen and Sorensen, 1987; Barrier, Billaud 
and Magadur, 1992) The rarity of PMR at this time may be explained by a lack of 
awareness of the condition, rising life expectancy or a genuine increase in the 
incidence of PMR since that time. A trend of increasing incidence and prevalence 
was seen in the work of Smeeth, Cook, and Hall (2006). The third paper from 
Eaton et al, which reported a prevalence of 0.3%, looked at a wide range of auto-
immune diseases and was published much more recently. However, it used all 
adult patients as the denominator rather focussing on older adults, and hospital 
rather than primary care records, leading to a lower prevalence estimate than 
other contemporaneous studies. (Eaton et al. 2010) 
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Overall, contemporary estimates of PMR prevalence suggest it is likely to affect 
between 0.5-1% of the population in countries with high numbers of people with 
northern European, and potentially also Mediterranean genetic heritage. The 
studies which show the highest prevalence are community based and there 
appears to be a trend of increasing PMR prevalence over time. 
 
1.13 Limitations of existing studies  
There are a number of limitations to the studies that have reported data on the 
incidence or prevalence of PMR. The majority of studies were performed in 
secondary care settings likely leading to an underestimate of disease burden of 
PMR. Whilst some primary care estimates exist, the number of studies available 
are limited. It has been estimated that in the UK the number of people aged 65 
and over will increase by around two thirds between 2008 and 2032. (Dunnell, 
2008) As the population of the United Kingdom continues to rapidly age, the lack 
of contemporaneous data of the epidemiology of PMR is concerning. 
 
1.14 Conclusion  
PMR has been recognised as a medical condition since the 19th Century and, in 
the UK, is mainly treated in primary care. However, a number of important clinical 
quandaries around PMR remain. First, estimates of the incidence and prevalence 
of PMR vary by almost a factor of ten depending on study design and location. 
Second, concerns remain regarding the existence of a cohort of patients who are 
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subject to prolonged glucocorticoid therapy given the long term effects of this 
therapy and potential impacts on inter-current comorbidity. Finally, current 
guidelines suggest that PMR is a diagnosis of exclusion, with an extensive list of 
conditions which preclude diagnosis, despite the fact that some of these 
comorbidities are common in the age group typically affected by PMR.   
In order to address these concerns, this thesis contains an up-to-date, large scale 
epidemiological study of the incidence, prevalence and treatment of PMR in UK 
primary care. Following this, a systematic review of literature will assess the 
current evidence around multimorbidity and the general health status of patients 
with PMR. Finally, large scale epidemiological case control and cohort studies 
will attempt to address gaps in the literature of the comorbidities associated with 
PMR, and the general health of patients with PMR both before and after 
diagnosis. 
This will create an up to date, detailed picture of the burden that PMR imposes 
on the UK healthcare system and the overall health of patients with a diagnosis 
of PMR. In achieving this it may then be possible to recognise that PMR can co-
exist with other common comorbidities as well as identifying whether any specific 
comorbidities are more common in patients with PMR.  
The following chapter explains the way in which these questions will be 
addressed. 
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Chapter 2 CLINICAL PRACTICE RESEARCH DATALINK 
This chapter will describe the Clinical Practice Research Datalink (CPRD), the 
data source used for this thesis. This will include how the data is collected, its 
demographic composition in relation to the UK population, the strengths and 
weaknesses of the dataset and which alternative datasets are available. 
 
2.1 Ethical considerations and research approval 
Formal ethical approval was not required as the Clinical Practice Research 
Datalink (CPRD) has generic ethical approval. However, in order to conduct 
publishable research, permission must be granted by the Independent Scientific 
Advisory Committee (ISAC). This committee was established by the Secretary of 
State for Health in February 2006 to review proposals for research using the 
MHRA’s CPRD and Yellow Card Scheme databases. 
The ISAC committee assesses the feasibility, quality and public health value of 
research studies proposing to use anonymised patient level data from the CPRD. 
It provides high-quality peer reviews on the scientific merit of research proposals 
submitted to them, and examines the medical, epidemiological and 
methodological merits of proposed studies. (ISAC, 2017) The ISAC committee 
include scientific and lay members. Scientific members provide advice on the 
medical, statistical, epidemiological and methodological aspects of protocols. Lay 
members provide advice where there may be potential governance issues 
associated with a study. Approval for this study was granted following the 
completion and successful review of the ISAC protocol form, (protocol number: 
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17_203RA), a copy of which is included as Appendix 1.  This approval process 
also provides further assurance that the methodologies employed in the studies 
described are robust. 
The CPRD is based on data taken from UK primary care. The following section 
describes the place of primary care within the UK healthcare system. 
 
2.2 UK Primary Healthcare System 
Almost all healthcare in the United Kingdom (UK) is delivered by the National 
Health Service (NHS). The NHS was founded following the Second World War 
in 1948, with the aims of providing universal, equitable and centrally funded 
healthcare that was free at the point of delivery. (Delamothe, 2008) It remains a 
public system funded by taxation and continues to provide free, or low-cost, 
healthcare to all residents of the UK. 
Around 90% of patient contact in the UK with the NHS is via primary care.  
(Hippisley-Cox and Vinogradova 2009) Primary care within the NHS is largely 
delivered by general practices. These are generally small, physician led 
organisations run on behalf of the NHS that are responsible for patients who live 
within a defined and agreed geographic area. (Roland, Guthrie, and Thome 
2012) Each person within the United Kingdom is entitled to register with a 
General Practice, and around 98% of the UK population are indeed registered 
with a practice. (Office for National Statistics 2012)  
Practices may employ a wide variety of healthcare professionals, including 
General Practitioners (GPs), Nurses, Pharmacists, Nurse Practitioners, 
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Occupational therapists, Psychologists, Counsellors and Paramedics. (Freund et 
al., 2015) The average population size each practice serves has increased over 
the last decade, as has the workload that each practice has to shoulder, (Grosios, 
Gahan and Burbidge, 2010) evidenced by the increase in the average number of 
consultations per patient per year. (Baird et al., 2016) 
Almost all general practices in the United Kingdom now use electronic healthcare 
records (EHR) to record patients’ medical information, although the choice of 
software used is dependent on the practice. (Roland, Guthrie and Thome, 2012) 
This includes software such as VISION® (Vision Electronic Health Record 
System, 2018) EMIS® (EMIS Electronic Health Record System, 2018) and 
SystmOneGP®. (SystmOne Electronic Health Record System, 2018) The shift to 
EHRs was, in part, following the introduction of the ‘Quality and Outcomes 
Framework’ (QoF). This scheme incentivised GPs by offering an increase in 
practice income of around 25% provided they achieved certain ‘targets’ in quality 
of care. In order for the attainment of these targets to be recorded and rewarded, 
EHRs were necessary, leading to the adoption of paperless records. (Roland, 
Guthrie and Thome, 2012) The system used to record and store diagnoses and 
other clinically relevant information in UK primary care is the Read code system, 
which is a hierarchical coded thesaurus of clinical terms. (NHS Digital, 2017) 
As well as primary care data, clinical diagnoses and treatments made in 
secondary and tertiary care are also recorded and coded in the EHR in UK 
primary care. This is because general practices act as the hub of the UK 
healthcare system. The GP is the gatekeeper of care for all non-emergency 
health problems in the UK and is responsible for referring patients for specialist 
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input. Therefore, each time a patient is seen in another NHS care setting, whether 
this is as an inpatient or outpatient, a summary of the outcome of this event is 
sent to the patient’s General Practice. The data in the summary is then coded 
and added to the patient’s EHR.  
GPs in the UK are expected to practise to a high clinical standard. The 
performance of GPs and practices are independently monitored through 
appraisals, QoF monitoring and Care Quality Commission (CQC) inspections. 
Clinical guidelines are published by the National Institute for Health and Care 
Excellence, which GPs are expected to follow to ensure best practice is followed.  
Therefore, management of disease should not vary greatly by practice or GP. As 
such, information taken from primary care data will reliably reflect disease 
epidemiology and management in the UK. 
In conclusion, the NHS achieves almost universal population coverage. Within 
this system General Practices, who act as information gatherers in the healthcare 
system, have enthusiastically adopted robust EHRs. The result of this is primary 
care services in the UK have longitudinal, electronically coded, contemporaneous 
and comprehensive clinical information recorded during routine clinical care for a 
large proportion of the UK population. These clinical records therefore provide an 
invaluable resource for collecting epidemiological data particularly around 
conditions, such as PMR, which are predominantly treated in primary care. 
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2.3 Data Source 
The data source that was used in this study is the Clinical Practice Research 
Datalink (CPRD). The CPRD is a governmental, not-for-profit research service 
that has been established for more than thirty years. It is a joint venture between 
the Medicines & Healthcare products Regulatory Agency (MHRA) and the 
National Institute for Health Research (NIHR), which is owned by the Department 
of Health (DoH) and operates within the NIHR. (ISAC, 2017) 
The CPRD began as a small local database named Value Added Information 
Medical Products (VAMP) before expanding and being renamed General 
Practice Research Database (GPRD). Subsequently, control was passed to the 
MHRA and the database evolved into the CPRD. 
The CPRD exists due to the underpinnings provided by primary care EHR.  The 
decision to contribute data to CPRD is voluntary and taken by individual 
practices, who do not receive financial reimbursement. Once a practice has 
enrolled all patients within the practice are automatically added, however they 
have the right to opt out of collection of their data at any time. CPRD contains 
anonymised information from 718 UK General Practices (7.5% of the total) and 
has over 17 million medical records from patients registered with one of these 
practices. The anonymisation procedure involves two separate processes in 
order that patient identifiable data is not visible either to external researchers or 
data processors within the CPRD. 
Two different levels of access to the CPRD exist, ‘GOLD’ and ‘AURUM’. CPRD 
GOLD contains information contributed by practices using VISION® software, 
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while AURUM contains data from practices utilising EMIS Web®. Each research 
institute that wishes to use CPRD must pay a fee to access it, in order that the 
DoH can continue to invest in, and develop, the dataset. 
The CPRD contains information across several domains, including patient 
demographics, diagnoses, symptoms, signs, prescriptions, referrals, 
immunisations, behavioural factors and tests. (Herrett, Gallagher, et al., 2015) 
Each new entry into a patient’s records creates a new line of data, to which 
information such as the date when the entry was added, the date to which it 
pertains, and the staff member inputting data, is recorded. There can be 
differences between dates of entry and the date upon which the event the entry 
is referring to occurred, for example if an entry was made retrospectively 
following an event. Information around which staff member inputs data is limited 
to a numerical identifier for each member of staff, therefore this too is 
anonymised. 
In order for data to be captured within the CPRD, the healthcare practitioner must 
select and enter a Read code. CPRD does not record when free text is inputted 
into records as a further precaution to ensure anonymity. Each Read code, which 
is a combination of numbers, letters and full stops, is translated to a unique 
Medical code in CPRD. This Medical code can then be used to identify which 
patients have a certain diagnosis. As the Medical code is composed only of 
numbers rather than combinations of symbols, data is simpler to process. 
Geographic information is divided into 10 regions of the UK. GPs are encouraged 
to record all encounters with patients and code any clinical information, therefore 
not all entries will reflect a ‘face to face’ appointment. The stored patient data is 
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anonymised and complies with existing ethical, governance and security 
regulations and frameworks.  
Each patient who contributes data to CPRD has a number of individual dates 
attached to their record indicating when they joined or left the database. These 
dates include: 1) the first registration date (frd), which is the date when a patient 
first joined the contributing practice; 2) the current registration date (crd), the date 
when a patient most recently joined the contributing practice; and 3) the up-to-
standard (uts) date, which is the date at which the practice was adjudged to reach 
internal quality standards. 
Indications that a patient has left the database include: 1) the transfer out date 
(tod), which is the date the patient left a practice; 2) the last collection date (lcd), 
the last date that data was collected from this practice; and 3) the date of death 
for a patient, if recorded. 
To increase the scope of the database beyond purely primary care, a subset of 
practices in England has been linked to other registries, for example Hospital 
Episode Statistics (HES). This provides access to data for these patients taken 
directly from secondary care. Other registries that patients in CPRD can be linked 
to include ONS mortality data and patient level index of multiple deprivation data. 
These provide more detailed information on deaths and the level of social 
deprivation in the area that the patient lives. This feature is valuable given that it 
has long been established that high levels of deprivation are strongly linked to 
social deprivation. (Rose and Marmot, 1981)  
CPRD can therefore supply extensive primary care based and linked secondary 
care patient data to researchers in the UK as well as internationally. Furthermore, 
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its use in rheumatology research has already been established by previous 
studies investigating PMR (Hancock et al., 2014; Muller et al., 2014) and other 
inflammatory rheumatological conditions, such as rheumatoid arthritis, gout and 
systemic lupus erythematosus. (Garcia-Rodriguez et al., 2009; Edwards et al., 
2012; Rees et al., 2014) 
 
2.4 CPRD strengths and weaknesses 
Strengths 
The CPRD database has been established for over 30 years and has been 
shown to be representative of the UK population in terms of age, sex and 
ethnicity; (Herrett, Gallagher, et al., 2015) furthermore it has been used 
extensively for primary care research. The CPRD employs rigorous internal 
checks and mechanisms to ensure that practices reach internal quality standards 
with the data they contribute. The date at which a practice attains this level is 
given in the data as the ‘up-to-standard’ date. Therefore, data collection can be 
limited to only that recorded after this event.  
The CPRD covers an extraordinarily large number of patients within a national 
health organisation. Such a large dataset has particular advantages, for example 
when looking to study relatively rare diseases where a large population is 
required to obtain sufficient sample size. (Dommett et al., 2012; Douglas et al., 
2013) The information recorded in CPRD is entirely clinical in nature, and is not 
driven by insurance or billing needs. Therefore, the database is less likely to 
exclude those who are from socioeconomically deprived or isolated backgrounds 
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who may not have health insurance or be able to access private healthcare. 
Furthermore, systems which are based upon billing information may inadvertently 
incentivise over-investigation or over-diagnosis by physicians whereas CPRD 
avoids this pitfall.  
The CPRD draws its data from routinely collected primary care. A subject of 
debate in clinical research surrounds the use of stringent inclusion and exclusion 
criteria in the selection of research subjects. Some researchers have questioned 
whether this may inadvertently lead to unbalanced recruitment of patients and 
reduced generalisability. (Kennedy-Martin et al., 2015) CPRD includes data on 
all patients with diagnoses made in the course of routine clinical care, with no 
inclusion or exclusion criteria. Therefore, research performed using this database 
has high generalisability to other patients in the UK and potentially further afield. 
Furthermore, the CPRD operates within stringent UK and European Union (EU) 
data protection laws, including the General Data Protection Register (GDPR), 
which work to ensure protection of patient information. A further layer of security 
to preserve patient anonymity is added by CPRD as it holds patient identifying 
and clinical data separately. 
 
Weaknesses 
Due to the way data is collected, clinical information is added only when patient 
records are updated. Therefore, the frequency of data collection is determined 
by patient attendance or contact with their GP. This is different to formal medical 
research studies in which data will be collected at pre-defined time points 
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following, for example, administration of therapy. As CPRD is a database of 
routine medical care irregular, or loss to, follow up is inevitable. However, it could 
be argued that this loss more accurately reflects typical patterns of illness in real 
life situations, providing information that is more reflective of actual clinical 
practice.  
Diagnoses in CPRD, as discussed, are based on the presence of a Read code 
for a disease. This means that a patient has been adjudged by a healthcare 
practitioner to satisfy diagnostic criteria for a condition. This threshold over which 
a disease is diagnosed is therefore likely to be different than would be seen in a 
controlled research study. Alongside this, the stringent inclusion and exclusion 
criteria which exist in many clinical studies do not exist in routine primary care. 
This would have the effect that, compared to patient samples used in research 
studies, patients diagnosed in primary care will form a much less homogenous 
group. This, however, improves the generalisability of the sample of patients 
selected as they are more likely to be representative of people with this condition 
in the general population.  
The use of Read codes to make a positive diagnosis necessitates that the 
opposite situation also applies, i.e. that the absence of a Read code must be 
interpreted as an absence of that disease. This may mean that some patients 
who have the symptoms of a disease but haven’t had a disease code recorded 
will not be captured by this dataset. Therefore, although positive predictive value 
tends to be high in CPRD, sensitivity may be lower. (Herrett, Thomas, et al., 
2010) Furthermore, once a Read code is recorded, they are not often removed 
from a patient’s EHR. This could mean, for example in the case of PMR, even if 
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a patient was subsequently diagnosed with rheumatoid arthritis (RA) both codes 
would remain in their EHR. 
CPRD provides access via linked datasets to information about deprivation 
indices, however there is limited access to socioeconomic data such as 
employment status which could provide further context to a patient’s health 
status. Also, as CPRD has been evolving for thirty years the extended features, 
such as data linkage, which are available in current and recent data, may not be 
available or incomplete depending on how far back in the dataset data is 
required, for example there is no access to test results prior to 2002.  
A final drawback to CPRD is the cost to gain the CPRD gold licence in order to 
obtain access to the dataset. This is considerable, at approximately £125,000 per 
year and is therefore beyond the means of individuals and many departments 
without significant resources. The cost in this study has been met by Keele 
University Research Institute for Primary Care and Health Sciences through 
pooled funding applications to undertake a range of CPRD related studies. 
 
2.5 Alternative data sources 
CPRD is one of three major primary care databases in the United Kingdom. The 
other two are QResearch and The Health Improvement Network (THIN).  
QResearch is a large primary care database which contains information on over 
12 million patients. (Chaudhry et al., 2017) The database is a non-profit 
collaboration between the University of Nottingham and Egton Medical 
Information Systems (EMIS). EMIS, as discussed earlier, is one of the three main 
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software platforms on which EHRs are based in UK primary care. QResearch, 
like CPRD, is anonymised and has continuing research and ethical approval from 
the East-Midlands – Derby Research Ethics Committee.  
THIN is a collaboration between In Practice Systems Ltd (INPS) and IQVIA, a 
company formed from a merger of IMS Health and Quintiles. INPS are 
responsible for the VISION EHR system. THIN data collection began in 2003 and 
the total number of patient records within the database is over 11 million. 
(Chaudhry et al., 2017) 
Of the three databases, CPRD has both the longest follow up and largest sample 
size. It also offers, for a cost, access to data taken both from VISION and EMIS 
systems, which is in contrast to QResearch and THIN. The way that data is 
recorded differs slightly between the EHRs. For example, the VISION EHR 
system is structured to record data using problem oriented medical records 
(POMR), rather than episode oriented medical records (EOMR). In POMR, 
medical and drug information must be linked to a specific coded problem, in 
contrast EOMR requires linkage to episode data. It has been postulated that by 
ensuring practitioners link clinical or prescribing data to a specific code reduces 
intra-patient coding variability, increasing data quality. (De Lusignan et al., 2015) 
As well as CPRD being larger in size and established longer, a greater number 
of academic articles have been published using CPRD data. A recent study 
found, between the years of 2004-2013, a total of 1,296 studies were published 
using data from one of these datasets. Of these, 825 (63.6%) used CPRD data, 
while 394 (30.4%) and 77 (5.9%) used THIN and QResearch respectively. As 
such, CPRD is more widely recognised and utilised in medical research.  
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CPRD is the longest established, largest and most referenced primary care 
database in the United Kingdom, therefore this was the resource selected for use 
in this thesis. 
 
2.6 Composition of CPRD 
CPRD has been established for over 30 years. The studies described in this 
thesis will begin in 1990 which will allow an investigation into whether any trends 
in the incidence and prevalence of PMR are present over a prolonged time 
period. During this period, the number of practices, and therefore patients, 
contributing to CPRD has changed, (figure 2-1) as has the size of contributing 
practices (figure 2-2).  
Figure 2-1: The number of patients and practices contributing data to CPRD 
each calendar year (1990-2016) 
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Figure 2-2: The mean number of patients registered with a contributing CPRD 
practice (1990-2016) 
 
 
The total number of patients contributing data to CPRD in any one calendar year 
has increased from around 1 million patients in 1990, to a peak of almost 7 million 
patients in 2011-2013. The number of contributing practices has declined since 
2013, which may be due to practices changing to an alternative EHR. This may 
have been an indirect consequence of the Health and Social Care Act (2012). 
This act mandated the formation of CCGs (Clinical Commissioning Groups), by 
GPs in order to commission services in their local area. This change meant that 
greater harmonisation between practices was necessary and led to practices in 
each area selecting a single EHR. 
In common with all practices in the UK, the average numbers of patients 
registered with each practice contributing to CPRD has increased. This has been 
driven by a number of factors, including the rapid decline in the number of “single-
handed” GP practices and corresponding increase in the number of practices 
formally amalgamating together. (Goodwin et al., 2011) 
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2.7 Descriptive statistics: a comparison between CPRD and UK 
population structures 
Descriptive statistics were used to describe demographic data of the CPRD and 
UK populations. In order to assert that CPRD continues to be representative of 
the UK population, the demographics of people alive and contributing data to 
CPRD in the latest full year of available data was compared to the general 
population. Demographic data available in CPRD includes age, sex and the 
region in which a practice is based. In CPRD, to help preserve anonymity, a 
patient’s exact date of birth is not given, instead the year of birth is recorded and 
from this the approximate age can be calculated. Sex and region data are coded 
as in table 2-1. 
Table 2-1: Coding of demographic characteristics in CPRD 
Demographic 
characteristic 
Code 
Sex  
Male 1 
Female 2 
Region  
North East 1 
North West 2 
Yorkshire & the Humber 3 
East Midlands 4 
West Midlands 5 
East of England 6 
South West 7 
South Central 8 
London 9 
South East Coast 10 
Northern Ireland 11 
Scotland 12 
Wales 13 
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To compare demographic data in CPRD and the UK population, information was 
extracted from CPRD and the mid-year estimates of the UK population in 2016 
published by the Office for National Statistics (table 2-2). (Office for National 
Statistics, 2016) In this table, the UK data is compared to CPRD both in total 
numbers and proportion, and then further stratifies the data by sex, age and 
country of origin.  
 
Table 2-2: Demographic characteristics of UK population compared to patients 
actively contributing data to CPRD in 2016 
Number of patients UK population (%) CPRD 2016 (%) 
Total 65,648,100 (100) 4,285,741 (100) 
Sex   
Male 32,377,700 (49.32) 2,067,411 (48.24) 
Female 33,270,400 (50.68) 2,218,330 (51.76) 
Age in 2016   
0-9 8,051,800 (12.27) 418,219 (9.76) 
10-19 7,404,000 (11.28) 441,854 (10.31) 
20-29 8,764,400 (13.35) 517,109 (12.07) 
30-39 8,587,700 (13.08) 574,786 (13.41) 
40-49 8,793,200 (13.39) 601,635 (14.04) 
50-59 8,698,700 (13.25) 573,261 (13.38) 
60-69 7,170,700 (10.92) 460,821 (10.75) 
70-79 5,006,600 (7.63) 357,647 (8.34) 
80-89 2,599,700 (3.96) 223,802 (5.22) 
90+ 571,200 (0.87) 116,607 (2.72) 
Country    
United Kingdom 65,648,100 (100) 4,286,456 (100) 
England 55,268,100 (84.19) 2,667,873 (62.25) 
Northern Ireland 1,862,100 (2.84) 210,067 (4.90) 
Scotland 5,404,700 (8.23) 676,994 (15.80) 
Wales 3,113,200 (4.74) 730,807 (17.05) 
 
The proportion of males and females in the UK population and CPRD data are 
similar, with a slightly smaller proportion of men in CPRD compared to the UK 
population. This is likely due to reduced utilisation of healthcare services in men 
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compared to women. (Wang et al., 2013) Relating to the regional distribution of 
practices, CPRD is relatively under-represented in patients from English 
practices compared to Northern Ireland, Scotland and Wales. This is likely due 
to variations in uptake of different EHR software by region. However, the genetic 
variation within UK is relatively low, (Leslie et al., 2015) and therefore the 
generalisability of CPRD data is maintained. To allow easier visualisation of the 
population structure of CPRD and the United Kingdom, population pyramids were 
created using this data (figures 2-3 and 2-4).  
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Figure 2-3: Population pyramid of patients contributing data to CPRD in 2016 
 
 
 
Figure 2-4: UK population pyramid derived from mid-year estimates (2016) from 
Office for National Statistics). (Office for National Statistics, 2016) 
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Both of these distributions correspond to a stage 4, contractive, population 
pyramid. Societies in this stage of population development have a declining birth 
rate, long life expectancy and a low death rate. The UK population is gradually 
ageing. In 1974 the ages at the 25th centile, median and 75th centile were 15.9, 
33.9 and 54.8; by 2014 this had increased to 21.1, 40 and 58.3 respectively.  
Although the two distributions are broadly similar, there appears to be some 
differences particularly at the extremes of age, where a greater proportion of 
older people and a smaller proportion of young people are contributing to CPRD 
compared to what you would expect given the overall UK population distribution. 
Below is a direct comparison of the population distribution (figure 2-5). 
 
Figure 2-5: Age distribution of patients enrolled in CPRD compared to UK 
population 2016. (Office for National Statistics, 2016) 
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It can be seen that the population distribution of patients contributing to CPRD 
closely approximates the UK population distribution between the ages of 25-29 
until 45-49; after which the distributions appear to be almost identical. However 
in under 25s and over 75s there is some divergence.  
The likely reason for this is that children and young people are less likely to 
present for review to their General Practitioners; as such they are also less likely 
to contribute data to the CPRD. Furthermore, this explains the reason why older 
patients are overestimated in CPRD, as they are more likely to be subject to 
active surveillance or follow up with multiple conditions, given that multi-morbidity 
and therefore need for access to medical services, is strongly associated with 
increasing age. (Salive, 2013) 
Figures 2-6 and 2-7 illustrate population data stratified into male and female 
distributions respectively. The difference at younger ages is accentuated in 
males, and there is also an increase in the proportion of male patients in the 
CPRD dataset who are entering early middle age (40-50 years old) compared to 
the overall population. These differences are likely explained by reduced male 
utilisation of primary care services in early adulthood (Wang et al., 2013) but then 
earlier development of chronic illness in men compared to women. (Oksuzyan et 
al., 2008) 
The difference between CPRD and the UK population structure in women is 
much less at a younger age and closely approximates the UK population for most 
of the age bands. The most pronounced difference between the UK and CPRD 
populations is found at the extreme of age; this again is likely a reflection of the 
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greater lifespan of women and the inevitable increase in the use of health 
services by patients who are older.  
Figure 2-6: Age distribution of male patients enrolled in CPRD compared to UK 
population 2016. (Office for National Statistics, 2016) 
 
 
Figure 2-7: Age distribution of female patients enrolled in CPRD compared to 
UK population 2016. (Office for National Statistics, 2016) 
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Having established the age distribution of people actively contributing data to 
CPRD in 2016 is similar to the UK population at the same time, it is important to 
assess whether this distribution is steady throughout the whole study period. 
Figure 2-8 illustrates the age distribution of patients in CPRD from 1990-2015 
and shows that the proportion of people within each age band remains similar 
across the whole study period. 
 
Figure 2-8: Proportion of people contributing data to CPRD, 1990-2015, stratified 
by age 
 
 
Therefore, it can be asserted that the CPRD database contains data on patients 
who are similar to the wider UK population, based on age, sex and geographical 
location. The differences observed in the population with regards to age group 
and sex are related to variations in utilisation of healthcare in these groups. Due 
to the way CPRD data are collected, whereupon patients only contribute data 
when they are followed up, these differences are inevitable. Regarding the 
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geographic variation, as discussed previously, practices are recruited to CPRD 
voluntarily. This will likely lead to clustering of practice recruitment in which a 
single practice initially joins and then provides positive feedback of the process 
to neighbouring organisations or alternatively where groups of practices join 
together following discussions at higher management, such as CCG, levels. As 
genetic variation between the constituent countries of the UK is low this is unlikely 
to affect the generalisability of results. 
 
2.8 Comparison between CPRD and HES linked patients 
Having established that the CPRD as a whole is representative of the UK 
population, further comparison is required to ascertain whether patients who 
contribute to CPRD and are from practices linked to secondary care datasets 
(section 2.3) are similar to the CPRD database as a whole. The demographic 
characteristics, stratified by sex, age and country, of patients contributing to 
CPRD in 2016 and those with linkage are summarised in table 2-3.  
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Table 2-3: Comparison between CPRD and linked patients  
CPRD 2016 (%) CPRD & linkage (2016) 
Number of patients   
Total 4,285,741 (100) 1,697,629 (100) 
Sex   
Male 2,067,411 (48.24) 827,693 (48.76) 
Female 2,218,330 (51.76) 869,936 (51.24) 
Age in 2016   
0-9 418,219 (9.76) 194,092 (11.43) 
10-19 441,854 (10.31) 183,236 (10.79) 
20-29 517,109 (12.07) 203,862 (12.01) 
30-39 574,786 (13.41) 230,742 (13.59) 
40-49 601,635 (14.04) 237,692 (14) 
50-59 573,261 (13.38) 230,599 (13.58) 
60-69 460,821 (10.75) 179,995 (10.6) 
70-79 357,647 (8.34) 133,836 (7.88) 
80-89 223,802 (5.22) 78,195 (4.61) 
90+ 116,607 (2.72) 25,380 (1.49) 
Country    
United Kingdom 4,286,456 (100) 1,697,629 (100) 
England 2,667,873 (62.25) 1,697,629 (100) 
Northern Ireland 210,067 (4.90)  
Scotland 676,994 (15.80)  
Wales  730,807 (17.05)    
 
From this data, it can be seen that the age ranges of the patients with linkage 
established are similar to those who only contribute to CPRD; as are the 
proportions of male and female patients. However, the country of origin is clearly 
different. This is due to the fact that healthcare is a devolved area. Healthcare is 
therefore the responsibility to the governments of Northern Ireland, Scotland and 
Wales and, as a result, are run along slightly different models to England. 
Therefore, access to linked data is only available between general practices and 
hospitals in England. However, overall, the demographics of the linked data is 
similar to the CPRD dataset. The next section will describe how PMR cases were 
identified in CPRD. 
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2.9 Case definition of polymyalgia rheumatica 
As previously discussed, case ascertainment in CPRD is defined by the presence 
of a Read code to indicate a positive diagnosis, the list of differential diagnoses 
in PMR is wide, (Kermani and Warrington, 2013) and no specific autoantibody 
exists to allow confirmation of diagnosis. (Floris et al., 2018)  
Therefore, the presence of a Read code alone may not be considered sufficient 
to establish whether a diagnosis of PMR has definitively been made. In order to 
improve case ascertainment, a PMR diagnosis was only considered to be valid if 
patients received at least two prescriptions for oral glucocorticoids; one within six 
months of the diagnosis date and the second within six months of the first 
prescription. This mirrored the approach taken in a number of other CPRD 
studies of PMR, including the most comprehensive estimate of its incidence by 
Smeeth et al (Smeeth, Cook and Hall, 2006) as well as other more recent 
publications. (Muller et al., 2014; Pujades-Rodriguez et al., 2016)  
Given the strong association between PMR and GCA, patients who also had this 
diagnosis were included. The Read codes used to identify patients with PMR 
were: N20..00 Polymyalgia rheumatica and N200.00, Giant cell arteritis with 
polymyalgia rheumatica. To further enhance case ascertainment, all patients who 
were below the age of 40 were excluded. PMR is rare in this age group and is 
likely to represent significantly atypical disease or an incorrect diagnosis.  
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2.10 Case definition of glucocorticoid prescriptions 
In order to identify glucocorticoid (GC) prescriptions in patients with PMR, all GC 
prescriptions recorded in CPRD using medications from the British National 
Formulary (BNF) chapter 6.3.2 “Glucocorticoid therapy” were included. (Royal 
Pharmaceutical Society, 2017) These included prednisolone, deflacort, 
dexamethasone, hydrocortisone, methylprednisolone and triamcinolone. All GC 
prescriptions that were orally or parenterally administered were included, and 
topical preparations were excluded. CPRD contains the name of the medication, 
the quantity prescribed, number of units of medication to be taken each day and 
prescription duration. The BNF produces a glucocorticoid equivalence chart in 
which the different potencies of different glucocorticoids are published. (Royal 
Pharmaceutical Society, 2017) Using this, all prescriptions were converted into 
strength equivalent to 5mg prednisolone. 
 
2.11 Case definition of comorbidities 
The comorbidities that were assessed during this study were identified using 
three sources: the Charlson comorbidity index, (Charlson et al., 1994) the results 
of a systematic review (chapter 5), and consultation with experts in the 
management of PMR, including both rheumatologists and GPs. This process is 
explained in detail in chapter 6.2.7. In this section, the Charlson comorbidity index 
and the process through which code lists for each comorbidity were produced 
are described. 
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The Charlson comorbidity index is a list of common chronic medical conditions in 
which each is assigned a score, the total of which is a useful predictor of mortality 
risk. (Charlson et al., 1994) The index contains 17 diagnostic categories across 
a range of health domains, and the value assigned to each is based on the 
severity of each condition. These conditions include vascular diseases such as 
myocardial infarction, congestive heart failure, peripheral vascular disease and 
cerebrovascular disease; as well as other conditions such as chronic pulmonary 
disease, dementia, diabetes mellitus (DM), or DM with chronic complications, 
rheumatological disease, peptic ulcer disease, renal disease, any malignancy 
(including leukaemia and lymphoma), metastatic solid tumour, mild liver disease, 
moderate or severe liver disease and HIV infection. The score that a patient 
obtains is therefore suitable to give an overview of an individual’s health status. 
This list has been used previously in studies of comorbidity in other inflammatory 
rheumatological diseases. (Kuo et al., 2016)   
The process through which comorbidities of interest for this study were identified 
is described in chapter 6.2.7. Once these comorbidities were identified, lists of 
Read codes were produced for each comorbidity. In contrast to PMR, which only 
has two diagnostic Read codes, many of the comorbidities investigated had 
multiple different Read codes to signify diagnosis. These can reflect severity of 
disease, for example chronic kidney disease stages, or different presentations of 
a similar pathological process, for example myocardial infarction or angina. In 
order to capture each relevant diagnosis, robust lists of Read codes were 
constructed. 
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The lists were constructed using the CPRD Medical Browser v1.4.0. This browser 
is searchable by Read code, Medical code and Read Terms. Medical codes, as 
previously discussed, are unique numerical codes for each Read code. Read 
Terms are a description of what each Read code signifies. When searching in 
this browser there is the facility to use an asterisk, which enables a search for 
any Read Term which begin with the letters selected.  As well as providing 
information on the Medical codes necessary, the browser also gives information 
as to how many times each code is recorded within CPRD and whether they are 
recorded in the Clinical, Referral or Test files.  
The code list for each comorbidity was then reviewed by RP and AS. For some 
of the comorbidities, code lists had already been produced and validated within 
the department and were therefore used to maintain consistency. For example in 
the case of vascular disease (Clarson et al., 2013) and fractures. (Paskins et al., 
2018) In these cases, code lists were produced for this thesis, but then compared 
to the existing lists. Any disagreements between them were reviewed and codes 
were either added or removed as appropriate. In the majority of cases however, 
due to the wide scope of this study and the large number of comorbidities, there 
were no existing lists.  
Unlike PMR case ascertainment, prescription data was not used to provide 
confirmation of disease status. This was due to the large range of comorbidities 
and the heterogeneous way in which they could be treated. The accuracy of using 
CPRD Read codes for diagnosis has been demonstrated in a wide range of 
morbidities. (Khan, Harrison and Rose, 2010; Nissen et al., 2017) Furthermore, 
unlike in the case of PMR, many of these comorbidities, for example 
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hypertension, diabetes and asthma, have established diagnostic tests or criteria, 
therefore the use of prescription data to corroborate diagnostic status was not 
necessary. 
 
2.12 Licensing 
The Institute of Primary Care and Health Sciences at Keele University holds a 
General Practice Online Database (GOLD) licence to download CPRD data and 
it will be analysed using Stata software, version 15.1. (StataCorp, 2017) 
 
2.13 Conclusion 
The CPRD is therefore a valid, robust, database containing information gathered 
from a large population, during the course of routine primary care, who are 
representative of the population of the United Kingdom as a whole. It is the largest 
and most utilised verified primary care database in the UK and arguably the 
world. (Williams et al., 2012) PMR is most commonly managed in primary care. 
Therefore, the CPRD is the most robust data source for an accurate, real world 
estimate of the number of patients with this condition. The following chapter 
describes the epidemiological study performed to investigate the incidence and 
prevalence of PMR in the United Kingdom, using data from CPRD. 
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Chapter 3 AN EPIDEMIOLOGICAL STUDY OF THE INCIDENCE 
AND PREVALENCE OF POLYMYALGIA RHEUMATICA IN THE 
UNITED KINGDOM 1990-2015 
This chapter is an epidemiological study of the incidence and prevalence of PMR 
in the UK in the period 1990-2015. This study will identify patients with PMR in 
primary care using the CPRD database. 
 
3.1 Introduction 
As discussed in chapter 1, existing estimates of the prevalence and incidence of 
PMR in patients aged over 50 years lie between 0.1-1% (C Salvarani et al., 1995; 
Hayward et al., 2014) and 12 - 113 per 100,000 person years, respectively. 
(Salvarani et al., 1991; Barraclough et al., 2008; Raheel et al., 2017) The 
proportion of patients with PMR has been shown to be strongly linked to 
geography; as latitude increases, so do PMR rates. (Buttgereit et al., 2016) The 
majority of cases of PMR (71-84%) are treated in primary care, (Barraclough et 
al., 2008; Yates et al., 2016) however much of the existing literature is based on 
secondary care hospital records. Therefore, the burden of disease may have 
been underestimated.  
Smeeth, Cook, and Hall 2006 used primary care data to estimate the incidence 
of PMR in the UK, reporting an overall rate of 84 per 100,000 person years, which 
was increasing with time. However, the final year of data published in this study 
was 2001, therefore more contemporaneous estimates of national data are 
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needed to guide health service provision.  The methods used by Smeeth, Cook, 
and Hall 2006 will be replicated in order to facilitate as accurate a comparison 
between the data as possible. The following chapter describes an investigation 
to quantify the overall incidence and prevalence of PMR in the UK using a large 
population-based database. This has been published as an extended report in 
the Annals of the Rheumatic Disease (appendix 3). 
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3.2 Methods 
3.2.1 Data source and study population 
This study was conducted using the CPRD, a large and robust database, which 
contains information collected in the course of routine primary care in the United 
Kingdom. The CPRD was described in detail in chapter 2. 
 
3.2.2 Incidence 
The study period chosen was between 1st January 1990 and 1st January 2016. 
This period represents the entire CPRD dataset from its inception to the time 
when the study was conducted, and represents a significant length of time to 
observe for trends in the incidence and prevalence of PMR.  
In order to calculate the amount of data (time) that each patient contributed, 
individualised study start and end dates had to be defined. Each patient included 
in this study contributed data from the latest of five events: 1) the study start date, 
2) the date at which they became forty years old, 3) the date they most recently 
registered at a participating practice plus six months, 4) the first registration date 
at a participating practice, or 5) the date at which the practice was adjudged to 
reach internal quality standards; known as the ‘up-to-standard’ date.  
PMR is very rare in patients aged less than 50 years old, with a mean age of 
onset reported to be approximately 73 years. (Doran et al., 2002) Forty years of 
age was chosen as a cut off in order to replicate the earlier work of Smeeth et al. 
(Smeeth, Cook and Hall, 2006) The up-to-standard date was used to ensure that 
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the data being collected from the practice was of sufficient standard. Adding an 
additional six months to the most recent registration date with a practice ensured 
prevalent cases were not included in the analysis. When a patient registers with 
a GP practice, their medical history is transferred to the EHR system at their new 
host practice. When this happens, historic diagnoses can be incorrectly coded as 
occurring on the date of registration. (Wallace et al., 2015) Therefore, this data 
was excluded.  
The date at which follow up ended for each patient was the earliest of five events: 
1) the end of study period (1st of January 2016), 2) the date when a patient 
transferred out of a practice, 3) the date of a patient’s death, 4) the last date of 
data collection from the practice, or 5) the date when they were diagnosed with 
PMR. 
As previously discussed, PMR cases were identified when they were found to 
have a PMR Read code (codes: N20..00 Polymyalgia rheumatica, N200.00 Giant 
cell arteritis with polymyalgia rheumatica) in their EHR, as well as a record of at 
least two prescriptions for oral glucocorticoids; one within six months of the 
diagnosis date and the second within six months of the first prescription. Again, 
this follows methodology undertaken by Smeeth, Cook, and Hall 2006. Patients 
could have a diagnosis of both PMR and GCA. Only the first occurrence of PMR 
was included, therefore all subsequent person-time and diagnostic codes were 
excluded. This process, by which the amount of time each patient contributed to 
the study, is summarised in figure 3-1.  
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Figure 3-1: Calculation of person time for each contributing patient 
 
 
3.2.3 Statistical analysis 
As discussed in chapter 1, incidence is calculated by dividing the total number of 
new cases by the time total person years of follow-up. Because PMR is a 
relatively rare condition, the incidence rate was expressed per 100,000 person 
years.  This is the same units as all but one of the existing studies into the 
incidence of PMR, promoting cross-study comparison. Incidence rates were 
stratified by age, sex, region and calendar year. Patient age was grouped into 
decades. Lexis expansion, which creates one observation per time interval per 
subject, (Hertz, 2001) was used to calculate incidence rates by year following the 
study start date of 1st January 1990.  
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A Poisson regression model was used to compare the absolute rate of PMR by 
patient characteristics and calculate incidence rate ratios (IRR) with 95% 
confidence intervals for each covariate, including sex, age, region and calendar 
year of diagnosis. Incidence rate ratios are, as the name suggests, ratios of two 
incidence rates. The calculation of an IRR for each covariate allows estimation 
of the increase, or decrease, in the risk of diagnosis with PMR that each covariate 
is responsible for.  
Poisson regression is a form of regression analysis. It is used to calculate 
expected frequencies when the data follows the Poisson Distribution. The 
Poisson Distribution is a discrete probability distribution for the counts of events 
that occur randomly in a given interval of time. It is suitable for use when a 
number of criteria are satisfied: that the event can be counted in whole numbers, 
that occurrences are independent, that the average frequency for the time period 
in question is known and that it is possible to count how many times an event has 
occurred. Therefore, it is ideal to be used to describe the distribution of rare 
events in a large population. 
The process of calculating an IRR involves obtaining the ratio of two incidence 
rates; the rate of the covariate in question and a reference rate. The reference 
rates for each group of covariates were taken from the same group to ensure 
subjects were not counted more than once. The rates used as the reference 
values for the covariates age, sex and region were the age band 50-59, males 
and patients resident in the North West of England respectively. The age range 
and region were chosen as they provided the greatest amount of person time. 
Males were chosen as the reference rate as the rate of PMR was higher in 
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females, therefore a more clinically relevant calculation was to obtain the 
increase in the risk of PMR diagnosis in females rather than the decrease in 
males. 
Age-adjusted incidences for each sex, region and year were calculated using 
standardisation. There are two different methods for calculating standardised 
rates: direct and indirect. Direct standardisation involves the calculation of age-
specific rates in each age group in the population and then applying these rates 
to weights from a standard population. Therefore, this is the theoretical rate which 
would have occurred if the observed age-specific rates applied in the standard 
population. Indirect standardisation involves the opposite approach, wherein the 
age specific rates of a known population are then applied to the number of people 
in each age group of the population of interest. (Naing, 2000) 
Age specific rates were calculated in this study, therefore, direct standardisation 
was employed. As this study included only people aged over 40 years then 
commonly employed standard populations, such as the European standard, 
(Eurostat, 2013) were not appropriate. Therefore, the standard population in this 
study was the total population across the whole study period and, as discussed 
in section 2.7, the CPRD population distribution is similar to the wider UK 
population distribution.  
In order to determine this, the total amount of person time each patient 
contributed to this study within each decade of age was calculated. This was 
calculated by using Lexis expansion (Hertz, 2001) to split the person time each 
patient contributed into decades following their date of birth. The amount of time 
that each patient contributed to the study in each decade of life was then totalled 
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and, finally, the overall value for each decade was converted to a proportion of 
the total person time (table 3-1).  
 
Table 3-1: The proportion of person time per decade 1990-2016 
Decade Proportion of time 
40 0.30 
50 0.26 
60 0.21 
70 0.15 
80 0.08 
90 0.01 
Total 1.00 
 
Following this the crude incident rate, then the product and finally the expected 
incident rate for each decade was calculated thus: 
𝑐𝑟𝑢𝑑𝑒 𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑡 𝑟𝑎𝑡𝑒 (𝑝𝑒𝑟 100,000 𝑝𝑒𝑟𝑠𝑜𝑛 𝑦𝑒𝑎𝑟𝑠 𝑝𝑒𝑟 𝑑𝑒𝑐𝑎𝑑𝑒)
=  
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑒𝑣𝑒𝑛𝑡𝑠
𝑝𝑒𝑟𝑠𝑜𝑛 𝑡𝑖𝑚𝑒
∗ 100,000 
𝑝𝑟𝑜𝑑𝑢𝑐𝑡 (𝑝𝑒𝑟 𝑑𝑒𝑐𝑎𝑑𝑒) = 𝑐𝑟𝑢𝑑𝑒 𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 𝑟𝑎𝑡𝑒 ∗ 𝑎𝑔𝑒 𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 
𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑡 𝑟𝑎𝑡𝑒 = ∑ 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑠 
 
3.2.4 Prevalence 
The point prevalence of PMR was calculated for each calendar year. This was 
done by dividing the total number of patients who had received a diagnosis of 
PMR at any time in the past and were alive and contributing data on 31st 
December of that year (numerator) by the total number of patients alive and 
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contributing data on that date (denominator). Therefore, this enabled inclusion of 
both incident and prevalent cases.  
 
3.2.5 Sensitivity analysis 
A number of sensitivity analyses were performed to ensure the validity of the 
study findings. First, to investigate whether a large number of prevalent cases 
were included after the current registration date, the total number and rate of 
diagnoses of PMR were calculated during this period. (Wallace et al., 2015) 
Second, the incidence rates without GC prescriptions were calculated over the 
study period. Finally, comparisons were made between results from this study 
and previous studies of incidence and prevalence, by Smeeth, Cook, and Hall 
and Yates et al. respectively. In the case of prevalence comparison, the age 
threshold for this study was increased to 55 years and the results recalculated in 
order to allow direct comparison.  
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3.3 Results 
3.3.1 Incidence 
A total of 5,364,005 individuals contributed 43.97 million person-years of follow-
up in the period 1990-2016. The total number of new occurrences of PMR that 
fulfilled the GC prescription criteria was 42,145. This equated to 90.4% of the 
total number of PMR cases recorded during this time. The overall incidence rate 
of PMR amongst patients aged 40 years and over was 95.9 [95% confidence 
interval (CI):  94.9, 96.8] per 100,000 person-years (table 3-2). Incidence rates 
were significantly higher at older ages: those aged over 70 years of age were 
almost ten times (IRR= 9.61 [95% CI 9.25, 9.98]) more likely to have PMR 
compared to those between the ages of 50 and 59 years. Females were 67% 
more likely to develop PMR compared to males (IRR= 1.67 [1.64-1.71]).  A 
marked variation in incidence rates by region was found (figure 3-3), with rates 
highest in the south west region of the UK (124.1 [120.6-127.6]) and lowest in the 
north east (65.0 [59.5- 70.9]).  
 
3.3.2 Prevalence of PMR 
The point prevalence of PMR in 2015 among patients aged over 40 years was 
0.85% (table 3-2) and was markedly different between males and females (0.6% 
and 1.16% respectively). This means that, given the UK population includes 32.8 
million people aged over 40 years, approximately 280,000 people had received 
a diagnosis of PMR. As part of a sensitivity analysis, prevalence was found to 
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increase to 1.7% (95% CI 1.69%, 1.71%) when the threshold for inclusion in the 
study increased to only those patients aged over 55 years. 
 
Table 3-2: Incidence rates of PMR, with incidence rate ratios, stratified by age, 
sex and region 
 Number of 
events 
Person 
time at 
risk * 
Rate per 100,000 (95% 
Confidence Intervals) 
Incidence Rate 
Ratio (95% 
Confidence 
Intervals) ** 
Age 
standardised 
Incidence Rate 
* ⁺⁺ 
Overall 42,145 439.70 95.9 (94.9, 96.8)   
Age      
40-49 409 129.96 3.2 (2.9, 3.47) 0.11 (0.10, 0.13)  
50-59 3,139 113.75 27.6 (26.7, 28.6) Reference  
60-69 9,683 91.62 105.7 (103.6, 107.8) 3.80 (3.65, 3.96)  
70-79 17,620 64.76 272.1 (268.1, 276.1) 9.61 (9.25, 9.98)  
80+ 10,405 33.05 314.9 (308.9, 321) 10.58 (10.17, 11.13)  
Sex      
Male 13,651 212.06 64.4 (63.3, 65.5)  Reference 69.22 
Female 28,494 227.64 125.2 (123.7, 126.6) 1.67 (1.64, 1.71) 114.87 
Region      
North East  500 7.69 65 (59.5, 70.9) 0.82 (0.75, 0.90) 62.54 
North West 3,843 49.36 77.9 (75.4, 80.4) Reference 77.54 
Yorkshire & the 
Humber 
1,286 16.91 76.1 (72.0, 80.3) 0.97 (0.92, 1.04) 73.62 
East Midlands 1,461 16.71 87.4 (83.1, 92.0) 1.14 (1.07, 1.21) 86.13 
West Midlands 4,207 41.45 101.5 (98.5, 104.6) 1.26 (1.21, 1.32) 98.44 
East of England 4,698 38.44 122.2 (118.8, 125.8) 1.56 (1.49, 1.62) 120.41 
South West 4,850 39.10 124.1 (120.6, 127.6) 1.45 (1.39, 1.51) 112.96 
South Central 4,754 46.70 101.8 (98.9, 104.7) 1.29 (1.24, 1.35) 101.57 
London 2,901 40.63 71.4 (68.9, 74.1) 0.97 (0.93, 1.02) 75.76 
South East Coast 5,167 43.89 117.7 (114.6, 121) 1.42 (1.36, 1.48) 110.23 
Northern Ireland 991 13.76 72 (67.7, 76.6) 0.93 (0.87, 1.00) 73.06 
Scotland 3,154 40.05 78.7 (76.0, 81.5) 1.03 (0.99, 1. 08) 81.51 
Wales 4,333 45.01 96.3 (93.5, 99.2) 1.16 (1.11, 1.21) 90.05 
* Per 100,000 person years 
** Adjusted for age, sex, region and year of diagnosis if not stratified as a covariate 
⁺⁺ Incidence rate is adjusted by age using overall proportion of person time contributed per 10 
year age category 
 
 
3.3.3 Incidence of PMR over time 
The variation in incidence rates of PMR over time are displayed in table 3-3 and 
figure 3-2. The rate of diagnosis of PMR dipped a little after 1990 until 1996 
before increasing significantly until just after the end of the last century; after this 
the rate of diagnosis of PMR remained relatively stable between 2003 and 2014.  
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Table 3-3: Incidence rates of PMR by calendar year 
Year 
 
Number 
of events 
Person years at 
risk (per 
100,000 person 
years) 
Rate per 100,000 
person years (95% 
confidence interval) 
Incidence Rate 
Ratio * 
Age standard-
ised Incidence 
Rate ⁺⁺ 
Point 
prevalence 
Overall 42,145 439.70 95.9 (94.9, 96.8)   0.84% 
1990 261 3.30 79.2 (70.1, 89.4) Reference 76.3 0.34% 
1991 336 4.54 74 (66.5, 82.3) 0.91 (0.77, 1.07) 69.4 0.38% 
1992 401 5.27 76.1 (69, 83.9) 0.94 (0.80, 1.09) 72.1 0.44% 
1993 464 6.02 77.1 (70.4, 84.4) 0.95 (0.81, 1.10) 71.9 0.49% 
1994 476 6.55 72.7 (66.5, 79.6) 0.90 (0.77, 1.04) 68.4 0.52% 
1995 548 7.06 77.7 (71.4, 84.4) 0.96 (0.83, 1.11) 74 0.57% 
1996 657 8.06 81.5 (75.5, 88) 1.01 (0.87, 1.16) 77.4 0.60% 
1997 754 9.34 80.7 (75.2, 86.7) 1.01 (0.88, 1.17) 77.6 0.62% 
1998 863 10.69 80.7 (75.5, 86.3) 1.01 (0.88, 1.16) 76.5 0.64% 
1999 1,239 13.00 95.3 (90.1, 100.8) 1.20 (1.05, 1.38) 91.7 0.66% 
2000 1,537 15.85 96.9 (92.2, 101.9) 1.23 (1.08, 1.40) 93.7 0.68% 
2001 1,792 17.75 100.9 (96.4, 105.7) 1.28 (1.13, 1.46) 98.1 0.71% 
2002 2,131 20.05 106.3 (101.9, 110.9) 1.36 (1.20, 1.55) 103.5 0.74% 
2003 2,211 21.49 102.9 (98.7, 107.3) 1.33 (1.17, 1.51) 101.4 0.77% 
2004 2,296 22.96 100 (96, 104.2) 1.30 (1.15, 1.48) 98.5 0.79% 
2005 2,348 23.73 99 (95, 103) 1.30 (1.14, 1.48) 98 0.80% 
2006 2,389 24.12 99.1 (95.2, 103.1) 1.30 (1.15, 1.48) 97.7 0.83% 
2007 2,451 24.45 100.3 (96.4, 104.3) 1.32 (1.16, 1.50) 99.7 0.83% 
2008 2,495 24.60 101.4 (97.5, 105.5) 1.33 (1.17, 1.51) 100.7 0.85% 
2009 2,447 24.64 99.3 (95.5, 103.3) 1.30 (1.15, 1.48) 98.2 0.85% 
2010 2,497 24.34 102.6 (98.6, 106.7) 1.35 (1.19, 1.53) 101.6 0.86% 
2011 2,379 23.83 99.8 (95.9, 103.9) 1.32 (1.16, 1.50) 99.1 0.87% 
2012 2,268 23.50 96.5 (92.6, 100.6) 1.28 (1.12, 1.45) 95.9 0.87% 
2013 2,198 22.51 97.6 (93.6, 101.8) 1.29 (1.14, 1.47) 96.8 0.88% 
2014 2,037 20.58 99 (94.8, 103.4) 1.30 (1.14, 1.48) 97.2 0.88% 
2015 1,603 17.60 91.1 (86.7, 95.6) 1.20 (1.05, 1.36) 89.1 0.85% 
* adjusted for region, age, sex  
⁺⁺ Incidence rate is adjusted by age using overall proportion of person time contributed per 10 year age 
band 
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Figure 3-2: Overall, male and female incidence of PMR 1990-2015 with 95% 
Confidence Intervals 
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Figure 3-3: Incidence rates of PMR by region 1990-2016 
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3.3.4 Sensitivity analysis 
The first sensitivity analysis confirmed that during the first six months after current 
registration date there was an excess of PMR diagnoses. This was apparent in a 
number of measurements following this date, including the absolute number of 
new diagnoses per year (figure 3-4) and per month, (figure 3-5) as well as the 
rate of new diagnoses per year (figure 3-6).  
 
Figure 3-4: Total number of new diagnoses of PMR following current 
registration date (years) 
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Figure 3-5: Total number of new diagnoses of PMR following current 
registration date (months) 
 
 
Figure 3-6: Incidence rate of new diagnoses of PMR following current 
registration date (years) 
 
 
The second part of the sensitivity analysis involved assessing whether using 
glucocorticoids as part of the inclusion criteria reduced the rate of PMR diagnosis 
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significantly. Over 90% of patients with a diagnosis of PMR had two GC 
prescriptions. The overall trend over time remained similar when the requirement 
for two prescriptions was reduced to only one or omitted entirely (figure 3-7). 
 
Figure 3-7: Comparison of incidence rates when using different GC inclusion 
criteria 
 
 
Finally, as part of the sensitivity analysis, the total number of person years in the 
current study and in the most recent similar study of PMR incidence by Smeeth, 
Cook, and Hall 2006 were compared. This is important, as the person years act 
as the denominator in the calculation of incidence. Although the inclusion criteria 
used in this study were almost the same in both studies, there were significant 
differences in the number of person years available between the two studies 
(figure 3-8).  
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Figure 3-8: Contributing person years over time in current CPRD database 
compared to previously reported data 
 
 
However, when the amount of person time available in this study was compared 
to three more recent CPRD studies, (West et al., 2014; Kuo et al., 2015; Abhishek 
et al., 2017) the amount of person time available for use as the denominator 
correlated much more closely (figure 3-9). 
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Figure 3-9: A comparison of person years available in recent CPRD studies of 
disease incidence 
 
 
Although the number of person years in Smeeth, Cook, and Hall 2006 was 
different, the incidence rates reported by them were similar to that reported in 
the current study (figure 3-10). 
Figure 3-10: A comparison of incidence rates of PMR in this study and 
previously reported by Smeeth et al 
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3.4 Discussion 
3.4.1 Main findings 
This study estimates the burden of PMR in the UK to be slightly higher than 
previously estimated. In 2015, around one in 120 adults aged over 40 had 
received a diagnosis of PMR, which, across the whole population, equates to 
approximately 280,000 people in the UK. Overall, the incidence of PMR during 
the study period 1990 to 2016 was 95.9 per 100,000 person years [94.9, 96.8]. 
However, although it increased until 2002, the incidence rate of PMR has 
stabilised after this time.  
 
3.4.2 Strengths and limitations  
This was the largest study ever conducted to calculate a true estimate of the 
incidence and prevalence of PMR. This study used robust methodology that has 
been replicated from previous studies in a large, established database of patients 
who are representative of the UK population. A limitation of this study could be 
that it only used primary care data. However, as discussed previously, the vast 
majority of patients are managed in primary care. (Barraclough et al., 2008; Yates 
et al., 2016) As well as this, in the UK, diagnoses made in secondary care are 
communicated to, coded and then recorded in the primary care EHR. Therefore, 
although this study examined patients in primary care, it will also contain 
information from treatment in secondary care. Therefore, the CPRD is the most 
appropriate setting to capture and accurately estimate the incidence and 
prevalence of PMR. 
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The accuracy of this study was increased by excluding prevalent cases by 
omitting the first six months of follow up after patients registered with a practice 
contributing to CPRD. This ensured only included newly incident cases were 
included when calculating rates, thus avoiding an over-estimate of the number of 
cases. 
However, the method of case ascertainment could be regarded as a potential 
limitation. In this study, the diagnosis of PMR was based on medical codes 
recorded by the primary care physicians, rather than research classification 
criteria. (Dasgupta et al., 2012) One reason for this was that there wasn’t 
sufficient consultation detail in CPRD to allow it. Patients may therefore 
subsequently be diagnosed with an alternative condition. However, it was found 
that more than 90% of patients with a diagnosis of PMR received at least two GC 
prescriptions. Furthermore, the rate of diagnosis was assessed in each year 
during the study period, and was found to be very similar even when prescription 
data requirements were varied or omitted entirely (figure 3-7). Finally, the use of 
GC prescriptions to confirm PMR diagnosis is well established and has been 
used by several studies previously. (Smeeth, Cook and Hall, 2006; Pujades-
Rodriguez et al., 2016)  
 
3.4.3 Comparison to other studies  
The highest incidence, 113 per 100,000 patients, previously reported was a study 
from the south west of England. (Hayward et al., 2014) Although the overall 
incidence rate for the whole of the UK in the current study was lower than this, 
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the estimate for this region was slightly higher (124.1 [120.6, 127.6]). In the 
United States, the most recent estimates of PMR incidence reported by Raheel 
et al was 63.9 per 100,000. This is lower than the findings in this study. However, 
Raheel et al’s study was not conducted in primary care and stricter diagnostic 
criteria, rather than diagnostic codes and record of GC treatment were used as 
inclusion criteria. (Raheel S, Crowson CS, 2016) 
Employing less strict diagnostic criteria may not necessarily be a weakness of 
the current study. PMR can present in a range of different ways and using stricter 
inclusion criteria may lead to the exclusion of those with atypical presentations or 
other comorbid diseases. Ensuring all those who were labelled and treated for 
PMR are included means an accurate estimate of the burden of disease that 
PMR places on the UK healthcare system can be reached. Furthermore, the 
clinical classification criteria for PMR are designed for recruitment into research 
studies, not clinical practise. 
As well as this, the study from Raheel et al was carried out in the United States, 
and was therefore based in a healthcare system that is structurally very different 
to that in the UK. In the UK, as previously discussed, access to healthcare is free 
and universal, however in the US it is estimated that up to 20% of working age 
people do not have health insurance, limiting access to healthcare (Okoro et al., 
2015) Therefore, epidemiological research  in the US may not be able to include 
a complete cross section of the population. Finally, whilst it can be argued that 
the definition of PMR used in the current study is not ideal, the estimated rates 
calculated were broadly in line with other studies that have used clinical 
classification criteria. Therefore the risk of misclassification is minimal.  
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Women were more likely to develop PMR, with a female to male ratio of 
approximately 2:1, reflecting previous studies. (e.g. Smeeth, Cook, and Hall 
2006) The strong association between older age and risk of developing PMR has 
been demonstrated before, with other studies reporting median age at diagnosis 
of 70 (Yates et al., 2016) or  75 years. (Barraclough et al., 2008) As rates of frailty, 
aches, pains, (Buckinx et al., 2015) and ESR levels (Moghadam-Kia and Werth, 
2010) increase with age, it is possible that primary care physicians may over 
diagnose PMR in at least some of these patients. 
The prevalence of PMR has been found to vary between 0.1% and 1% in North 
Europe and North America. (Eaton et al., 2010; Hayward et al., 2014) The 
prevalence of 0.85% in 2015 calculated in our study is consistent with this. In a 
recent study in a single large GP practice in the south of the UK, (Yates et al., 
2016) reported a prevalence of 2.27% in those aged 55 years and over. In the 
current study, when the exclusion criteria for age was likewise increased to all 
those under the age of 55, the prevalence increased to 1.7%. This discrepancy 
could be explained by the higher incidence of PMR in the south and east of the 
UK as well as the fact it utilised a much smaller sample of only 5,000 people. 
Given PMR is known to preferentially affect people of northern European 
descent, the results of this study are likely to be generalisable to countries with a 
significant proportion of people from this ethnic group. However, results reported 
in this study are less generalisable to countries at lower latitudes, as incidence 
and prevalence rates have been found to reduce with decreasing latitude. (C 
Salvarani et al., 1995; Gonzalez-Gay et al., 1999, 2009) 
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The incidence of PMR appears higher in the south of the UK compared to the 
north. This was also demonstrated by Smeeth et al. (Smeeth, Cook and Hall, 
2006) As discussed in chapter 1.2, genetic associations between specific Human 
Leukocyte Antigen molecules and GCA have been found, (Carmona et al., 2015) 
although none yet for PMR. (González-Gay, Matteson and Castañeda, 2017) A 
degree of variation in the genetic make-up of people in different regions around 
the UK has been demonstrated in a recent study of over 2,000 UK residents. 
(Leslie et al., 2015) This study was the first fine-scale dissection of subtle levels 
of genetic variation within a country, but did not examine the region of the genome 
which encodes for Human Leucocyte Antigens (HLA), as the genetic samples 
used in this study were obtained from patients with multiple sclerosis, a disease 
with strong HLA associations. As this is the area of the genome in which 
associations with GCA have been found, further analysis of genetic variation in 
HLA allele frequency in the UK may be required to be certain that genetic 
variation is not the cause of the variability in PMR incidence. However, if the 
genes for HLA vary in a similar manner to the rest of the genome, then it is 
unlikely that genetics are the reason for the difference in incidence of PMR, as 
the minor genetic variations observed by Leslie et al did not match with the 
changes in PMR incidence rates demonstrated in this study. 
Other potential reasons could include an association between social class and 
PMR, retirement of elderly people to the south of the UK, a viral aetiological 
agent, or environmental differences such as less sunlight exposure in the north 
of the UK leading to reduced vitamin D levels and vitamin D deficiency being 
diagnosed preferentially to PMR. One previous study assessed the link between 
social class and PMR diagnosis. (Hayward et al., 2014) It did not find a link 
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between PMR diagnosis and socioeconomic status, which was based upon 
occupation, educational level and perceived adequacy of income. However, this 
study only assessed respondents within a small region of the UK, which limits its 
generalisability. 
Smeeth, Cook, and Hall (2006) found that the incidence of PMR in the UK was 
increasing until 2001. This finding was replicated in the current study. After 2001 
however, the incidence rate plateaued. Although the incidence rates reported 
were similar, there were differences in the amount of person time available to act 
as denominator between this study and Smeeth et al's work. In the current study, 
there was significantly more person-time available in the time period covered by 
Smeeth et al, compared their study. 
This difference was due to gradual changes in the way that data has been 
collected by CPRD through its existence, and Smeeth et al’s data was based on 
a much earlier version of CPRD data (Full Feature-GPRD). The main differences 
were around the “up-to-standard” and “current registration” dates. In the earlier 
versions of CPRD, the “up-to-standard” date was calculated once for each 
practice and remained the same after this. Now, it is calculated monthly based 
upon the data that is being collected at that time. Second, the “current registration 
date” was not included at all in earlier versions of CPRD, only the “first registration 
date”. Therefore patients could contribute to the database even if they had 
periods of time in their records where they were not registered with that practice. 
Therefore, the current methods employed by CPRD to define when patients can 
contribute data, including the use of “up-to-standard” and “current registration 
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dates” provide for much more accurate data collection and account for the 
differences seen when compared to earlier versions of CPRD. 
 
3.4.4 Conclusion and clinical implications  
In conclusion, analysis of high quality routinely collected primary care data has 
enabled confirmation of the number of patients in the UK who are affected by 
PMR. Due to the ageing population, the prevalence of PMR in the UK is 
increasing, and in 2015 approximately 280,000 adults over 40 in the UK have 
received a diagnosis of PMR, although incidence rates appear to have stabilised. 
Therefore, a significant proportion of the UK population are affected by this 
important and potentially disabling condition.  
The treatment of PMR is well recognised but there are persisting concerns that a 
large proportion of patients are subject to prolonged GC therapy. The next 
chapter will aim to answer the question as to whether a proportion of patients 
receive prolonged GC therapy by assessing GC prescribing among the PMR 
cohort identified in this study. 
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Chapter 4 AN EPIDEMIOLOGICAL STUDY OF THE TREATMENT 
OF PMR IN THE UNITED KINGDOM 1990-2015 
This chapter is an epidemiological study of the management of PMR in the UK in 
the period 1990-2015. It will assess prescribing in patients with PMR in primary 
care using the CPRD database. 
 
4.1 Introduction 
In the UK, as described in chapter 3, polymyalgia rheumatica (PMR) occurs at a 
rate of 95.9 [95% confidence interval (CI):  94.9, 96.8] per 100,000 person-years, 
and 0.85% of people aged over 40 had received a diagnosis of PMR by 2015. 
This means around 280,000 people are currently, or have been, affected by this 
condition.  
The management of PMR is well established. Joint guidance released by the 
American College of Rheumatology (ACR) and the European League Against 
Rheumatism (EULAR) advises glucocorticoid (GC) treatment at moderate to low 
doses which, for most patients, should end by approximately two years. (Dejaco, 
Singh, Perel, et al., 2015; Buttgereit et al., 2016) This guidance was based on 
the results of a systematic literature review as well as taking current clinical 
practice into account. However, the authors acknowledged there was insufficient 
data to make evidence-based recommendations for all conceivable subgroups of 
patients with PMR. (Dejaco, Singh, Perel, et al., 2015) Furthermore, it has been 
suggested a large proportion of patients experience symptom flare upon 
cessation, or during GC therapy tapering (a “symptom tail’). (Mackie et al., 2014) 
 89 
 
Long term GC therapy is associated with a number of significant adverse effects, 
(Moghadam-Kia and Werth, 2010) which are both dose (Huscher et al., 2009) 
and duration (Walsh et al., 2001) dependent. These adverse events, or 
complications, comprise a wide range of conditions; for example hypertension, 
obesity, cardiovascular disease, type two diabetes, cataracts, osteoporosis and 
proximal myopathy. (Moghadam-Kia and Werth, 2010) As such, the treatment for 
PMR also encompasses the prevention and management of the potential 
complications associated with GCs. These complications are not only common, 
they can also significantly impair patients’ health and functional status. 
Furthermore, GC therapy side effects are a key concern of patients with PMR. 
(Tshimologo et al., 2018) 
The aim of this study is to quantify prescribing of GCs in those diagnosed with 
PMR using a large, population-based, database.  
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4.2 Methods 
The cohort of 42,145 patients, identified in chapter 3, was used for this study. 
The methods used to identify these patients were explained in the previous 
chapter. 
All GC prescriptions that were recorded in CPRD for these patients after their 
date of diagnosis, or index date, using medications from BNF chapter 6.3.2 
“Glucocorticoid therapy”, (Royal Pharmaceutical Society, 2017) were included in 
the main analysis. The GCs prescriptions used in the analysis included 
prednisolone, deflacort, dexamethasone, hydrocortisone, methylprednisolone 
and triamcinolone. As previously discussed, all GC prescriptions that were orally 
or parenterally administered were included and topical preparations were 
excluded. All GC prescriptions were then converted to a strength equivalent to 
prednisolone using the BNF glucocorticoid conversion calculator. (Royal 
Pharmaceutical Society, 2017) For example, a prescription for 20mg 
hydrocortisone is regarded as equivalent to 5mg of prednisolone. 
CPRD contains information about quantity of medication prescribed, the number 
of units of medication to be taken each day (numeric daily dose) and prescription 
duration. However, this information is not always complete, as it may be recorded 
in the EHR using free text, rather than a Read code. For example, in GC 
prescriptions where a ‘reducing regime is required’ then the phrase ‘as directed’ 
may be coded, with more specific instructions inputted as free text on the EHR. 
In order to solve this issue, researchers have used a variety of methods in 
previous studies of GC prescribing. For example, one recent study opted to use 
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“defined daily doses”, produced by the World Health Organisation, which are the 
average maintenance dose of a drug per day when used for its main indication 
in adults. (World Health Organisation, 2018) 
For this study, however, the method used to calculate duration of GC therapy 
was adapted from that used in a previous study of GC related adverse events. 
(Paskins et al., 2018) Using this method, the duration recorded for a prescription, 
if present in CPRD, was used in the first instance. If duration data was not 
available, then either the quantity prescribed, or the number to be taken per day, 
or the gap to the next prescription were used, in that order, to calculate the 
duration. If it was still not possible to calculate a duration at this time, then either 
the average duration of other similar prescriptions for that patient was used, or if 
this was not available, the average duration for that prescription in all patients. 
The method is summarised in the algorithm shown below (figure 4-1).  
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The primary outcome measure was duration of time from diagnosis, or index 
date, until completion of continuous GC therapy. Kaplan-Meier survival methods 
were used to calculate the median duration of time from diagnosis until 
completion of continuous GC therapy. (Kaplan and Meier, 1958) The Kaplan-
Meier estimator is a nonparametric statistic used to estimate survival from lifetime 
data. Nonparametric statistics refer to a statistical method where the data is not 
required to fit a normal distribution.  
A Kaplan-Meier analysis allows estimation of survival over time, even when 
patients join or leave a study at different times. At each interval, the probability of 
1. If available, duration of each prescription recorded in CPRD was used. 
2. If not, the duration of each prescription was the lowest of,  
a. the quantity of medication prescribed; or 
b. the gap until the next prescription (if this was <90days); or 
c. the quantity of medication prescribed divided by the daily dose (if this 
was recorded). 
3. If the duration was still missing, it was replaced with,  
a. the average of that patient’s duration for other prescriptions of the 
same drug with the same strength (if present); or 
b. the average duration for all other patients’ prescriptions of the same 
drug with the same strength. 
4. If prescription duration was >90 days, it was replaced as 90 days. 
5. The total duration was calculated as the sum of all prescription durations 
for each patient. 
 
Figure 4-1: Algorithm for calculating GC prescription length 
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survival, in this case continuation of GC therapy, was calculated. Patients who 
have died, transferred to a different practice, or left the study for any other reason 
were not counted as part of the denominator, or censored, after the time point 
when they left the study. 
The end of a treatment course was determined to have occurred when no further 
GC prescriptions occurred for 90 days after the calculated duration of the 
previous prescription. The 90-day period was chosen as it is the same as in 
previous CPRD based studies of medication use. (Vinogradova et al., 2016)  
The date of diagnosis with PMR, or index date, was the start date of the study for 
each patient. The date at which each follow up ended was the earliest of five 
events: 1) the end of study period (1st of January 2016), 2) the date when a 
patient transferred out of a practice, 3) the date of a patient’s death, 4) the last 
date of data collection from the practice, or 5) the date when continuous GC 
treatment ended. 
Further analyses carried out included extending the period of time defined as end 
of treatment from 90 days to six months and then until end of all GC therapy for 
that patient. This was to specifically examine patients who underwent multiple 
courses of GC therapy and assessed whether extending the length of time 
allowed between prescriptions led to an increase in total continuous treatment 
time. 
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4.2.1 Sensitivity Analysis 
For further analysis of treatment patterns, the average daily and total dose of GC 
prescribed, as well as cumulative treatment time and the total number of 
prescriptions and separate treatment courses each patient received were 
calculated. Dosage calculations were made, as discussed in section 2.10, by 
converting the strength of all medications to milligrams of prednisolone equivalent 
using the BNF conversion tables of equivalent anti-inflammatory doses. (Royal 
Pharmaceutical Society, 2017) Results were further stratified by starting GC 
dose, age and sex.  
The average and total dose, as well as total duration, of GC therapy were also 
calculated and compared to ascertain whether any association was seen 
between these variables. For example if a longer duration of therapy was 
associated with an increased total GC dose received.  
Two further analyses were carried out where the duration of prescriptions were 
recalculated. The first involved categorising separately patients who received a 
diagnosis with another rheumatological condition, either prior to PMR diagnosis, 
or in the two years subsequently. PMR guidelines suggest that the presence of 
other rheumatological conditions would preclude a diagnosis with PMR, and that 
treatment of PMR should end by two years following diagnosis, then this was an 
appropriate duration to include. Other rheumatological diagnoses were identified 
using Read code lists developed for a comorbidity study described in chapter 
6.2.7. Patients who received another rheumatological diagnosis could be at risk 
of prolonged GC therapy. 
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The second analysis involved categorising separately those patients who were 
subsequently referred to secondary care rheumatology services after index date. 
These patients were identified using Read codes. Patients who were referred to 
secondary care could represent atypical, or more severe, presentations of PMR 
analyses. Therefore, due to them potentially having more serious diseases, they 
may also be subject to longer treatment durations. 
Finally, the distribution of all GC prescriptions, including those made prior to index 
date was also assessed to investigate whether patients with PMR are prescribed 
GCs prior to a formal diagnosis being made. This analysis was performed to 
investigate to what extent GCs were used as a therapeutic trial prior to diagnosis. 
A therapeutic trial refers to a situation in which patients with non-specific 
symptoms are prescribed GCs and then monitored for a response. In this case, 
if the symptoms and inflammatory markers improve, then a diagnosis of PMR 
may then be made. Previous research has shown this is a diagnostic approach 
viewed as important in PMR. (Helliwell et al., 2018) 
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4.3 Results 
4.3.1 Main findings 
In total 1,242,841 GC prescriptions were issued to patients with a diagnosis of 
PMR. Of these prescriptions, 99.9% contained information about quantity of 
medication prescribed, and 48.3% about numeric daily dose. The median time 
taken for patients to stop continuous therapy was 1.31 years [Interquartile range 
[IQR] 0.65, 2.6] (figure 4-2). When the treatment gap was increased to six 
months, the median duration increased to 1.88 years [0.93, 4.00]. When total GC 
treatment time was reviewed, median duration increased further to 1.93 years 
[0.95, 4.03], meaning around 25% of patients received more than four years of 
therapy (figure 4-3). 
 Figure 4-2: Kaplan-Meier plot of time to completion of GC therapy (90 day 
period) 
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Figure 4-3: Kaplan-Meier plot of time to completion of GC therapy  
 
 
4.3.2 Sensitivity analysis 
The median first and average daily doses of GC received (in milligrams of 
prednisolone equivalent) were 15mg [IQR 8, 21] and 6mg [IQR 4, 9] (figure 4-4) 
respectively. However, 7,138 (16.9%) patients received, on average, greater than 
10mg GC per day. The median total dose of GC received (in grams of 
prednisolone equivalent) was 4g [IQR 2, 8] (figure 4-5). The distribution of 
average daily doses was positively skewed, reflecting the fact that the mean 
average daily dose which patients received (7.4mg [Standard deviation [SD] 4.9]) 
was higher than the median. 
Repeating analyses stratified by initial GC dose, age and sex was unremarkable, 
with only patients aged under 50 receiving significantly fewer prescriptions. 
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Figure 4-4: Average daily dose of GC in patients with PMR 
 
 
 
Figure 4-5: Total dose of GC received by patients with a diagnosis of PMR 
 
 
The next phase of analysis involved assessing whether an association existed 
between cumulative treatment time and average daily GC dose, (figure 4-6) 
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cumulative treatment time and total dose received, (figure 4-7) or total dose 
received and average daily dose (figure 4-8). 
 
Figure 4-6: Scatter plot showing relationship between average daily GC dose 
prescribed and duration of GC therapy 
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Figure 4-7: Scatter plot with linear regression line showing relationship between 
total GC dose prescribed and duration of GC therapy 
 
 
Figure 4-8: Scatter plot with linear regression line showing relationship between 
total GC dose prescribed and average daily GC dose 
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As is seen in figures 4-6 and 4-8, no association was seen when looking at the 
average daily dose of GC that a patient received compared to either the total GC 
dose received, or duration of GC therapy. However, demonstrated by the linear 
prediction line which was calculated from a linear regression, strong association 
existed between total dose of GC therapy received and duration of treatment 
(figure 4-7).  
The distribution of GC prescriptions around index date demonstrated that the 
absolute number of GC prescriptions began to increase prior to the index date 
(figure 4-9). 
 
Figure 4-9: Total number of GC prescriptions around index date 
 
 
The final part of the sensitivity analysis involved ascertaining whether GC 
prescription length was longer in patients who either had a coexistent 
rheumatology diagnosis or those who had been referred to rheumatology. In 
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these situations it was found that the median continual duration of GC therapy 
was indeed greater, at 1.49 [0.73, 3.16] (figure 4-10) and 1.55 years [IQR 0.79, 
3.06] (figure 4-11) respectively.  
Figure 4-10: Kaplan-Meier plot of time to completion of GC therapy (90 day 
period) in patients with another coexistent rheumatological diagnosis 
 
 
Figure 4-11: Kaplan-Meier plot of time to completion of GC therapy (90 day 
period) in patients referred to secondary care 
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4.4 Discussion 
4.4.1 Main findings 
Analysis of high quality routinely collected primary care data has confirmed that 
a significant proportion of patients with PMR receive prolonged treatment with 
GCs. The median time taken for patients to stop continuous therapy was 1.31 
years [Interquartile range [IQR] 0.65, 2.6] and the median total length of treatment 
was 1.93 years [0.95, 4.03]. This means that almost 25% of patients with a 
diagnosis of PMR received more than four years of GC therapy.  
 
4.4.2 Strengths and limitations  
This is the largest study yet to calculate a true estimate of the current treatment 
patterns of patients with PMR. The methodology is robust and the study was 
conducted in an established database that is representative of the UK population. 
The methods used for calculating GC duration and dose were robust and have 
been used in previously published work. (Paskins et al., 2018) Furthermore, as 
indicated before, most patients with PMR are managed exclusively in primary 
care. (Barraclough et al., 2008; Yates et al., 2016) Therefore, this is an 
appropriate place in which to perform this study. 
Cases were identified using Read codes and GC prescriptions, rather than 
clinical classification criteria. This method is well established and allows 
identification and analysis of treatment patterns for very large numbers of people 
diagnosed with PMR in routine clinical practice outside of the confines of 
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research studies. This gives a unique insight into real life medicine and what 
happens in current GP practice, compared to what guidelines suggest.  
Furthermore, as more than 90% of patients in this study received at least two GC 
prescriptions, the diagnosis of PMR is likely to be accurate for the majority of 
patients. 
Of the 1,242,841 GC prescriptions that were issued to the patients in this cohort, 
99.9% contained information about quantity of medication prescribed, and 48.3% 
about numeric daily dose. The almost universal capture of the number of 
medications issued per prescription was expected, given the way that 
prescriptions are generated by EHRs. However, around half of the prescriptions 
did not contain data on numeric daily dose, i.e. how many to take per day. This 
is perhaps to be expected given the long duration of GC therapy and the 
necessity for individualised regimens and patient self-management of GC 
reduction. For example, if the daily instructions were either ‘as directed’ (asd), or 
different doses on alternate days, or the patient was on an individualised reducing 
regime, then this data would not be available for CPRD. 
The algorithm to calculate the length of prescriptions, as well as other data such 
as average daily dose and total dose, was therefore important when data was 
missing. This algorithm was described in detail in chapter 4.2. All prescriptions 
were assumed to be for a maximum of 90 days. This methodology was in line 
with previous CPRD studies of duration of treatment in other conditions. 
(Vinogradova et al., 2016) It is likely, however, that this algorithm slightly 
underestimated the overall duration of treatment.  
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4.4.3 Comparison to other studies 
The initial GC dose patients received was between 8-21mg in 50% of patients, 
which corresponds well to the recommended starting dose of 12.5-25mg. 
(Dejaco, Singh, Perel, et al., 2015) Less than one fifth of patients (18.3%) 
received greater than 25mg. However, the median duration of treatment of 
patients with GC in this sample is less than that found by Shbeeb et al in their 
recent study into GC prescribing in a cohort of 359 patients with PMR in Olmsted 
County, Minnesota. (Shbeeb et al., 2018a) They found only 19% of patients 
discontinued therapy in the first year of their treatment compared to 27% in this 
study. However, the median dose prescribed in each study was similar, at around 
5-6mg. 
A number of reasons for the shorter treatment duration in the current study are 
possible. For example, in Shbeeb et al’s study, the patient sample may represent 
more severe variants of the condition, as their inclusion criteria were stricter. To 
be included in their study, and other Olmsted county reports of PMR, patients 
had to fulfil three criteria, 1) age 50 years or older; 2) bilateral aching and morning 
stiffness (lasting ≥ 30 min) persisting for at least 1 month and involving 2 of the 
following areas: neck or torso, shoulders or proximal regions of the arms, and 
hips or proximal aspects of the thighs; and 3) erythrocyte sedimentation rate 
elevated to > 40. (Doran et al., 2002) Introducing symptom and laboratory criteria 
mean it is likely that the number of patients included will reduce and that they 
may have more severe disease.  
Furthermore, there were methodological differences in the definition of the end 
of GC therapy. The main analysis in the current study used a gap of 90 days to 
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define completion of therapy. However, in Shbeeb et al’s work, the total length of 
therapy was used. In a sensitivity analysis, when the total duration of therapy was 
assessed, the median length of treatment increased to 1.93 years [Interquartile 
Range [IQR] 0.95, 4.03]. This means that one in four patients with PMR in the 
UK are subject to treatment with GC therapy for more than four years. 
There are several potential explanations for a prolonged symptom tail. It could in 
part represent a more severe subtype of PMR that requires more aggressive and 
prolonged treatment. Some of this group may actually have a different underlying 
GC responsive diagnosis, for example elderly onset rheumatoid arthritis, for 
which referral for secondary care review may be appropriate. Alternatively, it may 
represent GCs masking the symptoms of other inter-current comorbidities which 
flare upon reduction of GC treatment, or adrenal insufficiency following prolonged 
GC use. 
 
4.4.4 Sensitivity analyses 
Patients who subsequently received a referral to a secondary care 
rheumatological services and those with a coexistent rheumatological diagnosis 
both had on average longer durations of GC therapy. These patients are likely to 
represent people with PMR where there is uncertainty around diagnosis or a 
more severe subtype of PMR. Additionally, guidance advises that patients who 
require treatment in excess of two years should be referred for rheumatological 
review, (Dejaco, Singh, P, et al., 2015) and so it is unsurprising that this was 
found. 
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Graphs displaying the average daily, and total, dose of GC received took the form 
of positively skewed normal distributions with a mean average daily dose of 
7.4mg [Standard deviation [SD] 2.9], which was greater than the median average 
daily dose of 6mg [IQR 4, 9]. This provides further evidence for the existence of 
a group of patients who receive significantly higher doses of GC compared to 
guidelines.  
The total number of GC prescriptions received unsurprisingly peaked in the first 
year following diagnosis (index date) and reduced rapidly in the first two years 
following this before continuing to reduce at a lower rate. However, the absolute 
number of GC prescriptions actually began to increase the year before formal 
diagnosis was made. This is likely to be due to the non-specific signs that are 
characteristic of PMR. In these cases it may be that GPs are using GCs as part 
of the diagnostic pathway, in effect a ‘trial of treatment’, wherein patients with 
signs atypical to PMR are given GC therapy and subsequently coded as PMR if 
they improve with treatment.  
 It was found that the average daily dose of GC therapy received was not 
associated with either duration of treatment or total GC dose received. However, 
as could be expected, the total dose of GC received was well associated with 
duration of treatment. This finding is perhaps unsurprising, that patients who 
received prolonged GC treatment will receive higher doses of glucocorticoids, but 
drives home the importance of identifying these patients at an early stage in their 
treatment journey. If identified at an early stage, these patients who are at risk of 
prolonged therapy and therefore higher overall doses of GC, could either then be 
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referred for consideration of disease modifying anti-rheumatic drugs (DMARDs), 
or be monitored and treated more intensively for GC related complications. 
 
4.4.5 Clinical relevance 
Previous studies have shown that long-term GC treatment increases a person’s 
risk of a wide range of complications. (Moghadam-Kia and Werth, 2010) The risk 
of complications due to GC therapy have been divided into those which exhibit a 
linear, and those with a dose threshold, relationship.  Complications with a linear 
relationship, in which the risk of a complication increases gradually with an 
increased daily GC dose, include bruising, leg oedema, thin skin, and sleep 
disturbance. A dose threshold relationship is where the risk of a complication 
remains relatively low until the daily dose exceeds a certain threshold, after which 
it increases greatly. Examples of complications and the threshold doses include 
>5mg/day: cataracts, 5-7.5mg/day: epistaxis and weight gain, >7.5mg/day: 
depression, glaucoma and hypertension. (Huscher et al., 2009) 
Therefore, this study has made an important and clinically relevant discovery that 
a significant proportion of patients receive a high total dose of GC over a 
prolonged length of time. The next steps from this point are to attempt to discover 
the subgroups who are at high risk of prolonged, large GC doses.  
Why some patients are treated with higher doses of GCs may be due to variations 
in treatment regimens within regions. For example, in Bristol (UK), local 
rheumatologists and GPs created a rapid access diagnostic care pathway to 
identify and treat patients with PMR. Their treatment guidelines specified the use 
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of prednisolone at doses of 15mg per day for six weeks, followed by 12.5mg for 
the next six weeks and then 10mg for one year, prior to instituting a reducing 
regime of 1mg/month thereafter. (Quick and Kirwan, 2012) This may be 
particularly relevant to this study given the higher incidence of PMR in the 
southwest of England. Furthermore, this variation in treatment again emphasises 
that, although treatment guidelines exist, it is acknowledged there aren’t 
evidence-based recommendations for all subgroups of patients with PMR. 
(Dejaco, Singh, Perel, et al., 2015) This highlights a need for future research to 
create formal treatment and tapering regimes for all patients with PMR. 
 
4.4.6 Conclusion 
A significant proportion of patients with PMR receive prolonged treatment with, 
and therefore higher doses of, glucocorticoids. This is contrary to previously held 
beliefs that cure will typically be achieved within two years. Early identification of 
patients who are likely to be subject to prolonged GC therapy is a priority area 
for future research. These patients could then be fast-tracked to secondary care 
for consideration of GC-sparing agents. This research could take the form of 
detailed prospective observational cohort trials in which patients with suspected 
PMR are identified and clinically examined in detail to attempt to ascertain which 
factors present, if any, predispose people to an increased likelihood of prolonged 
therapy. 
This study, in a large population, confirms the existence of a prolonged ‘symptom 
tail’ in PMR; wherein a significant number of patients receive a higher average 
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daily dose, a larger total dose, more individual prescriptions of GC and receive 
their treatment over a longer period of time.  
The current incidence, prevalence and treatment patterns of patients with PMR 
have thus been established. It is now important to assess the overall health of 
patients with PMR. It is not clear whether patients with PMR have worse health 
than other patients of their age. If this is the case, this may influence the likelihood 
of patients being subject to prolonged treatment with GCs and exposure to the 
resultant increased risks of complications. The first step in this process is to 
conduct a systematic review of existing evidence of the frequency of 
comorbidities, which are present both before, and subsequently develop after 
diagnosis of, PMR.  
The following chapter describes a systematic review of literature in this area. 
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Chapter 5 COMORBIDITIES IN POLYMYALGIA RHEUMATICA: A 
SYSTEMATIC REVIEW  
This chapter is a systematic review of published literature around comorbidities 
present before and after diagnosis with PMR. 
 
5.1 Introduction 
In the two previous chapters, the incidence, prevalence and treatment of 
polymyalgia rheumatica, was determined using a general practice electronic 
record database. However, little is known of the overall health of patients with 
PMR before and after their diagnosis. The presence of multiple co-existent, or 
comorbid, diseases are common in the general population. (Barnett et al., 2012) 
It is not clear whether patients with PMR have a similar or different pattern of 
comorbidity than the general population.  
It is well established that patients with certain inflammatory rheumatological 
conditions are predisposed to developing cardiovascular disease (CVD), for 
example gout (Clarson et al., 2013) and rheumatoid arthritis (RA) (Avina-Zubieta 
et al., 2012). In patients with RA, this risk has been attributed to an increased 
prevalence of arterial atherosclerotic plaques, (Jonsson et al., 2001; Pamuk, Ünlü 
and Çakir, 2006) the quantity of which are correlated with levels of systemic 
inflammation, (Kumeda et al., 2002) as well as the duration of rheumatological 
disease. (Dessein et al., 2007) Patients with RA are also known to have a higher 
risk of lung diseases, (Brown, 2007) and certain types of cancers, particularly 
haematological malignancies. (Chen et al., 2011)  
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PMR shares many traits with RA - they are both rheumatological conditions 
characterised by increased levels of inflammation. Therefore, it is important to 
ascertain whether patients with PMR have a similar predisposition to an 
increased risk of certain conditions.  
Establishing whether patients with PMR are at a higher risk of certain 
comorbidities is even more significant given the clinical classification criteria 
produced to guide diagnosis of PMR. These guidelines, which are endorsed by 
the American College of Rheumatology and the European League Against 
Rheumatism, advise that in order to diagnose PMR the presence of other 
conditions that may cause similar symptoms must be excluded. (Dejaco, Singh, 
Perel, et al., 2015) Unfortunately, due to the wide range of symptoms, (especially 
in early presentation) and non-specific signs and investigations that are a part of 
PMR diagnosis, this list of potential conditions to exclude is extensive. (Dasgupta 
et al., 2008) 
These conditions include GCA, cancer and infections, as well as RA, 
fibromyalgia, hypothyroidism and drug-induced myalgia. Furthermore, once a 
diagnosis has been made, existing clinical guidelines suggest an evaluation of 
whether patients have comorbidities that put them at greater risk of side effects 
from GC treatment. (Dejaco, Singh, Perel, et al., 2015) Therefore, to assess 
whether these guidelines are practical, it is necessary to understand what 
proportion of patients with PMR actually have any of these comorbidities, both at 
diagnosis and after. 
A further complicating factor is that people aged over 50 years are most 
commonly affected by PMR. As aging is an important predictor of morbidity, 
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people in this age group frequently have more than one comorbidity. A recent 
study from Scotland found the proportion of adults with two or more chronic 
conditions increased from 30.4% between the ages of 45-64 years, to 64.9% and 
then greater than 80% in those aged 65-84 and over 85 years of age respectively. 
(Barnett et al., 2012) These findings have been replicated around the world, 
including in Italy where a recent observational study estimated that by the age of 
65 approximately 40% of people have multiple morbidities. (Lenzi et al., 2016)  
This systematic review aims to summarise the available evidence of the 
comorbidity profile of people with PMR. This will be the first review to assess 
comprehensively the evidence for all comorbidities and whether there is evidence 
for multiple comorbidities existing together. If the evidence shows that patients 
with PMR commonly have multiple comorbidities, then these may no longer be 
viewed as exclusion criteria precluding a diagnosis of PMR, potentially revealing 
the true burden of PMR to be higher than currently recognised. 
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5.2 Methods  
This study was a systematic review and narrative synthesis of research literature. 
Medical bibliographic databases were searched to identify articles containing 
data on any comorbidity that have been described either prior to, or following, a 
diagnosis of PMR.  
 
5.2.1 Data sources, searches and study selection 
The search was conducted in MEDLINE, Embase, PsycINFO and CINAHL from 
their inception until the date of search in November 2016.  
MEDLINE is a biomedical database which began in the 1960s and includes 
journal articles from 1946 onwards. It is run by the National Library of Medicine 
(NLM) in the United States. It holds citations from more than 5,200 journals from 
around the world but with a particular focus on North America. (US National 
Library of Medicine, 2018b) Alongside searches based around free text, it also 
has the additional functionality of the NLM controlled search vocabulary. These 
are named Medical Subject Headings (MeSH). MeSH terms are a hierarchically-
organised terminology for cataloguing information, and articles are indexed by 
expert staff at NLM. (US National Library of Medicine, 2018a) 
Embase is a database containing studies published in biomedical journals. It 
contains articles dating from 1947 and includes slightly more journals than 
MEDLINE, with a total of 8,500. However, while MEDLINE is free to use, Embase 
access incurs significant cost, but is available through the Keele Health Library. 
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Embase, similar to MEDLINE, has a hierarchically organised thesaurus based on 
biomedical indexing; within this database this system is called Emtree thesaurus. 
(Elsevier, 2017) Traditionally, Embase contained more European-centric 
research journal outputs, although many journals were indexed in both Medline 
and Embase. This meant the amount of coverage overlap between these two 
databases was previously estimated to lie between 34% (Smith et al., 1992) and, 
later, 70%. (Yonker et al., 1990) However, after 2010, Embase expanded 
significantly and now includes all MEDLINE titles. (Elsevier, 2017) 
CINAHL (Cumulative Index to Nursing and Allied Heath Literature) is published 
by EBSCO and contains more than 2½ million records. This database lists 
citations from 1981 and predominantly focusses on nursing, allied health 
disciplines and biomedicine. Similar to Medline, the indexing thesaurus used in 
CINAHL utilises MeSH terms. PsycINFO is produced by the American 
Psychological Association and contains abstracts in the field of psychology. It 
extends to approximately 3½ million abstracts from 1967 to the present. 
In order to ensure no studies were missed, all of these large databases were 
searched. The search strategy involved using ‘exploded’ “MeSH” or “thesaurus” 
terms “polymyalgia rheumatica” and “giant cell arteritis”. These were combined 
with the Boolean operator “or”. As these hierarchical index systems involve 
human input to index correctly, free text searches were also employed to find any 
study which included the free text “polymyalgia rheumatica”, “giant cell arteritis”, 
“PMR”, “GCA”, “Horton’s disease”, “Temporal arteritis”, “Cranial arteritis” or 
“senile arteritis”. In this way, the search strategy was as broad as possible to 
ensure all potentially relevant studies were included. Additional articles were 
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found by examining reference lists of included studies and an updated search 
was run in June 2018. 
Giant cell arteritis, which is a vasculitis that very commonly co-occurs with PMR, 
was included in the search strategy due to the high proportion, approximately 10-
30%, of patients with PMR who develop GCA at some point in the course of their 
disease. (Salvarani et al., 2002a; Weyand and Goronzy, 2003) It is clear that 
GCA is linked with PMR, but it was not to prove this association that studies 
referencing GCA were included.  Rather, the reason GCA was used in the search 
was that, given the large overlap between conditions, it is likely that some studies 
which are referenced as covering GCA only may actually also include patients 
with co-existent PMR. Therefore, ensuring these studies were carried forward 
beyond the title screening stage minimised the chance of missing potentially 
relevant studies. 
All the article titles identified were screened by a single reviewer (RP) against the 
inclusion and exclusion criteria. A random sample of 100 of these were reviewed 
by a second reviewer (TH) and agreement between decisions was assessed 
using adjusted Kappa calculation. (Byrt, Bishop and Carlin, 1993) Adjusted 
Kappa was used as a large number of studies were likely to be excluded, 
meaning this category would have a particularly high frequency compared to the 
included category. In order to determine adjusted Kappa, the observed 
agreement must first be determined, using the calculation detailed in table 5-1. 
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Table 5-1: Calculation of observed agreement 
  Observer 1 (RP)  
  Included Excluded Total 
Observer 
2 (TH) 
Included  a b g1 
Excluded c d g2  
 Total f1 f2 n  
 
𝑃𝑜𝑏𝑠 =
(𝑎 + 𝑑)
𝑛
 
 
Once observed agreement has been determined, the adjusted Kappa is 
calculated as below, where k is the number of categories. 
 
𝐴𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝐾𝑎𝑝𝑝𝑎 =  
𝑘𝑃𝑜𝑏𝑠 −  1
𝑘 − 1
 
 
All selected abstracts were then assessed by two reviewers (RP & TH). Any 
citation thought to be eligible by either reviewer was carried forward to full text 
review. Reasons for exclusion were recorded. Finally, the remaining full texts 
were reviewed by the same two authors and a list of papers to be included in the 
narrative synthesis was created. PRISMA guidelines were followed throughout 
the review process. (Moher et al., 2009) 
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5.2.2 Inclusion and exclusion criteria 
The inclusion criteria for this study were created around the aim of building a 
broad picture of the health of patients with PMR. The aims, as described earlier, 
were not to prove direct causation between PMR and specific conditions. Instead, 
the aim was to look for associations between PMR and a range of comorbidities, 
as well as the differences in the overall health status of patients with PMR 
compared to those without.   
Therefore, wide inclusion criteria were employed to ensure that this review was 
a sensitive as possible in finding and evaluating any evidence of comorbidities in 
patients with PMR. For a study to be included in this review, it must have met all 
the following criteria. 
1. Morbidity of interest: it must include patients with a diagnosis of PMR.  
2. Outcome of interest: it must report at least one comorbidity.  
3. Study design: must be either cross sectional, case-control or a prospective 
or retrospective cohort study. 
4. There were no date or language restrictions  
Including retrospective, contemporaneous and prospective studies allowed a full 
assessment of existing literature of any associations with comorbidities without a 
requirement that this association is causative. 
Potentially relevant studies that contained data on GCA were included until full 
text review, due to the overlap between PMR and GCA. If, at that point, the paper 
only contained data about GCA without reference to PMR, they were excluded. 
The reference lists of other systematic reviews that had assessed individual 
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comorbidities related to PMR were also reviewed to ensure relevant studies not 
identified in the search were included. 
If a study met any of the following exclusion criteria, they were removed from this 
analysis in order to ensure accuracy of findings.  
1. Studies which reported results for patients under the age of 40 years 
2. Randomised control trials (RCTs), review articles, conference abstracts 
3. Studies that reported only complications of GC. 
PMR is a disease of older adults. In order to make a diagnosis of PMR, clinical 
guidelines suggest patients must be aged over 50 years, (Dasgupta et al. 2012) 
therefore patients under 40 years old are likely to represent misdiagnosis or very 
atypical disease. 
RCTs were excluded as their sample populations were less likely to be 
representative of all patients with PMR. The patients recruited into RCTs are 
often homogenous, that is to say they tend to employ restrictive selection criteria 
and exclude patients who have, for example, comorbidities that may affect the 
outcome of the trial. By making treatment groups very similar, investigators have 
the best chance of ascertaining with accuracy of whether a treatment is effective 
or not. However, by employing strict exclusion criteria, sampling bias is 
introduced and the populations that are examined within these studies become 
less like patients found in routine general practice. (Kennedy-Martin et al., 2015) 
Therefore, these studies do not reflect routine clinical practice and cannot provide 
data which is generalisable to all patients with a diagnosis of PMR.   
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Review articles and conference abstracts were not included to ensure all articles 
were peer reviewed and fully referenced. In order to ensure that all conditions 
represented true comorbidities of PMR, rather than secondary complications of 
GC treatment, trials in which the outcome measures were GC complications only, 
were excluded. (Chuang et al., 1982; Behn, Perera and Myles, 1983; Gabriel et 
al., 1997; Proven et al., 2003; Mazzantini et al., 2012; Albrecht et al., 2018; 
Paskins et al., 2018; Shbeeb et al., 2018a) Although, due to the fact GCs are 
near universally prescribed in the treatment of PMR, it was not possible to include 
only studies which included GC naïve patients only.  
The reference section of all included papers were searched and any paper which 
was identified as meeting the previously detailed inclusion criteria were included. 
The screening process for these papers was the same as that employed for those 
identified during the initial database search.  
 
5.2.3 Quality assessment 
Both reviewers used the Newcastle-Ottawa scale, for case-control and/or cohort 
studies, (Wells et al., 2009) to evaluate the quality of studies.  The Newcastle-
Ottawa scale is an ongoing collaboration between the University of Newcastle, 
Australia, and Ottawa, Canada. Studies are judged on three outcomes: 1) 
selection and 2) compatibility of study groups as well as 3) ascertainment of either 
the exposure or outcome of interest. This scale was designed due to the difficulty 
of implementing and conducting non-randomised studies, such as case control 
and cohort trials. For example, because these types of studies are non-
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randomised, it can be difficult to ensure similarity between treatment or exposure 
groups. 
The scale is based on a star rating system and allows researchers to grade 
studies on their rigour. It relies on reviewers to assign a rating for each study in 
the three outcome areas. The checklist has received some criticism regarding 
low inter-rater reliability. (Hartling et al., 2013) However, it has been used in 
multiple published papers and importantly is endorsed for use in systematic 
reviews of non-randomised trials by the Cochrane collaboration. (Higgins and 
Green, 2011) 
 
5.2.4 Data extraction 
A standardised form was developed and used by both reviewers independently 
to ensure the uniformity and accuracy of data extraction (appendix 5). Information 
recorded from each study, including lead author name, publication year, sex, age, 
country and healthcare setting details were extracted. Further to this, other 
variables were also recorded, including population sizes, study design, 
chronology of data collection, (either prospective or retrospective), clinical criteria 
used in diagnosis of PMR, comorbidity(s) assessed, number and proportion of 
PMR or control patients affected by comorbidity, and the effect measures 
reported.  
Comorbidities were categorised into four groups, namely (1) malignant diseases, 
including haematological malignancies; (2) vascular diseases, including 
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coronary, cerebro-arterial and peripheral arterial disease; (3) mortality and (4) 
other comorbidities (e.g. endocrine, psychiatric and neurological diseases). 
 
5.2.5 Data analysis 
Using the total number of patients with PMR and their controls, an attempt was 
made to aggregate data to obtain pooled estimates of prevalence of 
comorbidities and odds ratios to quantify the strength of any apparent 
association.  
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5.3 Results  
5.3.1 Search results 
A total of 27,698 articles were identified in the four databases searched with a 
further 6 identified following review of references of other articles and 1 more in 
the updated search in June 2018. Of this total, 10,376 were duplicates and 
therefore removed, leaving 17,329 unique articles. Following application of 
inclusion and exclusion criteria during screening of titles, 17,042 further citations 
were excluded.  
Of the random selection of 100 of these articles, which were reviewed by a 
second author, the agreement between authors was assessed as below and 
found to be excellent (= 0.86).   
Table 5-2: Agreement between reviewers at title review stage 
 Observer 1 (RP)  
 Included Excluded Total 
Observer 
2 (TH) 
Included 0 6 6 
Excluded 1 93 94 
 Total 1 99 100 
 
𝑃𝑜𝑏𝑠 =
(𝑎 + 𝑑)
𝑛
 
𝑃𝑜𝑏𝑠 =
(0 + 93)
100
= 0.93 
𝐴𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝐾𝑎𝑝𝑝𝑎 =  
𝑘𝑃𝑜𝑏𝑠 −  1
𝑘 − 1
 
𝐴𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝐾𝑎𝑝𝑝𝑎 =  
(2 ∗ 0.93) −  1
2 − 1
= 0.86 
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At this stage, 287 papers remained for abstract review, which was undertaken by 
both reviewers. 131 studies were excluded at this time, leaving 156 for full text 
review. Following full text review, 41 studies were included for the analysis. The 
reasons for exclusion at full text review were: the subject of paper was GCA only, 
(n=77), review articles (n=13), articles describing investigation, treatment, 
genetics or prognosis (n=10) or others (n=15). This process followed PRISMA 
guidelines, (Moher et al., 2009) and is detailed in figure 5-1. 
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Figure 5-1:  Flowchart of study inclusion, adopted from PRISMA guidelines 
(Moher et al., 2009) 
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5.3.2 Articles included in the review 
Of the 41 included studies, 32 were cohort and 9 were case-control. 18 of the 
cohort studies did not use a formal comparator group. Of the 14 cohort studies 
with controls, six were based on national datasets, whereas 8 were either based 
on local datasets or patients presenting to clinics at the same hospital. PMR 
cases were defined from medical records in 16 studies, national registries in 19 
and national databases in the remaining 6 studies. Co-existent GCA cases were 
formally excluded in 6 studies and included, or not explicitly excluded, in 35 
studies. All but one study was from Europe (predominantly Scandinavia) or the 
United States.  
 
5.3.3 Quality assessment 
All the articles in this study used medical records or nationwide registries (based 
on medical records) to corroborate diagnosis of PMR and the chosen 
comorbidity. Therefore, they were awarded three or four stars for cohort or case 
selection using the Newcastle Ottawa criteria. All studies also achieved at least 
two stars for outcome measurement. However, many of the studies failed to 
recruit a comparator group, (n=19) instead using the population as a reference, 
therefore comparability scores were low for a number of the studies. The results, 
using the Newcastle-Ottawa scale, of quality assessment and the meta data 
(author, study location, year, study type, comorbidity and temporal relationship 
of comorbidity to PMR diagnosis) of each included study are summarised in table 
5-3. 
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Table 5-3: Studies included in systematic review 
Author Study 
Location 
Year Study Type Comorbidity(s) assessed Temporal Relationship 
of Comorbidity 
Quality Assessment 
Selection Comparability Outcome 
B. A. Bengtsson and 
Malmvall 
Sweden 1981 Cohort Vascular events Prospective 4 0 2 
Bowness et al. United 
Kingdom 
1991 Cohort Thyroid disease Prospective 4 0 2 
Juchet et al. France 1993 Cohort Thyroid disease Prospective 3 0 2 
Haga et al. Norway 1993 Cohort Cancer Prospective 4 1 2 
Schaufelberger, 
Bengtsson, and 
Andersson 
Sweden 1995 Cohort Mortality Prospective 4 0 2 
J T Gran et al. Norway 2001 Cohort Mortality Prospective 4 1 3 
Doran et al. United 
States 
2002 Cohort Mortality Prospective 4 0 2 
Uddhammar et al.  Sweden 2002 Cohort Mortality Prospective 3 0 3 
Myklebust et al.  Norway 2002 Cohort All cancer Both 4 2 3 
Myklebust et al.  Norway 2003 Cohort Mortality Prospective 4 1 3 
Askling et al. Sweden 2005 Case 
Control 
Lymphoma Retrospective 3 2 3 
H. M. Kremers et al. United 
States 
2005 Cohort Various Prospective 4 2 3 
Eaton et al. Denmark 2007 Cohort Autoimmune diseases Cross-sectional 4 0 2 
H. M. H. Kremers et 
al.  
United 
States 
2007 Cohort Vascular events Prospective 3 0 2 
Warrington et al.  United 
States 
2009 Cohort Peripheral Vascular 
Disease 
Prospective 4 2 2 
Lesley A Anderson 
et al.  
United 
States 
2009 Case 
Control 
Lymphomas Retrospective 3 2 3 
L A Anderson et al. United 
States 
2009 Case 
Control 
Myeloid malignancies Retrospective 3 2 3 
Lesley A Anderson 
and Engels 
United 
States 
2010 Case 
Control 
Leukaemia Retrospective 3 2 3 
Jianguang et al.  Sweden 2010 Cohort Malignancy Prospective 3 1 3 
Kristinsson et al.  Sweden 2010 Case control Myeloproliferative 
neoplasms 
Retrospective 3 2 3 
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Author Study 
Location 
Year Study Type Comorbidity(s) assessed Temporal Relationship 
of Comorbidity 
Quality Assessment 
Selection Comparability Outcome 
Lanoy and Engels United 
States 
2010 Case 
Control 
Skin Cancers Retrospective 3 2 3 
Eaton et al.  Denmark 2006 Cohort Psychiatric Retrospective 4 0 3 
Kang, Sheu, and Lin Taiwan 2011 Cohort Stroke Prospective 4 2 2 
Lindqvist et al.  Sweden 2011 Case 
Control 
Plasma cell cancers Retrospective 3 2 3 
Zoller et al.  Sweden 2012 Cohort Stroke Prospective 4 0 3 
Zöller et al.  Sweden 2012 Cohort Vascular events Prospective 4 0 2 
K. Hemminki, Liu, et 
al. 
Sweden 2012 Cohort Digestive tract cancer Prospective 4 0 2 
K. Hemminki, Liu, et 
al.  
Sweden 2012 Cohort Digestive tract cancer Prospective 4 0 2 
Kari Hemminki et al.  Sweden 2012 Cohort Female cancers Prospective 4 0 2 
Kari Hemminki et al.  Sweden 2012 Cohort Myeloma Prospective 4 0 2 
S. J. Chen et al. Taiwan 2012 Case control Schizophrenia Retrospective 3 2 3 
Li, Sundquist, and 
Sundquist  
Sweden 2012 Cohort Parkinson's disease Prospective 4 0 2 
Kari Hemminki, Li, et 
al. 
Sweden 2012 Cohort Obesity (hospitalisation) Prospective 4 0 2 
Muller et al.  United 
Kingdom 
2013 Cohort All cancer Prospective 4 2 3 
Hancock et al.  United 
Kingdom 
2014 Cohort Vascular events Prospective 4 2 2 
M. Fallah et al.  Sweden 2014 Cohort Non Hodgkins Lymphoma Prospective 4 0 2 
Mahdi Fallah et al.  Sweden 2014 Cohort Hodgkin lymphoma Prospective 4 0 2 
Pfefiffer et al.  United 
States 
2015 Cohort All cancers Both 3 2 3 
Pujades-Rodriguez 
et al.  
United 
Kingdom 
2016 Cohort Vascular events Prospective 4 2 2 
Bellan et al.  Italy 2017 Cohort Cancer Prospective 3 0 3 
Scrivo et al.  Italy 2018 Case control Diverticular disease Retrospective 3 2 3 
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5.3.4 PMR and cancer 
Seven studies, reporting twelve outcome measures, have assessed the risk of 
cancer diagnosis prior to PMR onset, (table 5-4). All of the studies were case 
control in design and they assessed the risk of haematogenous cancers. Most 
studies assessed the risk of lymphoma or myeloproliferative diseases. Of the 
twelve outcome measures reported, the rate of haematogenous cancers was 
significantly higher among patients with PMR in five; while in the other seven, no 
significant differences were observed.  
 
Table 5-4: Cancer prior to diagnosis with PMR 
Retrospective case-control studies 
Author Diagnosis Case PMR Control PMR Odds Ratio 
(95% CI) 
Case 
Rate (%) 
Control 
Rate (%) 
Anderson 
et al., 
(2009) 
Lymphoid 33,721 344 122,531 1,244 0.9 (0.8-1.0) 1.02 1.02 
Anderson 
et al. 
(2009) 
Myeloid 9,998 125 160,086 1,288 1.7 (1.4-2.1) 1.25 0.80 
Myelodys-
plastic 
3,758 55 42,886 518 1.5 (1.1-2) 1.46 1.21 
Anderson 
and 
Engels, 
(2010) 
HCL* 418 9 160,086 2,721 1.5 (0.5-3.9) 2.15 1.70 
Askling et 
al. (2005) 
All 
lymphoma 
42,676 114 78,487 250 0.8 (0.7-1.0) 0.27 0.32 
NHL* 28,355 88 52,164 187 0.9 (0.7-1.1) 0.31 0.36 
HL* 4,037 3 7,394 15 0.4 (0.1-1.3) 0.07 0.2 
CLL* 10,555 24 19,391 52 0.8 (0.5-1.4) 0.23 0.27 
Kristinsson 
et al. 
(2010) 
Any MPN* 11,039 46 43,550 104 1.7 (1.2-2.5) 0.42 0.24 
Lanoy and 
Engels, 
(2010) 
Cutaneous 
NHL* 
2,652 19 178,452 1,731 0.7 (0.5-1.1) 0.72 0.97 
Lindqvist et 
al. (2011) 
MM 19,112 56 75,408 116 1.9 (1.4-2.6) 0.29 0.15 
MGUS* 5,403 58 21,209 79 2.9 (2.1-4.1) 1.07 0.37 
* HCL (Hairy cell leukaemia), NHL (Non-Hodgkin lymphoma), HL (Hodgkin’s lymphoma), CLL 
(Chronic Lymphocytic Leukaemia), MM (Multiple myeloma), MPN (myeloproliferative 
neoplasm), MGUS (Monclonal gammopathy of undetermined significance) 
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Six studies reported prospective rates of any cancer diagnosis after diagnosis 
with PMR (table 5-5); two showed an increase in the proportion of people with 
PMR who developed cancer compared to controls, two were equivocal and the 
remaining two found the opposite.  
 
Table 5-5: Cancer following diagnosis with PMR 
Prospective cohort- combined cancer cases  
 
PMR 
cases 
Cancer 
cases 
Proportion 
(%) 
Controls Cancer 
cases 
Proportion 
(%) 
Muller et al. (2014) 2,877 667 23.18 9,942 1,938 19.49 
Bellan et al. (2017) 100 24 24.00 702 41 5.84 
Jianguang et al. (2010) 35,918 3,941 10.97 
   
Myklebust et al. (2002) 366 34 9.29 1,324 143 10.80 
Haga et al. (1993) 91 10 10.99 794 131 16.50 
Pfefiffer et al. (2015) 359 66 18.38 357 62 17.37 
Total* 39,711  4,742  21.12  13,119  2,315  17.65  
*Ji et al not included in calculation as no control group  
 
In six prospective cohort studies, the risk of 17 individual types of cancer following 
diagnosis with PMR was reported. Two studies showed an increase in the risk of 
Hodgkin’s (Mahdi Fallah et al., 2014) and non-Hodgkin’s lymphoma. (M. Fallah 
et al., 2014) Of the remaining four studies, three reported no difference in the 
rates of female cancers, (Kari Hemminki, Liu, Ji, et al., 2012) upper 
gastrointestinal cancers (K. Hemminki, Liu, Ji, et al., 2012a) or  myeloma. (Kari 
Hemminki, Liu, Forsti, et al., 2012) The final study reported no difference in 
mortality following diagnosis with gastrointestinal cancers (K. Hemminki, Liu, Ji, 
et al., 2012b) among people with or without PMR.   
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5.3.5 PMR and vascular disease 
A number of studies (n=8) assessed a variety of different vascular diseases in 
patients with PMR (table 5-6). In total, fifteen outcome measures were reported, 
however only seven gave comparable figures for patients without PMR. In each 
study with a comparator group the proportion of people with PMR who developed 
vascular disease was higher compared to controls.  
 
Table 5-6: Vascular disease and PMR 
Author PMR  
cases  
Comorbid 
condition 
Proportion 
(%) 
Controls Comorbid 
condition 
Proportion 
(%) 
Stroke 
Kang, Sheu, and Lin 
(2011) 
781 113 14.47 3,905 273 6.99 
Zoller et al. (2012) 16,496 1,981 12.01 
   
H. M. H. Kremers et al. 
(2007) 
276 58 21.01 
   
Hancock et al. (2014) 3,249 397 12.22 12,735 556 4.37 
Myocardial infarction 
H. M. H. Kremers et al. 
(2007) 
276 47 17.03 
   
Hancock et al. (2014) 3,249 460 14.16 12,735 575 4.52 
Zoller et al. (2012) 21,351 5,669 26.55 
   
Heart failure 
H. M. H. Kremers et al. 
(2007) 
276 68 24.64 
   
Peripheral vascular disease 
H. M. H. Kremers et al. 
(2007) 
276 35 12.68 
   
Hancock et al. (2014) 3,249 140 4.31 12,735 151 1.19 
(Warrington et al., 
2009) 
353 38 10.76 705 28 3.97 
Combined 
H. M. H. Kremers et al. 
(2007) 
276 208 75.36 
   
Hancock et al. (2014) 3,249 918 28.25 12,735 1,150 9.03 
Pujades-Rodriguez et 
al. (2016) 
9,776 2,272 23.24 105,504 21,559 20.43 
B. A. Bengtsson and 
Malmvall (1981) 
73 16 21.92 
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5.3.6 PMR and mortality 
Four studies assessed the association between PMR and mortality. Three 
reported reduced mortality among patients diagnosed with PMR (Gran et al., 
2001; Doran et al., 2002; Myklebust et al., 2003) while one found an increase, 
however this study did not differentiate between patients with PMR and GCA. 
(Uddhammar et al., 2002) 
 
5.3.7 PMR and other comorbidities 
An association between thyroid disease and PMR is unproven. Bowness et al., 
(1991) found an increase in the risk of hypothyroid disease with a relative risk 
[RR] of 3.2 [95% confidence interval [CI] 1.71, 5.91] however, Juchet et al. (1993) 
did not. One recent case control study found a significantly increased rate of 
diverticular disease prior to a diagnosis with PMR with an odds ratio [OR] of 4.06 
[95% CI 1.76, 9.35]. (Scrivo et al. 2018) 
No evidence has been found to associate PMR with psychiatric comorbidities, 
including schizophrenia (Eaton et al., 2006; Chen et al., 2012) and bipolar 
disease, (Eaton et al., 2006) although Li et al (2012) found a potential association 
between PMR and Parkinson’s disease [standardised incidence ratio [SIR] 1.25 
[95% CI 1.01, 1.53] and an association between PMR and hospitalisation due to 
obesity SIR 1.65 [1.22, 2.19] has also been reported. (Kari Hemminki, Li, et al., 
2012) 
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Two studies from the United States (Kremers et al., 2005; Pfefiffer et al., 2015) 
looked at wide ranges of different comorbidities, but the number of patients 
included in each study with PMR (n= 364 and n=193 respectively) were 
insufficient to find significant associations for the majority of the comorbidities. 
 
5.3.8 Data analysis 
Aggregation of data to calculate pooled odds and hazard ratios was attempted 
for vascular disease and cancer diagnoses; however, due to high levels of 
heterogeneity between the studies (88-100%), these results are not reported. 
Despite this, five studies reported the absolute numbers of patients developing 
cancer, which meant that a calculation could be made of the proportion of patients 
with and without PMR who went on to develop a neoplasm. The proportion with 
PMR who developed cancer was 21.12% compared to 17.65% of patients without 
PMR.  
Unfortunately, within the study periods reported, no more than two studies stated 
the absolute numbers of patients with and without PMR who developed stroke, 
myocardial infarction, heart failure, peripheral vascular disease or combined 
vascular disease outcomes respectively. Therefore, a proportion was not 
calculated for these morbidities.  
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5.4 Discussion 
5.4.1 Statement of principal findings 
This review found some evidence of an association between PMR and vascular 
disease and possibly cancer, particularly in the first six months following 
diagnosis. However, the evidence for this is not robust. 
 
5.4.2 PMR and cancer 
Retrospectively, prior to PMR diagnosis, five of the twelve outcomes reported by 
seven studies found an increased risk of cancer in patients who subsequently 
went on to develop PMR. All of these studies assessed haematogenous 
malignancies and also excluded PMR diagnoses made in the year prior to 
diagnosis of cancer, to reduce the risk of reverse causality- i.e. cancer causing 
PMR or PMR symptoms. 
Prospectively, after PMR diagnosis, there appeared to be an increase in the risk 
of cancer diagnosis, however it was concentrated in the first six months following 
diagnosis. This could be due to a number of reasons, for example surveillance 
bias. Surveillance bias exists where an index medical condition leads to the 
discovery of another due to the diagnostic work-up or follow up necessary for 
management of the index condition. (Haut and Pronovost, 2011)  A recent study 
from Scandinavia, authored by the same group that has produced many of the 
studies into comorbidities in PMR, illustrated this by demonstrating that rates of 
urological cancer were much higher following diagnosis with renal calculi. This 
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increase in the rate of cancers was concentrated in the first year following 
diagnosis, although some increase in risk persisted even after ten years of follow 
up. (Hemminki et al., 2017)  
A second potential reason for the apparent link between PMR and cancer, in the 
first six months following diagnosis, could be an element of misdiagnosis. Many 
of the features of PMR, such as myalgia, fatigue, weight loss, and raised 
inflammatory markers are also non-specific early features of some cancers. 
These explanations are supported by the fact that, as time passed, the rate of 
diagnosis of cancer dropped down to the background population rate. 
Furthermore, the treatment of PMR, a moderate dose of GC, will also in many 
cases lead to a temporary improvement in these constitutional symptoms. 
Regarding specific types of cancer following PMR diagnosis, a number of studies 
have looked into the associations between PMR and haematological cancers. 
Positive findings have been tentatively suggested for both Hodgkin’s and non-
Hodgkin’s lymphoma, (M. Fallah et al., 2014) Again, it may be the case that these 
results are again due to surveillance bias or incorrect diagnosis. However, an 
increase in the risk of lymphoma has been observed with RA. The reason for this 
has been postulated to be that the higher accumulated inflammatory activity in 
RA may lead to dysfunction within the immune systems of patients. (Hellgren et 
al., 2017) As PMR is also characterised by raised inflammatory levels, it could be 
that a similar mechanism may lie behind the apparent increase in rates of certain 
haematogenous malignancies in patients with PMR. 
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5.4.3 PMR and vascular disease 
The overall trend of results suggests PMR may be associated with an increased 
risk of the development of vascular disease. However, the two largest studies, 
which were both based on population data from the UK, reported conflicting 
results, Hancock et al (2014) stated that PMR was significantly associated with 
vascular disease, while Pujades-Rodriguez et al (2016) reported a reduction in 
the risk incidence rate ratio [IRR] of 0.88 [95% CI 0.83, 0.94]). Although, in the 
latter study and when only patients with PMR were included, there was a slight 
increase in the proportion of patients with PMR who went on to have a vascular 
event compared to controls (23.24% compared to 20.43%). 
These two studies employed similar approaches in selecting patients with PMR 
from UK databases. However, a number of small methodological differences 
existed between the studies. Hancock et al (2014) restricted the age of 
participants to only those aged >50 years while, in the study from Pujades-
Rodriguez et al (2016), the age restriction was patients aged >18 years. The 
difference in age distribution in each study may account for part the contrasting 
findings. Other differences were seen in the average number of years of follow 
up, at 7.8 and 3.13 respectively, as well as the total number of patients found 
with PMR: 3,249 compared to 11,320. As the follow up period was longer, it may 
be that the increased overall risk found by Hancock et al (2014) was concentrated 
further away from date of PMR diagnosis. However, as discussed previously, 
although the headline findings from Pujades-Rodriguez et al. (2016) were that no 
increase in the vascular risk was found, the rate of vascular events were still 
slightly higher than controls when PMR patients alone were considered.  
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Another potential reason for the inconsistency in evidence of the effect that PMR 
has upon vascular risk may be the modulating effect that GCs have upon levels 
on inflammation in the blood vessels of patients with PMR. As discussed earlier, 
the increased risk of vascular disease among patients with RA has been 
postulated to be due to higher levels of arterial atherosclerotic plaques, (Jonsson 
et al., 2001; Pamuk, Ünlü and Çakir, 2006) the quantity of which correlates with 
levels of inflammation (Kumeda et al., 2002) and duration of rheumatological 
disease. (Dessein et al., 2007) 
If the excess risk of vascular disease is strongly associated with the presence of 
inflammation in the body, then the administration of anti-inflammatory therapy, 
such as GCs, may reduce the excess vascular risk by lowering the levels of 
systemic inflammation. The study published by H. Kremers et al. (2007) appears 
to confirm this. In this study, the risk of vascular events was lower in patients with 
PMR who were treated with GCs compared to those who were not.  Further to 
this, it was noted by Hancock et al. (2014) that the excess vascular risk in PMR 
reduced over time; this could reflect declining levels of inflammation. This is in 
contrast to the lifelong increased inflammation associated with other 
rheumatological conditions, such as rheumatoid arthritis.  
However, to add a further layer of complexity, it is known that GC therapy alone 
increases a person’s risk of developing complications such as hypertension and 
obesity, (Moghadam-Kia and Werth, 2010) which are risk factors for vascular 
disease. Therefore, it may be that the reduction in vascular risk toward baseline 
levels observed in the months after diagnosis reflect either reduction in 
inflammation levels in the body due to successful treatment with GCs or a 
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reduction in the proportion of patients receiving GC therapy, or dose tapering in 
those who remain on treatment.  
Overall, although the evidence is not currently unanimous, it appears that a 
diagnosis of PMR increases an individual’s risk of vascular disease. However, 
further research in this area is needed to add clarity.  
 
5.4.4 PMR and mortality 
Conversely, the studies that reported the risk of mortality in patients with PMR 
found that the risk of death appears to reduce in the years following diagnosis 
with PMR. This was demonstrated in three out of the four studies that reported it 
as an independent outcome.  A possible explanation for this could again be 
surveillance bias. Patients with chronic illness (and especially for PMR where 
regular assessment, follow up and monitoring are advised) are more likely to be 
under active follow up for their condition and any developing morbidity, 
particularly if related to well recognised adverse effects of treatment, is likely to 
be identified and managed earlier. 
 
5.4.5 PMR and other morbidities 
Two studies found evidence that patients with PMR may be more likely to develop 
hypothyroidism, an immune mediated endocrine disease, (Bowness et al., 1991) 
and Parkinson’s disease, a neurological condition, (Li, Sundquist and Sundquist, 
2012) respectively. PMR and hypothyroidism both preferentially affect females, 
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therefore a similar autoimmune pathway may be present in both conditions. 
However, as has been pointed out, PMR does not share all the characteristics of 
traditional autoimmune conditions, for example it lacks specific autoantibodies. 
(Floris et al., 2018) 
Parkinson’s disease is a condition which predominantly affects older people, as 
does PMR, therefore this association may be a result of clustering of diagnoses 
in an older population. 
 
5.4.6 Strengths and weaknesses 
The main strength of the study was its deliberately broad scope, and stated aim 
to include any study in which the risk of any comorbidity, either before or after 
diagnosis with PMR.  A large number of duplicate studies were identified, which 
given the cross over between Embase and Medline databases, was to be 
expected. However, using both databases, although costly in terms of time 
through duplication of work and resources, ensured that every effort was made 
to include all studies which may be potentially relevant. Another strength was the 
exclusion of ‘grey literature’ after the initial broad search. This meant that only 
articles fully published in peer reviewed journals were included in the review, 
increasing the quality of the reviewed literature.  
The potential limitations in this study arose not due to the protocol but rather as, 
despite the requirement for them to be peer reviewed, the majority of studies 
were relatively poor quality. The main biases identified included selection bias, 
surveillance bias and a lack of adequate control groups.  
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Selection bias was a problem in the design of many of the studies in this review, 
as PMR cases were often drawn from secondary care, either from hospital 
discharge data or rheumatology outpatient clinics, (n=19) . Current UK guidelines 
suggest only referring patients who present atypically, or in the case of diagnostic 
or treatment uncertainty, (Dasgupta et al., 2010; Dejaco, Singh, Perel, et al., 
2015) meaning that, as previously discussed in the UK, 71-84% of patients with 
PMR are treated in the community by primary care physicians. (Barraclough et 
al., 2008; Yates et al., 2016) Therefore, the patient population in these studies 
may not accurately reflect the majority of those who are diagnosed with PMR. 
This may artificially inflate the apparent differences in development of 
comorbidities between patients with and without PMR. 
Another limitation is the risk of surveillance bias, as discussed earlier around the 
apparent changes in risk around cancer, vascular disease and overall mortality. 
Some of the case-control studies attempted to deal with this by excluding 
comorbid disease found in the year prior to diagnosis, (L A Anderson et al., 2009; 
Lesley A Anderson et al., 2009; Anderson and Engels, 2010; Lindqvist et al., 
2011). While Hancock et al. (2014) and Pujades-Rodriguez et al. (2016), in the 
two largest prospective observational cohort studies of vascular risk, selected 
controls that had contacted a primary care service in the year the index cases 
were diagnosed, in order to attempt to control for surveillance bias.  
Another weakness of a number of these studies, was that they assessed multiple 
variables, often >30 different autoimmune conditions. These studies were 
predominantly from Scandinavia, registry based and looked into links between 
autoimmune conditions and specific cancer types. Due to the large number of 
 141 
 
potential outcomes assessed, the risk of reporting a finding which was due to 
chance, a type I error, was much greater.  
Another important variable to address is the potential influence on the risk of 
comorbidities of GC therapy in PMR. As GCs are the only widely accepted 
treatment for PMR, it is not possible to include only studies where patients were 
not treated with GCs as, for ethical reasons, they did not exist. However, as 
previously discussed, studies that exclusively reported the risk of comorbidities 
directly related to GC therapy were excluded. Further to this, in patients with a 
diagnosis of PMR, the duration and total dose of GC therapy varies widely and 
GCs are used to treat a broad range of conditions in addition to PMR. Therefore, 
GC therapy could act as a confounder in these studies which is difficult to control 
for. 
A further drawback of the studies in this review was related to the fact that many 
of the cohort studies identified failed to include comparison groups (n=18). In 
these cases, indirect standardisation was used to calculate incidence or mortality 
ratios. The lack of matched comparison groups limits the accuracy and 
generalisability of many of the studies and meant they scored poorly using the 
Newcastle-Ottawa scale of quality assessment. However, as this study aimed to 
build up a picture of the overall health of patients with PMR, rather than prove 
causation, these studies were still regarded as useful. 
Furthermore, the range of comorbidities reported in the literature was more 
limited than expected, for example, there were no studies which explicitly 
examined the risks of important and common conditions such as diabetes 
mellitus and asthma or other chronic obstructive pulmonary disease. This 
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restricted range of comorbidities was due to the fact that many of the studies 
limited themselves to assessing a small number of comorbid conditions. Almost 
all the existing literature examined the link between PMR and cancer or vascular 
disease, to the neglect of other common conditions. The two studies which did 
attempt to look at a range of comorbidities were unfortunately underpowered. 
(Schaufelberger, Bengtsson and Andersson, 1995; Kremers et al., 2005) This 
means that the overall picture of the health of patients with PMR is not clear.  
 
5.4.7 Conclusion 
This review has found the overall standard of evidence regarding the prevalence 
of comorbidities in patients with PMR to be weak.  There may be an increased 
risk of vascular disease, and possibly cancer in patients with PMR. Weaker 
quality evidence suggests, however, that patients with PMR have a reduced 
mortality rate. Currently, there is little evidence around the wider health of 
patients with PMR either at the time of, or after, diagnosis. 
This lack of firm evidence of what comorbidities exist alongside, or are potentially 
associated with, PMR presents a problem for the pragmatic clinician, both in 
primary and secondary care. Current guidance suggest that during the diagnosis 
of PMR clinicians should exclude mimicking conditions, such as non-
inflammatory, inflammatory (such as giant cell arteritis or rheumatoid arthritis), 
drug-induced, endocrine, infective and neoplastic conditions. (Dejaco, Singh, 
Perel, et al., 2015) However, comorbidities are very common in the age group 
affected by PMR, (Piccirillo et al., 2008) and this review shows there is some 
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evidence that patients with PMR are at least as likely to be diagnosed with some 
of these conditions compared to the general population. This means in clinical 
practice, the coexistence of one of these comorbidities with PMR is almost 
inevitable and should not necessarily prevent or invalidate the diagnosis of PMR. 
This knowledge may allow re-evaluation of guidelines and may, in turn, lead to 
an increase in the estimates of incidence and prevalence of PMR. 
Further research is also required to ascertain the rate of diagnosis of 
comorbidities in patients with PMR and to confirm whether, and if so to what 
extent, a diagnosis of PMR imparts an excess risk of vascular disease or cancer. 
The following chapter describes large observational studies, based in primary 
care, of the prevalence of comorbidities before and after diagnosis in patients 
with PMR compared to matched controls. 
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Chapter 6 COMORBIDITIES IN POLYMYALGIA RHEUMATICA: 
EPIDEMIOLOGICAL CASE CONTROL AND COHORT STUDIES 
This chapter contains a retrospective observational case control study and a 
prospective observational cohort study of comorbidities in people with PMR using 
the Clinical Practice Research Datalink (CPRD). 
 
6.1 Introduction 
The mean age of onset of PMR is around 73 years. (Doran et al., 2002) As 
discussed in chapter 5.1, as people age, they are much more likely to develop 
multiple chronic diseases, this effect is particularly pronounced in patients who 
are over 70 years of age. (Barnett et al., 2012) Therefore, many patients with 
PMR are demographically likely to have one or more chronic diseases. 
The systematic review of existing literature described in the previous chapter 
found the overall standard of evidence of the rate of comorbidities in PMR was 
weak, and that there was no evidence at all for many conditions, such as asthma, 
COPD and diabetes. It is therefore uncertain whether a diagnosis with PMR 
affects the risk of being diagnosed with other comorbidities.  
The existing evidence is, therefore, limited both by the relatively narrow range of 
comorbidities assessed and the standard of evidence available. This chapter, 
which describes a large scale epidemiological study of a broad range of 
comorbidities in patients with PMR, aims to address both of these shortcomings. 
The broad range of comorbidities will increase the number of comorbid conditions 
assessed beyond what has previously been reported in PMR, while the large 
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scale of the study will ensure the study has sufficient power to derive meaningful 
conclusions.  
 
6.1.1 PMR and comorbidities 
In this study a comorbidity is defined as “any distinct additional entity that has 
existed or may occur during the clinical course of a patient who has the index 
disease [PMR] under study”. (Feinstein, 1970) It is important to establish which 
comorbidities coexist with PMR for a number of reasons. For example, as 
previously discussed, joint guidance produced by the American College of 
Rheumatology (ACR) and the European League Against Rheumatism (EULAR) 
suggests that in order to make a PMR diagnosis, relevant mimicking conditions 
be excluded. (Dejaco, Singh, Perel, et al., 2015)  
These mimicking conditions are extensive and include, but are not limited to, 
other  inflammatory diseases, for example giant cell arteritis (GCA) or rheumatoid 
arthritis (RA), non-inflammatory conditions (osteoarthritis), drug-induced 
symptoms (for example, side effects of statin medications) , endocrine (thyroid 
disorders), infections (influenza) and neoplastic diseases. Some symptoms 
(myalgia, fever, tiredness, weakness) and laboratory findings (elevated 
inflammatory markers) that appear around the onset of many of these conditions 
are similar to the hallmarks of PMR. The importance of ensuring that patients are 
not misdiagnosed with PMR instead of potentially life threatening conditions, 
such as cancer, is understandable.  
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However, different rheumatological diseases having similar presenting features 
is not unusual and does not necessarily preclude diagnosis with both conditions. 
For example, rheumatoid arthritis (RA) and fibromyalgia both cause patients 
increased pain, fatigue and disability. However, unlike in the guidelines for PMR, 
RA is not regarded as an exclusion in the diagnosis of fibromyalgia, indeed it is 
increasingly recognised that patients with RA are at high risk of subsequently 
developing fibromyalgia. (Gist et al., 2018) 
The guidelines for PMR are clinical classification, rather than diagnostic, criteria. 
These criteria were designed to produce homogenous groups of patients for 
research purposes, with a certainty of diagnosis greater than that required for 
routine clinical practice. However, in the absence of confirmed diagnostic criteria, 
it has been reported that clinical classification criteria are commonly used in 
clinical practice, particularly in rheumatological diseases. (June and Aggarwal, 
2014)  
Underpinning these guidelines was a study in which the sensitivity and specificity 
of a range of clinical and laboratory features of PMR were compared in patients 
with PMR to those with one of a number of other conditions, such as RA, 
connective tissue diseases, shoulder conditions, fibromyalgia and generalised 
osteoarthritis. (Dasgupta et al. 2012) The clinical features investigated in the 
study included duration of symptoms, neck or bilateral shoulder or hip girdle 
ache, weight loss, morning stiffness, shoulder or hip pain and tenderness as well 
as carpal tunnel syndrome and peripheral synovitis or other joint pain. The results 
of laboratory investigations such as CRP (C-reactive protein), ESR (Erythrocyte 
sedimentation rate), RF (Rheumatoid factor) and/or ACPA (anti–citrullinated 
protein antibody) were also assessed.  
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This study was unable to demonstrate any single symptom, sign or investigation 
that could differentiate between patients with a diagnosis of PMR when compared 
to those with other connective tissue diseases such as RA. Therefore, the study’s 
authors advised an approach to PMR diagnosis in which confirmation of the 
presence of certain symptoms and investigation findings, such as bilateral 
shoulder pain and elevated ESR or CRP, and that absence of others, particularly 
peripheral synovitis and positive RA serology, were necessary for diagnosis. A 
patient with this constellation of symptoms and investigation findings could then 
be regarded as likely to have PMR, although only in the absence of an alternative 
diagnosis. 
This tentativeness around diagnosis may have unintended consequences. 
Potentially patients may have a mimicking condition in addition to PMR, however, 
in this situation the guidelines would advise against a diagnosis of PMR being 
made. This could mean that current estimates of the incidence and prevalence 
of PMR underestimate the total burden of disease and mean that patients with a 
mimicking comorbidity may not be treated appropriately for their PMR. This effect 
may be exacerbated by the difficulty in recognising the difference between 
pathological increases in aching and pain compared to the well-established 
increases in frailty, aches, pains and even inflammatory markers that occur as 
people age. (Buckinx et al., 2015) Therefore, estimating the prevalence or 
likelihood of comorbidities in patients with PMR is important. 
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6.1.2 Reasons why comorbidities may be associated with PMR 
Further to this, as discussed in chapter five, uncertainty surrounds whether a 
diagnosis of PMR actually predisposes people to an increased likelihood of 
development of other important comorbidities. There are a number of potential 
pathways through which this situation may arise. For example, a theoretical 
comorbidity may be associated with PMR due to similar autoimmune 
inflammatory processes. (Eaton et al., 2010) Other reasons for an increased risk 
of a comorbidity in PMR could be due to the increased levels of inflammation that 
occur in PMR, or the treatment of PMR with GCs, or simply as a patient ages. 
Each of these will be considered in turn. 
 
6.1.3 Autoimmune association 
It is well established that several autoimmune conditions co-exist in patients and 
cluster within families, although the exact pathophysiological mechanism is not 
known. (Somers et al., 2006) Examples of these clusters include thyroid disease 
and pernicious anaemia, vitiligo and multiple sclerosis; type one diabetes and 
primary biliary cirrhosis, and rheumatoid arthritis with Sjogren’s syndrome. 
(Cárdenas-Roldán, Rojas-Villarraga and Anaya, 2013) PMR shares many 
characteristics with these conditions, such as raised inflammatory levels, 
improvement in symptoms following administration of GC therapy and an 
increased risk of diagnosis in women. Therefore, given PMR may share an 
autoimmune inflammatory process with other similar conditions, it may lie within 
a cluster of these diseases. 
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6.1.4 Links to raised inflammatory markers 
Current published evidence suggests that patients with PMR may have an 
increased risk of vascular disease. (Hancock et al., 2014) However, the overall 
level of evidence for many conditions was weak and no comprehensive 
investigation has been undertaken into all potential comorbidities. (Partington et 
al., 2018) This potential association with vascular disease could be similar to the 
relationship that has been proven between vascular disease and gout, (Clarson 
et al., 2013) as well as with rheumatoid arthritis (RA), (Avina-Zubieta et al., 2012) 
and systemic lupus erythematosus. (Maureen McMahon, Bevra H Hahn, 2013). 
Each of these three conditions are inflammatory in nature and are associated 
with an increased risk of vascular disease, in fact the latter two conditions are 
now included as part of the latest version of the QRISK3® calculator that is widely 
used in clinical practice. This calculator provides information to healthcare 
professionals to personalise primary prevention of cardiovascular disease by 
estimating the ten-year risk of a heart attack or stroke based on individual patient 
factors. (Hippisley-Cox, Coupland and Brindle, 2017) Given the 
pathophysiological similarity between these conditions, there is biological 
plausibility that PMR and vascular disease could also be associated.  
Some evidence for the association between levels of inflammation in PMR and 
development of vascular disease, as well as the reason for inconsistent study 
findings, was suggested in a small US study by Kremers. In this study it was 
shown that the risk of vascular events was lower in patients with PMR who were 
treated with GCs were compared to those who were not. (H. M. H. Kremers et al. 
2007)  This would add weight to the hypothesis that the inflammatory burden in 
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PMR is the driver for an increased risk of vascular disease; as GCs would reduce 
this burden of inflammation. Further to this, it was noted by Hancock that the 
observed excess vascular risk in PMR that reduced over time following diagnosis; 
this could reflect the progressive reduction in the level of inflammation in the body 
after diagnosis. (Hancock et al., 2014) 
 
6.1.5 Glucocorticoid complications 
The recommended, and only proven, treatment for PMR is glucocorticoids, of 
which the usual first choice agent in the UK is prednisolone. This class of 
medication is associated with significant and numerous adverse effects including 
increasing the risk of diabetes and hypertension, (Mazzantini et al., 2012) among 
other cited complications such as impaired immune response, cataracts, 
glaucoma and fragility fractures. (Moghadam-Kia and Werth, 2010) As such, GC 
related side effects need to be considered as potential co-morbidities that may 
present following diagnosis with, and treatment of, PMR. Furthermore, the use of 
prolonged GC therapy has also in itself been associated with an increased risk 
of cardiovascular disease. (Fardet, Petersen and Nazareth, 2012). As a result of 
this, the use of regular GC medication is also part of the QRISK3® calculator. 
(Hippisley-Cox, Coupland and Brindle, 2017) 
However, the differential contribution of GCs in the development of comorbidities 
may be difficult to estimate as they may, through different mechanisms, act to 
increase or decrease the risk of a comorbidity. For example, as long term GC 
treatment increases the risk of obesity, as well as diabetes and hypertension, 
then it will inevitably increase the risk of vascular disease. However, at the same 
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time, GCs will also reduce levels of inflammation in the body in patients with PMR, 
which may lower the risk of vascular disease. It may be that in patients with PMR, 
the overall the risk of vascular and other conditions remains the same when 
compared to matched controls due to this effect. 
 
6.1.6 Increasing morbidity due to age 
The rate of multimorbidity climbs steeply after the age of 50, from 30.4% between 
the ages of 45-64 years, to 64.9% and greater than 80% in those aged 65-84 and 
over 85 years of age respectively. (Barnett et al., 2012) As PMR predominantly 
affects older people it is very likely a significant proportion of them will also have 
other chronic health conditions. 
 
6.1.7 Study aims 
This uncertainty inherent in the natural history, diagnosis and potential illness 
course of PMR is communicated implicitly to patients. One recent study 
investigated the level of information given to patients with a new diagnosis of 
PMR and found that almost 40% of patients did not receive written information at 
the time of their diagnosis. (Tshimologo et al., 2018) Another survey of members 
of PMRGCAuk (a UK based charity which supports people with PMR or GCA) 
found that patients wanted to receive more information around reducing 
glucocorticoids and the risks and benefits of treatment. (Muller et al., 2018) 
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Therefore, it is of upmost importance to firmly establish the health of patients at 
the time of, and subsequent to, diagnosis of PMR. This will inform both clinical 
classification criteria and diagnostic pathways. Furthermore, this will sharpen 
primary care’s ability to monitor for signs of any comorbidities associated with 
PMR, and, where appropriate, to refer patients promptly to specialist care. 
The study hypothesis is that patients with PMR may have a greater number of 
comorbidities at the time of diagnosis when compared to similar patients who do 
not have PMR and, given the evidence discussed above, a predisposition to 
develop certain comorbidities, particularly vascular disease, neoplasia and 
autoimmune conditions.  
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6.2 Methods 
6.2.1 Data source  
This investigation included both retrospective case control, and prospective 
cohort, studies carried out using the Clinical Practice Research Datalink (CPRD), 
which was described in detail in chapter 2. To briefly recapitulate, data in CPRD 
is collected in the course of routine primary care consultations. Of people who 
live in the UK 98% are registered with a General Practitioner, (Office for National 
Statistics, 2012a) and around 90% of patient contacts in the UK with the NHS is 
via primary care. (Hippisley-Cox and Vinogradova, 2009) 
CPRD contains data collected on more than 17 million contributing patients within 
718 (7.5% of the total) UK general practices and is representative of the UK 
population in terms of age, sex and ethnicity. (Herrett, Gallagher, et al., 2015) In 
this study, the presence or absence of PMR and any comorbidity will be based 
on physician diagnoses recorded as Read codes. This follows the methodology 
used in previous CPRD studies of comorbidities. (Kuo et al., 2016; Rees et al., 
2017)  
 
6.2.2 Study population 
In this study, the exposed group were patients with a diagnosis of PMR recorded 
in their electronic healthcare records (EHR). They were identified in the study 
described in chapter 3. Each patient had a Read code diagnosis of PMR and two 
prescriptions of GCs, the first made within six months of PMR diagnosis, and the 
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second within six months of the first. No diagnoses of PMR made when patients 
were under the age of 40 years were accepted. This methodology replicates 
previous studies performed in CPRD of PMR. (Smeeth, Cook and Hall, 2006; 
Hancock et al., 2014; Muller et al., 2014; Paskins et al., 2018) In addition to these 
requirements, each patient must have at least three years of continuous follow 
up prior to date of diagnosis with PMR. The date of diagnosis with PMR is 
hereafter known as ‘the index date’.  
 
6.2.3 Matching 
Each case was matched with up to five and no fewer than three controls. The 
number of controls per case was set at this level for pragmatic reasons. The 
increased statistical power generated by matching ever more controls per case 
diminishes rapidly above five controls per case, (Clayton and Hills 2013) 
therefore this was an acceptable upper limit. Cases with fewer than five but 
greater than two matched controls were also included. This meant that the overall 
number of cases included could be maximised and specifically those cases 
where there a smaller pool of possible controls, for example the very elderly, were 
included in the study.  
The matching criteria employed were: 1) year of birth +/- 3 years, 2) sex and 3) 
registered in the same general practice. A further requirement was that in order 
for a control to be matched to a case, they must have been contributing data on 
the index date of their matched case. This index date of the case was then 
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assigned to each matched control.  Exactly the same as with the cases, all of the 
controls must have at least 3 years of follow up prior to the index date. 
 
6.2.4 Study period 
Data recorded between 1st January 1990 and 1st January 2016 was analysed. 
The study start and end dates differed for the case control and cohort studies. 
For the case control study, patients were included after the latest of four events: 
1) the study start date, 2) the date at which they became 40 years old, 3) the date 
they registered at a participating practice plus six months, or 4) the date at which 
the practice was adjudged to reach internal quality standards; known as the ‘up-
to-standard date’. As in the previous studies, (chapters 3 and 4) an additional six 
months was added to the most recent registration date with a practice in order to 
ensure prevalent diagnoses were not included in the analysis. Data collection 
ended one year prior to index date. This was to minimise the chance of 
surveillance bias - PMR may be more likely to be diagnosed after diagnostic 
investigations that occur as a result of the comorbid condition. This strategy has 
been employed in other case control studies of comorbidities found in patients 
with PMR and gout. (L A Anderson et al., 2009; Kuo et al., 2016)   
In the cohort study, the start of the study period was defined as the index date 
for each participant. Data collection ended at the earliest of five events: 1) the 
end of the study period, 2) the date when a patient transferred out of a practice, 
3) the date of death, 4) the last date of data collection from the practice, or 5) the 
date of diagnosis with a comorbidity.  
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6.2.5 Comorbidity prevalence 
Case Control 
For the case control study, the Charlson index score and prevalence of the 
stratified and composite comorbidities were calculated at three time points prior 
to index date. The time points were at five, two and one year prior to index date. 
Prevalence was calculated by dividing the total number of people with the 
comorbidity (numerator) by the denominator, which was either the number of 
patients with PMR or their controls. The denominator figure was the same at one 
and two years prior to diagnosis but slightly less at five years. This was because, 
in order for a patient to be included in this study they must have contributed data 
for at least three years prior to index date. Therefore, although all of the patients 
included in this study contributed data at one and two years prior to index date, 
not all had five or more years of data. 
 
Cohort 
The follow up period for the cohort study was ten years. There was no minimum 
requirement for follow up following index date. Therefore, some patients were 
able to leave the study before they had developed a comorbidity whilst others 
contributed 10 years of data. Each outcome was separately assessed and 
patients were defined as at risk if they had not developed the outcome of interest. 
Person time was censored at a number of time points: 
1) Ten years following index date 
2) Transfer away from a practice contributing to CPRD 
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3) Death due to any cause 
4) The final date that data was collected from this practice by CPRD 
The censored patients contributed data until the date at which they left the study. 
Therefore, at any specified time-point following index date, a patient could be 
classified as being in one of three states, either: 
1) Having developed the event of interest 
2) Being at risk of the event of interest 
3) Having previously been lost to follow up (censored) 
When calculating the cumulative prevalence of each comorbidity, or the Charlson 
comorbidity index value, all diagnoses made prior to index date were included in 
order to better estimate health status at each time point following index date.  
 
6.2.6 Covariates 
Alcohol consumption 
Alcohol consumption is recorded within CPRD as units of alcohol consumed per 
week. The formula for determining units of alcohol per drink is: 
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑑𝑟𝑖𝑛𝑘 (𝑚𝑙) ∗
𝐴𝑙𝑐𝑜ℎ𝑜𝑙 𝑏𝑦 𝑣𝑜𝑙𝑢𝑚𝑒 (%)
1,000 (𝑚𝑙)
= 𝐴𝑙𝑐𝑜ℎ𝑜𝑙 𝑢𝑛𝑖𝑡𝑠 
A pint (568ml) of moderate strength (4%) beer will therefore contain 2.3 units of 
alcohol. Recent UK government guidelines have reduced the recommended 
maximum weekly intake of alcohol to 14 units for both men and women. (“UK 
Chief Medical Officers’ Low Risk Drinking Guidelines”, 2016) As levels of alcohol 
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consumption vary during a person’s life then data recorded in CPRD will also. 
Therefore, for this study the most recent occasion this information was recorded 
prior to index date was used, which follows the methodology of other CPRD 
studies. (Paskins et al., 2018) 
Furthermore, following the methods of Paskins et al. (2018) and C.-F. Kuo et al. 
(2016), the alcohol consumption data was converted into four categories. These 
categories were, 1) those who had never consumed alcohol or did not at that 
time, 2) those who consumed less than 10 units of alcohol per week, 3) those 
who consumed 10 or more units of alcohol per week and, finally, 4) those where 
the data was missing.  
 
Smoking status 
Similarly, the smoking status, if recorded by the primary care electronic health 
record, is included in CPRD. Again, the last time status was recorded prior to 
index date was used. Three categories were created, 1) those who had never 
smoked or were currently ex-smokers, 2) current smokers and 3) those in which 
the data was missing.  Again, this follows the methods used by Paskins et al. 
(2018) and C.-F. Kuo et al (2016). 
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Body mass index data 
Body mass index (BMI) is calculated using the equation: 
𝐵𝑀𝐼 =
𝑤𝑒𝑖𝑔ℎ𝑡 (𝑘𝑔)
ℎ𝑒𝑖𝑔ℎ𝑡(𝑚)2
 
Following previous CPRD studies, five categories were created for this data 1) 
“underweight” (BMI <18.5), 2) “normal” (BMI 18.5-24.9), 3) "overweight” (BMI 25-
29.9), 4) "obese” (BMI>=30) or 5) "missing”. The categories created in this study 
follow convention in the interpretation of BMI. (‘Health Survey for England 2015: 
Adult overweight and obesity’, 2015)  
 
6.2.7 Comorbidities 
The selection of comorbidities utilised a three-step process.  
 
Stage one 
The initial starting point for selection of comorbidities was the Charlson 
comorbidity index. (Charlson et al., 1994) This index contains 17 diagnostic 
categories across a range of health domains that are each assigned a value 
according to their severity. By adding the scores together for each patient an 
overview of an individual’s health status can be obtained. This index has 
previously been mapped from the International statistical classification of 
diseases and related health problems (ICD) 9 classification to Read codes and 
has been used in previous studies of comorbidities in the CPRD dataset. (Kuo et 
al., 2016) The index has also been used in a study of comorbidities in patients 
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with PMR, albeit the study in question was of a small prospectively recruited 
cohort in the United States. (Kremers et al., 2005)  
The Charlson index contains the following comorbidities (table 6-1): 
 
Table 6-1: Charlson comorbidity index 
Broad disease groups  Condition  Points  
Vascular  
   
Myocardial infarction 1 
Congestive heart failure 1 
Peripheral vascular disease 1 
Cerebrovascular accident 1 
Neurological   
 
Hemiplegia, paraplegia  2 * 
Dementia 1 
Respiratory   Chronic pulmonary disease 1 
Autoimmune, 
Rheumatological and 
Musculoskeletal 
Any connective tissue disease 1 
Gastroenterology   Peptic ulcer disease  1 
Mild Liver disease  2 
Moderate or severe liver disease  3 
Endocrine   Diabetes  1  
Diabetes with chronic complications  2 **  
Renal   Renal disease  2 
Neoplastic  Solid tumour, leukaemia, lymphoma 2  
Metastatic solid tumours 6 + 
Infectious Diseases   Acquired immunodeficiency 
syndrome  
6 
* If hemiplegia do not count CVA separately 
** Do not count DM separately 
+ If metastatic do not count cancer separately 
 
 
Patients with higher scores calculated using the Charlson index, have higher 
mortality rates over a ten year period. (Charlson et al., 1994) The score has been 
validated in other conditions, including in patients with acute coronary syndrome 
(Radovanovic et al., 2014) and those discharged from hospitals in six countries. 
(Quan et al., 2011) Although the Charlson index was based on secondary care 
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data, it has also been used in primary care to define comorbidities. (Crooks, West 
and Card, 2015) 
As previously discussed, only one study has previously assessed the prevalence 
of comorbidities in patients with PMR using all of the Charlson index. (Kremers 
et al., 2005) However, the systematic review in chapter 5 showed that a number 
of studies have considered the association between PMR and individual or small 
groups of comorbidities from within it. These include between PMR and vascular 
diseases,  (B A Bengtsson and Malmvall, 1981; Warrington et al., 2009; Kang, 
Sheu and Lin, 2011; Zoller et al., 2012; Hancock et al., 2014; Pujades-Rodriguez 
et al., 2016) neurological,  (Li, Sundquist and Sundquist, 2012) rheumatological, 
(Eaton et al., 2007) endocrine, (Bowness et al., 1991; Juchet et al., 1993; Eaton 
et al., 2007) and neoplastic conditions.  (Haga et al., 1993; L A Anderson et al., 
2009; Anderson and Engels, 2010; Lanoy, Costagliola and Engels, 2010; 
Jianguang et al., 2010; Kristinsson et al., 2010; Lindqvist et al., 2011; K. 
Hemminki, Liu, Ji, et al., 2012a; Kari Hemminki, Liu, Forsti, et al., 2012; Kari 
Hemminki, Liu, Ji, et al., 2012; Hemminki et al., 2013; M. Fallah et al., 2014; 
Mahdi Fallah et al., 2014; Muller et al., 2014; Pfefiffer et al., 2015; Bellan et al., 
2017) 
 
Stage two 
The second stage of composing the list of comorbidities that were included in this 
study involved augmenting the Charlson index with conditions for which there 
had been previously published research in PMR found as part of the systematic 
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review in chapter 5. These morbidities were in addition to those listed in the 
Charlson index.  
Studies had previously been performed that looked for associations between 
PMR and thyroid disease, (Bowness et al., 1991; Juchet et al., 1993) 
Schizophrenia and other psychoses, (Eaton et al., 2006; Chen et al., 2012) all 
autoimmune conditions, (Eaton et al., 2007) Parkinson’s disease, (Li, Sundquist 
and Sundquist, 2012) obesity, (Kari Hemminki, Li, et al., 2012) and overall 
mortality. (Gran et al., 2001; Doran et al., 2002; Uddhammar et al., 2002; 
Myklebust et al., 2003) 
Of the conditions listed, in all but one there was sufficient clinical equipoise to be 
important to investigate, and so were included in the study. The single exception 
to this was obesity as it is not an outcome in itself, rather a risk factor for other 
conditions.  
The comorbidities that were included, and the reasoning for the inclusion of each, 
are detailed in table 6-2.  
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Table 6-2: Additional comorbidities identified from systematic review 
Disease groups Condition Rationale 
Neurological  
 
Parkinson’s disease Potentially similar presentation-  
stiffness/rigidity  found in both 
conditions 
Autoimmune, 
Rheumatological 
and 
Musculoskeletal 
Systemic lupus 
erythematosus 
As per Eaton et al. (2007)  
 
Assess likelihood of any 
connective tissue disease.  
 
Also assess for the presence of 
individual diseases. 
 
Many inflammatory 
rheumatological conditions may 
present with a polymyalgic 
picture and therefore be 
misdiagnosed. 
Systemic sclerosis 
Rheumatoid arthritis  
Sjogren's syndrome  
Psoriatic arthritis 
Raynaud’s disease 
Endocrine  
 
Thyroid disease May share an autoimmune 
pathway 
Psychiatric  
 
Schizophrenia 
May be linked to steroid usage Bipolar affective 
disorder 
Mortality The Charlson index aims to predict mortality therefore is 
not part of the index; however useful to investigate 
formally. 
 
 
Many of the conditions listed above form part of the differential diagnosis of 
polymyalgia rheumatica. In fact, as discussed previously, it is explicit in clinical 
classification criteria that most of these conditions be excluded prior to making a 
diagnosis of PMR. (Dasgupta et al., 2010, 2012) Therefore it is important to know 
with what regularity these morbidities coexist with PMR. Furthermore, this would 
provide information on whether GPs are in fact adhering to guidelines used for 
the diagnosis of PMR. If they are, it is likely that in patients with PMR, a previous 
diagnosis with one of the conditions listed as exclusions, such as cancer, would 
be much less likely.  
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Stage three 
Finally, the third stage in the identification of comorbidities that were assessed in 
this study involved discussion with experts in the diagnosis and management of 
PMR. These experts included three clinically and research active Consultant 
Rheumatologists, as well as discussion with two clinically active academic 
General Practitioners with extensive experience of co-ordinating studies on, and 
publishing results from, multiple research projects around the subject of PMR. 
A number of recommendations were made. First, to expand the list of 
comorbidities to include conditions that could be side effects or a complication of 
long-term glucocorticoid (GC) treatment.  The second recommendation was to 
include other extra-articular autoimmune conditions that may share a causative 
pathway with PMR. This hypothesis for this was that autoimmune diseases often 
coexist, for example rheumatoid arthritis and thyroid disease. (Somers et al., 
2006)  
The final recommendation was to, where possible, assess combined, or 
composite, outcomes as well as stratified comorbidities within disease 
categories. This meant combining outcomes from the final list of comorbidities 
into broad categories and assessing whether individuals had any event from 
within that category. The reason for this was to increase the sample size and 
therefore power to detect whether an effect exists. Some of the categories, for 
example autoimmune conditions, included conditions that are rarely diagnosed, 
therefore aggregating outcomes increased the statistical power of the test. 
 165 
 
The additions to the list of comorbidities that were suggested by the expert group 
are detailed in table 6-3 and the final list of stratified individual comorbidities and 
composite outcomes are shown in tables 6-4 and 6-5. 
Table 6-3: Comorbidities suggested following expert review 
Disease group Condition Rationale 
Vascular  Hypertension Linked to steroid usage 
Respiratory  Pulmonary fibrosis  Autoimmune condition 
Rheumatological 
and 
Musculoskeletal 
Osteoarthritis Similar symptom profile 
Osteoporosis Linked to steroid usage 
Hip fracture  
Radius fracture  
Vertebral fracture  
Gastroenterology  Inflammatory bowel 
diseases- IBD/Crohn’s 
Autoimmune conditions 
Endocrine  Addison’s disease  
Type One Diabetes Mellitus 
Infectious 
Diseases  
Urinary Tract Infection  Linked to impaired 
immunity and therefore 
steroid usage 
Upper Respiratory Tract 
Infection  
Lower Respiratory Tract 
Infection  
Cellulitis  
Ophthalmology Cataracts  Linked to steroid usage  
Glaucoma  
Psychiatry Depression  
Anxiety 
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Table 6-4: Final list of individual comorbidities for assessment 
Disease Group  Condition   Disease Group Condition   Disease Group  Condition  
Vascular   Myocardial infarction  Respiratory  COPD Gastroenterology  Peptic ulcer disease  
Congestive heart  
failure 
Chronic pulmonary  
disease + 
Moderate or severe  
liver disease 
Peripheral vascular  
disease  
Asthma Crohn’s disease 
Pulmonary fibrosis Ulcerative colitis 
Cerebrovascular  
accident  
Endocrine  
   
Diabetes +  Infectious Diseases   Acquired  
immunodeficiency  
syndrome + 
Diabetes with 
chronic 
complications +  
Hypertension 
Neurological Hemiplegia,  
paraplegia + 
Urinary Tract 
Infection * Type 1 diabetes 
mellitus Dementia Upper Respiratory 
Tract Infection * Parkinson’s disease Type 2 diabetes 
mellitus* Multiple sclerosis Lower Respiratory 
Tract Infection * Rheumatology 
and  
Musculoskeletal   
Systemic Lupus  
Erythematosus 
Hyperthyroidism 
Hypothyroidism Cellulitis * 
Systemic sclerosis Addison’s disease  Psychiatric   Schizophrenia 
Rheumatoid Arthritis Renal   Renal disease  Bipolar 
Sjogren's syndrome Neoplastic  Breast cancer  Depression 
Psoriatic arthritis Prostate cancer Anxiety 
Raynaud’s disease Lung cancer Ophthalmology   Cataracts * 
Osteoarthritis Colorectal cancer Glaucoma *  
Osteoporosis * Melanoma    
Hip fracture * Leukaemia, 
Radius fracture *  lymphoma 
Vertebral fracture * Metastatic solid 
tumours + 
Any other cancer 
+ Only used in calculation of Charlson index       * Prospective or related to GC dosage 
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Table 6-5: Composite comorbid outcomes for assessment 
Disease Group Outcomes included 
Cancer Breast, prostate, lung, colorectal, melanoma, 
leukaemia, lymphoma, or any other cancer  
Vascular Myocardial infarction, chronic heart failure, peripheral 
vascular disease, or cerebrovascular disease 
Respiratory Asthma, COPD, or lung fibrosis 
Gastroenterological Moderate liver disease, severe liver disease, peptic 
ulcers, Crohn’s disease, or ulcerative colitis 
Autoimmune Systemic lupus erythematosus, systemic sclerosis, 
rheumatoid arthritis, Sjogren’s syndrome, psoriatic 
arthritis, or Raynaud’s disease 
Endocrine  Hyperthyroidism, hypothyroidism, type 1 diabetes 
mellitus, type 2 diabetes mellitus, or Addison’s disease 
Neurologic Dementia, Parkinson’s disease, or multiple sclerosis 
Psychiatric Schizophrenia, bipolar affective disorder, depression, or 
anxiety 
Ophthalmology Cataracts or glaucoma 
Infections Urinary tract infection, upper respiratory tract infection, 
lower respiratory tract infection, or skin infection 
Fragility fractures Hip fracture, wrist fracture, or vertebral fracture 
 
Of this list of individual comorbidities, (table 6-4) not all the outcomes were 
individually reported. A small number of outcomes (n=6) are marked as only to 
be used as part of the Charlson index. There were two main reasons for excluding 
them from the main analysis. The first was in the case of conditions which are 
both rare and unlinked to autoimmune conditions, such as hemiplegia and 
paraplegia, which, following expert review, were not considered to have sufficient 
clinical equipoise. The second reason was where overlap exists between disease 
outcomes. For example, the Charlson index contains diabetes and diabetes with 
chronic complications; whereas following expert review it was felt more useful to 
assess the rates of type 1 and type 2 diabetes. In order that cases were not 
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counted multiple times, these comorbidities were used to calculate the Charlson 
index score but not reported individually.  
One outcome was omitted from both the case control and cohort studies. This 
was mortality. Mortality cannot be included in the case control study, as it must 
occur prospectively following diagnosis. It is not included in the cohort study as, 
although CPRD does contain information about date of death, detailed 
information is only included as part of a linked database to which not all CPRD 
patients are part of. This database is the Office for National Statistics Death 
registration data and will be analysed in a later study (chapter 7). Finally, when 
there were very small numbers of patients (cell count <5) within a category the 
results were reported as (<5) to preserve patient anonymity. 
The composite outcomes by disease groups (table 6-5) differs slightly to the 
individual outcomes listed in table 6-4, for example hypertension was not 
included as a vascular endpoint, as, although it is a disease in itself, it is not an 
outcome. 
As discussed in chapter two, each Read code has a unique medical code to 
identify it in the CPRD database. The total number of medical codes used in this 
study was 7,164, and the process used to identify them was described in chapter 
2.11. 
 
6.2.8 Statistical analysis 
Case Control analysis 
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For the case control study, conditional logistic regression was used to calculate 
the likelihood of a participant with or without PMR having previously been 
diagnosed with a comorbid disease. This likelihood will be expressed as an odds 
ratio with confidence intervals, which will be set at the 95% level. A confidence 
interval is an estimate of the values between which the true, population, value 
will lie. Setting the interval at 95% means there is a 1 in 20 chance of the true 
population mean lying outside these values. In the case of an odds ratio, if the 
confidence interval does not cross the value of 1, then the difference is regarded 
as being statistically significant. Furthermore, in addition to this, the width of a 
confidence interval provides further information on the precision of the estimate. 
(Prel et al., 2009)  
Logistic regression was used as it is the method of choice for examining 
associations in case-control studies when the outcome is dichotomous: i.e. 
predicting whether a subject is a case or control. The output is expressed in terms 
of coefficients, which are interpreted as giving the change in the log of the odds 
of being a case, per unit change in the risk factor considered. Conditional logistic 
regression is a variant of logistic regression that also enables control for the 
effects of potentially confounding variables in addition to those used in matching. 
(Silman and Macfarlane, 2002) Conditional logistic analysis differs from regular 
logistic regression in that the data are grouped and the likelihood is calculated 
relative to each group; that is, a conditional likelihood is used. Unadjusted odds 
ratios were calculated as well as ratios adjusted for confounding variables. The 
covariates used to calculate adjusted ratios were smoking status, alcohol 
consumption and BMI category. The reference categories used for each of the 
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covariates in the conditional logistic model were non-smokers, no alcohol 
consumption and those with normal BMI. 
 
Cohort analysis 
For the cohort study, the Charlson index score and cumulative probability of the 
stratified and composite comorbidities were calculated at index date and four 
further time points following this. The time points were at one, two, five and ten 
years after index date. This follows the methods used by Kuo et al (2016). The 
cumulative probability of disease is defined as an estimate of the total number of 
patients with the comorbidity (numerator) divided by the total number of patients 
contributing data to the study during that time period (denominator). This method 
takes into account loss to follow up and also provides 95% confidence intervals.  
Two functions are of particular interest when analysing study data, which is 
dependent on time. These are the cumulative survival function S(t) and the 
hazard function h(t). These functions can be broadly regarded as inverse to each 
other, in that S(t) is the probability of surviving without developing the condition 
up to the time-point t, while h(t) is the probability of developing it at that time 
having survived to without developing it up to that point.  In this study the h(t), the 
cumulative probability of comorbid disease development, and time to 
development of each comorbidity will be reported. 
In order to assess the likelihood of prospectively developing a comorbidity in the 
cohort study, the Cox regression model was utilised. This is also known as 
proportional hazards regression, because of the assumptions required to fit this 
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model. This model is used when the time to the development of an event, 
“survival time”, is the outcome of interest. Predictor variables can be binary, 
categorical or continuous. (Silman and Macfarlane, 2002) 
Survival time was initially synonymous with survival until death, however the 
technique has been extended to include time until a particular event, in this case 
development of a comorbidity. The model was used to calculate hazard ratios 
(HRs) for the likelihood of comorbidity in exposed (patients with PMR) compared 
to non-exposed (patients without PMR) groups. As in the logistic regression 
model used in the case control analysis, the hazard ratios were calculated 
unadjusted as well as adjusted, for smoking status, alcohol consumption and 
body mass index (BMI) category with 95% significance levels. In addition to these 
covariates, and in contrast to the conditional logistic regression, the hazard ratios 
were also adjusted for the matching variables age and sex, as the Cox model 
does not inherently account for the matched study design.  
Using Cox regression model is superior to simple analysis such as the average 
(mean) survival time for a number of reasons. Firstly, survival data is rarely 
distributed Normally therefore simple methods would give an incomplete picture. 
Furthermore, Cox regression is able to take into account differential amounts of 
follow up. It is inevitable during a prolonged follow up period that not all study 
participants will experience an event prior to the end of the study period. These 
patients, who are ‘lost to follow up’ for a number of different reasons, as 
discussed in chapter 6.2.5, are taken into account by Cox regression. 
Kaplan-Meier methods (Kaplan and Meier, 1958) are an effective way of 
estimating survival, or time without development of condition of interest. 
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However, it is limited to univariate analysis and therefore covariates or potential 
confounding factors cannot be included in the model. The Cox regression model 
(Cox, 1972) is superior in that multiple potential explanatory covariates, or 
confounders, can be included in the model to assess their influence on the 
likelihood of developing an event of interest over time.  
However, there are several assumptions that underpin Cox regression model: 
1) The first assumption is that the baseline hazard function is constant and 
common to all subjects in all of the comparison groups. The hazard 
function, i.e. the risk of developing the event of interest, for each group is 
the product of this baseline hazard and the predictors, or covariates. Thus, 
the covariates do not act on the baseline hazard function, only on the 
subsequent group-specific hazard function. 
2) The second assumption is that of proportional hazards, i.e. that the hazard 
ratio does not vary with time following index date. This assumption means 
that if the risk of developing a comorbidity in the exposed group is 50% 
higher than in the non-exposed group, then this excess risk will remain the 
same throughout the study period. 
3) The third assumption is that the censoring of data is non-informative, that 
is to say it is independent of the outcome. For example, in this study, there 
was no requirement for a specific follow up time after the index date. This 
was to prevent the exclusion of patients where the reason for their leaving 
the study was associated with an outcome of interest. For example if they 
died due to a myocardial infarct soon after index date 
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Finally, in order to test whether the hazards remain proportional, i.e. do not vary 
over time, Kaplan Meier methods were used to graphically plot and visualise the 
survival estimates over time. Furthermore, the models were fitted with robust 
standard errors, which offer greater resistance to outliers. (Huber, 1972) 
When calculating hazard ratios and Kaplan-Meier plots to describe the likelihood 
of a diagnosis with a comorbidity, all patients with a pre-existing diagnosis with 
that comorbidity were excluded from the analysis. This was to ensure the 
likelihood measure reported was of incident diagnosis following index date rather 
than the likelihood of, or time until, a patient had another record of a comorbidity 
in their EHR. This meant that each comorbidity had different denominators, these 
were calculated and reported. 
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6.3 Results 
6.3.1 Study demographics 
A total of 5.3 million patients who were actively contributing data to CPRD and 
aged over 40 during the study period were initially included in this study. From 
this initial sample, 42,145 PMR cases were identified, as described in chapter 4. 
Of these, 31,984 (75.9%) were matched to 149,436 controls, who fulfilled the 
previously outlined matching criteria. If a case had two or fewer matched controls, 
neither the cases nor controls were included. Demographic data collected for 
each patient included mean age at index date, sex, region of GP practice, 
smoking status, BMI category, alcohol consumption and the total time each 
patient actively contributed data to the study. The time each patient contributed 
was also stratified to before and after index date. This data is presented in table 
6-6.  
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Table 6-6: Demographic information for comorbidities study  
Total Cases Controls 
Observations 181,420 31,984 149,436 
Age at diagnosis (years) 
  
Mean (SD) 73.4 (8.9) 73.7 (9.0) 73.3 (8.8) 
Min / Max 43.0 / 100.3 43.0 / 100.3 43.0 / 99.8 
Sex (%) 
   
Male 58,818 (32.4) 10,596 (33.1) 48,222 (32.3) 
Female 122,602 (67.6) 21,388 (66.9) 101,214 (67.7) 
Region (%) 
   
North East  2,307 (1.3) 404 (1.3) 1,903 (1.3) 
North West 17,681 (9.7) 3,108 (9.7) 14,573 (9.8) 
Yorkshire & the Humber 5,376 (3.0) 964 (3.0) 4,412 (3.0) 
East Midlands 6,624 (3.7) 1,151 (3.6) 5,473 (3.7) 
West Midlands 18,967 (10.5) 3,297 (10.3) 15,670 (10.5) 
East of England 19,878 (11.0) 3,458 (10.8) 16,420 (11.0) 
South West 19,991 (11.0) 3,530 (11.0) 16,461 (11.0) 
South Central 19,958 (11.0) 3,545 (11.1) 16,413 (11.0) 
London 11,028 (6.1) 2,044 (6.4) 8,984 (6.0) 
South East Coast 21,574 (11.9) 3,823 (12.0) 17,751 (11.9) 
Northern Ireland 4,757 (2.6) 822 (2.6) 3,935 (2.6) 
Scotland 13,954 (7.7) 2,475 (7.7) 11,479 (7.7) 
Wales 19,325 (10.7) 3,363 (10.5) 15,962 (10.7) 
Total time at risk 
  
Mean (SD) 14.8 (5.5) 15.6 (5.4) 14.7 (5.5) 
Min / Max 3.0 / 27.0 3.2 / 27.0 3.0 / 27.0 
Pre-index date time at risk 
  
Mean (SD) 9.9 (5.0) 10.2 (5.1) 9.8 (5.0) 
Min / Max 3.0 / 26.9 3.0 / 26.9 3.0 / 26.9 
Post-index date time at risk 
  
Mean (SD) 5.0 (3.9) 5.4 (4.0) 4.9 (3.9) 
Min / Max 0.0 / 24.0 0.0 / 23.7 0.0 / 24.0 
BMI category (%)    
Normal (18.5-24.9) 57,080 (31.5) 9,998 (31.3) 47,082 (31.5) 
Underweight (<18.5) 3,291 (1.8) 401 (1.3) 2,890 (1.9) 
Overweight (25-29.9) 61,072 (33.7) 11,605 (36.3) 49,467 (33.1) 
Obese (>=30) 36,309 (20.0) 6,884 (21.5) 29,425 (19.7) 
Missing 23,668 (13.0) 3,096 (9.7) 20,572 (13.8) 
Smoking (%)    
Never/ex-smoker  149,851 (82.6) 27,603 (86.3) 122,248 (81.8) 
Smoker 21,070 (11.6) 3,218 (10.1) 17,852 (11.9) 
Missing 10,499 (5.8)  1,163 (3.6)  9,336 (6.2)  
Alcohol (%)    
Never/ex drinker 38,397 (21.2) 6,714 (21.0) 31,683 (17.5) 
<10 units per week 93,227 (51.4) 17,256 (54.0) 75,971 (41.9) 
10 or more units per week 24,997 (13.8) 4,551 (14.2) 20,446 (11.3) 
Missing 24,799 (13.7) 3,463 (10.8) 21,336 (11.8) 
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The average age at diagnosis, sex and region of GP practice were similar for 
both cases and controls, reflecting the matching criteria that were applied. 
Furthermore, the average age of the matched cases (73.7 years) was also almost 
identical to the mean age of cases in chapter 4 (73.8 years). This indicates that 
the matching process did not change the average age of study participants. The 
average length of time each patient contributed to the study was slightly different. 
The overall mean observation period was 14.8 years [standard deviation (SD) 
5.52], however for cases this figure was 15.6 years [SD 5.4] and for controls this 
was 14.7 years [SD 5.5].  
The three disease risk modifiers, BMI, smoking and alcohol consumption, were 
broadly similar between cases and controls. The main points of difference were 
that the data was more likely to be recorded in cases compared to controls for all 
the covariates. Furthermore, a higher proportion of cases were recorded as 
drinking greater than 10 units of alcohol per week (14.2% vs 11.3%). However, 
in the case of smoking, this situation was reversed and patients from the control 
group were more likely to be recorded as smokers in comparison to cases (10.1% 
vs 11.9%).  
 
6.3.2 Case control study 
Due to the large number of outcomes reported in this study, a number of 
abbreviations have been used in the table to improve formatting. The 
abbreviations are shown in table 6-7.  
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Table 6-7: Abbreviations for comorbid outcomes 
Comorbidity Abbreviation 
Leukaemia, lymphoma LL 
Cardiovascular disease CVD 
Congestive cardiac failure CCF 
Peripheral vascular disease PVD 
Cerebrovascular disease CVA 
Hypertension HTN 
Chronic obstructive pulmonary disease COPD 
Ulcerative colitis UC 
Systemic lupus erythematosus SLE 
Rheumatoid arthritis RA 
Osteoarthritis OA 
Type 1 Diabetes mellitus T1DM 
Type 2 Diabetes mellitus T2DM 
Multiple sclerosis MS 
Urinary tract infection UTI 
Upper respiratory tract infection URTI 
Lower respiratory tract infection LRTI 
 
The case control study included data on the prevalence of comorbidities in 
patients with PMR compared to their matched controls at three time points prior 
to index date (five years, two years and one year). The overall comorbidity burden 
that cases and controls were subjected to was estimated using the Charlson 
index score. The number, and proportion, of patients with each score were 
reported. Due to small numbers, all patients with a Charlson score of greater than 
5 were aggregated. The composite outcomes and Charlson index scores are 
summarised in table 6-8. 
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Table 6-8: Prevalence of composite outcomes and Charlson Index score (total number of cases and %) at specified time points 
prior to index date  
5y 2y 1y  
Charlson score Case Control Case Control Case Control 
0 13,640 (51.2) 65,882 (54.5) 13,952 (43.6) 70,405 (47.1) 12,974 (40.6) 66,094 (44.2) 
1 6,718 (25.2) 27,607 (22.8) 7,953 (24.9) 33,699 (22.6) 7,776 (24.3) 33,216 (22.2) 
2 3,667 (13.8) 15,716 (13.0) 5,125 (16.0) 23,278 (15.6) 5,421 (16.9) 24,431 (16.3) 
3 1,595 (6.0) 6,959 (5.8) 2,650 (8.3) 11,631 (7.8) 2,979 (9.3) 12,974 (8.7) 
4 649 (2.4) 2,880 (2.4) 1,315 (4.1) 5,676 (3.8) 1,542 (4.8) 6,645 (4.4) 
5 231 (0.9) 1,089 (0.9) 602 (1.9) 2,671 (1.8) 763 (2.4) 3,272 (2.2) 
Greater than 5 133 (0.5) 736 (0.6) 387 (1.2) 2,076 (1.4) 529 (1.7) 2,804 (1.9) 
Composite outcomes       
Cancer  2,118 (8.0) 10,246 (8.5) 3,287 (10.3) 16,455 (11.0) 3,627 (11.3) 18,233 (12.2) 
Vascular 4,964 (18.6) 21,065 (17.4) 7,443 (23.3) 32,462 (21.7) 8,003 (25.0) 34,888 (23.3) 
Respiratory 5,525 (20.7) 20,952 (17.3) 7,387 (23.1) 28,888 (19.3) 7,754 (24.2) 30,189 (20.2) 
Gastroenterological 1,621 (6.1) 7,060 (5.8) 2,211 (6.9) 9,706 (6.5) 2,325 (7.3) 10,091 (6.8) 
Immunological 1,212 (4.6) 4,445 (3.7) 1,728 (5.4) 6,278 (4.2) 1,874 (5.9) 6,659 (4.5) 
Endocrine 4,778 (17.9) 19,116 (15.8) 6,814 (21.3) 28,260 (18.9) 7,297 (22.8) 30,066 (20.1) 
Neurological 178 (0.7) 1,912 (1.6) 318 (1.0) 4,106 (2.7) 397 (1.2) 4,973 (3.3) 
Psychiatric 5,700 (21.4) 23,398 (19.4) 7,375 (23.1) 31,208 (20.9) 7,666 (24.0) 32,381 (21.7) 
Ophthalmological 2,519 (9.5) 10,208 (8.4) 3,620 (11.3) 14,573 (9.8) 4,061 (12.7) 16,203 (10.8) 
Infections 15,415 (57.9) 62,948 (52.1) 18,043 (56.4) 74,643 (49.9) 18,754 (58.6) 77,799 (52.1) 
Fragility fractures 1,342 (5.0) 6,337 (5.2) 1,592 (5.0) 7,685 (5.1) 1,701 (5.3) 8,208 (5.5) 
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Charlson Index 
Overall comorbidity burden, as measured by Charlson comorbidity index, was 
found to be higher prior to index date in cases compared to controls. A higher 
proportion of controls had a Charlson score of zero at all three time points when 
compared to cases (5y: 54.5% vs 51.2%, 2y: 47.1% vs 43.6% and 1y: 44.2% vs 
40.6%). Furthermore, the proportion of cases who had a Charlson index score of 
1-5 was higher at all three time points when compared to controls. However, 
although the numbers were small, a smaller proportion of cases had a Charlson 
index score greater than five compared to controls.  
 
Composite Outcomes 
In eight of the combined categories (vascular, respiratory, gastroenterological, 
immunological, endocrine, psychiatric, ophthalmological and infectious diseases) 
the prevalence of existing disease was higher in cases compared to controls at 
all three time points prior to index date. Conversely, three categories were 
associated with a reduced prevalence of comorbid disease in cases compared 
to controls at each time point prior to index date. These categories were cancer, 
neurological diseases and fragility fractures. Of the outcomes that could be 
related to GC therapy, two were higher in the case group (ophthalmologic 
diseases and infections), while one (fragility fractures) were more prevalent 
among controls. To look into further detail of these findings, the stratified 
outcomes are summarised in table 6-9.  
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Table 6-9: Prevalence of stratified comorbidities at specified time points prior to index date (total number of cases and %)    
5y 2y 1y   
Case Control Case Control Case Control 
Cancer       
Breast cancer 600 (2.3) 2,943 (2.4) 823 (2.6) 4,418 (3.0) 875 (2.7) 4,758 (3.2) 
Prostate cancer 160 (0.6) 805 (0.7) 320 (1.0) 1,512 (1.0) 380 (1.2) 1,747 (1.2) 
Lung cancer 22 (0.1) 135 (0.1) 45 (0.1) 261 (0.2) 57 (0.2) 357 (0.2) 
Colon cancer 207 (0.8) 1,014 (0.8) 327 (1.0) 1,650 (1.1) 378 (1.2) 1,870 (1.3) 
Melanoma 187 (0.7) 845 (0.7) 273 (0.9) 1,241 (0.8) 297 (0.9) 1,336 (0.9) 
LL 111 (0.4) 684 (0.6) 190 (0.6) 1,241 (0.8) 205 (0.6) 1,397 (0.9) 
Vascular 
CVD 3,437 (12.9) 13,656 (11.3) 4,909 (15.3) 19,976 (13.4) 5,193 (16.2) 21,123 (14.1) 
CCF 644 (2.4) 2,763 (2.3) 1,203 (3.8) 5,356 (3.6) 1,403 (4.4) 6,196 (4.1) 
PVD 712 (2.7) 3,091 (2.6) 1,146 (3.6) 5,159 (3.5) 1,286 (4.0) 5,701 (3.8) 
CVA  1,221 (4.6) 6,203 (5.1) 2,085 (6.5) 10,542 (7.1) 2,344 (7.3) 11,700 (7.8) 
HTN 10,664 (40.0) 45,133 (37.3) 14,921 (46.7) 64,312 (43.0) 15,711 (49.1) 67,636 (45.3) 
Respiratory 
 
Asthma 3,510 (13.2) 12,927 (10.7) 4,713 (14.7) 17,630 (11.8) 4,898 (15.3) 18,327 (12.3) 
COPD 2,873 (10.8) 11,330 (9.4) 4,017 (12.6) 16,365 (11.0) 4,310 (13.5) 17,450 (11.7) 
Lung fibrosis 64 (0.2) 223 (0.2) 124 (0.4) 405 (0.3) 166 (0.5) 483 (0.3) 
Renal  
Renal disease 1,092 (4.1) 4,539 (3.8) 2,686 (8.4) 11,027 (7.4) 3,362 (10.5) 13,653 (9.1) 
Gastroenterological 
Liver disease 157 (0.6) 837 (0.7) 239 (0.7) 1,302 (0.9) 270 (0.8) 1,426 (1.0) 
Peptic ulcers 1,131 (4.2) 4,898 (4.1) 1,501 (4.7) 6,608 (4.4) 1,552 (4.9) 6,800 (4.6) 
Crohn's disease 74 (0.3) 353 (0.3) 100 (0.3) 490 (0.3) 107 (0.3) 505 (0.3) 
UC 315 (1.2) 1,176 (1.0) 447 (1.4) 1,611 (1.1) 479 (1.5) 1,691 (1.1) 
Autoimmune and musculoskeletal 
SLE 24 (0.1) 129 (0.1) 37 (0.1) 182 (0.1) 38 (0.1) 190 (0.1) 
Systemic sclerosis 21 (0.1) 58 (0.0) 21 (0.1) 89 (0.1) 23 (0.1) 93 (0.1) 
RA 694 (2.6) 2,666 (2.2) 971 (3.0) 3,719 (2.5) 1,041 (3.3) 3,914 (2.6) 
Sjogren’s syndrome 57 (0.2) 188 (0.2) 91 (0.3) 282 (0.2) 98 (0.3) 311 (0.2) 
Psoriatic arthritis 116 (0.4) 361 (0.3) 160 (0.5) 529 (0.4) 173 (0.5) 565 (0.4) 
Raynaud's disease 297 (1.1) 1,118 (0.9) 445 (1.4) 1,649 (1.1) 501 (1.6) 1,786 (1.2) 
Osteoarthritis 10,009 (37.6) 38,092 (31.5) 13,888 (43.4) 53,979 (36.1) 14,776 (46.2) 57,048 (38.2) 
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5y 2y 1y   
Case Control Case Control Case Control 
Endocrine 
      
Hyperthyroidism 509 (1.9) 2,049 (1.7) 678 (2.1) 2,810 (1.9) 698 (2.2) 2,936 (2.0) 
Hypothyroidism 2,433 (9.1) 8,097 (6.7) 3,424 (10.7) 11,884 (8.0) 3,670 (11.5) 12,665 (8.5) 
T1DM 144 (0.5) 619 (0.5) 190 (0.6) 858 (0.6) 198 (0.6) 902 (0.6) 
T2DM 1,684 (6.3) 8,235 (6.8) 2,672 (8.4) 13,104 (8.8) 2,938 (9.2) 14,252 (9.5) 
Addison's disease 13 (0.0) 42 (0.0) 18 (0.1) 62 (0.0) 20 (0.1) 68 (0.0) 
Neurological 
Dementia 20 (0.1) 532 (0.4) 78 (0.2) 1,936 (1.3) 132 (0.4) 2,651 (1.8) 
Parkinson's disease 74 (0.3) 623 (0.5) 133 (0.4) 1,232 (0.8) 158 (0.5) 1,419 (0.9) 
MS 46 (0.2) 347 (0.3) 59 (0.2) 453 (0.3) 60 (0.2) 456 (0.3) 
Psychiatric       
Schizophrenia 38 (0.1) 464 (0.4) 53 (0.2) 648 (0.4) 53 (0.2) 666 (0.4) 
Bipolar disease 36 (0.1) 232 (0.2) 57 (0.2) 345 (0.2) 58 (0.2) 358 (0.2) 
Depression 4,334 (16.3) 17,607 (14.6) 5,623 (17.6) 23,676 (15.8) 5,862 (18.3) 24,597 (16.5) 
Anxiety 3,088 (11.6) 12,636 (10.5) 4,034 (12.6) 17,001 (11.4) 4,226 (13.2) 17,736 (11.9) 
Complications due to glucocorticoids 
Osteoporosis 1,205 (4.5) 4,949 (4.1) 2,061 (6.4) 8,728 (5.8) 2,349 (7.3) 9,882 (6.6) 
Hip fracture 139 (0.5) 912 (0.8) 258 (0.8) 1,854 (1.2) 307 (1.0) 2,186 (1.5) 
Wrist fracture 1,200 (4.5) 5,389 (4.5) 1,621 (5.1) 7,534 (5.0) 1,705 (5.3) 7,919 (5.3) 
Vertebral fracture 33 (0.1) 198 (0.2) 59 (0.2) 326 (0.2) 71 (0.2) 363 (0.2) 
Ophthalmological       
Cataracts 1,629 (6.1) 6,455 (5.3) 2,968 (9.3) 11,955 (8.0) 3,400 (10.6) 13,629 (9.1) 
Glaucoma 1,059 (4.0) 4,455 (3.7) 1,638 (5.1) 7,029 (4.7) 1,800 (5.6) 7,620 (5.1) 
Infections       
UTI 3,778 (14.2) 15,417 (12.8) 5,417 (16.9) 22,534 (15.1) 5,848 (18.3) 24,518 (16.4) 
URTI 13,692 (51.4) 54,512 (45.1) 18,248 (57.1) 74,708 (50.0) 19,227 (60.1) 78,927 (52.8) 
LRTI 649 (2.4) 2,733 (2.3) 973 (3.0) 4,091 (2.7) 1,061 (3.3) 4,407 (2.9) 
Skin infections 2,366 (8.9) 9,685 (8.0) 3,578 (11.2) 15,261 (10.2) 3,991 (12.5) 16,993 (11.4) 
Abbreviations: Leukaemia, lymphoma (LL), Cardiovascular disease (CVD), Congestive cardiac failure (CCF), Peripheral vascular disease (PVD), 
Cerebrovascular disease (CVA), Hypertension (HTN), Chronic obstructive pulmonary disease (COPD), Ulcerative colitis (UC), systemic lupus erythematosus 
(SLE), Rheumatoid arthritis (RA), Osteoarthritis (OA), Type 1 Diabetes mellitus (T1DM), Type 2 Diabetes mellitus (T2DM), Multiple sclerosis (MS), Urinary 
tract infection (UTI), Upper respiratory tract infection (URTI), Lower respiratory tract infection (LRTI) 
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Stratified outcomes 
When outcomes were stratified into individual comorbidities, the patterns present 
were broadly similar to composite outcomes, however there were some 
exceptions. 
 
Cancer 
In all but one of the stratified comorbidities, the prevalence of cancer was higher 
in controls compared to cases, albeit the differences were small. The single 
comorbidity in which this did not occur was melanoma, a type of skin cancer. In 
this case, the prevalence was similar at 5 and 1 years prior to index date and 
slightly higher among cases (0.9% vs 0.8%) two years prior to index date.  
 
Vascular 
A higher prevalence of vascular disease was seen among cases compared to 
controls. However, cerebrovascular disease bucked this trend and was actually 
slightly more prevalent in controls rather than cases. This difference persisted 
throughout each time point (5y: 5.1% vs 4.6%, 2y: 7.1% vs 6.5% and 1y: 7.8% 
vs 7.3%). However, the prevalence of other measured vascular outcomes, such 
as cardiovascular and peripheral vascular disease was higher at every time point 
among cases when compared to controls. 
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Other comorbidities 
All the stratified respiratory, autoimmune and musculoskeletal outcomes, 
including asthma, COPD, lung fibrosis, SLE, systemic sclerosis, rheumatoid 
arthritis, Sjogren’s disease, psoriatic arthritis, Raynaud’s disease and 
osteoarthritis, had higher prevalence in cases compared to controls.  
There was some divergence between composite and stratified outcomes in the 
case of gastroenterological, endocrine and psychiatric diagnoses. Despite the 
fact that, overall, these diagnoses had a higher prevalence in cases compared to 
controls, it was found that in the stratified outcomes of liver disease, type two 
diabetes, schizophrenia and bipolar disease, that prevalence was actually higher 
in controls. In the case of neurological outcomes, all were more common in 
controls when compared to cases. 
 
Comorbidities linked to GC prescription 
Although this study looked retrospectively, prior to diagnosis with PMR, the risk 
of comorbidities that were linked to GC therapy were also included. Within these, 
the proportion of patients who developed each type of infectious and 
ophthalmological comorbidity was higher among cases when compared to 
controls. Regarding the risk of fracture, the picture was more mixed. Although the 
proportion of patients with a diagnosis of osteoporosis was greater among cases 
when compared to controls, the proportion who had a recorded hip fracture was 
lower in cases. The proportion who had a record of either a wrist or vertebral 
fracture was similar between cases and controls.  
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In order to ascertain whether these differences in prevalence of comorbidities in 
patients with PMR and their matched controls is significantly different, conditional 
logistic regression was used to calculate odds ratios with 95% confidence 
intervals (both crude and adjusted for BMI category, sex, smoking status and 
alcohol consumption). The results of the composite outcomes are summarised in 
table 6-10. 
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Table 6-10: Odds ratios (with 95% confidence intervals) PMR vs controls of composite outcomes at time points prior to index date 
calculated using conditional logistic regression  
5y  2y  1y  
 
Unadjusted 
odds ratio 
Adjusted odds 
ratio 
Unadjusted 
odds ratio 
Adjusted odds 
ratio 
Unadjusted 
odds ratio 
Adjusted odds 
ratio 
Cancer 0.92 (0.87,0.97) 0.91 (0.86,0.95) 0.91 (0.88,0.95) 0.90 (0.87,0.94) 0.91 (0.87,0.94) 0.89 (0.86,0.93) 
Vascular 1.05 (1.02,1.09) 1.03 (0.99,1.07) 1.07 (1.04,1.10) 1.04 (1.01,1.07) 1.07 (1.04,1.10) 1.04 (1.01,1.07) 
Respiratory 1.25 (1.20,1.29) 1.22 (1.18,1.26) 1.26 (1.22,1.30) 1.23 (1.20,1.27) 1.27 (1.23,1.31) 1.24 (1.21,1.28) 
Gastroenterological 1.03 (0.97,1.09) 1.03 (0.97,1.09) 1.06 (1.01,1.11) 1.05 (1.00,1.10) 1.07 (1.02,1.12) 1.06 (1.02,1.12) 
Autoimmune 1.25 (1.17,1.33) 1.23 (1.15,1.31) 1.31 (1.24,1.38) 1.29 (1.22,1.36) 1.34 (1.27,1.42) 1.32 (1.25,1.39) 
Endocrine 1.17 (1.13,1.21) 1.14 (1.10,1.18) 1.17 (1.13,1.20) 1.13 (1.10,1.17) 1.18 (1.15,1.22) 1.14 (1.11,1.18) 
Neurological 0.40 (0.34,0.47) 0.41 (0.35,0.48) 0.34 (0.30,0.38) 0.35 (0.31,0.39) 0.35 (0.31,0.39) 0.36 (0.32,0.40) 
Psychiatric 1.16 (1.13,1.21) 1.16 (1.12,1.20) 1.16 (1.12,1.19) 1.15 (1.12,1.19) 1.16 (1.13,1.20) 1.15 (1.12,1.19) 
Ophthalmological 1.08 (1.03,1.13) 1.06 (1.01,1.12) 1.10 (1.06,1.15) 1.08 (1.04,1.13) 1.18 (1.13,1.22) 1.15 (1.11,1.20) 
Infections 1.33 (1.29,1.37) 1.29 (1.25,1.33) 1.36 (1.32,1.40) 1.31 (1.27,1.35) 1.44 (1.40,1.49) 1.39 (1.35,1.43) 
Fragility fractures 0.95 (0.89,1.01) 0.94 (0.89,1.01) 0.92 (0.87,0.98)  0.92 (0.87,0.97) 0.96 (0.91,1.01) 0.95 (0.90,1.01) 
 
 
 186 
 
Composite outcomes 
The results of conditional logistic regression analysis, which aimed to investigate 
the differences in prevalence between comorbidities in patients with and without 
PMR, found that many of the differences in prevalence of comorbidities 
previously described were statistically significant.  For a number of combined 
outcomes almost all of the calculated odds ratios at each of the three time points 
prior to index date showed a significant increase in the likelihood of having pre-
existing disease in patients with PMR. These outcomes included vascular, 
respiratory, gastroenterological, immunological, endocrine, psychiatric 
ophthalmological and infectious diseases.  
These findings mirror the increased prevalence of these conditions in patients 
with PMR compared to matched controls previously demonstrated and persisted 
following adjustment for BMI, smoking status and alcohol consumption. Similarly, 
in the case of cancers and neurological diseases, where a reduced prevalence 
of disease in patients with PMR had been seen, the differences were also found 
to be statistically significant. Finally, although the likelihood of patients with PMR 
having a recorded fragility fracture was significantly lower two years prior to index 
date, the differences observed at one and five years prior to index date were not 
significantly different.  
The stratified outcomes are tabulated in table 6-11. They are also graphically 
presented in figures 6-1 and 6-2 to allow for ease of interpretation. On these 
figures, the total number of patients with PMR who were diagnosed with each 
condition is also indicated. 
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Table 6-11: Odds ratios (with 95% confidence intervals) PMR vs controls of stratified outcomes at time points prior to index date 
calculated using conditional logistic regression  
5y  
 
2y  
 
1y  
 
 Unadjusted 
odds ratio 
Adjusted odds 
ratio 
Unadjusted 
odds ratio 
Adjusted odds 
ratio 
Unadjusted 
odds ratio 
Adjusted odds 
ratio 
Cancer 
      
Breast cancer 0.93 (0.85,1.02) 0.92 (0.84,1.01) 0.88 (0.81,0.95) 0.87 (0.81,0.94) 0.86 (0.80,0.93) 0.86 (0.80,0.92) 
Prostate cancer 0.85 (0.71,1.01) 0.84 (0.70,1.00) 0.94 (0.83,1.07) 0.93 (0.82,1.05) 0.97 (0.86,1.09) 0.95 (0.85,1.07) 
Lung cancer 0.69 (0.44,1.09) 0.68 (0.43,1.08) 0.78 (0.57,1.07) 0.77 (0.56,1.06) 0.73 (0.55,0.97) 0.72 (0.54,0.95) 
Colon cancer 0.90 (0.77,1.05) 0.89 (0.77,1.04) 0.90 (0.80,1.02) 0.89 (0.79,1.00) 0.92 (0.82,1.03) 0.91 (0.81,1.01) 
Melanoma 1.01 (0.86,1.19) 0.99 (0.85,1.17) 1.02 (0.89,1.16) 1.00 (0.88,1.14) 1.03 (0.90,1.16) 1.01 (0.89,1.14) 
LL 0.73 (0.60,0.90) 0.72 (0.59,0.88) 0.71 (0.61,0.82) 0.70 (0.60,0.81) 0.68 (0.58,0.78) 0.67 (0.58,0.77) 
Vascular 
      
CVD 1.13 (1.09,1.18) 1.10 (1.05,1.15) 1.16 (1.12,1.20) 1.11 (1.07,1.15) 1.16 (1.12,1.20) 1.12 (1.08,1.16) 
CCF 1.01 (0.92,1.11) 0.99 (0.91,1.09) 1.01 (0.94,1.07) 0.98 (0.92,1.05) 1.01 (0.95,1.08) 0.99 (0.93,1.05) 
PVD 1.01 (0.93,1.10) 1.02 (0.93,1.11) 1.01 (0.95,1.08) 1.01 (0.94,1.08) 1.03 (0.97,1.10) 1.03 (0.97,1.10) 
CVA 0.86 (0.80,0.91) 0.85 (0.79,0.90) 0.89 (0.85,0.93) 0.88 (0.83,0.92) 0.90 (0.86,0.94) 0.89 (0.85,0.93) 
HTN 1.11 (1.08,1.14) 1.06 (1.03,1.09) 1.17 (1.14,1.20) 1.11 (1.08,1.14) 1.18 (1.15,1.21) 1.12 (1.09,1.15) 
Respiratory  
Asthma 1.27 (1.22,1.32) 1.24 (1.19,1.29) 1.30 (1.26,1.35) 1.26 (1.22,1.31) 1.30 (1.26,1.35) 1.27 (1.22,1.31) 
COPD 1.16 (1.11,1.21) 1.15 (1.10,1.20) 1.17 (1.12,1.21) 1.16 (1.11,1.20) 1.18 (1.13,1.22) 1.17 (1.12,1.21) 
Lung fibrosis 1.28 (0.96,1.69) 1.24 (0.94,1.65) 1.42 (1.16,1.74) 1.38 (1.13,1.70) 1.60 (1.34,1.91) 1.56 (1.31,1.87) 
Renal   
Renal disease 1.06 (0.99,1.14) 1.04 (0.97,1.12) 1.15 (1.10,1.21) 1.13 (1.07,1.18) 1.18 (1.12,1.23) 1.15 (1.10,1.20) 
Gastroenterological  
Liver disease 0.85 (0.71,1.01) 0.85 (0.71,1.01) 0.86 (0.75,0.99) 0.85 (0.74,0.98) 0.89 (0.78,1.01) 0.88 (0.77,1.01) 
Peptic ulcers 1.03 (0.96,1.10) 1.03 (0.96,1.10) 1.04 (0.99,1.11) 1.04 (0.99,1.11) 1.05 (0.99,1.11) 1.05 (0.99,1.11) 
Crohn's disease 0.99 (0.77,1.28) 0.98 (0.76,1.27) 0.97 (0.78,1.20) 0.96 (0.78,1.20) 1.01 (0.82,1.24) 1.00 (0.81,1.23) 
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5y  
 
2y  
 
1y  
 
 Unadjusted 
odds ratio 
Adjusted odds 
ratio 
Unadjusted 
odds ratio 
Adjusted odds 
ratio 
Unadjusted 
odds ratio 
Adjusted odds 
ratio 
Ulcerative colitis 1.22 (1.08,1.39) 1.19 (1.05,1.35) 1.31 (1.18,1.46) 1.28 (1.15,1.42) 1.33 (1.20,1.48) 1.30 (1.18,1.45) 
Autoimmune and musculoskeletal  
SLE 0.88 (0.57,1.37) 0.88 (0.57,1.36) 0.97 (0.68,1.38) 0.96 (0.67,1.37) 0.95 (0.67,1.34) 0.94 (0.67,1.34) 
Systemic sclerosis 1.73 (1.04,2.86) 1.71 (1.03,2.84) 1.12 (0.69,1.80) 1.13 (0.70,1.82) 1.18 (0.74,1.86) 1.19 (0.75,1.88) 
Rheumatoid 
arthritis 
1.17 (1.07,1.28) 1.16 (1.07,1.27) 1.22 (1.14,1.32) 1.21 (1.13,1.30) 1.25 (1.17,1.34) 1.24 (1.15,1.33) 
Sjogren’s 
syndrome 
1.44 (1.07,1.95) 1.40 (1.04,1.90) 1.53 (1.21,1.94) 1.48 (1.17,1.88) 1.50 (1.19,1.89) 1.45 (1.16,1.83) 
Psoriatic arthritis 1.47 (1.19,1.82) 1.45 (1.17,1.79) 1.42 (1.19,1.70) 1.39 (1.16,1.67) 1.44 (1.21,1.71) 1.40 (1.18,1.67) 
Raynaud's disease 1.22 (1.07,1.39) 1.20 (1.05,1.37) 1.28 (1.15,1.42) 1.25 (1.12,1.39) 1.33 (1.20,1.47) 1.30 (1.18,1.44) 
Osteoarthritis 1.33 (1.29,1.37) 1.30 (1.26,1.34) 1.39 (1.36,1.43) 1.36 (1.32,1.39) 1.43 (1.39,1.47) 1.39 (1.35,1.43) 
Endocrine  
Hyperthyroidism 1.14 (1.04,1.26) 1.14 (1.03,1.26) 1.14 (1.05,1.24) 1.13 (1.04,1.24) 1.13 (1.03,1.22) 1.12 (1.03,1.22) 
Hypothyroidism 1.43 (1.36,1.50) 1.40 (1.34,1.47) 1.41 (1.36,1.47) 1.39 (1.33,1.44) 1.43 (1.37,1.49) 1.40 (1.34,1.46) 
T1DM 1.06 (0.88,1.27) 1.02 (0.85,1.23) 1.05 (0.89,1.23) 1.00 (0.85,1.17) 1.04 (0.89,1.21) 0.99 (0.85,1.16) 
T2DM 0.91 (0.86,0.96) 0.88 (0.83,0.93) 0.94 (0.90,0.99) 0.90 (0.86,0.94) 0.95 (0.91,1.00) 0.91 (0.88,0.95) 
Addison's disease 1.42 (0.76,2.68) 1.41 (0.75,2.65) 1.35 (0.79,2.29) 1.33 (0.78,2.26) 1.37 (0.83,2.26) 1.35 (0.82,2.24) 
Neurological and psychiatric  
Dementia 0.15 (0.10,0.24) 0.16 (0.10,0.25) 0.17 (0.13,0.21) 0.17 (0.14,0.22) 0.21 (0.18,0.25) 0.22 (0.18,0.26) 
Parkinson's 
disease 
0.51 (0.40,0.66) 0.51 (0.40,0.65) 0.49 (0.41,0.59) 0.49 (0.41,0.58) 0.51 (0.43,0.60) 0.50 (0.43,0.60) 
MS 0.62 (0.46,0.85) 0.64 (0.47,0.87) 0.63 (0.48,0.82) 0.65 (0.49,0.85) 0.63 (0.48,0.83) 0.66 (0.50,0.86) 
Psychiatric  
Bipolar disease 0.69 (0.49,0.99) 0.70 (0.49,1.00) 0.77 (0.58,1.02) 0.78 (0.59,1.03) 0.75 (0.57,1.00) 0.76 (0.58,1.01) 
Depression 1.17 (1.13,1.21) 1.17 (1.12,1.21) 1.15 (1.12,1.19) 1.15 (1.11,1.19) 1.16 (1.12,1.20) 1.15 (1.12,1.19) 
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5y  
 
2y  
 
1y  
 
 Unadjusted 
odds ratio 
Adjusted odds 
ratio 
Unadjusted 
odds ratio 
Adjusted odds 
ratio 
Unadjusted 
odds ratio 
Adjusted odds 
ratio 
Anxiety 1.14 (1.10,1.20) 1.14 (1.09,1.19) 1.15 (1.10,1.19) 1.14 (1.09,1.18) 1.15 (1.11,1.20) 1.14 (1.10,1.19) 
Schizophrenia 0.37 (0.26,0.52) 0.38 (0.28,0.54) 0.38 (0.29,0.51) 0.40 (0.30,0.53) 0.37 (0.28,0.49) 0.39 (0.29,0.51) 
Complications due to glucocorticoids  
Osteoporosis 1.11 (1.04,1.19) 1.10 (1.02,1.17) 1.12 (1.06,1.18) 1.10 (1.05,1.16) 1.13 (1.07,1.18) 1.11 (1.06,1.17) 
Hip fracture 0.65 (0.55,0.79) 0.66 (0.55,0.79) 0.61 (0.53,0.70) 0.61 (0.54,0.70) 0.61 (0.54,0.69) 0.62 (0.55,0.70) 
Wrist fracture 1.01 (0.94,1.08) 1.00 (0.94,1.07) 1.00 (0.95,1.06) 1.00 (0.94,1.05) 1.01 (0.95,1.06) 1.00 (0.94,1.05) 
Vertebral fracture 0.73 (0.51,1.06) 0.72 (0.50,1.04) 0.84 (0.64,1.12) 0.84 (0.63,1.11) 0.91 (0.70,1.18) 0.91 (0.70,1.17) 
Ophthalmological  
Cataracts 1.10 (1.03,1.16) 1.08 (1.02,1.14) 1.14 (1.09,1.19) 1.12 (1.07,1.17) 1.16 (1.11,1.21) 1.13 (1.08,1.18) 
Glaucoma 1.04 (0.97,1.12) 1.03 (0.96,1.10) 1.07 (1.01,1.13) 1.05 (0.99,1.11) 1.08 (1.03,1.14) 1.07 (1.01,1.13) 
Infections  
UTI 1.14 (1.10,1.19) 1.12 (1.08,1.17) 1.17 (1.13,1.21) 1.14 (1.11,1.18) 1.16 (1.12,1.20) 1.14 (1.10,1.17) 
URTI 1.36 (1.32,1.40) 1.32 (1.29,1.36) 1.40 (1.37,1.44) 1.36 (1.32,1.39) 1.42 (1.38,1.45) 1.37 (1.33,1.41) 
LRTI 1.06 (0.97,1.16) 1.06 (0.97,1.15) 1.10 (1.02,1.18) 1.10 (1.02,1.18) 1.11 (1.04,1.19) 1.11 (1.03,1.18) 
Skin infections 1.11 (1.05,1.16) 1.10 (1.04,1.15) 1.10 (1.06,1.15) 1.09 (1.04,1.13) 1.11 (1.06,1.15) 1.09 (1.05,1.13) 
Abbreviations: Leukaemia, lymphoma (LL), Cardiovascular disease (CVD), Congestive cardiac failure (CCF), Peripheral vascular disease (PVD), 
Cerebrovascular disease (CVA), Hypertension (HTN), Chronic obstructive pulmonary disease (COPD), Ulcerative colitis (UC), systemic lupus 
erythematosus (SLE), rheumatoid arthritis (RA), Osteoarthritis (OA), Type 1 Diabetes mellitus (T1DM), Type 2 Diabetes mellitus (T2DM), Multiple sclerosis 
(MS), Urinary tract infection (UTI), Upper respiratory tract infection (URTI), Lower respiratory tract infection (LRTI) 
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Figure 6-1: Likelihood of comorbidities prior to index date expressed as odds 
Ratios with 95% confidence intervals (unadjusted)  
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Figure 6-2: Likelihood of comorbidities prior to index date expressed as odds 
Ratios with 95% confidence intervals (adjusted) 
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Stratified outcomes 
Cancer 
Of the six main cancer types, after adjustment for alcohol consumption, BMI 
category, age, sex and smoking status, three showed no significant difference in 
diagnosis prior to index date (melanoma, prostate cancer and colon cancer), 
while in three there was a statistically significant reduction in the likelihood of 
diagnosis (breast cancer, lung cancer and leukaemia and lymphoma). 
 
Vascular 
After adjustment for the previously discussed covariates was applied, two 
vascular outcomes were significantly more likely in patients with PMR 
(hypertension and cardiovascular disease), while peripheral vascular disease 
and congestive cardiac failure did not show a significant difference. 
Cerebrovascular disease was significantly less likely in patients who had a 
diagnosis of PMR compared to their matched controls.  
 
Other comorbidities 
All of the respiratory outcomes, including lung fibrosis, asthma and COPD were 
significantly more likely in patients with PMR. Similarly, renal disease and all 
autoimmune conditions investigated, except systemic sclerosis and SLE were 
found to be significantly more likely in patients with PMR. In both systemic 
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sclerosis and SLE the confidence intervals were particularly wide. This was due 
to the low numbers of patients diagnosed with these conditions (n=23, n=28). 
Regarding gastroenterological and endocrine comorbidities, the picture was 
more mixed. The likelihood of ulcerative colitis, hypothyroidism and 
hyperthyroidism were significantly increased. However, the likelihood of peptic 
ulcers, Crohn’s disease, liver disease, Addison’s disease and type 1 diabetes 
mellitus were not significantly different between cases and controls. Finally, it 
was found that type 2 diabetes was significantly less likely in patients who 
subsequently went on to have a diagnosis of PMR. 
All neurological diagnoses tested were statistically significantly less likely in 
patients with PMR, including multiple sclerosis, Parkinson’s disease and 
dementia. Regarding psychiatric diagnoses, conditions which could be regarded 
as more severe illnesses, such as schizophrenia, were significantly less likely in 
patients with PMR. Although the reduction in the likelihood of previous bipolar 
disease in cases did not reach statistical significance. However, the more 
common and, usually, less severe psychiatric diagnoses of anxiety and 
depression, were significantly more likely to have occurred in patients who went 
on to receive a diagnosis of PMR.  
 
Comorbidities linked to GC prescription 
A significant increase in the risk of diagnosis with certain comorbidities, including 
cataracts, glaucoma and most infectious diseases, was observed in patients with 
PMR. However, although the likelihood of a diagnosis of osteoporosis being 
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made was significantly higher in cases compared to controls, the risk of a hip 
fracture was significantly lower in cases, while wrist and vertebral fractures were 
not seen to be significantly different in cases or controls.  
 
6.3.3 Cohort study 
The total number, proportion, and rate of new, or incident diagnoses with each 
comorbidity in patients with PMR compared to matched controls, at index date 
and four time points following this (one, two, five and ten years) are reported in 
table 6-12. The overall comorbidity burden that cases and controls were 
subjected to was estimated using the Charlson index score. The number and 
proportion of patients with each score are then described (table 6-13). Due to 
small numbers, all those with a Charlson score of greater than 5 were 
aggregated. Finally, the cumulative probability, with 95% confidence intervals, of 
each comorbidity is then tabulated (table 6-14). For the Charlson comorbidity 
index score and cumulative probability, existing diagnoses from prior to index 
date were included. 
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Table 6-12: Total number, proportion and rate of incident diagnoses of composite outcomes following index date  
Cases  Controls   
At risk Incident 
diagnoses 
% Rate (per 1,000) At risk Incident 
diagnoses 
% Rate (per 1,000) 
Cancer 27,990 3,484 12.4 238.1 (230.3,246.1) 129,044 14,645 11.3 238.4 (234.6,242.3) 
Vascular 23,340 3,964 17.0 335.8 (325.6,346.5) 112,013 14,080 12.6 266.0 (261.6,270.4) 
Respiratory 23,891 1,656 6.9 131.6 (125.4,138.1) 117,916 5,987 5.1 106.2 (103.5,108.9) 
Gastroenterological 29,524 743 2.5 47.1 (43.8,50.6) 138,885 2,598 1.9 38.5 (37.1,40.0) 
Autoimmune 29,600 1,482 5.0 96.8 (92.0,101.9) 142,414 1,460 1.0 21.2 (20.1,22.3) 
Endocrine 24,009 2,640 11.0 213.8 (205.8,222.1) 117,544 8,405 7.2 151.1 (147.9,154.3) 
Neurological 31,476 1,877 6.0 112.2 (107.3,117.4) 143,367 8,117 5.7 116.9 (114.4,119.4) 
Psychiatric 23,996 1,440 6.0 114.6 (108.8,120.6) 115,832 4,993 4.3 90.2 (87.7,92.8) 
Ophthalmological 26,680 3,464 13.0 258.6 (250.1,267.3) 127,763 10,934 8.6 184.3 (180.8,187.8) 
Infections 9,382 3,765 40.1 980.7 (949.9,1012.5) 54,009 16,412 30.4 762.6 (751.1,774.4) 
Fragility fractures 29,818 1,492 5.0 94.6 (89.9,99.5) 138,582 5,293 3.8 79.5 (77.4,81.7) 
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Table 6-13: Total number of cases and controls (%) with Charlson index score of composite outcomes following index date 
Charlson 
score  
At diagnosis After one 
year 
 Two years  Five years  Ten years  
Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls 
0 11,786 
(34.7) 
61,711  
(41.3) 
10,277  
(30.2) 
57,375 
(38.4) 
9,352  
(27.5) 
53,873  
(36.1) 
7,605  
(22.4) 
46,501  
(31.1) 
6,533 
(19.2) 
41,619  
(27.9) 
1 7,568  
(22.3) 
32,431 
 (21.7) 
7,219  
(21.2) 
31,229  
(20.9) 
6,910  
(20.3) 
30,178  
(20.2) 
6,256  
(18.4) 
27,949  
(18.7) 
5,615  
(16.5) 
26,456  
(17.7) 
2 5,732  
(16.9) 
25,398  
(17.0) 
6,014 
(17.7) 
26,254  
(17.6) 
6,072  
(17.9) 
26,775  
(17.9) 
6,173  
(18.2) 
27,808  
(18.6) 
6,136  
(18.1) 
27,991  
(18.7) 
3 3,369  
(9.9) 
14,319  
(9.6) 
3,843  
(11.3) 
15,560  
(10.4) 
4,190  
(12.3) 
16,669  
(11.2) 
4,681  
(13.8) 
18,702  
(12.5) 
4,951  
(14.6) 
20,118  
(13.5) 
4 1,843  
(5.4) 
7,753 
(5.2) 
2,306  
(6.8) 
8,968  
(6.0) 
2,600  
(7.7) 
10,031  
(6.7) 
3,105  
(9.1) 
12,277  
(8.2) 
3,530  
(10.4) 
13,742  
(9.2) 
5 960 
 (2.8) 
4,016 
 (2.7) 
1,208  
(3.6) 
4,872  
(3.3) 
1,404  
(4.1) 
5,533 
 (3.7) 
1,912  
(5.6) 
7,196  
(4.8) 
2,299 
 (6.8) 
8,418  
(5.6) 
Greater than 5 726  
(2.1) 
3,808 
 (2.5) 
1,117  
(3.3) 
5,178  
(3.5) 
1,456  
(4.3) 
6,377  
(4.3) 
2,252  
(6.6) 
9,003  
(6.0) 
2,920 
 (8.6) 
11,092  
(7.4) 
 
  
 197 
 
Table 6-14: Cumulative probability of composite outcomes (with 95% confidence intervals) following index date 
 At diagnosis After one year  Two years  Five years  Ten years   
Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls 
Composite outcomes          
Cancer 15.4  
(15.0,15.8) 
16.4  
(16.2,16.6) 
17.2  
(16.8,17.6) 
18.3  
(18.1,18.5) 
22.7  
(22.2,23.2) 
23.8  
(23.6,24.1) 
30.6  
(29.9,31.3) 
31.8  
(31.5,32.1) 
40.1  
(38.9,41.3) 
41.3  
(40.7,41.9) 
Vascular 30.5  
(29.9,31.0) 
28.2  
(28.0,28.4) 
32.7  
(32.2,33.2) 
30.0  
(29.7,30.2) 
38.9  
(38.4,39.5) 
35.1  
(34.9,35.4) 
47.7  
(47.0,48.4) 
42.8  
(42.5,43.2) 
57.5  
(56.3,58.6) 
51.5  
(50.9,52.1) 
Respiratory 27.5  
(27.0,28.0) 
23.2  
(23.0,23.4) 
28.5  
(28.0,29.0) 
24.0  
(23.8,24.3) 
31.1  
(30.5,31.6) 
26.4  
(26.1,26.6) 
34.8  
(34.2,35.4) 
29.6  
(29.3,29.8) 
39.5  
(38.5,40.5) 
33.2  
(32.7,33.7) 
Gastroenterological 8.6  
(8.3,8.9) 
7.9  
(7.8,8.1) 
9.0 
 (8.7,9.3) 
8.3  
(8.1,8.4) 
10.2  
(9.9,10.6) 
9.3  
(9.2,9.5) 
12.1  
(11.7,12.5) 
10.9  
(10.7,11.1) 
14.5  
(13.7,15.2) 
12.6  
(12.2,12.9) 
Autoimmune 9.6  
(9.2,9.9) 
5.2 
 (5.1,5.4) 
10.6  
(10.3,11.0) 
5.4 
(5.3,5.6) 
12.6  
(12.2,13.0) 
6.0 
(5.9,6.2) 
15.0  
(14.5,15.5) 
7.0  
(6.8,7.1) 
17.4  
(16.7,18.2) 
7.9  
(7.7,8.2) 
Endocrine 28.2  
(27.7,28.7) 
23.8  
(23.5,24.0) 
29.7  
(29.2,30.2) 
24.9  
(24.6,25.1) 
33.6  
(33.1,34.2) 
28.1  
(27.8,28.3) 
38.9  
(38.3,39.6) 
33.0  
(32.7,33.3) 
45.0  
(43.9,46.1) 
38.0  
(37.5,38.5) 
Neurological 2.5  
(2.3,2.6) 
5.3  
(5.2,5.4) 
3.3 
(3.1,3.5) 
6.2 
 (6.0,6.3) 
6.2  
(5.9,6.5) 
9.2  
(9.0,9.3) 
12.3  
(11.8,12.9) 
14.6  
(14.4,14.9) 
21.2  
(20.1,22.5) 
23.4  
(22.8,24.0) 
Psychiatric 27.0  
(26.5,27.5) 
24.5  
(24.3,24.8) 
27.9  
(27.4,28.4) 
25.2  
(25.0,25.5) 
30.3  
(29.8,30.8) 
27.2  
(26.9,27.4) 
33.5  
(32.9,34.1) 
29.8  
(29.5,30.1) 
36.9  
(36.0,37.9) 
32.9  
(32.5,33.4) 
Ophthalmological 19.5  
(19.1,20.0) 
16.8  
(16.6,17.0) 
21.9  
(21.4,22.4) 
18.3  
(18.1,18.5) 
27.6  
(27.1,28.1) 
22.6  
(22.4,22.9) 
34.8  
(34.2,35.5) 
29.2  
(28.9,29.5) 
43.8  
(42.6,45.0) 
36.5  
(35.9,37.1) 
Infections 74.5  
(74.0,75.0) 
68.0  
(67.7,68.2) 
77.0  
(76.6,77.5) 
70.4  
(70.1,70.6) 
82.6  
(82.1,83.0) 
76.1  
(75.9,76.4) 
88.3  
(87.9,88.8) 
82.6  
(82.3,82.8) 
92.2  
(91.5,92.8) 
88.0  
(87.6,88.4) 
Fragility fracture 7.9  
(7.6,8.3) 
8.4  
(8.2,8.5) 
8.7  
(8.4,9.0) 
9.0 
 (8.9,9.2) 
10.9  
(10.5,11.3) 
11.1  
(10.9,11.2) 
15.5  
(14.9,16.0) 
14.6  
(14.4,14.9) 
21.8  
(20.7,22.9) 
20.2  
(19.7,20.7) 
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Charlson Index 
The overall burden of comorbidities among patients with PMR and matched 
controls following index date, was measured using the Charlson comorbidity 
index. At the time of diagnosis as well as the four succeeding time points, the 
burden of disease was higher in cases compared to controls. The proportion of 
patients with PMR with a Charlson score of zero was lower at every measured 
point for cases compared to controls. The difference in the two proportions 
increased from 6.6% at time of diagnosis to 8.7% at ten years. Furthermore, the 
proportion of cases with a score of 1-5 was higher at diagnosis, as well as at one 
and two years after. However, similar to the case control study, the proportion of 
controls with a Charlson score of greater than 5 was higher. At every time point 
after diagnosis, the average Charlson comorbidity score was higher in cases 
compared to controls. 
 
Composite Outcomes 
In all but three of the combined outcomes the cumulative probability of a 
comorbidity being present either at index date, or developing one, two, five or ten 
years following it, was higher in patients with PMR compared to their matched 
controls. The composite outcomes with an increase in the cumulative probability 
of diagnosis were vascular, respiratory, gastroenterological, autoimmune, 
endocrine, psychiatric, and ophthalmological diseases. However, in two 
composite outcomes the converse was found. The proportion of patients who had 
an existing diagnosis of PMR and went on to develop any cancer or neurological 
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disease was lower compared to controls. This difference also persisted at each 
time point.  
Finally, in the case of fragility fractures, the picture was more mixed. Here, at the 
first three time points, at diagnosis and one and two years subsequently, the 
cumulative probability of a fragility fracture was higher in controls compared to 
cases (by 0.5%, 0.3% and 0.2% respectively). However, after five and ten years 
of follow up, the probability was higher in cases and the difference was increasing 
(0.9% and 1.6%).  
The total number, proportion and rate of diagnosis with stratified comorbidities 
are shown in table 6-15. Again, this table also illustrates the total number of 
patients who entered each analysis per comorbidity, after patients who had a pre-
existing diagnosis were excluded. The cumulative probability of a diagnosis with 
each comorbidity is then summarised in table 6-16.  
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Table 6-15: Total number of patients included in cohort study, total and rate of stratified comorbidity diagnosis  
Cases 
At risk 
New 
diagnoses 
% Rate (per 1,000) Controls 
At risk 
New diagnoses % Rate (per 1,000) 
Cancer 
Breast cancer 31,063 380 1.2 22.7 (20.5,25.1) 144,350 1,811 1.3 25.9 (24.7,27.1) 
Prostate cancer 31,508 402 1.3 23.7 (21.5,26.1) 147,408 1,457 1.0 20.3 (19.3,21.4) 
Lung cancer 31,915 425 1.3 24.6 (22.4,27.1) 148,869 2,087 1.4 28.8 (27.6,30.0) 
Colon cancer 31,569 409 1.3 24.0 (21.8,26.5) 147,294 1,759 1.2 24.6 (23.4,25.7) 
Melanoma 31,673 142 0.4 8.3 (7.0,9.8) 147,993 605 0.4 8.4 (7.8,9.1) 
Leukaemia, lymphoma 31,738 378 1.2 22.1 (20.0,24.4) 147,838 1386 0.9 19.3 (18.3,20.3) 
Vascular 
CVD 26,523 1,803 6.8 128.8 (122.9,134.8) 127,222 5,,966 4.7 97.3 (94.9,99.8) 
CCF 30,353 1,844 6.1 114.2 (109.1,119.5) 142,253 6,041 4.2 87.7 (85.5,89.9) 
PVD 30,529 1,117 3.7 68.6 (64.7,72.8) 143,157 3,241 2.3 46.7 (45.1,48.3) 
CVA 29,327 2,076 7.1 134.0 (128.3,139.8) 136,414 7,936 5.8 120.9 (118.3,123.6) 
HTN 15,416 3,269 21.2 445.1 (430.1,460.7) 78,654 12,646 16.1 366.2 (359.8,372.6) 
Respiratory 
Asthma 26,920 772 2.9 53.4 (49.8,57.3) 130,438 2,735 2.1 43.3 (41.8,45.0) 
COPD 27,405 1,337 4.9 92.1 (87.3,97.2) 130,887 4,787 3.7 76.2 (74.1,78.4) 
Lung fibrosis 31,784 234 0.7 13.6 (12.0,15.5) 148,859 629 0.4 8.7 (8.0,9.4) 
Renal  
Renal disease 27,755 5,167 18.6 377.0 (366.8,387.4) 132,747 16,517 12.4 270.1 (266.0,274.2) 
Gastroenterological  
Moderate liver disease 31,667 214 0.7 12.5 (10.9,14.3) 147,865 823 0.6 11.4 (10.7,12.2) 
Peptic ulcers 30,364 360 1.2 22.1 (19.9,24.5) 142,400 1,349 0.9 19.5 (18.5,20.6) 
Crohn's disease 31,873 28 0.1 1.6 (1.1,2.3) 148,907 78 0.1 1.1 (0.9,1.3) 
Ulcerative colitis 31,476 184 0.6 10.8 (9.4,12.5) 147,656 455 0.3 6.3 (5.8,6.9) 
Autoimmune and musculoskeletal 
SLE 31,940 36 0.1 2.1 (1.5,2.9) 149,237 35 0.0 0.5 (0.3,0.7) 
Systemic sclerosis 31,959 16 0.1 0.9 (0.6,1.5) 149,338 30 0.0 0.4 (0.3,0.6) 
Rheumatoid arthritis 30,562 1,079 3.5 67.4 (63.5,71.6) 145,335 701 0.5 9.9 (9.2,10.7) 
Sjogren’s syndrome 31,875 54 0.2 3.1 (2.4,4.1) 149,110 78 0.1 1.1 (0.9,1.3) 
Psoriatic arthritis 31,766 190 0.6 11.1 (9.6,12.8) 148,840 102 0.1 1.4 (1.2,1.7) 
Raynaud's disease 31,431 222 0.7 13.1 (11.5,14.9) 147,507 634 0.4 8.8 (8.2,9.6) 
Osteoarthritis 14,481 3,646 25.2 566.5 (548.4,585.2) 89,580 11,684 13.0 293.4 (288.1,298.8) 
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Cases 
At risk 
New 
diagnoses 
% Rate (per 1,000) Controls 
At risk 
New diagnoses % Rate (per 1,000) 
Endocrine 
Hyperthyroidism 31,240 201 0.6 11.9 (10.4,13.7) 146,381 605 0.4 8.5 (7.8,9.2) 
Hypothyroidism 27,978 977 3.5 65.6 (61.6,69.9) 136,028 3,454 2.5 52.7 (51.0,54.5) 
T1DM 31,774 53 0.2 3.1 (2.4,4.0) 148,485 147 0.1 2.0 (1.7,2.4) 
T2DM 28,646 1,998 7.0 132.6 (126.9,138.5) 134,003 5,688 4.2 88.3 (86.0,90.6) 
Addison's disease 31,963 32 0.1 1.8 (1.3,2.6) 149,362 34 0.0 0.5 (0.3,0.7) 
Neurological and psychiatric  
Dementia 31,770 1,687 5.3 99.6 (95.0,104.5) 145,852 7,439 5.1 105.4 (103.0,107.8) 
Parkinson's disease 31,796 260 0.8 15.1 (13.4,17.1) 147,810 1,013 0.7 14.1 (13.2,15.0) 
MS 31,923 7 0.0 0.4 (0.2,0.8) 148,971 26 0.0 0.4 (0.2,0.5) 
Psychiatric 
Bipolar disease 31,926 18 0.1 1.0 (0.7,1.7) 149,064 66 0.0 0.9 (0.7,1.2) 
Depression 25,855 1,167 4.5 85.5 (80.8,90.6) 123,888 3,683 3.0 61.7 (59.7,63.7) 
Anxiety 27,551 966 3.5 65.9 (61.8,70.2) 130,889 3,504 2.7 55.8 (54.0,57.7) 
Schizophrenia 31,928 19 0.1 1.1 (0.7,1.7) 148,760 84 0.1 1.2 (0.9,1.4) 
Complications due to glucocorticoids 
Osteoporosis 29,212 3,420 11.7 236.2 (228.4,244.3) 138,296 7,336 5.3 111.5 (108.9,114.0) 
Hip fracture 31,614 918 2.9 54.2 (50.8,57.8) 146,819 3,480 2.4 48.9 (47.3,50.6) 
Wrist fracture 30,184 574 1.9 35.5 (32.7,38.5) 141,118 2,114 1.5 31.0 (29.7,32.4) 
Vertebral fracture 31,903 210 0.7 12.2 (10.6,13.9) 149,015 424 0.3 5.8 (5.3,6.4) 
Ophthalmological 
Cataracts 28,141 3,121 11.1 217.9 (210.4,225.7) 133,985 9,658 7.2 154.0 (150.9,157.1) 
Glaucoma 30,038 898 3.0 56.2 (52.7,60.0) 141,196 2,998 2.1 44.1 (42.5,45.7) 
Infections 
UTI 25,585 3,121 12.2 242.1 (233.7,250.7) 122,860 10,995 8.9 192.2 (188.7,195.9) 
URTI 11,806 3,472 29.4 665.3 (643.6,687.8) 66,482 14,659 22.0 527.1 (518.7,535.8) 
LRTI 30,801 1,503 4.9 91.1 (86.6,95.8) 144,614 5,174 3.6 73.8 (71.8,75.8) 
Skin infections 27,560 3,242 11.8 230.7 (222.9,238.8) 130,571 10,359 7.9 168.7 (165.5,172.0) 
Abbreviations: Leukaemia, lymphoma (LL), Cardiovascular disease (CVD), Congestive cardiac failure (CCF), Peripheral vascular disease (PVD), Cerebrovascular disease 
(CVA), Hypertension (HTN), Chronic obstructive pulmonary disease (COPD), Ulcerative colitis (UC), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), 
Osteoarthritis (OA), Type 1 Diabetes mellitus (T1DM), Type 2 Diabetes mellitus (T2DM), Multiple sclerosis (MS), Urinary tract infection (UTI), Upper respiratory tract 
infection (URTI), Lower respiratory tract infection (LRTI) 
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Table 6-16: Cumulative probability of stratified outcomes (with 95% confidence intervals) following index date 
 At diagnosis After one year Two years Five years Ten years 
 Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls 
Cancer           
Breast cancer 3.2  
(3.0,3.4) 
3.9  
(3.8,4.0) 
3.4  
(3.2,3.6) 
4.1  
(4.0,4.2) 
4.1  
(3.9,4.3) 
4.9  
(4.8,5.0) 
5.2  
(4.9,5.5) 
6.0  
(5.8,6.1) 
6.6  
(6.1,7.2) 
7.5  
(7.2,7.8) 
Prostate cancer 2.0  
(1.8,2.2) 
1.7  
(1.6,1.7) 
2.2  
(2.0,2.4) 
1.9  
(1.8,1.9) 
2.8  
(2.6,3.0) 
2.4  
(2.3,2.5) 
3.6 
(3.4,3.9) 
3.3  
(3.2,3.5) 
4.7  
(4.2,5.2) 
4.6  
(4.3,4.8) 
Lung cancer 0.6  
(0.5,0.7) 
0.7  
(0.7,0.7) 
0.9  
(0.8,1.0) 
1.0  
(1.0,1.1) 
1.5  
(1.3,1.6) 
1.9  
(1.8,1.9) 
2.5  
(2.2,2.7) 
3.0  
(2.9,3.2) 
3.6  
(3.2,4.2) 
4.5  
(4.2,4.8) 
Colon cancer 1.6 
(1.5,1.7) 
1.8  
(1.7,1.8) 
1.8 
 (1.7,2.0) 
2.0  
(1.9,2.1) 
2.5  
(2.4,2.7) 
2.7  
(2.6,2.8) 
3.6  
(3.3,3.9) 
3.9  
(3.7,4.0) 
5.2  
(4.6,5.8) 
5.2  
(5.0,5.5) 
Melanoma 1.1  
(1.0,1.2) 
1.1  
(1.1,1.2) 
1.2  
(1.1,1.4) 
1.2  
(1.1,1.3) 
1.5  
(1.3,1.6) 
1.5  
(1.4,1.5) 
1.8  
(1.6,2.0) 
1.8  
(1.7,1.9) 
2.1  
(1.9,2.5) 
2.4  
(2.2,2.5) 
LL 1.2  
(1.1,1.3) 
1.3  
(1.3,1.4) 
1.4  
(1.2,1.5) 
1.5  
(1.4,1.6) 
2.0  
(1.8,2.1) 
2.1  
(2.0,2.2) 
2.7  
(2.5,3.0) 
3.0  
(2.9,3.1) 
4.0  
(3.5,4.5) 
4.0  
(3.7,4.2) 
Vascular 
CVD 18.9  
(18.5,19.4) 
16.6  
(16.4,16.8) 
20.0  
(19.6,20.5) 
17.4  
(17.2,17.6) 
23.1  
(22.6,23.6) 
19.8  
(19.5,20.0) 
27.2  
(26.6,27.8) 
23.1  
(22.8,23.4) 
32.5  
(31.4,33.5) 
27.5  
(27.0,28.0) 
CCF 6.6 
(6.3,6.8) 
5.9  
(5.8,6.1) 
7.6  
(7.3,7.9) 
6.7  
(6.6,6.8) 
10.5  
(10.1,10.8) 
9.0  
(8.9,9.2) 
15.1  
(14.6,15.7) 
12.7  
(12.5,13.0) 
20.9  
(19.8,21.9) 
17.8  
(17.3,18.3) 
PVD 5.5  
(5.3,5.8) 
5.0  
(4.9,5.1) 
6.2  
(5.9,6.5) 
5.4  
(5.3,5.5) 
7.9  
(7.5,8.2) 
6.7  
(6.6,6.8) 
10.9 
(10.4,11.4) 
8.7 
(8.5,8.9) 
14.5  
(13.7,15.4) 
10.6  
(10.3,11.0) 
CVA 9.9  
(9.6,10.2) 
10.3  
(10.2,10.5) 
10.9  
(10.6,11.3) 
11.3  
(11.2,11.5) 
14.4  
(14.0,14.8) 
14.4  
(14.2,14.6) 
19.8  
(19.2,20.4) 
19.3  
(19.0,19.6) 
27.0  
(25.9,28.1) 
25.3  
(24.7,25.8) 
HTN 55.4  
(54.9,56.0) 
51.0  
(50.7,51.2) 
57.6  
(57.1,58.2) 
52.8  
(52.5,53.0) 
62.6  
(62.0,63.1) 
57.6  
(57.4,57.9) 
68.9  
(68.2,69.5) 
63.8  
(63.4,64.1) 
74.2  
(73.2,75.1) 
69.8  
(69.3,70.3) 
Respiratory 
Asthma 17.0  
(16.6,17.5) 
14.0  
(13.8,14.2) 
17.5  
(17.1,17.9) 
14.4  
(14.2,14.6) 
18.9  
(18.5,19.4) 
15.5  
(15.3,15.7) 
20.6  
(20.1,21.1) 
16.8  
(16.6,17.1) 
23.1  
(22.3,23.9) 
18.4  
(18.0,18.7) 
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 At diagnosis After one year Two years Five years Ten years 
 Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls 
COPD 16.0  
(15.6,16.4) 
14.0  
(13.8,14.1) 
16.8  
(16.4,17.2) 
14.7  
(14.5,14.8) 
18.9  
(18.4,19.4) 
16.5  
(16.3,16.7) 
22.1  
(21.5,22.6) 
19.1  
(18.9,19.4) 
25.3  
(24.5,26.2) 
22.1  
(21.7,22.5) 
Lung fibrosis 0.9 
(0.8,1.0) 
0.5  
(0.5,0.5) 
1.0  
(0.9,1.1) 
0.6  
(0.5,0.6) 
1.3 
(1.2,1.4) 
0.8 
(0.8,0.9) 
1.9  
(1.7,2.2) 
1.3  
(1.2,1.4) 
2.7 
 (2.3,3.1) 
1.7  
(1.5,1.8) 
Renal 
Renal disease 16.9  
(16.5,17.4) 
14.0  
(13.8,14.2) 
20.1  
(19.6,20.5) 
16.1  
(15.9,16.3) 
28.3  
(27.8,28.9) 
22.6  
(22.4,22.9) 
39.8  
(39.0,40.5) 
32.1  
(31.7,32.4) 
52.3  
(51.1,53.6) 
42.7  
(42.0,43.3) 
Gastroenterological 
Liver disease 1.2  
(1.1,1.3) 
1.2  
(1.2,1.3) 
1.3  
(1.2,1.4) 
1.3  
(1.3,1.4) 
1.7  
(1.5,1.9) 
1.7  
(1.6,1.8) 
2.2 
(2.0,2.4) 
2.2  
(2.1,2.3) 
2.9  
(2.5,3.4) 
2.7  
(2.6,2.9) 
Peptic ulcers 5.6  
(5.3,5.9) 
5.2  
(5.1,5.4) 
5.8  
(5.5,6.0) 
5.4  
(5.3,5.6) 
6.4 
(6.1,6.7) 
6.0  
(5.8,6.1) 
7.3  
(7.0,7.7) 
6.8  
(6.6,6.9) 
8.6  
(8.0,9.1) 
7.8  
(7.5,8.1) 
Crohn's disease 0.4  
(0.3,0.5) 
0.4 
(0.4,0.4) 
0.4  
(0.3,0.5) 
0.4  
(0.4,0.4) 
0.5  
(0.4,0.5) 
0.4  
(0.4,0.5) 
0.5  
(0.4,0.6) 
0.5  
(0.4,0.5) 
0.6 
(0.5,0.8) 
0.5  
(0.5,0.6) 
UC 1.8  
(1.7,2.0) 
1.3  
(1.3,1.4) 
2.0  
(1.8,2.1) 
1.4  
(1.4,1.5) 
2.2  
(2.1,2.4) 
1.6  
(1.5,1.7) 
2.6  
(2.4,2.9) 
1.9 
(1.8,2.0) 
3.1  
(2.8,3.5) 
2.1 
(2.0,2.3) 
Autoimmune and musculoskeletal 
SLE 0.2  
(0.1,0.2) 
0.2  
(0.1,0.2) 
0.2  
(0.2,0.3) 
0.2  
(0.1,0.2) 
0.3  
(0.2,0.3) 
0.2  
(0.2,0.2) 
0.3  
(0.3,0.4) 
0.2  
(0.2,0.2) 
0.4  
(0.3,0.5) 
0.2  
(0.2,0.2) 
Systemic 
sclerosis 
0.1  
(0.1,0.1) 
0.1  
(0.1,0.1) 
0.1  
(0.1,0.1) 
0.1  
(0.1,0.1) 
0.1  
(0.1,0.2) 
0.1  
(0.1,0.1) 
0.2  
(0.1,0.2) 
0.1  
(0.1,0.1) 
0.3  
(0.1,0.4) 
0.2  
(0.1,0.2) 
RA 6.1  
(5.8,6.4) 
3.0  
(3.0,3.1) 
6.8  
(6.5,7.1) 
3.1  
(3.1,3.2) 
8.2  
(7.9,8.5) 
3.5  
(3.4,3.6) 
9.7  
(9.3,10.1) 
3.9  
(3.7,4.0) 
11.5  
(10.9,12.2) 
4.3 
 (4.1,4.5) 
Sjogren’s 
syndrome 
0.4  
(0.3,0.5) 
0.3 
(0.2,0.3) 
0.4  
(0.4,0.5) 
0.3  
(0.2,0.3) 
0.6  
(0.5,0.6) 
0.3  
(0.3,0.3) 
0.6  
(0.5,0.7) 
0.3  
(0.3,0.4) 
0.8  
(0.6,1.1) 
0.4  
(0.3,0.4) 
Psoriatic arthritis 0.9  
(0.8,1.0) 
0.5  
(0.4,0.5) 
1.1  
(0.9,1.2) 
0.5  
(0.4,0.5) 
1.3  
(1.2,1.5) 
0.5  
(0.5,0.5) 
1.7  
(1.5,1.9) 
0.6  
(0.5,0.6) 
2.0  
(1.7,2.3) 
0.6  
(0.6,0.7) 
Raynaud's 
disease 
1.9  
(1.8,2.1) 
1.5  
(1.4,1.5) 
2.1  
(1.9,2.2) 
1.6  
(1.5,1.6) 
2.4  
(2.3,2.6) 
1.8  
(1.7,1.9) 
3.1  
(2.9,3.4) 
2.2  
(2.1,2.3) 
3.7  
(3.3,4.1) 
2.7  
(2.5,2.9) 
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 At diagnosis After one year Two years Five years Ten years 
 Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls 
OA 58.6  
(58.0,59.1) 
43.5  
(43.2,43.8) 
61.4  
(60.9,62.0) 
45.2  
(44.9,45.4) 
67.3  
(66.7,67.8) 
49.7  
(49.4,50.0) 
73.3  
(72.7,73.9) 
55.7  
(55.4,56.1) 
78.6  
(77.6,79.5) 
61.3  
(60.8,61.9) 
Endocrine 
Hyperthyroidism 2.6  
(2.4,2.8) 
2.3  
(2.2,2.4) 
2.7  
(2.5,2.9) 
2.4  
(2.3,2.5) 
3.1  
(2.9,3.3) 
2.6  
(2.5,2.7) 
3.6  
(3.3,3.8) 
3.0  
(2.9,3.1) 
4.0  
(3.6,4.4) 
3.5 
(3.3,3.6) 
Hypothyroidism 13.8  
(13.4,14.2) 
10.1  
(9.9,10.2) 
14.3  
(13.9,14.7) 
10.5  
(10.4,10.7) 
15.9  
(15.5,16.4) 
11.9  
(11.7,12.1) 
18.4  
(17.9,18.9) 
14.1  
(13.8,14.3) 
21.4  
(20.6,22.3) 
16.4  
(16.0,16.8) 
T1DM 0.8  
(0.7,0.9) 
0.7 
(0.7,0.8) 
0.8  
(0.7,0.9) 
0.7  
(0.7,0.8) 
0.9  
(0.8,1.0) 
0.8 
(0.7,0.8) 
1.0  
(0.8,1.1) 
0.9  
(0.8,0.9) 
1.0  
(0.9,1.2) 
0.9  
(0.9,1.0) 
T2DM 12.9  
(12.6,13.3) 
11.8  
(11.7,12.0) 
14.1  
(13.7,14.4) 
12.6  
(12.4,12.7) 
16.9  
(16.5,17.4) 
14.8  
(14.6,15.0) 
20.8  
(20.2,21.4) 
18.2  
(18.0,18.5) 
25.3  
(24.4,26.3) 
21.9  
(21.4,22.3) 
Addison's 
disease 
0.1 
(0.1,0.1) 
0.1  
(0.1,0.1) 
0.1  
(0.1,0.2) 
0.1  
(0.1,0.1) 
0.2 
(0.1,0.2) 
0.1  
(0.1,0.1) 
0.3  
(0.2,0.4) 
0.1  
(0.1,0.1) 
0.3  
(0.2,0.4) 
0.1  
(0.1,0.2) 
Neurological 
Dementia 1.4  
(1.2,1.5) 
3.4  
(3.3,3.5) 
2.0  
(1.9,2.2) 
4.2  
(4.1,4.3) 
4.6  
(4.4,4.9) 
7.0  
(6.8,7.1) 
10.3 
(9.8,10.9) 
12.1 
(11.8,12.4) 
19.1 
(18.0,20.4) 
20.5 
(19.9,21.1) 
Parkinson's 
disease 
0.8  
(0.7,0.9) 
1.3 
(1.2,1.4) 
0.9  
(0.8,1.0) 
1.4  
(1.4,1.5) 
1.4  
(1.3,1.5) 
1.8  
(1.8,1.9) 
2.0  
(1.8,2.3) 
2.5  
(2.4,2.6) 
2.9  
(2.5,3.4) 
3.3  
(3.1,3.5) 
MS 0.2  
(0.2,0.3) 
0.3 
 (0.3,0.4) 
0.2  
(0.2,0.3) 
0.4  
(0.3,0.4) 
0.2  
(0.2,0.3) 
0.4  
(0.3,0.4) 
0.2  
(0.2,0.3) 
0.4  
(0.3,0.4) 
0.3  
(0.2,0.4) 
0.4  
(0.3,0.4) 
Psychiatric 
Schizophrenia 0.2  
(0.2,0.2) 
0.5  
(0.5,0.5) 
0.2 
(0.2,0.3) 
0.5  
(0.5,0.6) 
0.2  
(0.2,0.3) 
0.6  
(0.5,0.6) 
0.3  
(0.2,0.4) 
0.6  
(0.5,0.6) 
0.4  
(0.3,0.6) 
0.6  
(0.6,0.7) 
Bipolar disease 0.2  
(0.2,0.3) 
0.3  
(0.3,0.3) 
0.2  
(0.2,0.3) 
0.3  
(0.3,0.3) 
0.2  
(0.2,0.3) 
0.3  
(0.3,0.4) 
0.3  
(0.2,0.4) 
0.4  
(0.3,0.4) 
0.3  
(0.2,0.4) 
0.4  
(0.3,0.5) 
Depression 20.8  
(20.4,21.3) 
18.7  
(18.5,18.9) 
21.6  
(21.2,22.1) 
19.2  
(19.0,19.5) 
23.6  
(23.1,24.1) 
20.7  
(20.5,20.9) 
26.1  
(25.6,26.7) 
22.6  
(22.4,22.9) 
28.8  
(27.9,29.6) 
24.7  
(24.3,25.0) 
Anxiety 15.1  
(14.7,15.5) 
13.8  
(13.6,14.0) 
15.6  
(15.2,16.0) 
14.2  
(14.1,14.4) 
17.3  
(16.9,17.8) 
15.6  
(15.4,15.8) 
19.8  
(19.3,20.4) 
17.6  
(17.3,17.8) 
22.7  
(21.9,23.6) 
20.2  
(19.8,20.6) 
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 At diagnosis After one year Two years Five years Ten years 
 Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls 
Osteoporotic 
Osteoporosis 12.6  
(12.3,13.0) 
8.8  
(8.7,9.0) 
15.0  
(14.6,15.4) 
9.7  
(9.6,9.9) 
19.6  
(19.1,20.1) 
12.6  
(12.4,12.8) 
25.7  
(25.1,26.4) 
17.4  
(17.1,17.7) 
32.9  
(31.7,34.1) 
24.3  
(23.7,24.8) 
Hip fracture 1.7  
(1.5,1.8) 
2.3  
(2.2,2.3) 
2.1  
(1.9,2.3) 
2.7 
(2.6,2.8) 
3.4  
(3.2,3.7) 
4.0  
(3.9,4.1) 
6.3  
(6.0,6.8) 
6.5  
(6.3,6.7) 
11.4  
(10.5,12.4) 
10.6  
(10.1,11.0) 
Wrist fracture 6.3  
(6.0,6.6) 
6.2  
(6.1,6.3) 
6.6  
(6.3,6.9) 
6.5  
(6.3,6.6) 
7.4  
(7.1,7.8) 
7.4 
(7.2,7.5) 
9.2  
(8.8,9.6) 
8.7  
(8.5,8.9) 
11.3  
(10.6,12.0) 
10.8  
(10.5,11.2) 
Vertebral fracture 0.4 
(0.3,0.5) 
0.4  
(0.3,0.4) 
0.5  
(0.4,0.6) 
0.4  
(0.4,0.4) 
0.9  
(0.8,1.0) 
0.5  
(0.5,0.6) 
1.4  
(1.2,1.6) 
0.9  
(0.8,0.9) 
2.2  
(1.9,2.7) 
1.6  
(1.4,1.8) 
Ophthalmological 
Cataracts 14.5  
(14.1,14.9) 
12.3  
(12.1,12.4) 
16.6  
(16.2,17.0) 
13.6  
(13.4,13.7) 
21.7  
(21.2,22.2) 
17.4  
(17.2,17.6) 
28.6  
(28.0,29.3) 
23.3  
(23.0,23.6) 
37.4  
(36.2,38.7) 
30.1  
(29.6,30.7) 
Glaucoma 7.0  
(6.7,7.3) 
6.3  
(6.2,6.4) 
7.6  
(7.4,8.0) 
6.7  
(6.6,6.8) 
9.2  
(8.8,9.5) 
7.9  
(7.7,8.0) 
11.1  
(10.7,11.6) 
9.9  
(9.7,10.1) 
13.4  
(12.7,14.1) 
12.1  
(11.7,12.5) 
Infections 
UTI 22.8  
(22.3,23.3) 
20.3  
(20.0,20.5) 
24.6  
(24.1,25.1) 
21.7  
(21.5,21.9) 
29.4  
(28.8,29.9) 
25.9  
(25.7,26.2) 
37.2  
(36.5,37.9) 
32.5  
(32.2,32.8) 
46.9  
(45.7,48.2) 
40.6  
(40.0,41.2) 
URTI 66.9  
(66.4,67.5) 
59.6  
(59.3,59.8) 
69.2  
(68.7,69.7) 
61.7  
(61.5,62.0) 
74.5  
(74.0,75.0) 
67.1  
(66.8,67.3) 
80.3  
(79.7,80.8) 
73.3  
(73.0,73.6) 
85.0  
(84.2,85.8) 
79.3  
(78.8,79.7) 
LRTI 4.7  
(4.5,4.9) 
4.1 
(4.0,4.2) 
5.4 
(5.1,5.6) 
4.7  
(4.6,4.8) 
7.6 
(7.3,8.0) 
6.7  
(6.6,6.9) 
12.2  
(11.7,12.7) 
10.1  
(9.8,10.3) 
18.8  
(17.8,19.9) 
15.2  
(14.7,15.7) 
Skin infections 16.4 
(16.0,16.9) 
14.7  
(14.6,14.9) 
18.5 
(18.1,18.9) 
16.1  
(15.9,16.3) 
23.5  
(23.0,24.0) 
20.1  
(19.8,20.3) 
31.3  
(30.7,32.0) 
26.4  
(26.1,26.7) 
40.3  
(39.1,41.6) 
34.4  
(33.8,35.0) 
Abbreviations: Leukaemia, lymphoma (LL), Cardiovascular disease (CVD), Congestive cardiac failure (CCF), Peripheral vascular disease (PVD), 
Cerebrovascular disease (CVA), Hypertension (HTN), Chronic obstructive pulmonary disease (COPD), Ulcerative colitis (UC), systemic lupus 
erythematosus (SLE), rheumatoid arthritis (RA), Osteoarthritis (OA), Type 1 Diabetes mellitus (T1DM), Type 2 Diabetes mellitus (T2DM), Multiple 
sclerosis (MS), Urinary tract infection (UTI), Upper respiratory tract infection (URTI), Lower respiratory tract infection (LRTI) 
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Stratified outcomes 
Cancer 
Cancer diagnoses were stratified into six major cancer types, breast, prostate, 
lung, colorectal, leukaemia and lymphoma and melanoma. The cumulative 
probability of the majority of the individual cancer types was higher in the control 
group compared to patients with PMR. This was true at every time point in the 
case of breast, lung and colon cancer as well as leukaemia and lymphoma. In 
the case of prostate cancer, however, the cumulative probability of developing 
this was higher in cases rather than controls. Finally, the picture was mixed with 
melanoma as the cumulative probability was higher at times during follow up for 
either cases or controls. 
 
Vascular 
Following index date, the cumulative probability of most of the stratified vascular 
comorbidities, including cardiovascular disease, congestive cardiac failure, 
peripheral vascular disease and hypertension was consistently higher in patients 
with PMR when compared to those without. In each of these cases, the difference 
between cases and controls increased over the ten year follow up period. In the 
case of cerebrovascular disease, at the time of diagnosis and at one year of 
follow up the probability of developing this comorbidity was higher in controls 
rather than cases. However, after two years of follow up, the probability of 
cerebrovascular disease became higher in cases, similar to the other vascular 
comorbidities, although the difference was much less.   
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Other comorbidities 
All the stratified respiratory, autoimmune, endocrine, ophthalmological and 
infection related comorbidities exhibited an increased cumulative probability of 
diagnosis in people with PMR, and this was maintained over time. These 
comorbidities included asthma, COPD, lung fibrosis, systemic lupus 
erythematosus, rheumatoid arthritis, Sjogren’s syndrome, Psoriatic arthritis, 
Raynaud’s disease, osteoarthritis, hyper- and hypothyroid disease, type 1 and 
type 2 diabetes mellitus, Addison’s disease, cataracts, glaucoma as well as 
urinary tract, upper and lower respiratory tract and skin infections. 
All of the comorbidities within the gastroenterological and osteoporosis 
categories showed a sustained increase in the cumulative probability of diagnosis 
in patients with PMR, with the exception of liver disease and hip fractures. Liver 
disease had a very similar cumulative probability in both cases and controls, but 
was slightly higher in controls in the first five years following index date, and 
cases at ten years following index date. All other osteoporotic linked outcomes 
were higher in patients with a pre-existing diagnosis of PMR except hip fracture. 
In this case, similar to liver disease, the cumulative probability of this comorbidity 
was higher in the control group until ten years following index date, at which time 
it was higher in patients with PMR. 
 
Overall 
A number of chronic and acute conditions developed particularly high cumulative 
probabilities over the ten year follow up period in this study. For example, chronic 
conditions such as hypertension and osteoarthritis affected greater than half of 
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the patients across most of the study period. Furthermore, greater than 88% of 
patients in the study had received a code denoting that they had developed an 
infectious disease at ten years of follow up; with upper respiratory tract infections 
being particularly common. 
Of the other composite outcomes, more than 50% of patients had experienced a 
vascular event, and more than 40% had received a diagnosis of a cancer or 
developed a degree of renal disease. Psychiatric, respiratory, endocrine and 
osteoporosis related conditions affected more than 30% of patients. 
In order to ascertain whether these differences in cumulative probability of 
comorbidities in patients with PMR and their matched controls was significantly 
different, Cox proportional hazards regression was employed to calculate hazard 
ratios with 95% confidence intervals (both crude and adjusted for BMI category, 
age, sex, smoking status and alcohol consumption). However, prior to presenting 
these results, the data was tested to ensure that the Cox proportional hazard 
model criteria were not violated. 
 
Statistical testing of Cox proportional hazards 
As discussed in chapter 6.2.7, in order to ascertain whether the Cox proportional 
hazards model is an appropriate model, testing was performed to ensure that the 
proportional hazards requirement following index date was met. In order to do 
this, Kaplan-Meier survival estimates were produced to graphically assess 
whether the hazards altered between the covariates of interest. The Kaplan-
Meier charts are enclosed as appendix 6. 
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Reassuringly, for all the comorbid outcomes tested, the proportional hazards 
assumption was then met. Many of the comorbidities tested showed little 
difference in the rate of diagnosis between cases and controls, with survival 
curves often being very similar. Of the comorbidities in which differences in 
survival were seen, the hazards were proportional. Satisfied that the 
requirements of the model were met, the hazard ratios can be reported. 
 
Composite outcomes 
The results for the composite outcomes are summarised in table 6-17.  
Table 6-17: Hazard ratios (including 95% confidence intervals) illustrating 
likelihood of combined comorbidity following index date 
 Hazard ratio 
(unadjusted) 
Hazard ratio 
(adjusted) 
Cancer 1.00 (0.96,1.03) 0.98 (0.94,1.01) 
Vascular 1.26 (1.22,1.31) 1.23 (1.19,1.28) 
Respiratory 1.25 (1.18,1.31) 1.25 (1.18,1.32) 
Gastroenterological 1.22 (1.13,1.33) 1.21 (1.12,1.32) 
Autoimmune 4.62 (4.29,4.97) 4.68 (4.35,5.03) 
Endocrine 1.42 (1.36,1.48) 1.41 (1.35,1.47) 
Neurological 0.95 (0.90,1.00) 0.89 (0.84,0.93) 
Psychiatric 1.28 (1.20,1.35) 1.29 (1.21,1.36) 
Ophthalmological 1.40 (1.35,1.46) 1.37 (1.32,1.42) 
Infections 1.29 (1.24,1.33) 1.26 (1.22,1.31) 
Fragility fracture 1.18 (1.11,1.25) 1.14 (1.08,1.21) 
 
 
Composite outcomes 
Cox proportional hazard analysis was used to assess whether the differences 
observed in the incident rate of comorbidities after index date were significantly 
different in patients with or without PMR.  Most of the observed differences in 
incidence of composite outcomes, either increased or decreased, were found to 
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be significant. These results remained after adjustment for BMI category, 
smoking status, alcohol consumption, age and sex. 
The composite outcomes for which there was a statistically significant increased 
risk in patients with a diagnosis of PMR included vascular, respiratory, 
gastroenterological, autoimmune, endocrine, psychiatric, ophthalmological and 
infectious diseases, as well as fragility fractures. The largest effect size was seen 
with autoimmune conditions, for which a hazard ratio [HR] of 4.68 [95% 
confidence interval (CI) 4.35, 5.03] was calculated.  
The risk of cancer diagnosis was not found to be significantly different in cases 
or controls [HR 0.98 (0.94, 1.01)]. However, after adjustment for BMI, alcohol 
consumption and smoking, the risk of neurological diseases were found to be 
significantly reduced [HR 0.89, (0.84, 0.93)]. 
To examine these findings in greater detail, the stratified outcomes are tabulated 
in table 6-18. They are also graphically presented, with the total number of new 
diagnoses in patients with PMR indicated also, in figures 6-3 and 6-4 for ease of 
interpretation.  In these figures, autoimmune outcomes are not included as the 
hazard ratios were far greater than one. 
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Table 6-18: Hazard ratios (including 95% confidence intervals) illustrating 
likelihood of stratified comorbidities following index date  
HR (unadjusted) HR (adjusted) 
Cancer   
Breast cancer 0.87 (0.78, 0.98) 0.88 (0.79, 0.98) 
Prostate cancer 1.17 (1.04, 1.30) 1.11 (0.99, 1.24) 
Lung cancer 0.86 (0.77, 0.95) 0.86 (0.77, 0.95) 
Colon cancer 0.97 (0.87, 1.08) 0.95 (0.85, 1.06) 
Melanoma 0.99 (0.82, 1.19) 0.96 (0.80, 1.15) 
Leukaemia, lymphoma 1.15 (1.02, 1.28) 1.11 (0.99, 1.25) 
Vascular 
  
CVD 1.32 (1.26, 1.39) 1.30 (1.24, 1.37) 
CCF 1.30 (1.23, 1.37) 1.25 (1.19, 1.32) 
PVD 1.47 (1.38, 1.58) 1.44 (1.35, 1.55) 
CVA 1.10 (1.05, 1.16) 1.07 (1.02, 1.12) 
HTN 1.22 (1.17, 1.27) 1.21 (1.16, 1.25) 
Respiratory 
  
Asthma 1.24 (1.15, 1.35) 1.25 (1.15, 1.35) 
COPD 1.22 (1.14, 1.29) 1.23 (1.15, 1.30) 
Lung fibrosis 1.57 (1.35, 1.82) 1.50 (1.29, 1.75) 
Renal    
Renal disease 1.39 (1.35, 1.44) 1.34 (1.30, 1.39) 
Gastroenterological 
  
Moderate liver disease 1.09 (0.94, 1.27) 1.09 (0.94, 1.27) 
Peptic ulcers 1.13 (1.01, 1.27) 1.11 (0.99, 1.25) 
Crohn's disease 1.52 (0.99, 2.33) 1.52 (0.98, 2.33) 
Ulcerative colitis 1.72 (1.45, 2.04) 1.71 (1.44, 2.03) 
Autoimmune and musculoskeletal 
SLE 4.42 (2.77, 7.05) 4.65 (2.92, 7.40) 
Systemic sclerosis 2.20 (1.20, 4.06) 2.23 (1.21, 4.14) 
Rheumatoid arthritis 6.90 (6.27, 7.60) 6.99 (6.35, 7.70) 
Sjogren’s syndrome 2.95 (2.09, 4.18) 3.07 (2.16, 4.35) 
Psoriatic arthritis 8.03 (6.31, 10.22) 8.23 (6.46, 10.47) 
Raynaud's disease 1.48 (1.27, 1.72) 1.47 (1.26, 1.71) 
Osteoarthritis 1.93 (1.86, 2.00) 1.90 (1.83, 1.97) 
Endocrine 
Hyperthyroidism 1.41 (1.20, 1.65) 1.41 (1.20, 1.66) 
Hypothyroidism 1.25 (1.16, 1.34) 1.25 (1.16, 1.34) 
T1DM 1.54 (1.12, 2.11) 1.53 (1.11, 2.10) 
T2DM 1.51 (1.43, 1.59) 1.49 (1.42, 1.57) 
Addison's disease 4.00 (2.47, 6.49) 4.01 (2.48, 6.48) 
Neurological  
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HR (unadjusted) HR (adjusted) 
Dementia 0.93 (0.88, 0.98) 0.87 (0.82, 0.92) 
Parkinson's disease 1.07 (0.94, 1.23) 1.04 (0.90, 1.19) 
MS 1.16 (0.51, 2.68) 1.20 (0.52, 2.74) 
Psychiatric 
Bipolar disease 1.15 (0.68, 1.94) 1.20 (0.71, 2.03) 
Depression 1.40 (1.31, 1.49) 1.41 (1.32, 1.50) 
Anxiety 1.18 (1.10, 1.27) 1.19 (1.11, 1.28) 
Schizophrenia 0.95 (0.58, 1.57) 0.97 (0.59, 1.60) 
Complications due to glucocorticoids 
Osteoporosis 2.12 (2.03, 2.21) 2.11 (2.03, 2.20) 
Hip fracture 1.09 (1.02, 1.17) 1.05 (0.98, 1.13) 
Wrist fracture 1.14 (1.04, 1.25) 1.13 (1.03, 1.24) 
Vertebral fracture 2.05 (1.73, 2.42) 1.96 (1.66, 2.32) 
Ophthalmological 
Cataracts 1.41 (1.36, 1.47) 1.37 (1.32, 1.43) 
Glaucoma 1.28 (1.18, 1.37) 1.25 (1.16, 1.35) 
Infections 
  
UTI 1.25 (1.21, 1.31) 1.23 (1.18, 1.28) 
URTI 1.27 (1.22, 1.31) 1.25 (1.20, 1.29) 
LRTI 1.22 (1.15, 1.29) 1.18 (1.12, 1.25) 
Skin infections 1.36 (1.31, 1.42) 1.33 (1.28, 1.38) 
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Figure 6-3: Likelihood of comorbidities after index date expressed as hazard 
ratios with 95% confidence intervals (unadjusted)  
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Figure 6-4: Likelihood of comorbidities after index date expressed as hazard 
ratios with 95% confidence intervals (adjusted)  
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Stratified outcomes 
Cancer 
Of the six main cancer types, after adjustment for alcohol consumption, BMI 
category, age, sex and smoking status, two show no significant difference in 
diagnosis subsequent to index date (prostate cancer and melanoma), while four 
show a statistically significant reduction in the likelihood of diagnosis (leukaemia 
or lymphoma and colorectal, breast and lung cancers). The biggest reduction 
seen was in the risk of diagnosis of lung cancer in patients with PMR, where it 
dropped by 20%. Overall, however, the composite risk of cancer was not 
significantly reduced. 
 
Vascular 
After adjustment, all of the vascular outcomes were significantly more likely to 
occur after index date in patients with PMR. These included peripheral and 
cardiovascular disease, as well as congestive cardiac failure, hypertension and 
cerebrovascular disease. 
  
Comorbidities linked to GC prescription 
Most of these conditions, which included ophthalmological diagnoses such as 
cataracts and glaucoma, as well as osteoporosis, fragility fractures, and 
infectious diseases were significantly more likely to occur in patients with a 
previous diagnosis of PMR both before and after adjustment was applied. The 
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single exception to this was hip fractures, where no significant difference in the 
likelihood of development of this comorbidity was seen, albeit only in the adjusted 
group.  
 
Other comorbidities 
All of the comorbidities within the respiratory category, including lung fibrosis, 
asthma and COPD were statistically significantly more likely to be diagnosed in 
patients who had a pre-existing diagnosis of PMR. The risk of diagnosis with 
renal disease and all of the autoimmune comorbidities investigated, was also 
found to be significantly higher in patients with PMR.  
The risk of diagnosis with all endocrine comorbidities was found to be higher in 
patients with PMR. Specifically, the risk of Addison’s disease, hypothyroidism, 
hyperthyroidism and type 1 and 2 diabetes mellitus were all significantly higher 
in patients with PMR. However, in the case of gastroenterological comorbidities, 
a more mixed picture emerged. The risk was significantly higher in the case of 
ulcerative colitis, however there was no significant difference in the risk of 
Crohn’s, peptic ulcer and liver disease between patients with or without PMR. 
Patients with PMR were statistically significantly less likely to be diagnosed with 
dementia. No significant difference was seen between patients with PMR 
compared to those without in the risk of developing Parkinson’s disease or 
multiple sclerosis (MS). Regarding psychiatric diagnoses, similar to what was 
found in the case control study, the more common psychiatric diagnoses of 
anxiety and depression, which include cases of mild and moderate severity, were 
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significantly more likely to have occurred in patients who had a diagnosis of PMR. 
However, in the case of psychiatric illnesses that could be perceived as ‘more 
serious’, such as schizophrenia and bipolar disease, no significant difference in 
risk was observed. 
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6.4 Discussion 
6.4.1 Main findings 
This study has found that patients with PMR have a higher rate of comorbid 
diseases when compared to matched controls prior to, and after, diagnosis of 
PMR. There was a significantly increased risk of vascular, respiratory, renal, 
autoimmune, endocrine and psychiatric diseases both before and after index 
date in patients with PMR. Conversely, the risk of cancer and dementia was 
significantly lower in patients with PMR compared to their matched controls. 
These differences were again present before and after index date. Finally, 
following index date, the risk of glucocorticoid (GC) related conditions was higher 
in patients with PMR when compared to those without.  
This study is the first to provide a broad, comprehensive view of comorbidities in 
patients with PMR compared to matched controls and will inform discussion 
around whether the presence of certain comorbidities should indeed preclude its 
diagnosis.  
 
6.4.2 Charlson comorbidity index  
Both before and after diagnosis, an increased proportion of cases had a higher 
Charlson comorbidity index score. At the same time, the proportion of controls 
with a Charlson score of zero was greater. However, at most time points before 
and after index date, a greater proportion of controls had a Charlson index score 
of 5 or more, although the absolute number of patients were small. This indicates 
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that patients with PMR had, on average, a greater burden of comorbid disease, 
but also that patients with the highest burden of comorbidities were less likely to 
be diagnosed with PMR. 
 
6.4.3 Strengths and limitations  
This is the largest study investigating the association of PMR with a broad range 
of comorbidities both before and after a diagnosis of PMR. The comorbidities 
were selected using robust methodology and the data sample used comes from 
a large, established database of patients who are representative of the UK 
population. (Williams et al., 2012) Furthermore, as the majority of patients with 
PMR are managed exclusively in primary care, the patients are likely to be 
representative of people diagnosed with PMR. (Barraclough et al., 2008; Yates 
et al., 2016) Therefore, this is the most appropriate setting to conduct this study. 
As discussed in chapter 3, a potential limitation is ascertainment of cases. For 
PMR, the authenticity of these diagnoses is reinforced by requiring that all cases 
have at least two GC prescriptions as well as an appropriate medical code. This 
method has been used before in previously published studies in CPRD of PMR. 
(Smeeth, Cook and Hall, 2006; Hancock et al., 2014; Muller et al., 2014) 
The code lists used in these studies were, when possible, updated versions of 
lists previously composed for use in similar studies that used CPRD to estimate 
the risks of vascular disease, cancer and fragility fractures. (Hancock et al., 2014; 
Muller et al., 2014; Paskins et al., 2018) These lists were obtained with the 
authors’ consent, and meticulously checked for accuracy by two authors, (RP & 
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AAS) as discussed in chapter 2.11. Of the remaining conditions, for which no 
existing list was available, new lists were produced using the CPRD medical code 
browser and reviewed by two authors (RP & AAS), one of whom has a clinical 
background, the other who is an epidemiologist.  
In order to ensure as many patients were included in the study, there was no 
requirement for follow up after index date. This meant that patients who had a 
higher disease burden and may have been more likely to die close to index date 
were kept in the study. If there had been a minimum requirement for follow up 
after index date then these patients, with a higher burden of comorbidity, would 
have been excluded. 
Incomplete data is a potential limitation of this study, particularly when using 
covariates such as BMI, alcohol and smoking to produce adjusted odds and 
hazard ratios. In this study, 13.7% of patients had no record of alcohol 
consumption, 13% BMI measurement and 5.8% smoking status. The proportion 
of patients without this data is improved compared to previous CPRD studies, in 
which around 20% of patients had no alcohol or BMI data recorded. (Herrett, 
Bhaskaran, et al., 2015) Furthermore, the proportion of missing data in this 
observational study of routinely collected health records compares favourably to 
other methods of data collection, such as surveys. (Coste et al., 2013) It is likely 
that patients without data are healthier, with lower rates of smoking, alcohol 
excess or obesity. This is because it is more likely that primary care healthcare 
teams would record this information in patients who smoked, drank excess 
amounts of alcohol or were obese. 
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Another potential limitation is a consequence of the deliberate desire to maintain 
the broad scope of this study. By examining such a wide range of comorbidities, 
there is the potential to find significant results due to the number of comparisons 
made. This is known as a Type I error, or an error caused by multiple testing. As 
the confidence intervals were set to 95%, one in twenty tests undertaken would 
therefore produce a significant result through chance alone. In mitigation of this 
the aim of this study was to assess for possible associations between PMR and 
other comorbidities, it was not designed to prove causation. By investigating the 
overall health of patients with PMR and examining for potential trends in 
comorbidity prevalence, potential areas for future research could be identified. 
The broad range of comorbidities and the relatively advanced average age of 
study participants also meant that some of the conditions assessed were rare, in 
the prospective study, where patient’s previous diagnoses were excluded. This 
meant that for these comorbidities, the analyses were underpowered to find 
significant associations, but because the case control study looked 
retrospectively, the overall risk of comorbidities could still be ascertained. 
Finally, the other main risks of bias in this study were surveillance bias and 
diagnostic overshadowing. Surveillance bias occurs where a patient within the 
case, or exposure group, are subject to increased surveillance, examinations or 
investigations compared to controls. In this study, patients with PMR, due to 
either the prodromal features of PMR, or increased follow up after diagnosis, 
including regular blood tests, will be at increased risk of comorbidities being 
identified compared to the control group. This effect has been seen in different 
specialities. An observational study of patients following a diagnosis with renal 
calculi found that they were subsequently more likely to be diagnosed with cancer 
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at a variety of sites, and that this increase persisted for up to ten years following 
index date. (Hemminki et al., 2017) 
Diagnostic overshadowing is a concept that is commonly linked to psychological 
or psychiatric conditions. In this, physical symptoms that a patient may complain 
of are inadvertently to their psychiatric illness. (Shefer et al., 2014) It may be that 
this effect takes place when those with an existing serious psychiatric or 
neurological disease, such as schizophrenia or dementia, present with symptoms 
of PMR. The symptoms may then be attributed entirely to the existing condition 
rather than PMR. However, diagnostic overshadowing might just as easily affect 
other serious medical conditions; for example, this effect may also be a factor in 
the apparent reduction in the risk of cancer in patients with PMR. Cancers can 
cause constitutional symptoms similar to PMR, and, as discussed previously, this 
fact is explicitly taken into account in the clinical classification criteria in PMR. 
(Dasgupta et al., 2010, 2012) In these criteria it is suggested that conditions such 
as cancer should be excluded in patients presenting with suspected PMR.  
 
6.4.4 Comparison to other studies  
Vascular disease 
As discussed in chapter five, there have been eight previous studies that 
assessed the risk of vascular disease, prospectively, following a diagnosis with 
PMR. (B.-Å. Bengtsson and Malmvall, 1981; Kremers et al., 2005; Kang, Sheu 
and Lin, 2011; Kermani and Warrington, 2011; Zoller et al., 2012; Zöller et al., 
2012; Hancock et al., 2014; Pujades-Rodriguez et al., 2016) These studies 
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reported a range of outcomes.  Most of these studies found an increase in the 
risk of vascular disease in patients with PMR.  
One of the two largest studies, by Hancock et al. (2014) used the GPRD dataset, 
a precursor of the CPRD database. In this paper, the adjusted hazard ratio [95% 
CI] of first vascular event was 2.6 [2.4, 2.9]. This is much greater than in the 
current study where the equivalent result was 1.23 [1.19, 1.28]. The effect size in 
this study was similar retrospectively, where the odds ratio of any vascular 
disease prior to diagnosis was 1.04 [1.01, 1.07]. Both of the observed increases 
in risks were statistically significant however. The study from Hancock et al 
(2014) utilised a smaller sample size (n= 3,249) and was drawn from patients 
with a diagnosis of PMR between 1987 and 1999. The larger sample size and 
more recent data collection in this study may account for the reduction in effect 
size.  
A second, more recent, study by Pujades-Rodriguez et al. (2016) found a 
significant overall reduction in the risk of vascular diseases (incidence rate ratio 
0.88 [0.83,0.94]). This study was drawn from the CALIBER (CArdiovascular 
disease research using LInked Bespoke studies and Electronic Health Records) 
dataset. This database links 225 primary care practices to hospital and mortality 
data. In their study, the number of PMR cases was smaller than the current study 
(n=9,776), as was the number of controls (n=105,504), even though each PMR 
patient was matched to more (up to 10) controls. The other main difference with 
this and the current study was the total median follow up after index date for the 
Pujades-Rodriguez paper of 3.1 years, compared to 5.0 years in the current 
study.  
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The difference in results between the apparent reduction in risk of vascular 
disease in Pujades-Rodriguez’s (2016) study and the current study could be for 
a number of reasons. As discussed in chapter 5, Pujades-Rodriguez (2016) did 
not use a strict age inclusion criteria, patients aged over 18 were included, rather 
than the higher threshold of forty years employed in this study. Alternatively the 
difference in follow up or the larger sample size may allow more accurate 
assessment of the risk. Finally, the main endpoints reported in this study, that of 
composite outcomes of coronary and death or fatal and non-fatal cardiovascular 
disease take into account mortality data. However, when only patients with pure 
PMR and any vascular outcome were considered, the proportion of PMR cases 
who developed a vascular outcome was indeed higher, (23.2%) compared to 
those without (20.4%).  
This proportion was less that what was seen in the current study where, after two 
years of follow up, 38.9% of cases and 35.1% of controls had at least one record 
of vascular disease in their notes. The difference in these proportions can be 
explained as, similar to Hancock et al (2014), patients in the Pujades-Rodriguez 
(2016) study were intentionally vascular disease free at outset. However, this 
was not the case in the current study when cumulative probability was calculated, 
in order that the most accurate representation of disease burden be described. 
Furthermore, although the absolute numbers are much higher in the current 
study, the difference in the proportion of PMR cases and controls with a vascular 
disease was similar in both studies, at 2.8% for Pujades-Rodriguez and 3.8% in 
the current study. 
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Cancer 
Six studies (Haga et al., 1993; Myklebust et al., 2002; Jianguang et al., 2010; 
Muller et al., 2014; Pfefiffer et al., 2015; Bellan et al., 2017) have previously 
estimated the risk of cancer in patients after diagnosis with PMR. Two found a 
higher proportion of patients with PMR subsequently developed cancer, two were 
equivocal, while two found the opposite. In the current study, the risk of cancer 
prior to index date was lower in patients with PMR (Odds ratio 0.89 [0.86, 0.93]) 
although this reduction in risk was not observed subsequent to index date 
(Hazard ratio 0.98 [0.94, 1.01]).  
After ten years of follow up, around 40% of cases and controls had been 
diagnosed with cancer. The mean follow up after index date was 4 years for both 
cases and controls. Therefore, ten years after the index date, the study sample 
had reduced significantly. However, this correlates well with estimates that half 
of the UK population will be diagnosed with cancer during their lifetime. (Cancer 
Research UK 2019) 
Upon stratification of cancer risks, it can be seen that the risk of most of the 
outcomes, particularly breast, colorectal, leukaemia, lymphoma and lung was 
higher in controls rather than cases. It may be, in this case, that this is due to 
diagnostic overshadowing as discussed earlier. The single cancer with a 
consistently increased rate among patients with PMR was prostate cancer. As 
PMR predominantly affects women and prostate cancer exclusively affects men, 
this apparent increase in risk could be erroneous.  
The only previous study of UK primary care data was carried out in GPRD, this 
was the forerunner of CPRD. In this study, the risk of cancer diagnosis was higher 
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in the first six months after diagnosis before returning to the baseline rate. The 
differences in this study included that it used an earlier iteration of CPRD and had 
a smaller sample size (n= 12,819 total). As well as that, all the patients identified 
were vascular disease free at outset. These factors may have contributed to the 
differences in results. Shared risk factors between vascular disease and certain 
cancers exist, for example smoking increases the risk of vascular disease and a 
large number of cancers, particularly lung, excluding these patients may have 
introduced bias into the study design.  
 
Autoimmune conditions 
As discussed in chapter one, whether PMR is an autoimmune or auto-
inflammatory disease remains a matter of debate. (Floris et al., 2018) One study 
categorised immunological diseases into either autoimmune or auto-
inflammatory. (McGonagle and McDermott, 2006) Of the comorbidities assessed 
in the current study, thyroid diseases, rheumatoid arthritis (RA), Sjogren’s 
disease, systemic lupus erythematosus (SLE) and systemic sclerosis (SS) were 
all categorised as polygenic autoimmune conditions. Crohn’s disease, ulcerative 
colitis, type one diabetes and osteoarthritis were proposed to be polygenic auto-
inflammatory diseases, while psoriatic arthritis was classified as mixed. 
Applying this to the results from this study, of the autoimmune diseases, thyroid 
diseases, RA and Sjogren’s disease were strongly associated with PMR 
diagnosis both before and after index date. The picture was more mixed in the 
case of SLE and SS however, where the retrospective increase in the risk of 
diagnosis in patients who went on to develop PMR did not reach statistical 
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significance. Of the auto-inflammatory conditions, ulcerative colitis and 
osteoarthritis were statistically significantly associated with PMR both before and 
after index date, as indeed was psoriatic arthritis. However, no significant 
difference was observed with type one diabetes and Crohn’s disease. 
Overall, these results provide more evidence that PMR should be grouped as an 
immunological condition. However, whether it ought to sit within the 
subcategories of autoimmune or auto-inflammatory is less clear. Complicating 
the picture is a number of factors. The first is misdiagnosis, for example, although 
OA is an auto-inflammatory condition and is strongly linked to PMR, the 
presenting features of both conditions- pain, aching and stiffness are very similar. 
Furthermore, although OA is traditionally thought of as non-inflammatory, it is 
well recognised to have an inflammatory component. (Glyn-Jones et al., 2015)  
The issue of misdiagnosis between PMR and RA, particularly Elderly-onset 
rheumatoid arthritis (EORA), was discussed in chapter 1 and could be part of the 
reason why such a strong link with PMR, particularly prospectively, was found. 
In this case, patients with an existing diagnosis of PMR and difficulty reducing 
GC were perhaps then investigated further and later received a diagnosis of RA. 
Other associations that were not found to be significant, for example between 
PMR and SLE or SS were likely a reflection of those conditions’ rarity and the 
relative rarity of PMR. In these conditions, although the rate of diagnosis was 
higher in patients with PMR, there were insufficient numbers, and therefore 
power, for significant differences to be observed. 
Previous research into whether PMR co-exists with other autoimmune conditions 
was performed by Eaton et al. (2007). In this study, PMR was included within an 
 228 
 
epidemiological study of 33 autoimmune conditions in Denmark. Consistent with 
the findings in this study, an increase in the risk of Sjogren’s disease, SLE, SS, 
psoriatic arthritis, ulcerative colitis and Crohn’s disease was found. However, this 
study also investigated, and found an increase in, the risk of multiple sclerosis 
(MS). This contrasts with the current study in which the risk of MS was 
significantly reduced both before and after index date. Similar to cancer 
diagnoses, this reduction may have been due to diagnostic overshadowing.   
Some work has also been done around the risk of thyroid disease in patients with 
PMR, (Bowness et al., 1991; Juchet et al., 1993) the results of which were 
equivocal. This contrasted with this study where the risk of both hypo- and 
hyperthyroid disease was greater before and after index date in patients with 
PMR.  
The results from this study support the conclusion that PMR should be 
categorised as an immunological disease. However, the statistically significant 
associations which exist across both autoimmune and auto-inflammatory 
conditions make it difficult to firmly subcategorise PMR at this point in time.  
 
Glucocorticoid related conditions 
Shbeeb et al. (2018) published a cohort study of 359 patients with PMR and an 
equal number of comparators, investigating the likelihood of GC related 
complications (including diabetes mellitus, hypertension, cataracts and fragility 
fractures). The controls in the study were subjects without PMR who were 
matched by age and sex. They found a statistically significant increase only in 
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the incidence of cataracts over the median follow up period of 5.8 years hazard 
ratio (HR) 1.72 [1.23, 2.41]. All of the other measured outcomes were found to 
be non-significantly reduced (diabetes mellitus, hypertension and hip or any other 
fracture) or increased (hyperlipidaemia and vertebral or Colles fractures). 
Paskins et al. (2018) published a CPRD based study into patients with PMR and 
GCA, and found an increase in the rate of fragility fractures.  
In this study, similar to Paskins et al, the risk of any fragility fractures was found 
to be higher in patients with PMR. Within the stratified outcomes, the risk of 
vertebral fracture was significantly higher in patients with PMR, while the risk of 
hip fracture was less in those with PMR.  Interestingly, a similar pattern of an 
increase in the risk of vertebral fracture and a reduction in the risk of hip fracture 
in patients with PMR was observed by Shbeeb et al (2018). Furthermore, this 
study replicated their findings of an increased risk of cataracts and also found an 
increase in the risk of glaucoma, which was not assessed by Shbeeb et al (2018). 
However, contrary to Shbeeb et al’s (2018) findings, the risk of type two diabetes 
was significantly higher in patients with PMR in this study.  
In this study, the risk of osteoporosis was found to be higher in patients with PMR, 
however the risks of each type of fragility fracture was more mixed. It may be that 
GPs are alert to the dangers of long term GC treatment in PMR and therefore 
intervene to reduce the risk of fragility fractures by providing more active and 
earlier treatment, such as bisphosphonate medication. 
Other GC related outcomes, specifically those linked to infectious diseases, have 
not previously been reported. As would be expected, given the 
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immunosuppressant properties of GCs, the rates of infectious diseases were all 
found to be significantly higher in patients with a history of PMR. 
 
Other comorbidities 
Psychiatric comorbidity  
Previous studies have found no association between PMR and psychiatric 
comorbidities such as schizophrenia (Eaton et al., 2006; Chen et al., 2012) and 
bipolar disease, (Eaton et al., 2006). In this study, patients with PMR were 
actually observed to have a significantly reduced risk of diagnosis with 
schizophrenia prior to index date. This may be due to diagnostic overshadowing. 
Schizophrenia is a severe, enduring disorder that is known to cause disability, as 
well as cognitive and functional impairment. (Grande et al., 2016; Owen, Sawa 
and Mortensen, 2016)  
The risk of depression and anxiety was found to be higher in patients with PMR, 
which is perhaps linked to the chronic nature of the pain and stiffness associated 
with PMR. Furthermore, it is well established that depression is linked to 
multimorbidity (Read et al., 2017) and, as has been established in this study, 
patients with PMR have higher rates of comorbidities compared to controls. A 
recent postal study of a cohort of 704 patients in the UK with a diagnosis of PMR 
within the last three years confirmed that 15% of patients reported current 
depressive symptoms. (Vivekanantham et al., 2018) 
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Neurological comorbidity 
One previous study found an increase in the risk of Parkinson’s disease in 
patients with PMR. (Kari Hemminki, Li, et al., 2012) However, the current study 
found the risk of Parkinson’s disease, MS and dementia was significantly lower 
in patients with PMR prior to index date. After index date, the risk of dementia 
was significantly reduced, however no significant difference was seen in the risk 
of MS or Parkinson’s disease. Again, it may be that the rates of PMR in patients 
with these conditions are similar, but, due to diagnostic overshadowing, PMR is 
under-diagnosed in these groups.  Although not specifically relating to PMR, it is 
becoming better recognised that that chronic pain in elderly patients with 
cognitive decline is under-diagnosed. (Cravello et al., 2019) 
A number of reasons for this could be postulated, for example communication 
difficulties as a result of cognitive impairment, or, even when a history of aching 
or pain is elicited, GPs downplaying them or viewing them as part of the disease 
process in dementia. Furthermore, the converse could also be true, that patients 
who do not have another serious condition may be more likely to receive a 
diagnosis of PMR. In this case, patients who present to GPs with vague, poorly 
localised symptoms such as myalgia, stiff joints or tiredness may be more likely 
to receive a diagnosis of PMR because of the absence of another definable 
cause. 
Rather than the apparent associations seen in this study being entirely due to 
biological factors, it may be that human factors around competing health priorities 
and the short amount of time GPs have to make clinical decisions mean that 
certain comorbidities appear less frequently in patients with PMR. These possible 
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complicating factors might also have an effect on the possible associations 
between other comorbidities and PMR, such as cancer.  
 
Endocrine comorbidity 
Conditions within this category have been discussed previously as either 
autoimmune or relating to GC usage. The risk of diagnosis of Addison’s disease 
may be higher in patients with PMR, but, despite the size of this study, there was 
insufficient statistical power to show a significant association. 
 
Renal and Respiratory comorbidities 
As discussed in chapter 5.4, the existing literature does not contain estimates of 
the risk of respiratory and renal diseases in patients with PMR. As such, this is 
the first study to estimate these figures. From this data, it appears that the risk of 
renal disease, asthma, lung fibrosis and COPD are significantly higher in patients 
with PMR both prior to, and following, index date. There could be a number of 
reasons for this difference. Among these could be surveillance bias, links to 
pathological processes or shared immunological processes.  
Surveillance bias could explain the increased risk of diagnosis with renal disease. 
Patients with PMR are likely to have regular blood tests as part of their follow up, 
and given that it has been estimated that up to one million people in the UK may 
have undiagnosed renal disease, (Kerr et al., 2012) it may be simply that PMR 
follow up means these patients are more likely to be identified. 
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The increased risk of diagnosis with asthma in patients with PMR could be due 
to shared immunological pathways. Asthma and PMR are both conditions that 
are characterised by inflammation, responsiveness to GC treatment and possibly 
an autoimmune cause. (Tedeschi and Asero, 2008) Similarly, although the cause 
of pulmonary fibrosis can be occupational, it is often idiopathic and, similar to 
PMR it displays some responsiveness to GC therapy. (Richeldi, Collard and 
Jones, 2017) Therefore there may be some shared immunological processes and 
it is conceivable that this could in part account for some of the observed increase 
in risk of asthma and lung fibrosis in patients with PMR. 
 
6.4.5 Conclusion and clinical implications  
This study is the first to estimate total disease burden in patients with PMR before 
and after diagnosis. In conclusion, patients with PMR have a greater number of 
comorbidities when compared to matched controls prior to, and after, diagnosis. 
Specifically, the risks of vascular, renal, respiratory and psychiatric conditions are 
increased, as are the risks of GC related comorbidities. Reassuringly, however, 
the risks of cancer and neurological diseases appear to be significantly less in 
patients with PMR, although, as discussed previously, this apparent reduction in 
risk may be due to ascertainment bias. 
The associations between certain comorbidities and PMR that have been 
observed in this study mean that practical recommendations could be made in 
the management of PMR. 
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1. Increased surveillance for important comorbidities in patients with a 
diagnosis of PMR. 
 
Some of the comorbidities which are seen to be at higher risk in patients with 
PMR may have been detected due to surveillance bias. However, others, such 
as vascular disease and psychiatric comorbidities such as depression and 
anxiety, may be due either to the inflammatory pathophysiology of PMR, the 
symptoms caused by the disease itself or even the treatment for it. As such, 
patients with a diagnosis of PMR need to be screened thoroughly for the 
development of these conditions.  
Furthermore, given these observed associations between PMR and vascular 
disease, practitioners need to emphasise the importance of timely reduction and 
withdrawal of GC therapy where possible. Also, maintaining a holistic approach, 
through advising smoking cessation, diet management as well as active blood 
pressure and cholesterol control should be stressed.  
 
2. Confirmation that PMR can exist alongside other immunological 
diagnoses. 
 
Immunological conditions cluster together and this study has confirmed that the 
presence of PMR greatly increases a patient’s chances of a diagnosis with 
another immunological condition. Some of these diagnoses may be 
misclassifications, where patients with PMR go on to be re-diagnosed with 
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another condition such as RA. However, this study has shown that patients with 
PMR also have an increased risk of immunological conditions prior to index date. 
PMR should be regarded as an immunologically mediated disease and no longer 
as a diagnosis of exclusion.  
 
3. PMR should be considered more strongly in patients with existing cancer 
or neurological diagnoses. 
 
In patients with PMR a previous diagnosis of either cancer or a serious 
neurological disease, PMR is much less likely to be diagnosed. It may be that 
some of these potential PMR cases are missed due to diagnostic overshadowing. 
Therefore, it could be argued that current clinical classification criteria, which note 
that the presence of these comorbidities may preclude a diagnosis of PMR, 
perhaps ought to be challenged.  
The next chapter involves an analysis of a subset of these patients in this study. 
It will look at linked data on admissions to hospital, including reasons for 
admission, as well as mortality data taken from linked datasets in order to assess 
whether the observed differences in morbidity rate affect hospital admission or 
mortality in patients with PMR.  
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Chapter 7 COMORBIDITIES IN POLYMYALGIA RHEUMATICA: 
SECONDARY CARE LINKED DATASETS 
This chapter contains the results of three studies. The first is a prospective 
analysis of the rate of hospital admissions after index date in patients with PMR 
compared to matched controls. The second is a retrospective case control and 
prospective cohort analysis of the reasons for hospital admission before and after 
index date in the same patient sample. The third study in this chapter is a 
prospective mortality analysis, again comparing patients with PMR to matched 
controls. These studies will be carried out using datasets linked to the CPRD. 
 
7.1 Introduction 
In the previous chapter it was established that patients with polymyalgia 
rheumatica (PMR) have a greater number of comorbidities than patients who 
were matched by age, sex and practice, on their primary care electronic health 
records. It was found that patients with PMR were more likely to have a recorded 
diagnosis of vascular, respiratory and autoimmune conditions. Conversely, it was 
demonstrated that patients with PMR were less likely to have a recorded 
diagnosis of neoplastic and dementia. 
CPRD contains data collected and coded within primary care. Many of the 
comorbidities previously studied are diagnosed and managed in primary care. 
However, some comorbid conditions investigated are diagnosed and managed 
largely in secondary care. Although, due to the ‘hub and spoke’ model of the 
NHS, even these types of conditions, such as myocardial infarctions, should also 
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be recorded in primary care electronic medical records. This study will assess 
secondary care data to assess the impact of the greater burden of comorbidities 
seen in the previous chapter on the health of patients with PMR. 
This chapter will investigate the prevalence and likelihood of admission to 
hospital, with a comorbidity, in patients with PMR compared to their matched 
controls using data taken from secondary care. In addition, the mortality rate of 
patients with PMR will be compared to those without. The databases used in this 
study will be Hospital Episode Statistics (HES) and the Office for National 
Statistics (ONS). From these datasets, information can be obtained regarding the 
number of hospital admissions, primary reasons for hospital admission, mortality 
rates and causes of death. 
The use of linked data will allow the testing of a number of hypotheses. The first 
uses HES data to investigate whether the increased rate of comorbidities in 
primary care data in patients with PMR is translated to differences in hospital 
admission rates or reasons for admissions. The second aim is to investigate 
whether differences in comorbidities diagnosed in primary and secondary care 
are associated with differences in mortality rates and causes of death in patients 
with PMR compared to matched controls. 
 
7.1.1 Data Linkage 
Of the practices contributing data to CPRD, only practices based in England are 
eligible for linkage to further datasets. Of those practices, 75% have consented 
to link data. (Herrett, Bhaskaran, et al., 2015) Where consent exists, patient level 
data is linked via NHS Digital (previously known as the Health and Social Care 
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Information Centre) to other established data sources. (NHS Digital) NHS Digital 
is regarded as a trusted third party and anonymises data from hospitals and 
CPRD to ensure security of patient information. 
The linkages between CPRD and other datasets have been established at 
different times. Hospital Episode Statistics (HES) data can originate from as early 
as 1997 and at the time the data was analysed runs until December 2017. Death 
registration data, from the Office for National Statistics, is available from January 
1998 until February 2018. Each linked dataset will now be considered in turn. 
 
7.1.2 Hospital Episode Statistics 
Hospital Episode Statistics (HES) is a database that contains coded information 
from secondary care linked to patients contributing to CPRD. This database 
provides information on hospital admissions for linked patients across a number 
of domains.  
Similar to the main CPRD database, the primary recorded diagnosis in the linked 
data is recorded as a code. However, instead of using the Read code 
classification system, the International statistical classification of diseases and 
related health problems (ICD) 10 system is used. The ICD 10 system is 
maintained by the World Health Organisation and has been in use since 1994. It 
contains codes for diseases, which will be used in this study, and also for 
symptoms, signs, social findings and a number of other domains. The code is 
hierarchical and consists of a letter followed by two numbers before a full stop. 
For example codes beginning with the letter ‘C’ or ‘D’ encompass all neoplastic 
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diseases. For greater specificity more numbers, after the full stop, can be 
employed, for example C75.1 refers specifically to a malignant neoplasm of the 
pituitary gland. (World Health Organisation, 2016) The comorbidities which will 
be investigated in this study will be the same as those identified in chapter 6, the 
investigation into comorbidities in patients with PMR in primary care.  
Currently, there are few studies in medical literature wherein data on rates of 
hospital admissions in patients with PMR have been published. In 2018, an 
abstract was presented at the American College of Rheumatology annual 
meeting, where information around hospital admission rates, diagnoses made, 
duration and readmissions in patients with PMR, who were identified in the 
Olmsted County cohort, were described and compared to matched controls. No 
significant differences were observed in this cohort. (Raheel et al., 2018) These 
findings have not yet been published in a peer reviewed journal however. 
One further piece research is a study using Hospital Episode Statistics which was 
published as a ‘letter to the editor’ in Rheumatology. In this, it was reported that 
the rates of admission in the UK due to either giant cell arteritis (GCA) or PMR 
was increasing over time, from 2002-2013. However, rates of sight loss were not 
reducing. (Mollan et al., 2015) As there is a paucity of research in this field, it is 
important to address the rate of admission to hospital among patients with PMR 
and, further to this, the reasons for admission. 
There are a number of existing studies into comorbidities in patients with PMR 
which are based on national registries of hospital admission data and were 
described in chapter 5. However, these studies, which are mainly based in 
Scandinavia, also used hospital admission data as the basis for identification of 
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cases of PMR. This could underestimate the true prevalence of PMR and also 
lead to the exclusion of patients with less severe PMR because, as previously 
discussed, the majority of patients with PMR are diagnosed and managed in 
primary care and, as advised in guidance, only referred for specialist review at 
times of atypical clinical presentation. (Barraclough et al., 2008; Yates et al., 
2016)  
One existing study, which used a primary care dataset linked to secondary care 
data, was an investigation into whether PMR was associated with vascular 
disease. (Pujades-Rodriguez et al., 2016) In this study, a higher proportion of 
patients with PMR developed vascular disease. However, overall, when 
outcomes such as mortality due to vascular disease was included, PMR patients 
actually fared better than their matched controls. 
This study will utilise a linked national database that covers all hospital 
admissions in England. It will investigate the rate of, and reasons for, hospital 
admissions in patients with a diagnosis of PMR in their primary care records, 
compared to matched controls. This will provide a more accurate estimate of the 
true rate of hospital admission and reasons for this in all patients with PMR, rather 
than only those who have perhaps a more severe subset of PMR and were 
diagnosed in secondary care. In carrying out this study, the aim will be to assess 
the validity and severity of the differences in comorbidity prevalence described in 
chapter 6, by assessing the degree to which the increased levels of comorbid 
disease impacts on levels of healthcare utilisation.   
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7.1.3 Death Registration data 
Using linked death registration data, from the Office for National Statistics (ONS) 
this study will estimate survival in patients with PMR compared to matched 
controls. 
Death registration data linked to CPRD currently covers the period from January 
1998 until February 2018. This dataset contains information on the official date 
of death, the date of registration of death as well as the underlying cause of death 
and any other contributing factors given. (Dedman et al., 2018) 
As discussed in chapter 5, the impact of PMR on mortality has been reported in 
four studies. Of these, three found a reduced mortality among patients with PMR, 
(Gran et al., 2001; Doran et al., 2002; Myklebust et al., 2003) while one study, 
which did not differentiate between patients with PMR and GCA, found an 
increase. (Uddhammar et al., 2002) 
In chapter 6 primary care data shows that patients with PMR appear to be less 
healthy, defined as a greater proportion of them have been diagnosed with one 
or more comorbid condition, than matched patients without PMR. However 
existing studies, although small, estimate that patients with PMR may actually 
have a reduced mortality rate compared to patients without the condition. By 
using linked mortality data produced by the Office for National Statistics, an 
answer to the question of the effect that PMR has on mortality will be produced.  
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7.2 Methods 
7.2.1 Patient sample 
Patients included in this study were identified from the case control and cohort 
CPRD analyses described in chapter 6. All patients from those analyses who 
were registered with a practice for which linkage was established to either the 
HES or ONS mortality datasets were included. As data linkage has only been 
established for practices in England, patients from practices in Northern Ireland, 
Scotland and Wales were not included in this analysis.  
The patient sample used for this study was taken from the study described in 
chapter 6. The sample was already matched by age, sex and registered practice. 
As data linkage availability is defined by practice, equal proportions of cases and 
controls, who were similar in age and sex, were included in this study. Therefore, 
cases and controls should remain similar according to matching criteria, however 
to ensure this is the case, demographic information, including sex, age, and 
region will be tabulated.  
Linkage between the HES and ONS datasets and the CPRD was established at 
different times, and the last date of data collection was also different for each 
linked dataset. Therefore, the number of cases and controls included, as well as 
the amount of time they contributed, was different in the HES and ONS mortality 
analyses. This will be explained in more detail in sections 7.2.2 and 7.2.6. 
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7.2.2 Hospital admissions 
The first part of the analysis looked at rate of hospital admissions after index date. 
For cases, the index date was the date of diagnosis with PMR, for controls it was 
the date that their matched case was diagnosed.  HES Admitted Patient Care 
data contains details of all admissions and attendances at English NHS 
healthcare providers. All NHS healthcare providers in England, including acute 
hospitals, primary care trusts and mental health trusts provide data contribute to 
this database. Augmented care data, including intensive care or high 
dependency units is also available. (CPRD, 2019) 
A large number of domains of information are provided, (Dedman and Murray-
Thomas, 2018) the domains of information relevant to this study are tabulated 
below (table 7-1). 
 
Table 7-1: HES linked dataset domains 
Domain Descriptors 
spno Spell number uniquely identifying a hospitalisation 
admidate Date of admission 
discharged Date of discharge 
admimeth Method of admission 
duration Duration of hospitalisation (days) 
 
The spell number provides a unique identification for each hospitalisation, while 
the admission and discharge dates ensure chronology of admissions can be 
established and also allow corroboration of the duration date provided in the HES 
dataset. The method of admission pertains to the setting that a patient has been 
admitted from. This is important to define who has referred the patient, where 
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from, and with what degree of urgency. The different types of admission code 
and definitions are tabulated below (table 7-2). 
 
Table 7-2: Admission method codes and descriptions 
Code Description 
Elective admission, when the decision to admit could be separated in 
time from the actual admission 
11 Waiting list 
12 Booked 
13 Planned 
Emergency Admission, when admission is unpredictable and at short 
notice because of clinical need: 
21* Accident and emergency or dental casualty department of the Health 
Care Provider  
22* GENERAL PRACTITIONER: after a request for immediate admission 
has been made direct to a Hospital Provider, i.e. not through a Bed 
bureau, by a GENERAL PRACTITIONER or deputy 
23* Bed bureau 
24* Consultant Clinic, of this or another Health Care Provider  
25* Admission via Mental Health Crisis Resolution Team 
2A* Accident and Emergency Department of another provider where 
the PATIENT had not been admitted  
2B* Transfer of an admitted PATIENT from another Hospital Provider in an 
emergency   
2C Baby born at home as intended  
2D* Other emergency admission  
28* Other means 
Maternity Admission, except when the intention is to terminate the 
pregnancy 
31 Admitted ante-partum 
32 Admitted post-partum 
Other Admission not specified above 
82  The birth of a baby in this Health Care Provider 
83 Baby born outside the Health Care Provider except when born at home 
as intended. 
81 Transfer of any admitted PATIENT from other Hospital Provider other 
than in an emergency 
(NHS Digital, 2018) 
* Included in the hospital admissions analysis 
 
For the analysis of number of hospital admissions, elective admissions were not 
included. Therefore, patients undergoing planned operations or regular dialysis 
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were excluded from the study and only those that were coded as emergency 
admissions were included. The codes, and therefore admissions, which were 
included are starred in the table above. 
For the later study, of admissions due to a comorbidity, (section 7.2.3) all 
admissions, both elective and emergency, were included.  
The time at which patients were at risk of admission during this study was the 
difference between the study start and end dates. These dates were calculated 
individually per patient. The study start date was defined as the index date. As 
the study sample was based on the one described in chapter 6, it included 
patients admitted from 1990 onwards. However, any cases diagnosed prior to 
April 1997, the date at which HES data collection began, were excluded because 
HES data was not available for some of their time at risk. 
Data collection ended at the earliest of five events: 1) December 2017 (the final 
date of HES data collection)  2) the date when a patient transferred out of their 
HES/CPRD contributing practice, 3) the date of death, or 4) the last date of data 
collection from the practice. The aim of the study was to find the total number and 
rate of admissions, therefore patients were allowed to have multiple admissions 
and remain in the study until the end of data collection for that patient. 
Therefore, at any specified time-point following index date, a patient could be 
classified as being in one of four states, that of: 
1) Being at risk of admission (n=0) 
2) Being admitted (n=1) 
3) Being at risk of further admissions (n≥1) 
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4) Having previously been lost to follow up (censored) 
In some cases, a patient may have more than one record of admission per 
hospitalisation, as defined by spell number. This could be due to failed 
discharges or erroneous recording of admission and discharge dates. Previous 
studies of hospital admissions using HES data reported the first admission in a 
treatment spell. (Anselmi et al., 2017; Han et al., 2017) This is therefore the 
approach that was taken in this study.  
This process used is described in detail below. Three figures will be used to 
explain different permutations of admission dates. For example, in figure 7-1, 
there are two consecutive records for a single patient that were both acceptable 
for this study. In these, the discharge date of the first admission is before the 
admission date of the second.  
 
Figure 7-1: Data management of admissions data (1) 
 
 
Figure 7-2 shows a different situation in which two consecutive records have the 
same admission date in the same treatment spell. In this case, if the discharge 
date for the second admission was the same or earlier than the first record, then 
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the second admission (and any further admissions in that spell) was removed. If 
the discharge date for the second admission date was later than the first 
admission, then the first discharge date was amended to the later date, and the 
second admission was then removed. In this scenario it is possible that either the 
patient mistakenly had two admissions recorded or that they were transferred 
during their admission. 
 
Figure 7-2: Data management of admissions data (2)  
 
 
Figure 7-3 describes where two admissions for the same treatment spell fell 
within the same time period. In this case, the second admission date is after the 
first admission date, but before the first discharge date. 
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Figure 7-3: Data management of admissions data (3)  
 
 
Here, similar to figure 7-2, if the second discharge date was either before or the 
same as the first discharge date then the second admission was removed from 
the dataset. If the second discharge date was later then the first discharge date, 
then the first discharge date was changed to reflect the second record’s later date 
and then the second admission was removed. 
As a result of this, the duration of some admissions changed and therefore the 
duration of each amended admission was recalculated using the new discharge 
dates.  
 
7.2.3 Comorbidities 
The second part of the analysis looked at the reasons for hospital admissions 
before, and after, index date. HES, as discussed earlier, provides information on 
multiple domains. Hospital based healthcare professionals routinely complete 
summaries of admissions to send to the patient’s General Practitioner (GP), 
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which include the primary reason for admission, procedures carried out and a list 
of past medical history for each patient. These provide valuable information to 
GPs and Consultants alike. The aim of this study is to ascertain which 
comorbidities have led to hospital admissions. As discussed previously, unlike in 
the hospital admissions study, (section 7.2.2) both emergency and elective 
admissions were included for this analysis. 
The comorbidities of interest in this study were the same comorbidities that were 
tested in the previous study (chapter 6) and the rationale for the choice of each 
comorbidity has already discussed in detail in a previous chapter (6.2.7). 
However, the coding system in HES is different to that used in CPRD. In CPRD, 
as previous discussed, diagnoses are based on Read codes. However, in HES 
the coding system used is ICD-10. In order to ensure access to robust and 
authenticated code lists to verify reasons for hospital admission, NHS digital 
publish a freely available, with permission, list of ICD-10 codes with diagnoses 
via the NHS Technology Reference Data Update Distribution (TRUD) service. 
(NHS Digital, 2015) It is this list that was used to identify comorbidities in this 
study. The ICD-10 codes that were included are listed in appendix 7. 
 
7.2.4 Case control 
The case control study assessed the proportion of cases and controls who had a 
hospital admission prior to index date with a comorbidity of interest. The time at 
which patients are at risk of admission during this study was the difference 
between the study start and end dates. Patients were included in the study after 
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the latest of four events: 1) the study start date 1st April 1997 (this is the date that 
HES data begins), 2) the date at which they became 40 years old, 3) the date 
they registered at a participating practice plus six months, or 4) the date at which 
the practice was adjudged to reach internal quality standards; known as the ‘up-
to-standard date’. Data collection ended at index date. The study sample was the 
same as in the admissions study described in (7.2.2) as all those with an index 
date prior to the study start date were again excluded. 
The prevalence of hospital admission with a primary diagnosis of either one of 
the stratified or composite comorbidities were calculated prior to index date. 
Prevalence was calculated by dividing the total number of people with an 
admission for which the primary diagnosis was one of the comorbidities of 
interest (numerator) by the number of patients with PMR, or their controls 
(denominator). Furthermore, using the same methodology as the case control 
study in chapter 6, the likelihood of admission was described. The likelihood of 
admission was expressed as an odds ratio calculated using conditional logistic 
regression and were adjusted for smoking status, alcohol consumption and BMI 
category.  
 
7.2.5 Cohort  
The cohort study assessed a number of different measures of the likelihood of 
admission with a comorbidity in cases compared to controls, including the total 
number of admissions, the rate of admission due to each comorbidity per 10,000 
person years and the likelihood of admission due to a comorbidity, which was 
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expressed as a hazard ratio. These ratios were adjusted for smoking status, 
alcohol consumption and BMI category as well as age and sex. For all of these 
calculations, patients with a record of admission due to that comorbidity prior to 
index date were excluded from the analysis.  
The start and end date of the study were calculated individually for each patient. 
The start date was defined as the same as index date. The index date was either 
the date of diagnosis with PMR (cases) or, in the case of controls, the date of 
diagnosis of their matched case. Data collection ended at the earliest of five 
events: 1) 1st December 2017 (end of the period of time that HES encompasses), 
2) the date when a patient transferred out of a practice, 3) the date of death, 4) 
the last date of data collection from the practice, or 5) the date of admission with 
the specified comorbidity. The study sample was the same as in the admissions 
study (7.2.2).  
Similar to the cohort study in chapter 6, there was no minimum requirement for 
follow up following index date. Due to this, some patients were lost to follow up 
before they developed a comorbidity. These patients contributed data until the 
point at which they left the study. 
Therefore, at any specified time-point following index date, a patient could be 
classified as being in one of three states, that of: 
1) Having developed the event of interest 
2) Being at risk of the event of interest 
3) Having previously been lost to follow up (censored) 
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Again, using the same methods employed in chapter 6, the hazard ratio of 
admission due to each comorbidity was calculated using Cox proportional 
hazards and reported with 95% confidence intervals.  
 
7.2.6 Mortality analysis 
The final analysis was to ascertain whether differences in rates of comorbid 
diseases or hospital admissions, translated into changes in mortality. In order to 
provide estimates of mortality rates among patients with PMR and matched 
controls, the Office for National Statistics Death Registration database was used. 
This database is also linked to CPRD. The same patient sample as in Chapter 6 
was used. The start of this study was defined as the index date which, as 
discussed previously, was the date of diagnosis of PMR for the case and their 
matched controls. Follow up continued until the earliest of several events: 1) 1st 
January 2018 (the end of the period of time that ONS Death Registration data 
encompasses), 2) the date when a patient transferred out of a practice, 3) the 
last date of data collection from the practice, or 4) the date of death.  
The primary outcome measures were total number of deaths in cases and control 
groups, as well as mortality rate per 1,000 person years. Estimates of survival 
were also constructed using Kaplan-Meier methods. As these were time to event 
analyses and mortality data is only available from January 1998, all cases, and 
their matched controls, with diagnoses made prior to this date were excluded 
from the analysis. ONS Death Registration data includes the date of death and 
the date the death was registered. For this study the date of death was used. 
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A Poisson regression model, as described in chapter 3.2.3, was used to compare 
the mortality rate of PMR compared to controls, by calculating mortality rate ratios 
(IRR) with 95% confidence intervals. 
Secondary outcome measures assessed included the cause of death. During 
registration of death in the United Kingdom, the certifying physician has to record 
the cause of death. This information may or may not be augmented by the results 
of a post-mortem examination of the body. Information about the cause of death 
is included within ONS Death Registration data. The primary cause of death was 
also tabulated by cases and controls. The cause of death, similar to HES data, is 
coded using the ICD-10 classification system. In the ONS dataset however, 
unlike HES, the description of a code is also included. Therefore there is no 
necessity to use a code list in order to describe this information. 
 
7.2.7 Statistical analysis 
Descriptive statistics were used to find average age of cases and controls as well 
as proportion of cases and controls per region, sex, smoking status, BMI 
category, alcohol consumption as well as follow up prior to, or following, index 
date as appropriate. These calculations were performed to ensure that cases and 
controls remain similar after removing patients who were registered with unlinked 
practices. The study demographics were checked on three occasions, once for 
all patients with linkage eligibility, once for patients contributing data to analyses 
of hospital admissions (including the case control and cohort studies) and once 
for patients contributing to the mortality analysis. 
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Regarding hospital admissions, the total number, and the rate of admissions for 
cases and controls was calculated. The number of admissions during the study 
period was the numerator and total follow up was the denominator. The rate was 
expressed per 1,000 person years. The hazard ratio with 95% confidence 
intervals, was calculated using Cox proportional hazards model. 
The mean duration of each admission by case was calculated. This data was 
also categorised and presented as proportions of admissions lasting up to and 
including 0, 1, 3, 7, 14, 30 and 90 days. The total number of admissions per time 
period following index date was calculated. These time periods were within 1, 1-
3, 3-6, and 6-12 months following index date. This reflects previous studies using 
the HES dataset, which also examined the period up until 12 months after index 
date, for example following an admission due to heart failure. (Bottle et al., 2016) 
Finally, Kaplan Meier methods were used to demonstrate time to first admission 
in cases and controls.  
Some of the comorbidities included in the analysis, had very few admissions. In 
these cases, in order to protect patient anonymity, the prevalence or probability 
was censored and expressed as “<5”. Also, in these cases, measures of 
likelihood, either odds or hazard ratios were not calculated as there was 
insufficient power to generate meaningful results.  
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7.3 Results 
7.3.1 Study demographics 
A total of 181,420 matched patients were initially included in the study. Of these, 
113,034 (62.3%) were registered at a practice which was linked to secondary 
care and ONS datasets and therefore eligible for these analyses. Of the patients 
who were excluded a similar proportion were cases and controls (table 7-3). 
 
Table 7-3: Number of patients removed from study without linkage  
Case Control Total 
Retained 20,083 (62.8%)  92,951 (62.2%) 113,034 (62.3%)  
Not included in the study 11,901 (37.2%) 56,485 (37.8%) 68,386 (37.7%)  
 
Demographic data for the remaining patients, including mean age at index date, 
sex, region of GP practice, smoking status, BMI category and alcohol 
consumption is presented in table 7-4. Follow up time is not presented here as it 
differs depending on which linked database was used (HES or ONS). 
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Table 7-4: Demographic information for comorbidities study 
Variable Total  Case  Control  
Age    
Mean (SD) 73.5 (8.9) 73.8 (9.0) 73.5 (8.8) 
Min/max 43.0 / 99.8 43.2 / 99.8 43.0 / 99.8 
Sex (%) 
Male 36,484 (32.3) 6,627 (33.0) 29,857 (32.1) 
Female 76,550 (67.7) 13,456 (67.0) 63,094 (67.9) 
Region (%) 
North East 1,816 (1.6) 318 (1.6) 1,498 (1.6) 
North West 14,437 (12.8) 2,542 (12.7) 11,895 (12.8) 
Yorkshire & the Humber 4,060 (3.6) 728 (3.6) 3,332 (3.6) 
East Midlands 3,071 (2.7) 537 (2.7) 2,534 (2.7) 
West Midlands 15,978 (14.1) 2,776 (13.8) 13,202 (14.2) 
East of England 16,546 (14.6) 2,896 (14.4) 13,650 (14.7) 
South West 17,806 (15.8) 3,169 (15.8) 14,637 (15.7) 
South Central 14,655 (13.0) 2,623 (13.1) 12,032 (12.9) 
London 8,168 (7.2) 1,541 (7.7) 6,627 (7.1) 
South East Coast 16,497 (14.6) 2,953 (14.7) 13,544 (14.6) 
BMI category 
Normal(18.5-24.9) 36,347 (32.2) 6,412 (31.9) 29,935 (32.2) 
Underweight (<18.5) 2,065 (1.8) 234 (1.2) 1,831 (2.0) 
Overweight (25-29.9) 38,101 (33.7) 7,247 (36.1) 30,854 (33.2) 
Obese (>=30) 22,128 (19.6) 4,235 (21.1) 17,893 (19.2) 
Missing 14,393 (12.7) 1,955 (9.7) 12,438 (13.4) 
Smoking 
Non-smoker 94,164 (83.3) 17,359 (86.4) 76,805 (82.6) 
Smoker 12,714 (11.2) 2,003 (10.0) 10,711 (11.5) 
Missing 6,156 (5.4) 721 (3.6) 5,435 (5.8) 
Alcohol 
Never / no current 22,638 (20.0) 3,978 (19.8) 18,660 (20.1) 
<10 units per week 58,406 (51.7) 10,873 (54.1) 47,533 (51.1) 
10 or more units per week 16,764 (14.8) 3,062 (15.2) 13,702 (14.7) 
Missing 15,226 (13.5) 2,170 (10.8) 13,056 (14.0) 
 
The average age at diagnosis, sex and region of GP practice were very similar 
between cases and controls, reflecting the matching criteria that were applied. 
Cases were slightly older than controls, by an average of 0.3 years. 
The three disease risk modifiers, BMI, smoking and alcohol consumption, were 
broadly similar between cases and controls. Data was less likely to be missing in 
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cases compared to controls, for example 13.4% of controls had no BMI recorded 
compared to 9.7% of cases. Cases were less likely to smoke (86.4% compared 
to 82.6%, and more likely to drink nothing or fewer than 10 units per week (73.9% 
compared to 71.1%), however they were more likely to be recorded as 
overweight or obese.  
 
7.3.2 Hospital admissions 
Following removal of patients where the index date was prior to the 
commencement of the HES database linkage, a total of 108,208 patients 
remained for analysis. Table 7-5 shows the proportion of excluded patients by 
case type. 
Table 7-5: Number of patients removed from study as index date prior to study 
start date (HES)  
Case Control Total 
Retained 19,197 (95.59%)  89,011 (95.76%) 108,208 (95.73%)  
Not included in the study 886 (4.41%) 3,940 (4.24%) 4,826 (4.27%)  
 
The proportion of patients excluded was small - less than 5% of linkage eligible 
records. A very similar proportion of cases and controls were excluded. The 
demographic information of patients included in the hospital admissions analyses 
are described in table 7-6. In addition to the previous table (7-4), the average 
time at risk contributed by cases and controls is also included. As this patient 
sample will be used in the hospital admissions, case control and cohort studies, 
time at risk before and after index date is shown. 
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Table 7-6: Demographic details Hospital admissions 
Domain Case Control Total 
Mean age (SD) 73.8 (9.1) 73.5 (8.8) 73.6 (8.9) 
Sex (%) 
  
 
Male  6,365 (33.2) 28,707 (32.3) 35,072 (32.4) 
Female 12,832 (66.8) 60,304 (67.7) 73,136 (67.6) 
Region (%) 
  
 
North East 308 (1.6) 1,443 (1.6) 1,751 (1.6) 
North West 2,406 (12.5) 11,262 (12.7) 13,668 (12.6) 
Yorkshire & the Humber 655 (3.4) 3,010 (3.4) 3,665 (3.4) 
East Midlands 505 (2.6) 2,386 (2.7) 2,891 (2.7) 
West Midlands 2,652 (13.8) 12,630 (14.2) 15,282 (14.1) 
East of England 2,712 (14.1) 12,821 (14.4) 15,533 (14.4) 
South West 3,062 (16.0) 14,183 (15.9) 17,245 (15.9) 
South Central 2,559 (13.3) 11,760 (13.2) 14,319 (13.2) 
London 1,480 (7.7) 6,381 (7.2) 7,861 (7.3) 
South East Coast 2,858 (14.9) 13,135 (14.8) 15,993 (14.8) 
Total time at risk (years)  
Mean (SD) 18.4 (2.8) 18.1 (3.1) 18.2 (3.1) 
Pre-index date time at risk (years)  
Mean (SD) 8.6 (4.3) 8.2 (4.2) 8.3 (4.2) 
Post-index date time at risk (years)  
Mean (SD) 9.9 (4.6) 9.9 (4.6) 9.9 (4.6) 
BMI category 
  
 
Normal (18.5-24.9) 6,132 (31.9) 28,896 (32.5) 35,028 (32.4) 
Underweight (<18.5) 222 (1.2) 1,781 (2.0) 2,003 (1.9) 
Overweight (25-29.9) 7,004 (36.5) 29,911 (33.6) 36,915 (34.1) 
Obese (>=30) 4,160 (21.7) 17,526 (19.7) 21,686 (20.0) 
Missing 1,679 (8.7) 10,897 (12.2) 12,576 (11.6) 
Smoking    
Non-smoker 16,761 (87.3) 74,346 (83.5) 91,107 (84.2) 
Smoker 1,867 (9.7) 10,180 (11.4) 12,047 (11.1) 
Missing 569 (3.0) 4,485 (5.0) 5,054 (4.7) 
Alcohol    
Never / no current 3,828 (19.9) 17,994 (20.2) 21,822 (20.2) 
<10 units per week 10,486 (54.6) 46,076 (51.8) 56,562 (52.3) 
10 or more units per week 2,973 (15.5) 13,339 (15.0) 16,312 (15.1) 
Missing 1,910 (9.9) 11,602 (13.0) 13,512 (12.5) 
 
The demographic details in this sample of linked patients are similar to the larger 
sample containing all the patients with data linkage. This is to be expected given 
less than 5% of the patients, and a similar proportion of cases and controls, were 
excluded from this analysis. 
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Having satisfied the precondition that the cases and controls are similar, 
descriptive statistics relating to admissions, including number with at least one 
admission, the overall rate of admissions and the duration of admissions is 
tabulated below (table 7-7).  
 
Table 7-7: Admission rates following index date  
Cases Controls Total 
Number who have at least one admission (%) 
  12,783 (66.6) 51,832 (58.23) 64,615 (59.7) 
Admission rate per 1,000 person years (95% CI) 
 235.05 
(232.88,237.24) 
173.45 
(172.58,174.32) 
184.34 
(183.53,185.15) 
Hazard ratio 1.18 (1.17, 1.19)  
 
Duration of admissions 
Median (IQR) 5 (1, 13) 5 (1, 12) 5 (1, 13) 
Min / max 0.0 / 335.0 0.0 / 434.0 0.0 / 434.0 
Mean (95% CI) 10.6 (10.4, 10.8) 11.4 (11.4, 11.5) 11.3 (11.2, 11.3) 
 
The proportion of cases with at least one episode of hospitalisation is greater 
than controls (67% compared to 58%). Furthermore, the rate of admissions, per 
1,000 person years is higher at 235.1 for cases, compared to 173.5 in controls. 
The hazard ratio shows that cases are around 18% more likely to be admitted to 
hospital compared to controls. However, it is noted that the average duration of 
admission was the same in cases and controls, with a median of 5 days for each. 
In order to better visualise the average length of stay, the duration of admissions 
are presented graphically in figure 7-4.  
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 Figure 7-4: Duration of admission by case 
 
 
It can be seen that a greater proportion of admissions for cases were of shorter 
duration (zero, 1, 2-3 or 4-7 days), while admissions of 8-14, 15-30 or 31-90 days 
were proportionally more likely in controls. This shows that, although patients 
with PMR were more likely to be admitted to hospital, their matched controls had 
on average longer admissions. The mean duration of admissions, with 95% 
confidence intervals was higher than the median values, at 10.6 days (10.4, 10.8) 
for cases and 11.4 days (11.4, 11.5) for controls.  
To investigate further the effect that a diagnosis of PMR had on hospital 
admissions the time until first admission following index date is demonstrated 
using Kaplan-Meier analysis (figure 7-5).  
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Figure 7-5: Kaplan-Meier estimates of time to first admission by case 
 
It can be seen that for the proportion of the patients with PMR, half have been 
admitted to hospital on at least one occasion five years after index date, while for 
controls this becomes the case more than six years after index date. The 
difference in likelihood of an admission persists over a ten year period after index 
date. 
Finally, the number of admissions per categorised time period is described in 
table 7-8 and shown in figure 7-6. In order to preserve anonymity, if fewer than 5 
admissions were recorded for cases or controls, or fewer than 10 overall, then 
this data is not presented.  
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Table 7-8: Absolute number and proportion admitted following index date 
Number of admissions (%) 
 Case Control Total 
Less than one month 
0 18,773 (97.8) 87,624 (98.4) 106,397 (98.3) 
1 406 (2.1) 1,308 (1.5) 1,714 (1.6) 
2 16 (0.1) 72 (0.1) 0,088 (0.1) 
3 <5 (0.0) 7 (0.0) <10 (0.0) 
4 <5 (0.0) <5 (0.0) <10 (0.0) 
5 + <5 (0.0) <5 (0.0) <10 (0.0) 
One to three months 
0 18,407 (95.9) 86,429 (97.1) 104,836 (96.9) 
1 703 (3.7) 2,290 (2.6) 2,993 (2.8) 
2 80 (0.4) 244 (0.3) 324 (0.3) 
3 <5 (0.0) 41 (0.0) 46 (0.0) 
4 <5 (0.0) 6 (0.0) <10 (0.0) 
5 + <5 (0.0) 6 (0.0) <10 (0.0) 
Three to six months 
0 18,114 (94.4) 85,284 (95.8) 103,398 (95.6) 
1 909 (4.7) 3,182 (3.6) 4,091 (3.8) 
2 139 (0.7) 457 (0.5) 596 (0.6) 
3 30 (0.2) 65 (0.1) 95 (0.1) 
4 <5 (0.0) 16 (0.0) 20 (0.0) 
5 + <5 (0.0) 7 (0.0) <10 (0.0) 
Six to twelve months 
0 17,350 (90.4) 82,281 (92.4) 99,631 (92.1) 
1 1,424 (7.4) 5,303 (6.0) 6,727 (6.2) 
2 301 (1.6) 1,048 (1.2) 1,349 (1.2) 
3 86 (0.4) 262 (0.3) 348 (0.3) 
4 27 (0.1) 70 (0.1) 97 (0.1) 
5 + <5 (0.0) 47 (0.1) 56 (0.1) 
 
The majority of patients do not have an admission in each time period, therefore 
figure 7-6 is scaled to 70-100% in order to better demonstrate any differences 
observed. 
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Figure 7-6: Number of admissions per time period 
 
 
Table 7-8 and figure 7-6 demonstrate that at all time periods controls were less 
likely to have been admitted and cases were more likely to have multiple 
admissions. 
 
7.3.3 Case control study 
Due to the large number of outcomes reported in this study a number of 
abbreviations have been used in the tables. The abbreviations are shown in table 
7-9.  
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Table 7-9: Abbreviations for comorbid outcomes 
Comorbidity Abbreviation 
Leukaemia, lymphoma LL 
Cardiovascular disease CVD 
Congestive cardiac failure CCF 
Peripheral vascular disease PVD 
Cerebrovascular disease CVA 
Hypertension HTN 
Chronic obstructive pulmonary disease COPD 
Ulcerative colitis UC 
Systemic lupus erythematosus SLE 
Rheumatoid arthritis RA 
Osteoarthritis OA 
Type 1 Diabetes mellitus T1DM 
Type 2 Diabetes mellitus T2DM 
Multiple sclerosis MS 
Urinary tract infection UTI 
Upper respiratory tract infection URTI 
Lower respiratory tract infection LRTI 
 
The first part of the analysis of comorbidities, prior to index date, was to look at 
the prevalence of admission to hospital with one of the composite outcomes prior 
to index date. These are summarised in table 7-10. 
 
Table 7-10: Prevalence of composite comorbidities prior to index date  
Case (%) Control (%) 
Cancer  1,191 (6.2) 6,462 (7.3) 
Vascular 1,924 (10.0) 8,298 (9.3) 
Respiratory 374 (1.9) 1,522 (1.7) 
Gastroenterological 1,755 (9.1) 6,140 (6.9) 
Immunological 320 (1.7) 457 (0.5) 
Endocrine 153 (0.8) 762 (0.9) 
Neurological 21 (0.1) 415 (0.6) 
Psychiatric 77 (0.4) 538 (0.6) 
Ophthalmological 2,238 (11.7) 8,759 (9.8) 
Infections 851 (4.4) 3,683 (4.1) 
Fragility fractures 332 (1.7) 2,326 (2.6) 
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A smaller proportion of cases were admitted with a neoplastic, neurological, 
endocrine, psychiatric, ophthalmic or infectious disease compared to controls. 
However a higher proportion of cases were admitted with vascular, respiratory, 
gastroenterological, immunological conditions and fragility fractures. 
In order to gain a better understanding of the detail of what conditions contribute 
most to the composite outcomes, table 7-11 shows the conditions stratified into 
individual comorbidities. 
A similar pattern to the composite comorbidities was seen when outcomes are 
stratified. Admissions due to neoplastic, neurological, psychiatric and endocrine 
conditions were either as common or more common in controls compared to 
cases. Similarly, most admissions due to vascular, respiratory or 
gastroenterological diseases were more common in cases.  
It is observed in many of the categories the number of admissions was under 
five, even among controls. In these cases, to preserve anonymity, the exact 
number recorded was censored. 
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Table 7-11: Prevalence of admission with stratified comorbidities prior to index 
date  
Cases (%) Controls (%) 
Cancer   
Breast cancer 222 (1.2) 1,231 (1.4) 
Prostate cancer 118 (0.6) 557 (0.6) 
Lung cancer 20 (0.1) 217 (0.2) 
Colon cancer 150 (0.8) 847 (1.0) 
Melanoma 30 (0.2) 188 (0.2) 
LL 39 (0.2) 332 (0.4) 
Vascular 
  
CVD 441 (2.3) 1,849 (2.1) 
CCF 191 (1.0) 952 (1.1) 
PVD 192 (1.0) 809 (0.9) 
CVA  309 (1.6) 1,778 (2.0) 
HTN 49 (0.3) 329 (0.4) 
Respiratory 
 
Asthma 124 (0.6) 314 (0.4) 
COPD 208 (1.1) 0,996 (1.1) 
Lung fibrosis 19 (0.1) 103 (0.1) 
Renal  
Renal disease 23 (0.1) 180 (0.2) 
Gastroenterological 
 
Liver disease 33 (0.2) 158 (0.2) 
Peptic ulcers 1,650 (8.6) 5,760 (6.5) 
Crohn's disease 30 (0.2) 91 (0.1) 
Ulcerative colitis 65 (0.3) 232 (0.3) 
Autoimmune and musculoskeletal 
SLE <5 (0.0) 13 (0.0) 
Systemic sclerosis <5 (0.0) <5 (0.0) 
Rheumatoid arthritis 52 (0.3) 349 (0.4) 
Sjogren’s syndrome <5 (0.0) <5 (0.0) 
Psoriatic arthritis <5 (0.0) <5 (0.0) 
Raynaud's disease <5 (0.0) <5 (0.0) 
Osteoarthritis 1,881 (9.8) 6,952 (7.8) 
Endocrine 
Hyperthyroidism 9 (0.0) 50 (0.1) 
Hypothyroidism 7 (0.0) 23 (0.0) 
T1DM 18 (0.1) 129 (0.2) 
T2DM 52 (0.3) 304 (0.3) 
Neurological and psychiatric 
Dementia 6 (0.0) 232 (0.3) 
Parkinson's disease <5 (0.0) 87 (0.1) 
MS <5 (0.0) 46 (0.1) 
Psychiatric  
Schizophrenia <5 (0.0) 36 (0.1) 
Bipolar disease 6  (0.0) 65 (0.1) 
Depression 42 (0.2) 276 (0.3) 
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Cases (%) Controls (%) 
Anxiety 26 (0.1) 157 (0.2) 
Complications due to glucocorticoids 
Osteoporosis 43 (0.2) 184 (0.2) 
Hip fracture 197 (1.0) 1,446 (1.6) 
Wrist fracture 126 (0.7) 846 (1.0) 
Vertebral fracture <5 (0.0) <5 (0.0) 
Ophthalmological   
Cataracts 2,166 (11.3) 8,534 (9.6) 
Glaucoma 124 (0.6) 390 (0.4) 
Infections   
UTI 92 (0.5) 376 (0.4) 
URTI 43 (0.2) 123 (0.1) 
LRTI 520 (2.7) 2,209 (2.5) 
Skin infections 227 (1.2) 1,095 (1.2) 
Abbreviations: Leukaemia, lymphoma (LL), Cardiovascular disease (CVD), Congestive cardiac failure 
(CCF), Peripheral vascular disease (PVD), Cerebrovascular disease (CVA), Hypertension (HTN), 
Chronic obstructive pulmonary disease (COPD), Ulcerative colitis (UC), Systemic Lupus Erythematosus 
(SLE), rheumatoid arthritis (RA), Osteoarthritis (OA), Type 1 Diabetes mellitus (T1DM), Type 2 Diabetes 
mellitus (T2DM), Multiple sclerosis (MS), Urinary tract infection (UTI), Upper respiratory tract infection 
(URTI), Lower respiratory tract infection (LRTI) 
 
Whether the observed differences in prevalence of admissions were statistically 
significant is now estimated. Conditional logistic regression was used to calculate 
odd ratios with 95% confidence intervals. There were, however, a number of 
stratified comorbidities in which an insufficient number of admissions were 
recorded to generate accurate estimates. In these cases, therefore, odds ratios 
were not calculated. The conditions for which odds ratios were not calculated 
included: SLE, systemic sclerosis, Sjogren’s syndrome, psoriatic arthritis, 
Raynaud's disease, thyroid disease, dementia, Parkinson's disease, MS, 
schizophrenia and bipolar disease. The odds ratios are tabulated below (table 7-
12) and graphically illustrated also (figure 7-7). The odds ratio of a pre-existing 
admission due to any immunological disease was particularly high (3.27, [2.83, 
3.79]), therefore this was not included in the forest plot (figure 7-7) in order to 
allow better visualisation of the other outcomes.  
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Table 7-12: Odds ratios PMR vs controls of admission due to a comorbidity prior to index date 
Comorbidity OR (95% CI) Comorbidity OR (95% CI) 
Cancer  0.82 (0.77,0.88) Immunological 3.27 (2.83,3.79) 
Breast cancer 0.84 (0.73,0.97) Rheumatoid arthritis 0.69 (0.51,0.92) 
Prostate cancer 0.93 (0.76,1.14) Osteoarthritis 1.27 (1.21,1.35) 
Lung cancer 0.41 (0.25,0.64) Endocrine 0.89 (0.75,1.07) 
Colon cancer 0.80 (0.67,0.95) T1DM 0.63 (0.38,1.03) 
Melanoma 0.73 (0.49,1.08) T2DM 0.75 (0.55,1.01) 
Leukaemia, lymphoma 0.53 (0.38,0.75) Neurological 0.24 (0.15,0.37) 
Vascular 1.04 (0.99,1.10) Psychiatric 0.66 (0.52,0.84) 
CVD 1.06 (0.96,1.18) Depression 0.72 (0.52,0.99) 
CCF 0.89 (0.76,1.04) Anxiety 0.76 (0.50,1.15) 
PVD 1.11 (0.94,1.30) Fragility fractures 0.63 (0.56,0.71) 
CVA 0.77 (0.68,0.87) Osteoporosis 1.08 (0.77,1.51) 
HTN 0.69 (0.51,0.94) Hip fracture 0.60 (0.51,0.70) 
Respiratory 1.13 (1.01,1.27) Wrist fracture 0.67 (0.55,0.81) 
Asthma 1.79 (1.45,2.21) Ophthalmological 1.18 (1.12,1.24) 
COPD 0.97 (0.83,1.13) Cataracts 1.17 (1.11,1.23) 
Lung fibrosis 0.82 (0.50,1.35) Glaucoma 1.48 (1.20,1.81) 
Gastroenterological 1.34 (1.27,1.42) Infections 1.04 (0.96,1.12) 
Moderate liver disease 0.99 (0.68,1.45) UTI 1.13 (0.89,1.42) 
Peptic ulcers 1.34 (1.27,1.43) URTI 1.60 (1.13,2.27) 
Crohn's disease 1.49 (0.98,2.25) LRTI 1.05 (0.95,1.16) 
Ulcerative colitis 1.26 (0.95,1.66) Skin infections 0.92 (0.80,1.07) 
Renal  
 
 
Renal disease 0.58 (0.37,0.90) 
Abbreviations: Odds Ratio (OR) Leukaemia, lymphoma (LL), Cardiovascular disease (CVD), Congestive cardiac failure (CCF), Peripheral vascular disease (PVD), 
Cerebrovascular disease (CVA), Hypertension (HTN), Chronic obstructive pulmonary disease (COPD), Ulcerative colitis (UC), systemic lupus erythematosus (SLE), 
rheumatoid arthritis (RA), Osteoarthritis (OA), Type 1 Diabetes mellitus (T1DM), Type 2 Diabetes mellitus (T2DM), Multiple sclerosis (MS), Urinary tract infection (UTI), 
Upper respiratory tract infection (URTI), Lower respiratory tract infection (LRTI) 
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Figure 7-7: Odds ratios of admission with specified comorbidity in patients with 
PMR vs controls prior to index date 
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Only a small number of stratified or composite outcomes reached statistical 
significance. Of the composite outcomes, controls were significantly more likely 
to be admitted with neoplastic or psychiatric diseases and fragility fractures, while 
case were more likely to be admitted with gastroenterological and 
ophthalmological conditions. The increase in the risk of admissions in PMR in 
vascular and respiratory conditions was not statistically significant. 
Regarding stratified outcomes, admissions with most of the different cancer 
types, including breast, colorectal, leukaemia and lymphoma as well as lung 
cancer are significantly less likely to have occurred in patients who went on to 
develop PMR. Alongside these outcomes, admissions due to cerebrovascular 
disease, hypertension and renal disease were also significantly less likely. 
Conversely, patients with PMR are significantly more likely to have experienced 
an admission due to asthma, osteoarthritis, peptic ulcers, cataracts, glaucoma 
and upper respiratory tract infections. 
 
7.3.4 Cohort study 
The first part of the prospective analysis into admission due to comorbidities 
following index date was an assessment of the total number, proportion and rate 
of new admissions with composite comorbidities in cases and controls. Table 7-
13 describes this.   
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Table 7-13: Total number, proportion and rate (per 10,000 person years) of new admissions with composite outcomes following 
index date  
Cases 
   
Controls 
   
Comorbidity At risk New 
admissions 
% Rate (95% CI) At risk New 
admissions 
% Rate (95% CI) 
Cancer  17,820 2,663 14.9 287.3 (276.6,298.4) 81,446 12,090 14.8 313.9 (308.4,319.6) 
Vascular 16,915 3,639 21.5 422.8 (409.2,436.7) 79,195 12,873 16.3 348.6 (342.6,354.7) 
Respiratory 18,781 928 4.9 96.1 (90.1,102.5) 87,294 3,185 3.6 78.9 (76.2,81.7) 
Gastroenterological 18,810 411 2.2 42.6 (38.7,46.9) 87,411 1,538 1.8 38.2 (36.3,40.1) 
Immunological 18,787 663 3.5 69.6 (64.5,75.1) 88,415 406 0.5 10.0 (9.0,11.0) 
Endocrine 19,016 332 1.7 33.9 (30.5,37.8) 88,079 1,118 1.3 27.5 (25.9,29.2) 
Neurological 19,170 340 1.8 34.3 (30.9,38.2) 88,472 2,010 2.3 49.0 (47.0,51.2) 
Psychiatric 19,102 145 0.8 14.7 (12.5,17.3) 88,246 638 0.7 15.7 (14.5,16.9) 
Ophthalmological 16,693 3,832 23.0 468.7 (454.1,483.7) 78,823 12,835 16.3 357.4 (351.2,363.6) 
Infections 18,207 3,376 18.5 357.0 (345.1,369.2) 84,737 11,894 14.0 296.7 (291.4,302.0) 
Fragility fractures 18,809 1,480 7.9 153.2 (145.6,161.3) 86,278 6,007 7.0 149.8 (146.1,153.7) 
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The rate of admission with any comorbidity following diagnosis is consistently 
higher in cases compared to controls, with the only exception being admissions 
with cancer and neurological diseases. The number of cases and controls varied 
with each composite outcome as any patients with a record of admission with 
one of the comorbidities prior to index date were excluded.  
Table 7-14 describes the total number, proportion and rate of admissions due to 
one of the stratified outcomes by case. A number of the stratified comorbidities 
had fewer than ten recorded admissions. These included SLE, systemic 
sclerosis, Sjogren’s disease, psoriatic arthritis, Raynaud’s disease, 
hypothyroidism, MS, schizophrenia, bipolar affective disorder, and vertebral 
fracture. Where there were fewer than five admissions, these outcomes are 
displayed as <5 to preserve anonymity.   
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Table 7-14: Total number, proportion and rate (per 10,000 person years) of admissions with stratified outcomes after index date  
Cases 
   
Controls 
   
 
At risk New admissions % Rate (95% CI) At risk New admissions % Rate (95% CI) 
Cancer 
        
Breast cancer 18,931 224 1.2 22.6 (19.8,25.8) 87,488 1,296 1.5 31.5 (29.9,33.3) 
Prostate cancer 19,066 179 0.9 18.2 (15.8,21.1) 88,387 839 0.9 20.6 (19.3,22.1) 
Lung cancer 19,173 294 1.5 29.7 (26.5,33.3) 88,774 1,416 1.6 34.5 (32.8,36.4) 
Colon cancer 19,022 351 1.8 35.9 (32.3,39.8) 88,023 1,563 1.8 38.5 (36.7,40.5) 
Melanoma 19,165 66 0.3 6.7 (5.2,8.5) 88,792 324 0.4 7.9 (7.1,8.8) 
Leukaemia, lymphoma 19,150 212 1.1 21.5 (18.8,24.6) 88,622 923 1.0 22.6 (21.2,24.1) 
Vascular 
        
CVD 18,669 967 5.2 100.7 (94.6,107.3) 86,748 3,125 3.6 78.0 (75.3,80.7) 
CCF 18,982 982 5.2 99.9 (93.9,106.4) 87,919 3,461 3.9 84.9 (82.1,87.8) 
PVD 18,977 557 2.9 57.2 (52.6,62.1) 88,078 1,518 1.7 37.4 (35.5,39.3) 
CVA 18,842 1,258 6.7 129.2 (122.2,136.5) 86,871 5,266 6.1 130.6 (127.1,134.1) 
HTN 19,134 155 0.8 15.7 (13.5,18.4) 88,630 549 0.6 13.4 (12.4,14.6) 
Respiratory 
       
Asthma 19,050 131 0.7 13.4 (11.3,15.9) 88,609 409 0.5 10.0 (9.1,11.0) 
COPD 18,962 659 3.5 67.6 (62.6,72.9) 87,867 2,357 2.7 58.0 (55.7,60.4) 
Lung fibrosis 19,180 116 0.6 11.7 (9.8,14.1) 88,954 319 0.4 7.8 (7.0,8.7) 
Renal  
        
Renal disease 19,170 131 0.7 13.3 (11.2,15.7) 88,805 455 0.5 11.1 (10.1,12.2) 
Gastroenterological 
      
Moderate liver disease 19,156 88 0.5 8.9 (7.2,11.0) 88,822 319 0.4 7.8 (7.0,8.7) 
Peptic ulcers 18,962 258 1.4 26.5 (23.4,29.9) 87,997 1,064 1.2 26.3 (24.7,27.9) 
Crohn's disease 19,155 28 0.1 2.8 (2.0,4.1) 88,885 58 0.1 1.4 (1.1,1.8) 
Ulcerative colitis 19,118 56 0.3 5.7 (4.4,7.4) 88,698 170 0.2 4.2 (3.6,4.8) 
Autoimmune and musculoskeletal 
     
SLE 19,193 7 N/A N/A 88,994 6 N/A N/A 
Systemic sclerosis 19,196 <5 N/A N/A 89,003 14 0.0 0.3 (0.2,0.6) 
Rheumatoid arthritis 19,124 216 1.1 22.0 (19.3,25.2) 88,551 225 0.3 5.5 (4.8,6.3) 
Sjogren’s syndrome 19,197 <5 N/A N/A 89,011 <5 N/A N/A 
Psoriatic arthritis 19,197 <5 N/A N/A 89,011 <5 N/A N/A 
Raynaud's disease 19,197 <5 N/A N/A 89,011 <5 N/A N/A 
Osteoarthritis 16,981 2,532 14.9 295.2 (283.9,306.9) 80,592 7,141 8.9 193.2 (188.8,197.8) 
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Cases 
   
Controls 
   
 
At risk New admissions % Rate (95% CI) At risk New admissions % Rate (95% CI) 
Endocrine 
       
Hyperthyroidism 19,185 12 0.1 1.2 (0.7,2.1) 88,944 49 0.1 1.2 (0.9,1.6) 
Hypothyroidism 19,190 10 N/A N/A 88,981 46 0.1 1.1 (0.8,1.5) 
T1DM 19,175 26 0.1 2.6 (1.8,3.9) 88,842 89 0.1 2.2 (1.8,2.7) 
T2DM 19,137 196 1.0 19.9 (17.3,22.9) 88,657 550 0.6 13.5 (12.4,14.6) 
Neurological and psychiatric 
      
Dementia 19,189 247 1.3 24.9 (22.0,28.2) 88,697 1,593 1.8 38.8 (37.0,40.8) 
Parkinson's disease 19,189 54 0.3 5.5 (4.2,7.1) 88,911 297 0.3 7.2 (6.5,8.1) 
MS 19,195 9 N/A N/A 88,940 31 0.0 0.8 (0.5,1.1) 
Psychiatric 
       
Schizophrenia 19,196 <5 N/A N/A 88,945 32 0.0 0.8 (0.6,1.1) 
Bipolar disease 19,188 9 N/A N/A 88,914 62 0.1 1.5 (1.2,1.9) 
Depression 19,143 65 0.3 6.6 (5.2,8.4) 88,609 272 0.3 6.6 (5.9,7.5) 
Anxiety 19,167 61 0.3 6.2 (4.8,7.9) 88,795 259 0.3 6.3 (5.6,7.2) 
Complications due to glucocorticoids 
     
Osteoporosis 19,151 314 1.6 31.9 (28.6,35.6) 88,800 594 0.7 14.5 (13.4,15.7) 
Hip fracture 18,975 1,150 6.1 117.7 (111.1,124.7) 87,306 4,918 5.6 121.1 (117.8,124.5) 
Wrist fracture 19,040 293 1.5 29.9 (26.7,33.5) 88,000 1,189 1.4 29.4 (27.7,31.1) 
Vertebral fracture 19,197 <5 N/A N/A 89,011  <5 N/A N/A 
Ophthalmological 
      
Cataracts 16,770 3,808 22.7 463.0 (448.6,478.0) 79,099 12,730 16.1 353.0 (346.9,359.2) 
Glaucoma 19,048 145 0.8 14.8 (12.6,17.4) 88,511 488 0.6 12.0 (11.0,13.1) 
Infections 
       
UTI 19,092 111 0.6 11.3 (9.4,13.6) 88,565 453 0.5 11.1 (10.1,12.2) 
URTI 19,149 59 0.3 6.0 (4.6,7.7) 88,857 195 0.2 4.8 (4.1,5.5) 
LRTI 18,595 2,882 15.5 297.4 (286.8,308.5) 86,480 10,120 11.7 247.6 (242.8,252.5) 
Skin infections 18,922 701 3.7 71.9 (66.7,77.4) 87,711 2,187 2.5 53.9 (51.7,56.3) 
Abbreviations: Leukaemia, lymphoma (LL), Cardiovascular disease (CVD), Congestive cardiac failure (CCF), Peripheral vascular disease (PVD), Cerebrovascular disease 
(CVA), Hypertension (HTN), Chronic obstructive pulmonary disease (COPD), Ulcerative colitis (UC), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), 
Osteoarthritis (OA), Type 1 Diabetes mellitus (T1DM), Type 2 Diabetes mellitus (T2DM), Multiple sclerosis (MS), Urinary tract infection (UTI), Upper respiratory tract infection 
(URTI), Lower respiratory tract infection (LRTI) 
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The number of comorbidities for which the risk of admission over the study period 
was greater than 1% was low. Comorbidities for which the risk of admission was 
greater than 1% included, breast, lung and colorectal cancer, leukaemia and 
lymphoma, asthma, COPD, pulmonary fibrosis, osteoarthritis, dementia, 
osteoporosis, hip and wrist fractures, cataracts, lower respiratory tract and skin 
infections, peptic ulcers and all vascular outcomes except hypertension. The rate 
of admission with neoplastic and neurological conditions was higher in controls 
compared to cases. The rate of admission with vascular, respiratory, 
gastroenterological, rheumatoid arthritis, osteoarthritis, endocrine, psychiatric, 
ophthalmological and infectious diseases was higher in cases. The rate of 
admission for hip fracture was higher in controls, however, the rate for wrist 
fracture was higher among cases.  
Whether the differences in the risk of admission with each comorbidity was 
significant was investigated using Cox proportional hazards, to calculate hazard 
ratios (HR), the results of which are displayed in table 7-15. To ensure sufficient 
power, hazard ratios were only calculated where comorbidities had greater than 
10 admissions following index date. Finally, to test the proportional hazards 
assumption, Kaplan-Meier estimates of time to first admission with each 
comorbidity were also produced graphically for each comorbidity. The Kaplan-
Meier charts are enclosed as appendix 8. 
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Table 7-15: Hazard Ratios of admission with comorbidities in patients with PMR vs controls following index date 
Comorbidity HR (95% CI) Comorbidity HR (95% CI) 
Cancer  0.88 (0.84,0.92) Immunological 7.01 (6.18,7.94) 
Breast cancer 0.71 (0.62,0.82) Rheumatoid arthritis 3.99 (3.31,4.81) 
Prostate cancer 0.84 (0.71,0.99) Osteoarthritis 1.48 (1.42,1.55) 
Lung cancer 0.84 (0.74,0.96) Endocrine 1.18 (1.04,1.33) 
Colon cancer 0.89 (0.79,1.00) Hyperthyroidism 0.98 (0.52,1.86) 
Melanoma 0.80 (0.61,1.04) T1DM 1.18 (0.76,1.83) 
Leukaemia, lymphoma 0.91 (0.78,1.06) T2DM 1.41 (1.20,1.66) 
Vascular 1.15 (1.11,1.20) Neurological 0.65 (0.58,0.73) 
CVD 1.22 (1.13,1.31) Dementia 0.59 (0.52,0.67) 
CCF 1.08 (1.01,1.16) Parkinson's disease 0.71 (0.53,0.95) 
PVD 1.46 (1.32,1.61) Psychiatric 0.91 (0.76,1.10) 
CVA 0.93 (0.87,0.98) Depression 0.97 (0.74,1.27) 
HTN 1.12 (0.94,1.35) Anxiety 0.94 (0.71,1.24) 
Respiratory 1.17 (1.09,1.26) Fragility fractures 0.96 (0.91,1.02) 
Asthma 1.28 (1.05,1.56) Osteoporosis 2.09 (1.82,2.40) 
COPD 1.13 (1.03,1.23) Hip fracture 0.90 (0.84,0.96) 
Lung fibrosis 1.41 (1.13,1.74) Wrist fracture 0.97 (0.86,1.11) 
Gastroenterological 1.08 (0.97,1.20) Ophthalmological 1.26 (1.21,1.31) 
Moderate liver disease 1.11 (0.88,1.41) Cataracts 1.26 (1.21,1.31) 
Peptic ulcers 0.97 (0.84,1.11) Glaucoma 1.18 (0.98,1.42) 
Crohn's disease 1.96 (1.25,3.08) Infections 1.13 (1.09,1.17) 
Ulcerative colitis 1.36 (1.01,1.84) UTI 0.98 (0.79,1.20) 
Renal  
 
URTI 1.22 (0.91,1.63) 
Renal disease 1.14 (0.94,1.39) LRTI 1.12 (1.08,1.17)   
Skin infections 1.26 (1.15,1.37) 
Abbreviations: Cardiovascular disease (CVD), Congestive cardiac failure (CCF), Peripheral vascular disease (PVD), Cerebrovascular disease (CVD), Hypertension (HTN), 
Chronic obstructive pulmonary disease (COPD), Osteoarthritis (OA), Type 1 Diabetes mellitus (T1DM), Type 2 Diabetes mellitus (T2DM), Multiple sclerosis (MS), Urinary 
tract infection (UTI), Upper respiratory tract infection (URTI), Lower respiratory tract infection (LRTI) 
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Hospital admissions with cancer and neurological diseases following index date 
were significantly less likely in cases compared to controls. However, cases were 
significantly more likely to be admitted with vascular, respiratory, immunological, 
endocrine, ophthalmological and infectious diseases. In the case of 
gastroenterological and renal diseases, as well as fragility fractures, no 
significant difference was observed. 
In the case of the stratified outcomes with a risk of admission greater than 1%, a 
number of the differences in risk were found to be statistically significant. 
Outcomes where the risk of admission was higher in controls compared to cases 
included breast and lung cancer, cerebrovascular disease, dementia and hip 
fractures. The comorbidities where the increased risk of admission in people with 
PMR reached statistical significance included cardiovascular and peripheral 
vascular disease, congestive cardiac failure, asthma, COPD, pulmonary fibrosis, 
rheumatoid and osteoarthritis, as well as osteoporosis, cataracts, glaucoma and 
lower respiratory tract and skin infections. 
In order to visualise these findings more clearly, they are reproduced in a forest 
plot, figure 7-8. On this some comorbidities with very strong associations (hazard 
ratio ≥2) are omitted. These comorbidities include combined immunological 
outcomes, Crohn’s disease and rheumatoid arthritis. 
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Figure 7-8: Hazard Ratios of admission with comorbidities in patients with PMR 
vs controls following index date 
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The next section analyses whether the observed differences in hospital 
admissions with comorbidity, or the differences in likelihood of comorbid 
diagnosis observed in chapter 6, impact upon mortality rates in patients with PMR 
compared to matched controls. 
 
7.3.5 Mortality analysis 
The time frame covered by ONS mortality data is different to that covered by HES 
data, therefore the number of patients contributing data is different in this 
analysis. Following removal of patients where the index date was prior to the 
commencement of the study period, a total of 106,744 patients remained for 
analysis using the ONS mortality statistics. Table 7-16 shows the proportion of 
excluded patients by case type. 
 
Table 7-16: Number of patients removed from study as index date prior to study 
start date (ONS)  
Case Control Total 
Retained 18,943 (94.3%) 87,801 (94.5%) 106,744 (97.4%) 
Not included in the study 1,140 (5.7%) 5,150 (5.5%) 6,290 (5.6%) 
Total 20,083 92,951 113,034 
 
Of the patients with linkage established, nearly 95% were included in the mortality 
analysis and a similar proportion of cases and controls were excluded. However, 
in order to establish how the reduction in sample size has affected the 
demographics of the remaining patients, demographic information, including 
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mean age at index date, sex, region of GP practice, smoking status, BMI category 
and alcohol consumption are presented in table 7-17. 
Table 7-17: Demographic data (ONS sample)  
Total Case Control 
Age    
Mean (SD) 73.6 (8.9) 73.8 (9.1) 73.5 (8.9) 
Sex (%) 
   
Male 34,559 (32.4) 6,273 (33.1) 28,286 (32.2) 
Female 72,185 (67.6) 12,670 (66.9) 59,515 (67.8) 
Region (%) 
  
North East 1,740 (1.6) 306 (1.6) 1,434 (1.6) 
North West 13,428 (12.6) 2,366 (12.5) 11,062 (12.6) 
Yorkshire & the Humber 3,574 (3.4) 639 (3.4) 2,935 (3.3) 
East Midlands 2,853 (2.7) 499 (2.6) 2,354 (2.7) 
West Midlands 15,032 (14.1) 2,609 (13.8) 12,423 (14.1) 
East of England 15,320 (14.4) 2,674 (14.1) 12,646 (14.4) 
South West 17,137 (16.1) 3,042 (16.1) 14,095 (16.1) 
South Central 14,075 (13.2) 2,517 (13.3) 11,558 (13.2) 
London 7,732 (7.2) 1,456 (7.7) 6,276 (7.1) 
South East Coast 15,853 (14.9) 2,835 (15.0) 13,018 (14.8) 
BMI category 
  
Normal(18.5-24.9) 34,552 (32.4) 6,052 (31.9) 28,500 (32.5) 
Underweight (<18.5) 1,986 (1.9) 0,221 (1.2) 1,765 (2) 
Overweight (25-29.9) 36,515 (34.2) 6,923 (36.5) 29,592 (33.7) 
Obese (>=30) 21,521 (20.2) 4,132 (21.8) 17,389 (19.8) 
Missing 12,170 (11.4) 1,615 (8.5) 10,555 (12) 
Smoking 
   
Non-smoker 90,111 (84.4) 16,582 (87.5) 73,529 (83.8) 
Smoker 11,823 (11.1) 1,827 (9.6) 9,996 (11.4) 
Missing 4,810 (4.5) 0,534 (2.8) 4,276 (4.9) 
Alcohol 
   
Never / no current 21,546 (20.2) 3,779 (19.9) 17,767 (20.2) 
<10 units per week 55,927 (52.4) 10,369 (54.7) 45,558 (51.9) 
10 or more units per week 16,133 (15.1) 2,942 (15.5) 13,191 (15) 
Missing 13,138 (12.3) 1,853 (9.8) 11,285 (12.9) 
Total time at risk 
  
Mean (SD) 16.0 (4.4) 16.3 (4.1) 15.9 (4.4) 
Pre-index date time at risk 
 
Mean (SD) 8.1 (4.1) 8.3 (4.2) 8.0 (4.1)  
Post-index date time at risk   
Mean (SD) 7.9 (4.6) 8.0 (4.4) 7.9 (4.6) 
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The average age at diagnosis, sex and region of GP practice were very similar 
between cases and controls. The mean age of cases was greater than controls, 
by 0.3 years. 
The three disease risk modifiers, BMI, smoking and alcohol consumption, were 
again broadly similar between cases and controls. Data was less likely to be 
missing in cases compared to controls, for example 12% of controls had no BMI 
recorded compared to 8.5% of cases. A higher proportion of cases were recorded 
as drinking greater than 10 units of alcohol per week (15.5% vs 15%) whereas 
the control group were again actually more likely to be recorded as smokers in 
comparison to cases (11.4% vs 9.6%). 
The total number and the proportion of patients with PMR and controls who died 
is shown in table 7-18. Over the total time period, which was on average 8 years 
of follow up following index date, a higher proportion of cases died compared to 
controls (31.9% and 31.0%). The mortality rates were similar, at 39.9 and 39.2 
per 1,000 patient years for cases and controls respectively. This equated to a 
non-significant increase in the mortality rate ratio, calculated using Poisson 
regression, of 1.02 (0.99, 1.05). 
 
Table 7-18: Number and proportion of deaths in patients with 
PMR compared to matched controls  
Total Deaths (%) Rate per 1,000 (95% 
confidence interval)  
    
Control  87,801 27,224 31.01 39.2 (38.7, 40) 
Case 18,943 6,046 31.92 39.9 (38.9, 41) 
Mortality rate ratio 1.02 (0.99, 1.05) 
Total 106,744 33,270 31.17 39.3 (38.9, 39.7) 
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In order to illustrate the difference in mortality rates between cases and controls, 
Kaplan-Meier methods were used to construct two survival curves. Figure 7-9 
shows survival over the first ten years following index date; while figure 7-10 
extends the follow up period to twenty years. 
 
 
Figure 7-9: Kaplan-Meier plot of survival in first 10 years following index date in 
patients with PMR compared to matched controls 
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Figure 7-10: Kaplan-Meier plot of survival following index date until end of 
follow up in patients with PMR compared to matched controls 
 
 
Although the rate of death is non-significantly increased in patients with PMR, it 
can be seen that in the first eight years following index date, the proportion of 
people who died was actually higher in the control group. After around nine to 
ten years after index date the mortality was higher among patients with PMR. 
However, the number of patients who were continuing to contribute data to the 
study at that time reduced considerably. 
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Causes of death 
ONS Mortality data also contains information on the cause of death. The most 
common causes of death and the proportion of total deaths for cases and controls 
are shown in table 7-19. 
 
Table 7-19: Causes of death, ICD-10 classification, total number (%) 
 Cases  Controls  
1 Chronic ischaemic heart 
disease 
464 (7.7) Chronic ischaemic heart 
disease 
1,810 (6.7) 
2 Acute myocardial infarction 409 (6.8) COPD 1,652 (6.1) 
3 COPD 327 (5.4) Acute myocardial infarction 1,651 (6.1) 
4 Malignant neoplasm: 
Bronchus or lung 
316 (5.2) Malignant neoplasm: 
Bronchus or lung 
1,631 (6.0) 
5 Bronchopneumonia 258 (4.3) Bronchopneumonia 989 (3.6) 
6 Pneumonia 243 (4.0) Atherosclerotic heart 
disease 
967 (3.6) 
7 Atherosclerotic heart 
disease 
187 (3.1) Pneumonia 889 (3.3) 
8 Vascular dementia 123 (2.0) Alzheimer disease 790 (2.9) 
9 Urinary tract infection 115 (1.9) Malignant neoplasm: 
Breast 
709 (2.6) 
10 Malignant neoplasm: 
Pancreas 
109 (1.8) Vascular dementia 604 (2.2) 
11 Cerebrovascular disease 108 (1.8) Cerebrovascular disease 585 (2.2) 
12 Alzheimer disease 106 (1.8) Malignant neoplasm 
without specification 
460 (1.7) 
13 Malignant neoplasm without 
specification. 
103 (1.7) Malignant neoplasm: 
Pancreas 
447 (1.6) 
14 Malignant neoplasm: Breast 99 (1.6) Urinary tract infection 416 (1.5) 
15 Other interstitial pulmonary 
diseases 
93 (1.5) Malignant neoplasm: Colon 410 (1.5) 
16 Congestive heart failure 84 (1.4) Malignant neoplasm: 
Oesophagus 
371 (1.4) 
17 Malignant neoplasm: Colon 84 (1.4) Malignant neoplasm: 
Bladder 
312 (1.2) 
18 Aortic (valve) stenosis 71 (1.2) Congestive heart failure 309 (1.1) 
19 Cerebral infarction 68 (1.1) Intracerebral haemorrhage 302 (1.1) 
20 Malignant neoplasm: 
oesophagus 
67 (1.1) Other respiratory disorders 291 (1.1) 
 Others 2,612 
(43.8) 
Others 11,629 (41.6) 
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Of the five most common causes of death there is little variation between cases 
and controls, all include ischaemic heart disease, acute myocardial infarction, 
COPD, lung cancer and pneumonia. There are more neoplastic causes of death 
among controls compared to cases. Among cases, lung, pancreatic, breast and 
colon cancers, as well as cancers without a specified primary were among the 
most common causes of death; while in the control group all of these are also 
seen as well as oesophageal and bladder cancers.  
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7.4 Discussion 
7.4.1 Main findings 
This study found that patients with PMR had a similar mortality rate to matched 
controls. However, they also had an increased risk of non-elective admission to 
hospital, although on average for a shorter duration. Regarding causes of 
hospital admissions, there are a number of stratified comorbidities that are either 
significantly more or less likely to lead to admission in patients with PMR when 
compared to controls both before and after index date. The conditions where the 
risk of admission was significantly higher in patients with PMR were asthma and 
cataracts. The comorbidities with a significantly reduced risk of admission in 
patients with PMR are breast and lung cancer as well as cerebrovascular disease 
and hip fractures. 
When assessing composite outcomes, patients with PMR were more likely to be 
admitted to hospital both before and after index date with respiratory, 
immunological and ophthalmological conditions. Patients without PMR were 
more likely to be admitted to hospital with any cancer or neurological diagnosis. 
This study is the first to present a broad, comprehensive view of hospital 
admissions in a large group of patients with PMR who were diagnosed in primary 
care. Furthermore, it is the largest study to estimate the effect that a diagnosis of 
PMR has upon life expectancy and confirms that patients with a diagnosis of 
PMR do not have a significantly reduced life expectancy. 
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7.4.2 Strengths and limitations  
This study, investigating associations between PMR and mortality and 
admissions to hospital, utilised a large dataset and a broad range of comorbidities 
and looked at the period of time before, and after, diagnosis with PMR. The 
comorbidities were selected using robust methodology and the patient sample 
used comes from a large, established database of patients who are 
representative of the UK population. (Williams et al., 2012) As the sample of 
patients with PMR were drawn from primary care and, as previously discussed, 
the majority of patients with PMR are managed exclusively in this setting, this 
sample is therefore highly representative of people diagnosed with PMR in the 
UK. (Barraclough et al., 2008; Yates et al., 2016) 
The linked databases that were used in this study, Hospital Episode Statistics 
(HES) and Office for National Statistics (ONS) Death Registration data are large, 
well established and validated sources of information used to guide national 
healthcare policy. (Herbert et al., 2017) They have been used to report hospital 
admission rates and trends in mortality for a number of different diseases and 
health complaints. (Morgan et al., 2017; Parisi et al., 2017; Stewart et al., 2017) 
As discussed in chapter 3, a potential limitation is the initial ascertainment of 
cases. In CPRD it is not possible to authenticate diagnoses by ensuring each 
patient fulfils validated classification criteria for PMR research. For PMR 
generally, there are no diagnostic criteria nor specific diagnostic test, therefore 
even if access to individual patients were possible, confirmation of diagnosis can 
never be fully achieved. Therefore, ensuring that all patients have at least two 
GC prescriptions in their records provides more confidence in the diagnosis of 
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PMR. This method has been used before in previously published studies in 
CPRD of PMR. (Smeeth, Cook and Hall, 2006)  
In this analysis, the comorbidities were coded using the ICD-10 classification 
system. The use of NHS Digital approved code lists ensures the veracity of the 
codes that were analysed. Again, however, diagnoses cannot be authenticated 
by cross checking with symptoms or investigations made. It has long been 
established that incorrect coding of hospital discharges or death registration data 
can occur. Some studies have estimated errors in hospital discharge letters of up 
to 55%, (Tsopra et al., 2019) while others estimate that cardiovascular causes of 
death may be overstated in mortality data. (Lakkireddy et al., 2004) However, a 
case study from the ONS found that only 12% of the broad underlying cause of 
death needed to be amended following medical examiner scrutiny. (Office for 
National Statistics, 2012b) Furthermore, there is no reason to suppose that the 
presence of PMR would lead to a difference in error rate compared to those 
without PMR. 
Another potential limitation of this study is a consequence of the deliberate desire 
to maintain a broad scope within this study. As in the previous investigations in 
this thesis, there was a risk of multiple testing leading to multiple significant 
findings. As the confidence interval used to investigate the significance of findings 
was set at 95%, it is to be expected than 1 in 20 significant findings could have 
been discovered by chance. However, the aim of this study was to provide an 
overview of the health of PMR rather than to prove causation, therefore the 
conclusions of the study are limited to reflect this. 
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Also, this study looked specifically at hospital admissions. A number of these 
conditions, particularly autoimmune diseases, present at a younger age, and are 
unlikely to be coded as the primary reason for an emergency hospital admission 
in elderly patients. In these cases where very few admissions were recorded, to 
reduce the risk of overestimating the probability of admission, those outcomes 
were censored. 
Two other potential biases, similar to the previous investigation described in 
chapter 6, are surveillance bias and diagnostic overshadowing. People who are 
diagnosed with PMR may be more likely to be followed up more closely in primary 
care and therefore have more comorbidities recorded in the primary care EHRs 
However, this is likely to have less effect on the likelihood of admission to 
secondary care. Finally, better diagnosis of comorbidities may actually lead to 
improved treatment and therefore case survival. As referenced previously, a 
Swedish research group found that patients with renal calculi were more likely to 
have a cancer diagnosis in the years following. (Hemminki et al., 2017) This 
demonstrates that closer surveillance may lead to earlier detection, and therefore 
more effective treatment of serious diseases. 
The other main potential bias was diagnostic overshadowing, which may have 
led to the apparent reduction in admissions with neoplastic or neurological 
diseases. Diagnostic overshadowing, as previously discussed, is the situation in 
which physical symptoms that a patient may complain of are inadvertently 
misattributed to a pre-existing illness. (Shefer et al., 2014) This concept could be 
extended to also include cancer. If patients have a pre-existing diagnosis of 
cancer they are much less likely to then be diagnosed with PMR as the symptoms 
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of malaise, pain, stiffness and fever could be attributed instead to their neoplasm. 
This theory is reinforced by the fact that cancer is regarded as an exclusion 
criteria in the diagnosis of PMR. (Dejaco, Singh, Perel, et al., 2015) 
 
7.4.3 Summary of hospital admissions with comorbidities and 
comparisons to existing literature  
Vascular disease 
The only previous study that assessed the link between PMR and cardiovascular 
disease using hospital datasets was produced by Pujades-Rodriguez et al. 
(2016). In this, four linked data sources were used, these included CPRD, the 
Myocardial Ischaemia National Audit Project disease registry, (Herrett, Smeeth, 
et al., 2010) HES and the ONS national death registry. In this study, the incidence 
of fatal and non-fatal CVDs was slightly lower in patients with compared to those 
without PMR/GCA (adjusted IRR=0.88, (95% CI 0.83 to 0.94)).  
When analysing patients with pure PMR, the endpoint “coronary and CVD death 
composite” was reported. This included stable angina, myocardial infarction, 
coronary heart diseases not otherwise specified and any cardiovascular death. 
In this, the incidence rate ratio was reported as 0.91 [0.83, 1.00]. The limitations 
of this study, as discussed previously, include a limited age restriction such that 
all adults over 18 years were included, as well as a relatively short mean follow 
up period of 3.1 years.  
In the current study, the mean follow-up period was longer and the number of 
patients with PMR was larger. The likelihood of a patient subsequently diagnosed 
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with PMR having a hospital admission with any vascular disease was non-
significantly raised prior to index date OR 1.04 [(95% confidence interval) 0.99, 
1.10], and significantly increased following index date HR [1.15 [1.11, 1.20]. 
Furthermore, a higher proportion of cases had chronic ischaemic heart disease 
listed as a cause of deaths (7.7% vs 6.7%) and the same was true for acute 
myocardial infarction (6.8% vs 6.1%).  
The risk of admission with cardiovascular disease following index date was 
higher in patients with PMR. As this study looked at hospital admissions, rather 
than simply a GP Read code, it is unlikely that surveillance bias was the cause 
for this. This is further evidenced by the fact that death from cardiovascular 
disease was higher in patients with PMR when compared to matched controls. 
Therefore it appears, although the difference is small, that there is indeed an 
increased risk of cardiovascular disease and mortality among patients with PMR.  
 
Cancer 
Previous studies into the risk of cancer among patients with PMR have focused 
on the risk of diagnosis with the disease rather than admission to hospital. The 
results reported have been equivocal, with some authors suggesting the risk of 
cancer may be increased following PMR diagnosis, while others did not. (Haga 
et al., 1993; Myklebust et al., 2002; Jianguang et al., 2010; Muller et al., 2014; 
Pfefiffer et al., 2015; Bellan et al., 2017) In chapter 6, the risk of cancer diagnosis 
in a patient’s primary care record was seen to be significantly lower among 
patients with a diagnosis of PMR. 
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The risk of admission to hospital with a cancer diagnosis as the primary problem 
was reduced in patients with PMR when compared to matched controls. This 
reduction in risk was present both before and after index date. The reduction in 
the risk of cancer diagnosis was also reflected in mortality data. Overall, of the 
top 20 causes of death, 11.7% of PMR cases were cancer related, compared to 
16% of controls. 
Again, diagnostic overshadowing may still play a part in this result. As PMR 
classification criteria make clear, cancer is considered a differential to be 
excluded rather than a potential comorbidity with PMR. (Dasgupta et al., 2012; 
Dejaco, Singh, Perel, et al., 2015) Therefore it may be that this apparent 
‘protection’ that PMR provides against neoplastic disease diagnosis or mortality 
is rather a result of a reluctance to make a diagnosis of PMR in patients with 
cancer.  
Furthermore, the mainstay of treatment for PMR, glucocorticoids, are often used 
in the management of cancer. This is because the GCs are potent anti-
inflammatories and often have side effects beneficial for patients with cancer, 
such as increased appetite and energy levels. GCs are also considered safe to 
use in cancer as the GC receptor is not considered an oncogene. (Pufall, 2015) 
Therefore, it may be that patients with cancer may develop PMR, but due to the 
fact the treatment for cancer can also include GC therapy, their symptoms would 
improve or resolve with the GCs and therefore not be identified as a PMR case.  
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Autoimmune 
As discussed previously, whether PMR is an autoimmune or auto-inflammatory 
disease remains a matter of debate. (Floris et al., 2018) Pertaining to this, an 
epidemiological study of the co-existence of 33 autoimmune conditions, including 
PMR, was conducted in Denmark by Eaton et al (2010). They found, among 
patients with PMR, an increase in the risk of Sjogren’s disease, systemic lupus 
erythematosus, systemic sclerosis, psoriatic arthritis, ulcerative colitis and 
Crohn’s disease. This study also found an increase in the risk of multiple sclerosis 
(MS) in patients with PMR. 
In this study of hospital admissions, the rarity of a hospital admission being 
recorded as primarily due to an autoimmune condition meant that any 
associations were difficult to define. This is in part due to the relatively advanced 
age of the cases and controls, averaging over 70 years, as many of the 
autoimmune conditions present in younger age groups. Of the autoimmune 
conditions, there were enough admissions for rheumatoid arthritis (RA) only, both 
before and after index date, to calculate likelihood ratios.  Prior to index date, the 
risk of admission was significantly lower in people who went on to develop PMR 
compared to controls. After diagnosis this pattern was reversed. Again, similar to 
the outcomes with cancer, it may be that in patients with an existing diagnosis of 
RA clinicians are less likely to subsequently diagnose PMR. 
When the outcomes were combined, the risk of admission with any autoimmune 
condition was higher both before and after index date. Therefore it appears, in 
corroboration of the CPRD data, PMR is strongly linked to autoimmune 
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conditions, but to demonstrate a link to admissions with specific comorbidities is 
difficult in linked data due to the rarity of admissions. 
 
Glucocorticoid related conditions 
As previously discussed, a recent cohort study of 359 patients from the United 
States assessed the likelihood of GC related complications in patients with PMR. 
(Shbeeb et al., 2018b) This study found no significant differences in almost all 
measured outcomes, including diabetes mellitus, hypertension, hyperlipidaemia 
and hip, vertebral or Colles’ fracture. The only outcome in which a statistically 
significant outcome was noted was the incidence of cataracts Hazard ratio (HR) 
1.72 [1.23, 2.41]. A study from the UK based on CPRD by Paskins et al. (2018) 
found that in patients with PMR and GCA the rate of fragility fractures were 
increased. 
Many of the findings from the analysis of comorbidities in CPRD were borne out 
in this study of hospital admissions. Again, patients with PMR were significantly 
more likely to have an admission due to ophthalmological conditions and 
infectious diseases. However, the risk of admission due to a fragility fracture was 
not demonstrated to be significantly different, although in chapter 6, it was noted 
that patients with PMR had an increased risk of diagnosis with osteoporosis. This 
may reflect that GPs are aware of the risk of prolonged GC treatment with regards 
to bone mineral density. Therefore patients with PMR may be referred for the 
correct investigation and treatment to prevent complications such as hip fractures 
developing. 
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Another potential reason could be that, as discussed in chapter 6, patients with 
a previous diagnosis of cancer are less likely to be diagnosed with PMR. Cancer 
is a known risk factor for pathological fractures. Therefore, it may be that the 
excess risk of pathological fracture in the control group is similar to the excess 
risk of fracture conferred by the use of long term GC therapy in the PMR group.  
Regarding infectious diseases, it is likely that the immunosuppressive actions of 
GCs do indeed mean that patients on long term GC therapy are at higher risk of 
developing infectious diseases. Furthermore, the risk of admission with the well-
recognised ophthalmological complications of GC therapy- that of cataracts and 
glaucoma- was seen to be higher in patients with PMR.  
 
Other comorbidities 
Psychiatric 
Previous studies have found no association between PMR and psychiatric 
comorbidities such as schizophrenia (Eaton et al., 2006; Chen et al., 2012) and 
bipolar disease, (Eaton et al., 2006). In this study, due the very small numbers of 
patients who were admitted to hospital with these conditions, it was not possible 
to draw a conclusion as to whether having a diagnosis of PMR affects this 
measure.  
The risk of admission due to depression and anxiety was not found to be 
significantly different in cases and controls. Again, this reflects the rarity of 
admissions due to these causes in this age group rare.  
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Neurological 
One previous study found an increase in the risk of Parkinson’s disease in 
patients with PMR. (Kari Hemminki, Li, et al., 2012) In chapter 6 it was found that 
the risk of serious neurological conditions, such as Parkinson’s disease, MS and 
dementia was significantly lower in patients with PMR prior to index date. The 
possibility that this risk reduction was due to diagnostic overshadowing was 
discussed. When looking in this analysis at the rates of hospital admission, with 
a neurological diagnosis being the primary reason for stay in hospital, the small 
numbers of patients admitted precluded the calculation of a likelihood ratio for 
most outcomes. However, it was seen that the risk of being admitted following 
index date with dementia or Parkinson’s disease was lower in patients with PMR 
compared to controls.  
Again, the reason for this may be that the rates of PMR in patients with these 
conditions may be similar but due to diagnostic overshadowing PMR is under-
diagnosed in these groups.  Although not specifically relating to PMR, it is 
becoming better recognised that chronic pain in elderly patients with cognitive 
decline is under-diagnosed. (Cravello et al., 2019) 
 
Endocrine 
The risk of admission due to type one diabetes was not significantly different 
before or after index date. However, although the risk of admission due to type 2 
diabetes was no different in patients with PMR before index date, it became 
significantly higher after index date. This may be due to GC treatment either 
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increasing the risk of type two diabetes developing or existing type two diabetes 
becoming uncontrolled and necessitating admission. 
 
Renal and Respiratory 
As discussed in chapter 5.4, existing literature does not contain estimates of the 
risk of respiratory and renal diseases in patients with PMR. As such, this is the 
first study to estimate these figures. Prior to diagnosis, the risk of admission due 
to renal disease is significantly lower in those who went on to develop PMR. After 
index date there was no significant difference. In chapter 6 it was seen that renal 
disease was more likely to be diagnosed in patients with PMR, but it does not 
appear to mean consequently, that patients are more likely to receive hospital 
treatment for the same.  
Prior to index date the risk of admission due to asthma was significantly higher 
in patients with PMR, however the risk of admission due to COPD or lung fibrosis 
were not significantly different. Following index date, the risk of admission was 
significantly higher in all three respiratory conditions. The increased risk of 
diagnosis and admission with respiratory conditions has not previously been 
noted. It may be that there is a shared pathological process between PMR and 
these respiratory diseases, particularly as all three conditions have an 
inflammatory, GC responsive, pathophysiological process. 
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7.4.4 Hospital admissions  
One previous investigation into hospital admission rates in patients with PMR has 
been published. It was presented as an abstract at the American College of 
Rheumatology annual meeting and found that patients with and without PMR had 
similar rates of hospitalisation (rate ratio 1.03 [0.95, 1.11)) and that the average 
length of stay was 4.4 and 4.7 days in patients with and without PMR respectively. 
(Raheel et al., 2018)  
In this study, however, the admission rate was found to be significantly higher in 
patients with PMR. The median duration of admissions for cases and controls 
was the same at 5 days, although a higher proportion of controls had slightly 
longer admissions. Both of these findings are similar to that reported in the 
previous analysis by Raheel et al (2018). In this analysis, the mean length of stay 
(with 95% confidence intervals) was 10.6 (10.4, 10.8) for patients with PMR, while 
in controls it was 11.4 (11.4, 11.6). This shows the length of stay was significantly 
greater in controls. However, the fact the mean duration of stay was much greater 
than the median was likely caused by a small number of very prolonged 
admissions. As a result of this, the median value provides a clearer insight into 
the average length of stay. This phenomenon has been noted before in analyses 
of length of hospital admissions. (Lee, Fung and Fu, 2003) 
The increased rate of hospital admission is apparent from the index date and 
persisted throughout the follow up period. Furthermore, patients with PMR were 
found to be more likely to have multiple admissions within each measured time 
period up to 2 years after index date. 
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7.4.5 Mortality analysis  
Four previous studies have estimated mortality in patients with PMR, with three 
of the four studies demonstrating reduced levels of mortality (Gran et al., 2001; 
Doran et al., 2002; Myklebust et al., 2003), and one an increase in mortality. 
(Uddhammar et al., 2002) However, the number of patients with PMR included 
in these studies were much smaller than in this analysis, at 398, 378, 315 and 35 
for Gran (2001), Doran (2002), Myklebust (2003) and Uddhamer (2002) 
respectively. 
In this study, over the first 8 years following index date, the mortality rate was 
slightly lower in patients with PMR compared to controls. However, over the 
entire study period, there was found to be no significant difference, with an 
incident rate ratio of 1.02 [0.99, 1.05]. This study therefore provides further 
evidence that PMR does not affect mortality and is therefore reassuring for those 
who receive a diagnosis of PMR.  
The causes of death are similar between cases and controls. However, there is 
a small increase in the number of patients who died from vascular diseases 
among cases and a corresponding decrease in those recorded to have occurred 
due to neoplasms.  
 
7.4.6 Conclusion and clinical implications  
This study is the first to estimate the rate and reason for hospital admissions 
before and after diagnosis in patients with PMR and matched controls. 
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Furthermore, it is the largest sample of PMR to provide an estimate of the effect 
that PMR has on mortality. In conclusion, patients with PMR are more likely to be 
admitted to hospital compared to matched controls, although when they are 
admitted it is for a slightly shorter duration. 
Both before and after index date, patients with PMR are significantly more likely 
to be admitted to hospital due to asthma and cataracts and significantly less likely 
to be admitted due to breast or lung cancer as well as cerebrovascular disease 
and hip fractures. Overall however, the mortality rate in patients with PMR, when 
compared to matched controls, is not significantly different, although there are 
some minor variations in the recorded cause of death.  
The most important observation is that, although patients with PMR are more 
likely to be admitted to hospital, the overall mortality rate is no different.  
The reason for increased hospital admissions in patients with PMR may be 
related to their index condition, as some may have been initially diagnosed in 
hospital. Following this period immediately after index date, the increase in the 
rate of admissions may be due to surveillance bias, with more intensive follow up 
and testing such that patients with PMR are more likely to then be admitted to 
hospital for further management.  
The comorbidities that are associated with an increased risk of admission to 
hospital before and after index date in patients with PMR include asthma and 
glaucoma. After index date, a 15% increase in the risk of admission due to 
vascular disease was noted. In patients without PMR, they were significantly 
more likely to be admitted to hospital with neurological and neoplastic conditions.  
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However, despite the increased risk of admission due to vascular causes and 
reduced risk of admission with neoplastic disease, the overall mortality rate 
among cases and controls was similar. 
The risk of admission due to most glucocorticoid related side effects following 
index date was greater in patients with PMR compared to controls. These 
comorbidities included ophthalmological and infectious diseases. This is likely 
due to GC therapy either causing impairment of the immune system in patients 
with PMR or as a result of a known complication of GC treatment. Both of these 
types of complications, unfortunately, cannot be prevented by any prophylactic 
treatment aside from simply reducing and stopping GC therapy. However, as 
discussed in chapter 4, a large proportion of patients are subject to prolonged 
GC therapy. In contrast to this, the risk of admission due to fragility fractures was 
not found to be significantly different, this could reflect that, although a diagnosis 
of osteoporosis is more likely in patients with PMR who are prescribed GC 
treatment, the risk of a fragility fracture can be mitigated by effective preventative 
treatment by GPs. In order to prevent these complications, future research may 
need to investigate different approaches to the treatment of PMR. This could 
mean either an emphasis on rapid reduction of GC therapy, or earlier transfer to 
steroid sparing medications in susceptible patients. 
Finally, the risk of admission with asthma was significantly higher before and after 
index date. This is not a comorbidity that has been comprehensively investigated 
in the past. Given that, as discussed earlier, PMR shares many features with 
asthma, future research priorities could be to explore whether there are any 
shared autoimmune pathways involved in the development of these conditions. 
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The final chapter in this thesis is the conclusion, to draw together the findings of 
each of the previous chapters. 
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Chapter 8 CONCLUSION 
8.1 Main findings  
This thesis examined the epidemiology of polymyalgia rheumatica (PMR) in the 
UK. Using a large, validated and nationally representative database, five different 
studies were conducted to describe, understand and compare various aspects of 
PMR epidemiology, including the incidence and prevalence of PMR, PMR 
treatment, the comorbidity burden associated with PMR, hospital admissions and 
mortality. The main findings are as follows: 
1. PMR affects 1 in 120 adults aged over 40 in the UK. 
2. PMR is more common in women than men. 
3. The prevalence of PMR increases with age, and has the highest incidence 
in over 70s. 
4. Since the new century, the incidence of PMR has been steady in patients 
aged over 40, ranging from 90-100 new cases per 100,000 person years.  
5. The median time to stop continuous GC treatment was 1.31 years (IQR 
0.65, 2.6). 
6. The median time to discontinue all GC treatment was 1.93 years (0.95, 
4.03). 
7. There is a strong association between duration of treatment and total GC 
dose. 
8. The existing evidence investigating the association between PMR and key 
comorbidities is currently lacking and hindered by low quality studies  
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9. There is a statistically significant increased risk of vascular, respiratory, 
renal, autoimmune, endocrine and psychiatric diagnoses in patients with 
PMR both before and after diagnosis. 
10. There is a statistically significant reduced risk of diagnosis with cancer and 
dementia in patients with PMR both before and after diagnosis. 
11. Patients with PMR are more likely to be admitted to hospital following 
diagnosis compared to age and sex matched controls. 
12. People with PMR do not have an excess mortality risk and PMR does not 
affect life expectancy  
 
This chapter will summarise the main findings of this thesis, a detailed 
epidemiological study of PMR.  Findings discussed will include the incidence, 
prevalence and treatment of PMR, as well as comorbidities, hospital admissions 
and the mortality rate associated with PMR. Further to this, the main strengths 
and weaknesses, as well as clinical implications and conclusions of the thesis 
will be presented. 
 
8.2 Incidence and prevalence  
The prevalence of PMR among patients aged over 40 years old in the UK is 
0.85%. This equates to one patient who has received a diagnosis with PMR for 
every 120 of the population of this age, or approximately 280,000 people. 
Although the incidence of PMR was steady after the year 2000, point prevalence 
of PMR increased over the study period of 1990-2015, due to the aging 
population.  
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The case definition for PMR used in this study was a diagnostic code and 
evidence of two prescriptions of glucocorticoid (GC) therapy in the primary care 
electronic health record (EHR). Of the two GC prescriptions, the first must be 
within six months of diagnosis date and the second within six months of the 
previous prescription. This case definition has been used previously in CPRD 
studies of PMR incidence and prevalence.  
PMR was found to be 67% more common in women, reflecting the findings of 
previous PMR research and the pattern observed with most autoimmune 
diseases. The prevalence of PMR increases with age. PMR is very rare under 
the age of 60 years, but then increases with each successive decade thereafter. 
This correlates with existing estimates of the median age of diagnosis between 
70 to 75 years of age. 
The epidemiology of PMR shows substantial variation both between, and within, 
countries. Worldwide, PMR has higher prevalence at more northerly latitudes. 
However, within the UK, the regional variation is inverted. The southern regions 
of the UK show a higher incidence and prevalence when compared to northern 
areas. This pattern has been observed previously. The increased risk of 
diagnosis with PMR in southern regions of the UK is unexpected, as patients in 
these areas tend to have better health and longer life expectancy. As PMR 
diagnosis rates increase with age, the increased incidence in the south of the UK 
could be due to an older population, but the increased rate remained following 
adjustment for age. In chapter 6 it was seen that patients with a pre-existing 
diagnosis of cancer or neurological conditions were less likely to then be 
diagnosed with PMR. Therefore, it may be that PMR is preferentially diagnosed 
in patients without severe, enduring comorbid disease. Another reason for the 
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difference in incidence could be variations in genetic susceptibility to PMR 
between different UK regions, however this is probably unlikely due to the relative 
homogeneity of the genetic composition of the UK. Therefore, other reasons such 
as a link to vitamin D exposure, socio-economic status, or as part of the 
generalised increase in autoimmune diseases in higher income countries (British 
Society of Immunology, 2016) could be postulated as playing a role in the 
increased prevalence in the south of the UK.  
The incidence of PMR in patients aged over 40 in the UK during the period 1990-
2016 was 95.9 per 100,000 patient years. The most recent previous estimate 
found that the incidence of PMR was 84 per 100,000 person years. Furthermore, 
this study found that the incidence of PMR was increasing over the time period 
1990 – 2001. The current study replicated this increase in incidence until the year 
2000. However, after that time the incidence rate plateaued. The prevalence of 
PMR continued to rise over the whole study period however. This could be for a 
number of reasons. First, as the population ages, a greater proportion of people 
are of an age where they are susceptible to PMR. Second, PMR is a chronic 
disease, which is not known to have a significant impact on mortality; therefore, 
once a patient has been diagnosed they remain part of the prevalent pool. Finally, 
CPRD coverage began close to the start of the study period, therefore diagnoses 
with PMR that occurred prior to this date may not have been recorded, leading 
to a slight underestimate of prevalence in the first years of the study. 
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8.3 Treatment of PMR  
PMR is treated almost exclusively using glucocorticoids (GC). This thesis 
examined current treatment patterns of GCs for patients with a diagnosis of PMR 
in the UK. This was then compared to existing guidelines. The length of GC 
treatment was associated with the total dose of GC received. The end of 
treatment was defined in three ways, either as a gap of 90 days, or six months, 
between consecutive prescriptions, or until no further GCs were prescribed. In 
these cases, the median time to end of treatment was 1.31, 1.88 and 1.91 years, 
respectively. Treatment guidelines for PMR suggest that treatment should 
conclude two years after diagnosis and, as such, these findings suggest that ‘best 
practice’ is being followed. However, a proportion of patients are subject to 
prolonged GC treatment. In this study, when total therapy was considered, 25% 
of patients received more than 4 years of GC treatment. This confirms the 
presence of a ‘symptom tail’ of GC therapy in patients with PMR. 
The average daily dose of GC treatment was 5mg and the initial dose received 
was between 8-21mg in 50% of patients. The average dose and initial dose 
received therefore correlated well with clinical guidance. Most patients with PMR 
in the UK complete GC therapy in a timely manner at appropriate doses. 
However, the identification of patients who may be subject to prolonged GC 
therapy should be a priority for future research in order that they can be referred 
to secondary care at an early stage for consideration of ‘steroid sparing’ therapy. 
(Dejaco, Singh, Perel, et al., 2015) 
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8.4 PMR and comorbidities  
Comorbidities are commonly found in people diagnosed with PMR, as would be 
expected from the demographics of the study population. The overall comorbidity 
burden of patients with PMR was compared to controls matched by age, sex and 
practice using the Charlson comorbidity index. Patient with PMR had more 
comorbidities at one, two and five years prior to diagnosis. Furthermore, there 
was a statistically significant increase in the risk of diagnosis with vascular, 
respiratory, gastroenterological, immunological, endocrine, psychiatric 
ophthalmological and infectious diseases in patients with PMR. However, there 
was also a statistically significant reduction in the risk of diagnosis with cancer or 
a neurological disease. 
A similar pattern was seen after diagnosis of PMR. The overall burden of disease, 
measured by the Charlson comorbidity index, was higher in patients with PMR 
compared to controls, at diagnosis as well as one, two, five and ten years later. 
Further to this, and following exclusion of prevalent cases, a significant increase 
in the risk of new diagnoses with vascular, respiratory, gastroenterological, 
autoimmune, endocrine, psychiatric, and ophthalmological diseases was 
observed in patients with PMR after index date. Again, however, the risk of 
diagnosis with cancer or neurological diseases was significantly reduced in 
patients with PMR.  
Current clinical classification criteria suggest that when making a diagnosis of 
PMR, clinicians should actively exclude other ‘mimicking’ conditions such as 
rheumatoid arthritis, endocrine, infective and neoplastic conditions. (Dejaco, 
Singh, Perel, et al., 2015) These guidelines, as well as diagnostic 
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overshadowing, may account for part of the reason that the risk of cancer was 
lower in patients with PMR.  
It may be more clinically pragmatic in future, therefore, to amend guidelines, 
specifically allowing for the diagnosis of PMR in the presence of comorbidities 
such as cancer. Another approach may be, through disseminating the findings of 
this thesis in scientific literature, increasing clinician awareness of the fact that 
PMR may be underdiagnosed in patients with serious underlying medical 
conditions such as cancer or neurological diseases. Furthermore, greater 
emphasis should be placed in the education of clinical practitioners that the 
clinical classification criteria were not designed or intended for use as diagnostic 
criteria, and only exist to guide recruitment into clinical trials.  
Previous studies investigating comorbidity in people with PMR have primarily 
focused on the likelihood of patients with PMR developing vascular disease and 
cancer, with some smaller studies looking for associations with other 
autoimmune conditions. This study has found that there does appear to be an 
increase in the risk of diagnosis with vascular disease in the years following 
diagnosis with PMR. The data in this thesis suggests that PMR is strongly 
associated with other autoimmune diseases. However, due to the rarity of some 
of these conditions, and the relatively advanced age at which PMR is diagnosed, 
there were often quite small numbers of patients captured by these analyses. 
However, the observed association with other autoimmune conditions reinforces 
the idea that PMR should also be regarded as an autoimmune or auto-
inflammatory condition.  
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Further to this, although previously no other investigation has looked into 
associations with respiratory conditions, the risk of diagnosis with asthma was 
significantly increased both before and after diagnosis in patients with PMR.  
A number of findings which were unexpected were also seen in this study. For 
example, although the risk of osteoporosis was significantly greater in patients 
with PMR, the risk of hip fractures were significantly reduced prior to index date, 
and not significantly different after, in patients with PMR. Given the prolonged 
duration of glucocorticoid therapy, it is surprising that the risk of hip fracture was 
not much greater in patients with PMR. It may be that clinical practitioners are 
more aware of the increased risk of osteoporosis in patients with PMR and so 
are referring patients appropriately for investigation and subsequent treatment. 
This could explain the increased risk of osteoporosis and the neutral effect on 
risk of hip fracture. A further complicating factor is that patients with PMR are less 
likely to have a previous diagnosis of cancer. As metastatic cancer is a 
recognised cause of pathological fractures, it may be that under diagnosis of 
PMR in this group leads to an underestimate of the burden of hip fractures in 
patients with PMR. 
Another unexpected finding was the significantly increased risk of asthma and 
COPD in patients with PMR, despite the fact that they were less likely to be 
recorded as smokers. This could be due to a number of factors. Patients with 
asthma may indeed be less likely to smoke, as it would exacerbate their 
condition. However, as COPD is strongly linked with tobacco exposure, and more 
common in patients with PMR, it is surprising that the rate of smoking is reduced 
in this group. In this thesis, as per other CPRD studies, smoking status was 
defined by three categories- current smokers and those where data were 
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missing, as well as never- and ex-smokers, who were included in the same 
category. The most recent record of smoking status to index date was used. It 
may be that patients who developed COPD are more likely to have stopped 
smoking to prevent further lung damage, and therefore a higher proportion of 
patients with PMR were ex-smokers rather than never-smokers when compared 
to controls. 
Finally, as the treatment for PMR is a course of glucocorticoids, which in many 
cases is of prolonged duration, it is important to assess the risk of GC related 
complications. An increased risk of vascular disease, hypertension, type two 
diabetes, peptic ulcers, osteoporosis, cataracts and glaucoma was indeed 
demonstrated among patients with PMR. This finding itself may in part be due to 
surveillance bias, in that patients receiving GC therapy are followed up more 
intensively to monitor for complications, which could cause an apparent increase 
in the risk of diagnosis with these conditions.  
 
8.5 Hospital admissions and mortality  
The increased rate of comorbidities seen in patients with PMR translated into an 
increased hospitalisation rate following diagnosis. Patients with PMR were 18% 
more likely to be admitted to hospital following diagnosis compared to their 
matched controls, although the average duration of admission among patients 
with PMR was shorter. Regarding reasons for admission, a statistically significant 
increase in admissions due to asthma or cataracts was observed in patients with 
PMR. Equally, however, a statistically significant decrease in the risk of 
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admission in patients with PMR was also observed with either breast or lung 
cancer, as well as cerebrovascular disease and hip fractures. 
The increase in the risk of admission due to cataracts is to be expected given the 
necessity for prolonged GC therapy. However, the increased risk of admission 
with asthma suggests again that there may be a shared pathogenesis between 
PMR and asthma. 
The overall increased rate of hospital admissions did not lead to an increase in 
the mortality rate among patients with PMR, however. This reflects what has 
been seen in previous, albeit smaller, studies into mortality in PMR. The causes 
of death in patients with PMR were broadly similar compared to their matched 
controls, although a slightly higher proportion of patients with PMR died due to 
vascular causes and a slightly lower proportion died due to neoplastic conditions.  
In this study it was demonstrated that patients with PMR were less likely than 
controls to have a previous diagnosis of cancer. Therefore, it could be speculated 
that if PMR has a neutral effect on survival then, through the exclusion of patients 
with cancer, the PMR group should actually have improved survival when 
compared to matched controls. It may be that this is mitigated by the increased 
rates of vascular disease in patients with PMR that were seen after index date. 
The overall consequence of these two effects may be that net survival is similar.  
 
8.6 Strengths and weaknesses  
This thesis used the CPRD database to create a detailed picture of the 
epidemiology of PMR. There are several strengths to the work in this thesis. First, 
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CPRD is a large database that is representative of the population of the UK. 
Therefore, selection bias was minimised. Second, this database consists of data 
collected in the course of routine clinical care. It is therefore a reflection of 
genuine day-to-day clinical practice. This contrasts with the data that may be 
recorded during a prospectively recruited cohort study. Third, this is the first study 
that has described treatment patterns in patients with PMR as well as the 
comorbidities that were present before and after diagnosis, as well as the 
likelihood of, and reasons for, admission to hospital. Fourth, the methods used in 
this study have been used in previous CPRD epidemiological studies. Finally, 
although making estimates of the incidence, prevalence and mortality of patients 
with PMR has been performed previously, this study is novel in the size of the 
sample and duration of follow up, both of which are much greater than previously 
seen.   
A criticism of the database could be that it was not possible to corroborate each 
diagnosis with a patient’s clinical notes. Regarding PMR diagnosis, the use of 
two GC prescriptions to justify case selection is well established, and the vast 
majority of patients fulfilled this criterion, suggesting that the diagnostic code was 
correctly applied to most patients. To improve the study, criteria to validate the 
diagnosis formally could be created for CPRD; however, this would be 
complicated by the lack of formal diagnostic criteria for PMR.  
The same criticism could be made regarding the diagnosis of comorbidities. 
Again, it was not possible to corroborate each comorbid diagnosis with the clinical 
record for each patient. However, reassuringly, often the findings from the case 
control and cohort studies, such as an increased risk of vascular disease and 
reduced risk of cancer diagnoses were subsequently replicated in the analysis of 
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linked data, including hospital admissions and mortality data. The fact these 
findings were consistent across multiple datasets using primary and secondary 
care data and, crucially, different coding systems (Read codes and ICD-10), 
provide reassurance that the diagnoses are accurate.  
Finally, a further weakness of the CPRD is that of missing data. Information in 
electronic health records in primary care is collected in the course of routine 
clinical care, rather than specifically for research, therefore records are not 
always fully complete. For example information about risk factors, such as 
smoking, blood pressure, alcohol intake and BMI, which may influence whether 
patients develop a wide range of comorbidities, may be missing. However, as 
electronic health records have been in existence for around two decades, and 
also due to the impact of the quality outcomes framework incentivising general 
practices to record administrative data (Roland, Guthrie and Thome, 2012), the 
proportion of patients where data is missing has reduced markedly in the last 
twenty years. (Herrett, Bhaskaran, et al., 2015) 
 
8.7 Relevance to clinical practice and research 
Clinically, this thesis has proven that a large proportion of patients with PMR 
receive large doses of GCs therapy. Furthermore, there is an increase in the risk 
of GC related side effects overall in patients with PMR. Therefore, the 
identification of patients who may be subject to prolonged GC therapy should be 
a priority at the earliest stage possible in their diagnosis and subsequent 
treatment journey. This is in order that they could be considered for ‘steroid 
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sparing’ therapy, as per current PMR guidelines. (Dejaco, Singh, Perel, et al., 
2015) 
The strong association seen between PMR and other autoimmune and auto-
inflammatory conditions suggests that future research could examine whether 
specific auto-antibodies for PMR can be identified. This would also assist in the 
diagnostic process. Further to this, the identification of genetic markers that 
cause an individual’s risk of PMR to be elevated could be another research 
priority.  
Moreover, patients with PMR were found to have a statistically significant 
increase in the risk of diagnosis, both before and after index date, with asthma. 
As both PMR and asthma have a, currently, undefined polygenic basis of 
susceptibility; it may be a productive area for future research to assess whether 
there is either a shared genetic pathway. Another area of research could be to 
assess whether the early exposure to repeated doses of glucocorticoid therapy 
that is seen in asthma could be a part of the reason for the significantly increased 
risk of asthma prior to index date in patients with PMR.  
The question of whether previous exposure to glucocorticoids may have an effect 
on the likelihood of later development of PMR could be addressed using the 
CPRD database. However, as discussed previously, as data collection for CPRD 
began in 1990, this may not be early enough to provide this answers. Other ways 
to investigate this hypothesis may involve case control studies of patients 
recruited following a new diagnosis of PMR in primary care, however this may be 
subject to recall bias.  
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Finally, it appears that a diagnosis of PMR appears to have a neutral effect on 
mortality. However, the case control study found that patients with PMR were 
less likely to have received a previous diagnosis of cancer. Once the findings 
from this thesis are publicised in peer review journals, a more inclusive approach 
to the diagnosis of PMR may be encouraged. This may then address the possible 
under diagnosis of PMR in patients with cancer. After this, it may be necessary 
to re-evaluate the effect PMR has on mortality. The neutral effect of PMR on 
mortality observed in the current study may be caused by the increase in the risk 
of vascular disease in this patient group balancing the reduction in the risk of 
previous cancer diagnosis among patients with PMR. Therefore, following 
inclusion of these patients, the risk of mortality may actually rise slightly in 
patients with PMR.   
 
8.8 Final conclusion  
In conclusion, the CPRD has been used successful to answer a number of 
important epidemiological and clinical research questions. This thesis provides 
comprehensive evidence of the epidemiology of PMR in the UK, including 
incidence, prevalence, treatment patterns, comorbidities, hospital admissions 
and mortality. The methodologies used in this study can further be applied to 
other, similarly under-researched conditions. 
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APPENDICES 
APPENDIX 1: ISAC application form 
PROTOCOLS FOR RESEARCH USING THE CLINICAL PRACTICE RESEARCH 
DATALINK (CPRD)   
For ISAC use only 
 
Protocol No. 
 
Submission 
date 
 
..17_023..... 
 
...17/10/2017...
.. 
 
IMPORTANT 
Please refer to the guidance for ‘Completing 
the ISAC application form’ found on the CPRD 
website (www.cprd.com/isac). If you have any 
queries, please contact the ISAC Secretariat at 
isac@cprd.com. 
 
SECTION A: GENERAL INFORMATION ABOUT THE PROPOSED RESEARCH 
STUDY 
 
1. Study Title§ (Please state the study title below) 
Polymyalgia rheumatica in primary care: an epidemiological investigation into 
occurrence and comorbidities. 
 
§Please note: This information will be published on the CPRD’s website as part of its 
transparency policy.  
2. Has any part of this research proposal or a related proposal been 
previously submitted to ISAC?  
Yes *   No   
3. Has this protocol been peer reviewed by another Committee? (e.g. grant 
award or ethics committee) 
Yes*    No   
4. Type of Study (please tick all the relevant boxes which apply) 
 
Adverse Drug Reaction/Drug 
Safety    
 Drug Effectiveness                               
Drug Utilisation                 Pharmacoeconomics       
Disease Epidemiology 
  
 Post-authorisation Safety                        
Health care resource utilisation  Methodological  Research                                     
Health/Public Health Services 
Research   
            Other*                                                                                   
 
5. Health Outcomes to be Measured§ 
§Please note: This information will be published on CPRD’s website as part of its 
transparency policy. 
 
Please summarise below the primary/secondary health outcomes to be measured in 
this research protocol: 
 
 Incidence and prevalence of polymyalgia rheumatica (PMR) 
 Comorbidities in patients before and after PMR diagnosis    
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6. Publication: This study is intended for (please tick all the relevant boxes 
which apply): 
 
Publication in peer-reviewed journals     Presentation at scientific conference  
Presentation at company/institutional meetings  Regulatory purposes   
Other*       
SECTION B: INFORMATION ON INVESTIGATORS AND COLLABORATORS 
 
7. Chief Investigator§  
Please state the full name, job title, organisation name & e-mail address for 
correspondence - see guidance notes for eligibility. Please note that there can only 
be one Chief Investigator per protocol.  
Dr Alyshah Abdul Sultan, Research Fellow, Keele University, 
a.abdul.sultan@keele.ac.uk 
 
§Please note: The name and  organisation of the Chief Investigator and  will be 
published on CPRD’s website as part of its transparency policy 
 
CV has been previously submitted to ISAC    CV number:  14_191 
A new CV is being submitted with this protocol               
An updated CV is being submitted with this protocol        
8. Affiliation of Chief Investigator (full address) 
Institute for Primary Care and Health Sciences 
Keele University 
Staffordshire 
ST5 5BG 
9. Corresponding Applicant§ 
Please state the full name, affiliation(s) and e-mail address below: 
Dr Richard Partington, Clinical Research Fellow, Keele University, 
r.partington@keele.ac.uk 
§Please note: The name and  organisation of the corresponding applicant and their 
organisation  name will be published on CPRD’s website as part of its transparency 
policy 
Same as chief investigator       
CV has been previously submitted to ISAC    CV number:        
A new CV is being submitted with this protocol               
An updated CV is being submitted with this protocol        
10. List of all investigators/collaborators§  
Please list the full name, affiliation(s) and e-mail address* of all collaborators, other 
than the Chief Investigator below: 
 
§Please note: The name of all investigators and their organisations/institutions will be 
published on CPRD’s website as part of its transparency policy 
 
Other investigator: Dr Sara Muller, Keele University, s.muller@keele.ac.uk 
CV has been previously submitted to ISAC    CV number:  15_165 
A new CV is being submitted with this protocol               
An updated CV is being submitted with this protocol        
 
Other investigator: Professor Christian Mallen, Keele University, 
c.d.mallen@keele.ac.uk 
CV has been previously submitted to ISAC    CV number:  
073_15CESP 
A new CV is being submitted with this protocol               
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An updated CV is being submitted with this protocol        
 
Other investigator: Dr Toby Helliwell, Keele University, t.helliwell@keele.ac.uk 
CV has been previously submitted to ISAC    CV number:        
A new CV is being submitted with this protocol               
An updated CV is being submitted with this protocol        
 
11. Conflict of interest statement*  
Please provide a draft of the conflict (or competing) of interest (COI) statement that 
you intend to include in any publication which might result from this work 
The authors declare no conflict of interest, financial or otherwise, with respect to this 
work; we had full access to all of the data in this study and take complete 
responsibility for the integrity of the data and the accuracy of the data analysis. 
12. Experience/expertise available  
Please complete the following questions to indicate the experience/ expertise 
available within the team of investigators/collaborators actively involved in the 
proposed research, including the analysis of data and interpretation of results. 
 
 Previous GPRD/CPRD Studies  Publications using 
GPRD/CPRD data 
None                        
1-3                         
> 3                         
 
Experience/Expertise available  Yes No 
Is statistical expertise available within the research team? 
If yes, please indicate the name(s) of the relevant investigator(s)   
Dr Alyshah Adbul Sultan and Dr Sara Muller are qualified and 
experienced in a range of statistical techniques  
  
Is experience of handling large data sets (>1 million records) 
available within the research team? 
If yes, please indicate the name(s) of the relevant investigator(s) 
Dr Alyshah Abdul Sultan and Dr Sara Muller have previously worked on 
a number of large CPRD studies 
  
Is experience of practising in UK primary care available to or 
within the research team? 
If yes, please indicate the name(s) of the relevant investigator(s)  
Dr Richard Partington, Professor Christian Mallen & Dr Toby Helliwell 
are all practising GPs in the West Midlands and Northwest of England 
  
13. References relating to your study 
Please list up to 3 references (most relevant) relating to your proposed study:  
1. Smeeth L, Cook C, Hall  a J. Incidence of diagnosed polymyalgia rheumatica 
and temporal arteritis in the United Kingdom, 1990-2001. Ann Rheum Dis. 
2006;65(8):1093-1098. doi:10.1136/ard.2005.046912. 
2. Kuo C-F, See L-C, Luo S-F, et al. Gout: an independent risk factor for all-
cause and cardiovascular mortality. Rheumatology (Oxford). 2010;49(1):141-
146. doi:10.1093/rheumatology/kep364. 
3. Muller S, Hider SLS, Belcher J, Helliwell T, Mallen CD. Is cancer associated 
with polymyalgia rheumatica? A cohort study in the General Practice 
Research Database. Ann Rheum Dis. 2014;73(pagination):ate of Pubaton: 10 
Ju 2013. doi:10.1136/annrheumdis-2013-203465 
SECTION C: ACCESS TO THE DATA  
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14. Financial Sponsor of study§ 
§Please note: The name of the source of funding will be published on CPRD’s 
website as part of its transparency policy 
Pharmaceutical Industry            Please specify name and country:      
Academia              Please specify name and country: Keele 
University, UK 
Government / NHS             Please specify name and country:      
Charity              Please specify name and country:      
Other              Please specify name and country:      
None    
15. Type of Institution conducting the research 
 
Pharmaceutical Industry             Please specify name and country:      
Academia               Please specify name and country: Keele 
University, UK 
Government Department             Please specify name and country:      
Research Service Provider             Please specify name and country:      
NHS               Please specify name and country:      
Other               Please specify name and country:      
16. Data access arrangements 
The financial sponsor/ collaborator* has a licence for CPRD GOLD and will extract  
the data                               
The institution carrying out the analysis has a licence for CPRD GOLD and will 
extract the data**         
A data set will be provided by the CPRD¥€             
CPRD has been commissioned to extract the data and perform the analyses€                                       
  
Other:           
If Other, please specify:        
17. Primary care data  
Please specify which primary care data set(s) are required) 
Vision only (Default for CPRD studies                       Both Vision and EMIS®*           
 
EMIS® only*          
       
Note: Vision and EMIS are different practice management systems. CPRD has 
traditionally collected data from Vision practice. Data collected from EMIS is 
currently under evaluation prior to wider release.  
*Investigators requiring the use of EMIS data must discuss the study with a member 
of the CPRD Research team before submitting an ISAC application 
 
Please state the name of the CPRD Researcher with whom you have discussed 
your request for EMIS data: 
Name of CPRD Researcher           Reference number (where available)          
Date of contact          
 
SECTION D: INFORMATION ON DATA LINKAGES 
 
18. Does this protocol seek access to linked data 
Yes*   No          If No, please move to section E. 
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19. Please select the source(s) of linked data being requested§ 
§Please note: This information will be published on the CPRD’s website as part of its 
transparency policy.  
 
 ONS Death Registration Data                             MINAP (Myocardial Ischaemia National Audit Project)   
 HES Admitted Patient Care                   Cancer Registration Data* 
 HES Outpatient                                     PROMS (Patient Reported Outcomes Measure)** 
 HES Accident and Emergency               CPRD Mother Baby Link 
 HES Diagnostic Imaging 
Dataset          
 Pregnancy Register 
  
 Practice Level Index of Multiple Deprivation (Standard) 
 Practice Level Index of Multiple Deprivation (Bespoke) 
 Patient Level  Index of Multiple Deprivation*** 
 Patient Level Townsend Score *** 
 Other**** Please specify:      
20. Total number of linked datasets requested including CPRD GOLD  
 
Number of linked datasets requested (practice/ ’patient’ level Index of Multiple 
Deprivation, Townsend Score, the CPRD Mother Baby Link and the Pregnancy 
Register should not be included in this count)  2 
 
Please note:  Where ≥5  linked datasets are requested, approval may be required 
from the Confidentiality Advisory Group (CAG) to access these data 
 
21. Is linkage to a local¥ dataset with <1 million patients being requested?  
Yes *   No   
22. If you have requested one or more linked data sets, please indicate 
whether the Chief Investigator or any of the collaborators listed in question 
5 above, have access to these data in a patient identifiable form (e.g. full 
date of birth, NHS number, patient post code), or associated with an 
identifiable patient index. 
Yes*             No   
23. Does this study involve linking to patient identifiable data (e.g. hold date of 
birth, NHS number, patient post code) from other sources? 
Yes    No   
SECTION E: VALIDATION/VERIFICATION 
 
24. Does this protocol describe a purely observational study using CPRD 
data? 
Yes*    No**   
25. Does this protocol involve requesting any additional information from 
GPs?  
Yes*    No   
26. Does this study require contact with patients in order for them to complete 
a questionnaire? 
Yes*    No   
27. Does this study require contact with patients in order to collect a sample? 
Yes*    No   
SECTION F: DECLARATION 
 
28. Signature from the Chief Investigator 
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 I have read the guidance on ‘Completion of the ISAC application form’ 
and ‘Contents of CPRD ISAC Research Protocols’ and have understood 
these; 
 I have read the submitted version of this research protocol, including all 
supporting documents, and confirm that these are accurate.  
 I am suitably qualified and experienced to perform and/or supervise the 
research study proposed. 
 I agree to conduct or supervise the study described in accordance with the 
relevant, current protocol  
 I agree to abide by all ethical, legal and scientific guidelines that relate to 
access and use of CPRD data for research  
 I understand that the details provided in sections marked with (§) in the 
application form and protocol will be published on the CPRD website in line 
with CPRD’s transparency policy. 
 I agree to inform the CPRD of the final outcome of the research study: 
publication, prolonged delay, completion or termination of the study. 
 
Name: Dr Alyshah Abdul Sultan           Date:21/08/2017     e-Signature (type name): 
Dr Alyshah Abdul Sultan            
 
 
PROTOCOL INFORMATION REQUIRED 
 
 
Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
A. Study Title§ 
§Please note: This information will be published on CPRD’s website as part of its 
transparency policy 
 
Polymyalgia rheumatica in primary care: an epidemiological investigation into 
occurrence and comorbidities. 
B. Lay Summary (Max. 200 words)§ 
Polymyalgia rheumatica (PMR) is a common inflammatory rheumatological condition 
that affects people over the age of 40. PMR causes stiffness and pain in the 
shoulders and hips. It has been estimated that approximately 2.43% of women and 
1.66% of men will develop PMR in their lifetime and that each year around 8 in every 
10,000 people over 40 in the UK develop the condition. Steroid tablets are the main 
treatment, but some find it difficult to stop taking these medicines.  Various studies 
have been published that suggest that people who have PMR are at an increased 
risk of developing heart disease, stroke and certain types of blood cancer. 
 
The knowledge of how common PMR is, and which medical conditions may be 
linked with it, will lead to better diagnosis and treatment of patients with this 
condition. The first study will update our knowledge of the occurrence of PMR in 
England and Wales; this was last investigated in a study over 15 years old. 
Secondly, we will investigate which other medical conditions are more likely to occur 
in people with PMR before and after their PMR diagnosis, which will help to 
understand why people find it difficult to stop taking steroids.  
C. Technical Summary (Max. 200 words)§ 
§Please note: This information will be published on CPRD’s website as part of its 
transparency policy 
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Applicants must complete all sections listed below 
Sections which do not apply should be completed as ‘Not Applicable’ 
 
Polymyalgia rheumatica (PMR) is a common inflammatory rheumatological 
condition. Treatment involves low dose glucocorticoids, and is generally effective, 
although some patients have problems with treatment withdrawal.  
 
The risk of developing PMR varies depending on geographic location. The most 
recent data from the UK, from 1996 to 2002, showed an incidence of 8 per 10,000 
per year in people aged over 40 years.  
 
Little is known about comorbidities that may coexist with PMR. This project will 1) re-
estimate the incidence and prevalence of PMR in the UK, 2) measure comorbidities 
before and after PMR diagnosis. For the first aim: incidence rate per 10,000 years, 
between 1990 and 2017; and point prevalence on 31st March 2017 will be 
calculated. 
 
For the second, patients with PMR will be individually matched to four controls. 
Using a nested case-control study, we will calculate the prevalence of individual 
comorbidities for cases and controls. Odds ratios (OR) and 95% confidence intervals 
will be obtained using conditional logistic regression. We will then calculate the 
cumulative probability of each comorbidity up to 10 years after the index date using 
Kaplan-Meier plots for comorbidities occurring after PMR diagnosis. We will 
calculate hazard ratios using Cox regression model. 
 
 
D. Objectives, Specific Aims and Rationale 
The overall objective of this project is to use data from the CPRD to quantify the 
occurrence and comorbidity profile of patients with PMR: 
Specific aims   
1. To quantify the yearly and average incidence between 1990 and 2017 and 
point prevalence in March 2017 of PMR in the UK and assess its variation by 
age, gender, social class, calendar year and geographical region.  
2. To measure the frequency of comorbidities before and after PMR diagnosis 
compared to matched controls.  
Rationale  
Our current best knowledge of the epidemiology of PMR in the UK comes from a 
study conducted using data from the General Practice Research Database from 
1990 to 2002. (Smeeth, Cook and Hall, 2006) Whilst this study was, at the time, a 
helpful aid to understanding the burden of PMR, it is now out-of-date. We are a 
society that is rapidly ageing (Dunnell, 2008) and there are increasing concerns 
about the health service’s ability to cope with the demands of older people with 
multiple comorbidities. (Moffat and Mercer, 2015) Therefore we propose to update 
the information regarding the incidence and prevalence of the condition.  
 
In terms of comorbidities, we have conducted a systematic review and identified a 
number of small scale studies, which provided inconsistent estimates of the 
association of PMR with various comorbidities. Much of the evidence is focused 
around autoimmune conditions. Large scale studies exist but only report a limited 
number of outcomes which does not provide a complete picture of the pattern of 
comorbidity in people with PMR. Furthermore, previous estimates may be biased, as 
cases were only recruited from secondary care, yet the majority of patients are 
managed exclusively in primary care. (Barraclough et al., 2008; Yates et al., 2016) 
Bringing information about the incidence and prevalence of PMR up to date will lead 
to a better understanding of the disease burden that PMR causes. Furthermore, 
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investigating which comorbidities and iatrogenic symptoms that are likely to be 
present at and following diagnosis, will help to understand the potential ‘symptom 
tail’ that has been described in PMR (Mackie et al., 2014) 
E. Study Background 
Polymyalgia Rheumatica (PMR) is a common inflammatory condition, affecting 
people over the age of 40. Clinically, PMR is characterised by persisting muscle 
stiffness, pain and tenderness, predominantly around the neck or shoulder and 
pelvic girdles. (Salvarani, Cantini and Hunder, 2008) These symptoms are usually 
accompanied by raised inflammatory markers. 
 
The lifetime risk of developing PMR has been estimated to be approximately 2.43% 
for women and 1.66% for men. (Crowson et al., 2011) The incidence varies 
depending on geographic location. The highest incidence has been found in Norway, 
at 112.6 per 100,000 people; (Gran and Myklebust, 1997) this compares to between 
41.3 and 84 per 100,000 in the UK, Denmark and Sweden. (Boesen and Sorensen, 
1987; Schaufelberger, Bengtsson and Andersson, 1995; Elling, Olsson and Elling, 
1997; Smeeth, Cook and Hall, 2006) The lowest incidence and prevalence, between 
12.7 and 18.7 per 100,000 has been demonstrated in southern Europe. (Salvarani et 
al., 1991; Gonzalez-Gay et al., 1999) The most recent population based incidence 
and prevalence study (Smeeth, Cook and Hall, 2006) based on UK data is over a 
decade old. Due to demographic changes in this time, more contemporaneous data 
are needed to improve planning of health services around disease burden. 
 
Classification criteria for PMR require a patient to be aged over 40 years in order 
that they are eligible to be diagnosed with PMR. (Dasgupta et al., 2012) 
Furthermore, it has been demonstrated that PMR is more frequently diagnosed as 
people age, (Smeeth, Cook and Hall, 2006) as does the risk of developing 
comorbidities. (Piccirillo et al., 2008) Therefore, the population of patients with PMR 
may be at high risk of multiple comorbidities. Findings from our systematic review 
revealed a number of studies that have investigated whether PMR is associated with 
specific comorbidity(s). These comorbidities include vascular disease, cancer and 
some neurological and mental health conditions. (B. A. Bengtsson and Malmvall, 
1981; Haga et al., 1993; Myklebust et al., 2002; Kremers et al., 2005; Eaton et al., 
2006; L A Anderson et al., 2009; Kristinsson et al., 2010; Lanoy and Engels, 2010; 
Jianguang et al., 2010; Lindqvist et al., 2011; Kang, Sheu and Lin, 2011; Kermani 
and Warrington, 2011; Li, Sundquist and Sundquist, 2012; Chen et al., 2012; Zoller 
et al., 2012; Kari Hemminki, Liu, Ji, et al., 2012; M. Fallah et al., 2014; Mahdi Fallah 
et al., 2014; Muller et al., 2014; Hancock et al., 2014; Pfefiffer et al., 2015; Pujades-
Rodriguez et al., 2016; Bellan et al., 2017) However, the results of these studies 
have been mixed, with some showing increases in certain conditions (e.g. stroke) 
and others showing no association. Much of the current literature draws on analysis 
of large Scandinavian health databases and uses standardisation to compare rates 
of outcomes in those with PMR to the general population. Although large, these 
studies were unable to take account of the socio-demographic make-up of the 
population. Other studies (Kremers et al., 2005; Pfefiffer et al., 2015) have been 
conducted in relatively small samples (e.g. n=193, n= 359). 
 
The majority of previous studies have selected PMR patients from secondary care 
clinics or from hospital discharge data. As PMR is largely managed in primary care 
and only a very small minority of patients would be admitted to hospital, these 
sampling frames are likely to have introduced spectrum bias, making the results less 
generalisable. Although there is some understanding of the complications caused by 
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glucocorticoid treatment for PMR, there is currently no clear understanding of what 
conditions are comorbid with PMR, either before or after diagnosis. We know very 
little about the wider health of these patients. This study will be the first to look at a 
comprehensive list of comorbidities in a large group of patients with a matched 
comparator group. A primary care database study will be the best way of obtaining 
this data given that an estimated 70% of cases of PMR are dealt with exclusively in 
primary care. (Yates et al., 2016)  
 
Alongside this, recent work with patient groups has suggested a ‘symptom tail’ 
whereby a symptom flare is reported as treatment is withdrawn, further knowledge of 
the overall health state of these patients may help to understand this phenomenon. 
This has been referred to in recently released guidelines (Dejaco, Singh, Perel, et 
al., 2015) which have stated that patients with comorbidities or who are at high risk 
of relapse be considered for specialist referral and alternative or glucocorticoid 
sparing therapies However, the guidelines are not specific as to what constitutes 
these comorbidities or risk factors. This study aims to address this gap. 
 
This study will compare the morbidities in the primary care records of those with 
PMR to an age, gender and general practice matched control group to assess which 
morbidities are present before and after PMR diagnosis and how this compares to 
the general population of this age. By improving our understanding of the 
comorbidities and iatrogenic symptoms that are likely to be present as glucocorticoid 
dose for PMR is reduced, this study will help us to understand the potential 
‘symptom tail’ that has been described in PMR. (Mackie et al., 2014)  
 
F. Study Type 
 
The first aim of this study is to describe the prevalence and incidence of PMR in the 
UK between 1990 and 2017 and look at trends in diagnosis by calendar year. This 
will be a descriptive study. 
 
The second aim of our study is to consider the association between PMR and other 
morbidities before and after PMR diagnosis. This will be a hypothesis testing study 
where our null hypothesis will be that there is no difference in the 
prevalence/incidence between PMR cases and the general population without PMR.  
G. Study Design 
The study design chosen will be a retrospective cohort study. We will identify PMR 
cases from CPRD and a general population comparison group without PMR. 
H. Feasibility counts 
 
Based on our feasibility analysis, we anticipate more than 15,000 incident cases of 
PMR between 1990 and 2010. This will give us enough statistical power to quantify 
the burden of comorbidities before and after diagnosis. 
I. Sample size considerations 
 
The first part of our study (Aim 1) is purely descriptive; therefore no power 
calculation is necessary. 
For our second aim, we will first compare the prevalence of comorbidities between 
PMR cases and four matched controls. This will give a total sample size of 75,000. 
We anticipate more than 80% power to detect odds ratio of 1.40 for comorbidities 
with prevalence of 0.5% (e.g. renal disease) and more than 90% to detect odds ratio 
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of 1.15 for condition with the overall prevalence of around 5% (e.g. diabetes) in the 
general population with alpha 0.05. 
In terms of looking at comorbidities after PMR diagnosis, we anticipate 8% of 
controls will consult for relatively common condition such as diabetes over a 10-year 
period (i.e. 0.8% per annum), as per Kuo et al. (Kuo, 2014) Our sample size will 
provide 90% power to detect hazard ratio of 1.30. For rare outcomes such as renal 
disease, with the annual incidence of 0.4%, we will have more than 80% power to 
detect hazard ratio of 1.4. 
 
J. Data Linkage Required (if applicable):§ 
§Please note that the data linkage/s requested in research protocols will be 
published by the CPRD as part of its transparency policy 
 
To better ascertain certain comorbidities such as heart disease, cancer cases and 
mortality, we will utilise Hospital Episode Statistics (HES) and Office of National 
Statistics (ONS) mortality data. This linkage will form part of our sensitivity analysis. 
 
We may also be able to use HES to identify additional cases that were not identified 
in CPRD, although the evidence shows that PMR is predominantly diagnosed and 
managed in primary care. (Barraclough et al., 2008; Yates et al., 2016) However, 
HES linkage will be useful for identifying comorbidities, particularly those which are 
managed predominantly in secondary care.  
K. Study population 
For our first aim, as per Smeeth et al (Smeeth, Cook and Hall, 2006) we will analyse 
all individuals aged 40 or over registered within CPRD HES between 1990 and 
2017. Only acceptable patients contributing data within the up-to-standard (UTS) 
period will be included.  To calculate point prevalence, our denominator will include 
all registered patients within CPRD who are live and contributing data on 31st March 
2017. For our incidence rate analysis, we will only include patients registered within 
CPRD between 1990 and 2017 with no history of PMR before the study start date. 
Cases and person-time within the first six months of patients’ registration with the 
practice will be excluded to avoid inclusion of prevalent cases. Incidence will be 
expressed as per Smeeth et al, (Smeeth, Cook and Hall, 2006) per 10,000 person 
years. Alongside this, we will present incidence rates by age, gender, social class, 
calendar year and geographical region. 
  
The study start date will be defined as the latest of: 1st of January 1990, up-to-
standard date and patient current registration date. The study end date will be 
defined as the earliest of 31 of March 2017, transferred out date, date of death and 
the last date of data collection from practice.  
 
For our second aim, we will restrict our cohort to PMR patients with at least 3 years 
of continuous registration with a practice prior to their first PMR code. Each patient 
will be assigned an index date corresponding to the date of their first PMR diagnosis. 
Those with less than 1 year of follow-up before or after the index date will be 
excluded.  
 
As part of sensitivity analysis we will look at patients with HES linkage. In these 
patients, which constitute around 60% of the total population of CPRD, the start date 
of the study will be 1st April 1997, reflecting when this linkage was established. 
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For sensitivity analysis using linked HES data we will amend the study start date to 
the latest of: patient current registration date + 6 months, the practice up-to-standard 
date and the start of HES collection- 1st April 1997. The study end date will be 
defined as the earliest of: practice last collection date, patient deregistration date, 
study end date and HES last collection date.  
L. Selection of comparison group(s) or controls 
 
For our second aim, individuals in the selected sample will each be individually 
matched to four controls based on year of birth, (± 3 years ) sex, general practice 
and follow-up time (±2 years). Controls will be assigned an ‘index’ date, which will be 
the same as the date of their matched PMR case. As with PMR cases, we will 
exclude controls if they have less than 3 years of follow-up before or less than 1 year 
of follow-up after index date.  In doing this, we are following the same methodology 
as Kuo et al, (Kuo, 2014) a study into comorbidities in gout performed using CPRD.  
M. Exposures, Health Outcomes§ and Covariates  
§Please note: Summary information on health outcomes (as included on the ISAC 
application form  above )will be published on CPRD’s website as part of its 
transparency policy 
 
 
PMR definition (for Aims 1 and 2): People aged 40 or over who have a first diagnosis 
of polymyalgia rheumatica entered into their general practice record while registered 
with a practice contributing to the CPRD during the study period. The Read codes to 
be used are enclosed in appendix 5. People with a diagnosis of GCA prior to 
diagnosis of PMR will be included as cases. Furthermore, to be included, cases will 
have to have received at least two prescriptions for oral glucocorticoids; one within 
six months of the diagnosis date, with the two prescriptions being within 6 months of 
each other, used to indicate a clinical response to glucocorticoids. This is following 
the same methodology of Smeeth et al. (Smeeth, Cook and Hall, 2006)  
 
Outcome (Aim 2): the table in appendix 3 outlines the comorbidities to be included 
as exposures. These were derived from a combination of three separate processes 
1. Review of the Charlson Comorbidity Index, (Charlson et al., 1994) 2. Results from 
a systematic review, carried out as part of this project, 3. Expert consensus from a 
group of rheumatologists and GPs experienced in the management of PMR.  
 
The Charlson comorbidity index was chosen as the basic list of comorbidities in a 
study into comorbidities in gout. (Kuo et al., 2010) As gout and PMR affect a similar 
age group, it is appropriate to assess for similar comorbidities. This list has been 
adapted and successfully used with an electronic database which used the ICD 9 
classification (Deyo, Cherkin and Ciol, 1992)  and subsequently then translated into 
Read codes for use in UK primary care databases. (Khan et al., 2010) We 
supplemented this list with comorbidities identified from our systematic review and 
discussion with experts in the management of PMR. 
 
Our systematic review identified 17,328 unique studies, of which we reviewed 282 
abstracts and 155 full text. In total 40 studies were included in narrative synthesis. 
These included case control, cohort and cross sectional studies which presented 
original data on comorbidities in PMR. 
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For the purpose of this project, we will examine the following comorbidities, where 
possible, we will stratify these into specific conditions: 
 Vascular 
 Neurological 
 Respiratory  
 Rheumatological and Musculoskeletal 
 Gastroenterology 
 Endocrine  
 Renal 
 Neoplastic  
 Infections  
 Psychiatric  
 Ophthalmology 
 
Specific conditions that will be included within these headings are tabulated in 
appendix 3. The Codes list are also given in appendix 5.  
 
As the list of comorbid conditions is quite large and some conditions quite rare, it is 
anticipated that in some cases there may be small numbers of patients affected. We 
will aim to aggregate this data into larger groups to increase the likelihood of 
producing robust data. This will also fulfil a second objective, that of reducing the 
chance of unintentional (deductive) breaches of patient confidentiality. We also, in 
keeping with CPRD policy, will not report any cell which contains fewer than five 
events. 
 
Covariate (aim 2):  
For each patient, we will extract information on their smoking status, alcohol 
consumption and body mass index using the most recent measure before the index 
date. 
N. Data/ Statistical Analysis 
 
Aim 1 
We will calculate crude incidence rate of PMR by dividing the total number of new 
cases by the total person-years of follow-up. We will stratify incidence by age, 
gender, region, social class (using the patient level index of multiple deprivation) and 
calendar year. We will use Poisson regression model to assess the impact of 
covariates (e.g. age, gender) on the incidence of PMR. For each year, we will also 
calculate age standardised incidence rate and assess trends in incidence rate over 
time. To calculate point prevalence, we will identify all validated PMR cases (i.e. 
having received two courses of GC prescriptions within six months of diagnosis) on 
the 30th of March 2017 (including incidence and prevalent) and divide them by all the 
patients registered within CPRD who are alive and contributing data on that date. 
For the cases to be considered part of the prevalence study they will also need to 
have been prescribed GCs +/- six months around 31st March 2017. As part of 
sensitivity analysis we will alter this time to assess what effect this has on the 
prevalence. 
 
We have considered the risk of inaccurate date of diagnosis caused by patients 
registering with a practice and their prevalent conditions, such as PMR, being 
recorded as having occurred at the time of registration. To address this, we will 
investigate the number of times PMR is recorded in the period following current 
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registration date. Once the incidence has reduced to a steady baseline we will define 
this as the baseline rate and use this cut off to define the start date of the study.  
 
Aims 2 
We will use similar methods used by Kuo. (Kuo, 2014) 
We will first calculate the prevalence of individual comorbidities for PMR cases and 
controls. This will be done by dividing the number of patients with each comorbidity 
(numerator) by the number of incident PMR cases or matched controls 
(denominator). We will consider comorbidities ever recorded before the index date. 
Odds ratios (OR) and 95% confidence intervals will be calculated to examine the 
association between PMR and previously existing comorbidity using conditional 
logistic regression. We will adjust our estimates for various sociodemographic and 
life-style related factors (e.g. age, body mass index (BMI), smoking status, alcohol 
consumption and socioeconomic status). 
 
For both cases and control, we will then calculate the cumulative probability of each 
comorbidity up to 10 years after the index date using Kaplan-Meier plots. We will 
stratify these by individual years after the index date. For those at risk of developing 
a given comorbidity (not having such comorbidity at index date) we will calculate 
hazard ratios using Cox regression model. We will adjust our analysis for age, 
smoking status, BMI and alcohol consumption. The assumption of proportional 
hazards will be tested using Schoenfeld residuals. We will attempt to take account of 
the matching in the study design by using a frailty term. However, experience tells us 
that it can be difficult to get these models to converge due to the flat shape of the 
likelihood. If convergence is a problem, we will fit the models with robust standard 
errors, rather than with a frailty term. 
 
To strengthen our findings, we will carry out sensitivity analyses. These analyses will 
perform two main functions, the first will vary the definition of PMR to ascertain 
whether this alters the rates of diagnosis of comorbidities found; therefore assessing 
the validity of the diagnosis of PMR. The second will check how similar HES linked 
data is to the rest of CPRD.  
 
To address the first aim of the sensitivity analysis, assessing the validity of diagnosis 
of PMR, we will alter the definition of PMR in the following ways:  
 
1) We will remove the requirement to have GC prescription in order to confirm 
diagnosis of PMR 
2) All patients with PMR who are subsequently diagnosed with a GCA will be 
excluded (testing the assumption that these patients will have a more severe 
disease and therefore should not be included as PMR) 
3) Excluding all patients who are subsequently diagnosed with conditions which may 
cause similar symptoms to PMR, such as Rheumatoid arthritis or cancer (again, 
testing the assumption that these are incorrectly classified as PMR cases). 
 
The second main aim of sensitivity analysis will be to check how similar the HES 
linked data is to the rest of CPRD. This will involve repeating our analyses on 
patients with HES link data to assess the impact of hospital data on our estimates 
and overall conclusions. 
 
O. Plan for addressing confounding 
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Associations of PMR with age and gender are already well-known. Hence matching 
by these factors will allow some degree of control for any confounding effect they 
might have. Furthermore, we will also adjust our relative risks for a wide range of 
covariates including BMI, smoking status, alcohol consumption and social status.  
 
P. Plans for addressing missing data  
Based on our previous work, we anticipate that around 25%, 7% and 23% of 
patients will have missing information on BMI, smoking status and alcohol 
consumption respectively. These missing data will be considered as a separate 
category and will be included in our regression model. We do not believe that these 
data are likely to be missing at random, and therefore we will not use multiple 
imputation methods. 
Q. Patient or user group involvement (if applicable) 
The idea for this study originated in work with patients that described a ‘symptom 
tail’ in PMR when attempting to withdraw glucocorticoid therapy. Discussions with 
various stakeholder groups, including the charity PMRGCAuk, have led us to the 
proposed project. 
 
In order to ensure that a comprehensive list of comorbidities are studied a focus 
group has been held. This group consisted of local GPs, experienced in managing 
PMR, together with rheumatologists. They were consulted as to their opinions as to 
which comorbidities ought to be considered. The combination of professionals from 
Primary and Secondary Care gave both generalist and specialist perspectives. 
 
The information from this group was further informed by the results of a systematic 
review into evidence that currently exists on the subject. 
 
R. Plans for disseminating and communicating study results, including 
the presence or absence of any restrictions on the extent and timing of 
publication  
 
Results of this study will be published in peer-reviewed journals and presented at 
appropriate conferences. They will also be disseminated through our local 
implementation research team and to PMRGCAuk for their members. 
 
S. Limitations of the study design, data sources, and analytic methods  
 
The main limitation to this study involves ensuring the diagnosis of PMR is correct. A 
set of classification criteria ‘for identifying patients appropriate for enrolment into 
clinical trials of novel medications for the treatment of PMR, and studying long-term 
outcomes in more homogeneous patient cohorts’ has been produced. (Dasgupta et 
al., 2012) However, these are not explicit diagnostic criteria, furthermore, in this 
study which will be based on a primary care database it is not practical to ensure all 
patients have fulfilled these criteria. To improve validity of diagnosis we will ensure 
that each patient has had at least two glucocorticoid prescriptions in the six months 
following diagnosis. 
 
Overlapping diagnoses also present a potential limitation, most commonly between 
GCA and PMR. Around 16-21% of patients with PMR will later develop GCA 
(Salvarani, Cantini and Hunder, 2008) and around 40-60% of people with GCA will 
develop PMR (Franzen, Sutinen and Knorring, 1992; C. Salvarani et al., 1995; C 
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Salvarani et al., 1995; Kermani and Warrington, 2013; Weyand and Goronzy, 2014). 
These conditions are linked, although GCA is more severe and the pathological 
processes are separate, we will therefore only assess GCA patients who also have 
PMR. 
 
Ensuring that we search for all relevant comorbidities. The choice of comorbidities to 
search for has been partly informed via a focus group including both rheumatologists 
and GPs with an interest in PMR and also a systematic review into existing 
literature. 
 
There are a large number of comorbidities within this study, the aim of which is to 
provide a robust analysis of any comorbidity which may occur in patients with PMR. 
Where possible we will combine the comorbidities into one of the eleven disease 
group areas listed previously. To deal with the issue of multiple testing we will 
strengthen our analysis using a smaller p value to calculate confidence intervals, for 
example 99%, to reduce the likelihood of false positives being found.  
 
Another potential limitation is under ascertainment of comorbidities. Not all 
comorbidities will be captured via primary care administration. The risk of this will of 
course be higher in conditions which are predominantly treated in secondary care 
such as myocardial infarctions. To assess this risk we perform sensitivity analysis 
using the HES linkage data. 
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APPENDIX 2: List of glucocorticoids used in the analysis 
Product 
code 
Name Active 
ingredient 
Dose 
44 Prednisolone 5mg gastro-resistant tablets Prednisolone 5mg 
95 Prednisolone 5mg tablets Prednisolone 5mg 
186 Dexamethasone 500micrograms/5ml oral 
solution 
Dexamethasone 100mcg/ml 
229 Cortisone 25mg tablets Cortisone acetate 25mg 
557 Prednisolone 2.5mg gastro-resistant tablets Prednisolone 2.5mg 
578 Prednisolone 1mg tablets Prednisolone 1mg 
955 Prednisolone 5mg soluble tablets Prednisolone  5mg 
1063 Prednisolone sodium phosphate Prednisolone 5mg 
1280 Dexamethasone 2mg tablets Dexamethasone 2mg 
1709 Hydrocortisone pellets 2.5 mg loz 
  
1971 Betnesol 500microgram soluble tablets  Betamethasone 
sodium 
phosphate 
500mcg 
2044 PREDNISONE 2.5 MG TAB 
  
2130 Methylprednisolone 4mg tablets Methylpred-
nisolone 
4mg 
2368 Prednisolone 2.5mg tablet Prednisolone 2.5mg 
2390 PREDNISOLONE E/C 1 MG TAB 
  
2704 Prednisolone 25mg tablets Prednisolone 25mg 
2799 PREDNISOLONE 10 MG TAB 
  
2949 Prednisone 5mg tablets Prednisone 5mg 
3059 PREDNISOLONE 50 MG TAB 
  
3345 Sintisone Tablet  Prednisolone 
Steaglate 
 
3418 Hydrocortisone 10mg tablets Hydrocortisone 10mg 
3543 Chloramphenicol & hydrocortisone oint eye 
  
3557 Prednisone 1mg tablets Prednisone 1mg 
3969 DEXAMETHASONE 8 MG TAB 
  
3992 Deflazacort 6mg tablets Deflazacort 6mg 
4535 Hydrocortisone 20mg tablets Hydrocortisone 20mg 
4779 Dexamethasone 500microgram tablets Dexamethasone 500mcg 
4943 Dexamethasone 2mg/5ml oral solution 
sugar free 
Dexamethasone  400mcg/1ml 
5157 Dexamethasone 2mg/5ml oral solution Dexamethasone 2mg/5ml 
5490 Deltacortril 5mg gastro-resistant tablets  Prednisolone 5mg 
5913 Deltacortril 2.5mg gastro-resistant tablets  Prednisolone 2.5mg 
6098 Hydrocortone 10mg tablets  Hydrocortisone 10mg 
7286 Betamethasone 500microgram soluble 
tablets sugar free 
Betamethasone  500mcg 
7548 Cortisone 5mg capsules Cortisone acetate 5mg 
7584 PREDNISOLONE 4 MG TAB 
  
7710 PREDNISOLONE 15 MG TAB 
  
7934 PREDNISONE 30 MG TAB 
  
8261 Medrone 16mg tablets  Methylpred-
nisolone 
16mg 
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Product 
code 
Name Active 
ingredient 
Dose 
9375 Deflazacort 1mg tablets Deflazacort 1mg 
9727 Prednisolone 50mg tablets Prednisolone 50mg 
9994 Decadron 500microgram tablets  Dexamethasone 500mcg 
10552 Methylprednisolone 16mg tablets Methylpred-
nisolone 
16mg 
10574 Cortisone acetate 5mg tablets Cortisone 
Acetate 
5mg 
10683 Medrone 2mg tablets  Methylpred-
nisolone 
2mg 
10684 Methylprednisolone 2mg tablets Methylpred-
nisolone 
2mg 
10754 Hydrocortistab 20mg Tablet  Hydrocortisone 20mg 
10864 Betamethasone 500microgram tablets Betamethasone 500mcg 
11149 Betnelan 500microgram tablets  Betamethasone 500mcg 
12398 Cortelan 25mg Tablet  Cortisone acetate 25mg 
12400 Cortisyl 25mg Tablet  Cortisone acetate 25mg 
13043 Hydrocortone 20mg tablets Hydrocortisone 20mg 
13522 PREDNISOLONE 2 MG TAB 
  
13615 PREDNISONE 10 MG TAB 
  
14076 Hydrocortisone 5mg/5ml Oral solution Hydrocortisone 5mg/5ml 
14172 Methylprednisolone 100mg tablets Methylpred-
nisolone 
100mg 
15471 HYDROCORTISONE 25 MG TAB 
  
15555 Medrone 4mg tablets Methylpred-
nisolone 
4mg 
15617 Ledercort 4mg Tablet  Triamcinolone 
Acetonide 
4mg 
16724 PREDNISONE 50 MG TAB 
  
17101 DEXAMETHASONE 750 MCG TAB 
  
17410 Deflazacort 30mg tablets Deflazacort 30mg 
18042 Medrone 100mg tablets  Methylpred-
nisolone 
100mg 
18637 Cortistab 25mg Tablet  Cortisone acetate 25mg 
19141 Prednisolone 5mg soluble tablets  Prednisolone  5mg 
19908 Triamcinolone 2mg Tablet Triamcinolone 
Acetonide 
2mg 
20095 Precortisyl forte 25mg Tablet  Prednisolone 25mg 
20577 Calcort 6mg Tablet  Deflazacort 6mg 
20670 PREDNISOLONE E/C 
  
21218 Dexsol 2mg/5ml oral solution  Dexamethasone  400mcg/ml 
21417 Prednisolone 5mg tablets  Prednisolone 5mg 
21465 BETAMETHASONE .1 MG TAB 
  
21833 Decortisyl 5mg Tablet  Prednisone 5mg 
21903 Oradexon-organon 2mg Tablet  Dexamethasone 2mg 
22555 Calcort 1mg tablets  Deflazacort 1mg 
22827 BETAMETHASONE .1 MG  
  
22894 HYDROCORTISONE 4 MG  
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Product 
code 
Name Active 
ingredient 
Dose 
23111 Triamcinolone 4mg Tablet Triamcinolone 
Acetonide 
4mg 
23210 Cortistab 5mg Tablet  Cortisone 
Acetate 
5mg 
23512 Precortisyl 5mg Tablet  Prednisolone 5mg 
24014 Ledercort 2mg Tablet  Triamcinolone 
Acetonide 
2mg 
24716 PREDNISOLONE E/C 
  
25272 Precortisyl 1mg Tablet  Prednisolone 1mg 
27083 BETAMETHASONE VALERATE .1 MG TAB 
  
27889 PREDNISOLONE 
  
27959 PREDNISOLONE 
  
27962 Deltastab 1mg Tablet  Prednisolone 1mg 
28375 Prednisolone 2.5mg gastro-resistant tablets Prednisolone 2.5mg 
28376 Prednisolone 2.5mg Gastro-resistant tablet  Prednisolone 2.5mg 
28859 Deltastab 5mg Tablet  Prednisolone 5mg 
29112 Calcort 30mg tablets  Deflazacort 30mg 
29333 Prednisolone 5mg tablets  Prednisolone 5mg 
31327 Prednisolone steaglate 6.65mg tablet Prednisolone 
Steaglate 
6.65mg 
31532 Prednisolone 5mg gastro-resistant tablets  Prednisolone 5mg 
32803 Prednisolone 5mg gastro-resistant tablets  Prednisolone 5mg 
32835 Prednisolone 5mg tablets  Prednisolone 5mg 
33691 Prednisolone 5mg Gastro-resistant tablet  Prednisolone 5mg 
33988 Prednisolone 5mg Tablet  Prednisolone 5mg 
33990 Prednisolone 5mg Tablet  Prednisolone 5mg 
34109 Prednisolone 5 mg gastro-resistant tablet Prednisolone 5mg 
34393 Prednisolone 5mg gastro-resistant tablets  Prednisolone 5mg 
34404 Prednisolone 1mg tablets  Prednisolone 1mg 
34452 Prednisolone 1mg tablets  Prednisolone 1mg 
34461 Prednisolone 2.5mg gastro-resistant tablets Prednisolone 2.5mg 
34631 Prednisolone 1mg Tablet  Prednisolone 1mg 
34660 Prednisolone 1mg tablets  Prednisolone 1mg 
34748 Prednisolone 1mg tablets  Prednisolone 1mg 
34781 Prednisolone 5mg tablets  Prednisolone 5mg 
34801 Dexamethasone 0.5mg/5ml Oral solution  Dexamethasone 100mcg/ml 
34880 Dexamethasone 2mg tablets  Dexamethasone 2mg 
34914 Prednisolone 1mg Tablet  Prednisolone 1mg 
34915 Dexamethasone 500microgram tablets  Dexamethasone 500mcg 
34978 Prednisolone 1mg tablets  Prednisolone 1mg 
36055 Dexamethasone 2mg Tablet  Dexamethasone 2mg 
38022 Hydrocortisone 10mg/5ml oral suspension Hydrocortisone 2mg/1ml 
38054 Hydrocortisone Tablet Hydrocortisone 
 
38407 Prednisolone 20mg tablet Prednisolone 20mg 
41335 Calcort 6mg tablets  Deflazacort 6mg 
41515 Prednisolone 5mg tablets  Prednisolone 5mg 
41745 Prednisolone 25mg tablets  Prednisolone 25mg 
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Product 
code 
Name Active 
ingredient 
Dose 
43544 Prednisone 5mg Tablet  Prednisone 5mg 
44380 Prednisone 1mg modified-release tablets Prednisone 1mg 
44723 Prednisone 5mg modified-release tablets Prednisone 5mg 
44802 Lodotra 5mg modified-release tablets  Prednisone 5mg 
44803 Lodotra 2mg modified-release tablets  Prednisone 2mg 
45234 Dexamethasone 100microgram capsules Dexamethasone 100mcg 
45302 Prednisolone 5mg Tablet  Prednisolone 5mg 
46711 Prednisone 2mg modified-release tablets Prednisone 2mg 
47142 Prednisolone 5mg Soluble tablet  Prednisolone  5mg 
50225 Betnesol 500microgram soluble tablets  Betamethasone  500mcg 
51722 Hydrocortisone 5mg/5ml oral suspension Hydrocortisone 1mg/1ml 
51753 Prednisolone 1mg tablets  Prednisolone 1mg 
51824 Hydrocortisone 5mg/5ml oral suspension 
sugar free 
Hydrocortisone 1mg/1ml 
51849 Hydrocortisone 1mg/5ml oral suspension 
  
51871 Hydrocortisone 2mg capsules 
  
51872 Hydrocortisone 2.5mg capsules Hydrocortisone 2.5mg 
52053 Hydrocortisone 3mg/5ml oral suspension 
  
52396 Dexamethasone 1mg/5ml oral solution Dexamethasone 200mcg/ml 
53143 Cortisone 25mg tablets  Cortisone acetate 25mg 
53207 Dexamethasone tablets Dexamethasone 
 
53313 Prednisolone 20mg/5ml oral suspension Prednisolone 4mg/1ml 
53336 Prednisolone 25mg tablets  Prednisolone 25mg 
53705 Cortisone acetate 5mg Capsule  Cortisone acetate 5mg 
54118 Prednisolone 25mg/5ml oral suspension Prednisolone 5mg/1ml 
54432 Lodotra 1mg modified-release tablets Prednisone 1mg 
54434 Prednisolone 2.5mg/5ml oral suspension Prednisolone 500mcg/ml 
54793 Dexamethasone 2mg/5ml oral suspension Dexamethasone 400mcg/ml 
54794 Hydrocortisone 20mg modified-release 
tablets 
  
55024 Prednisolone 5mg/5ml oral solution Prednisolone 1mg/1ml 
55401 Dexamethasone 500microgram tablets  Dexamethasone 500mcg 
55480 Prednisolone 2.5mg gastro-resistant tablets  Prednisolone 2.5mg 
56347 Dexamethasone 5mg/5ml oral solution Dexamethasone 1mg/1ml 
56443 Dexamethasone 10mg/5ml oral solution 
  
56891 Prednisolone 1mg tablets  Prednisolone 1mg 
57931 Hydrocortisone 20mg tablets  Hydrocortisone 20mg 
58000 Prednisolone 5mg tablets  Prednisolone 5mg 
58234 Prednisolone 10mg/5ml oral solution Prednisolone 2mg/1ml 
58369 Prednisolone 5mg tablets  Prednisolone 5mg 
58384 Prednisolone 1mg tablets  Prednisolone 1mg 
58987 Prednisolone 5mg gastro-resistant tablets  Prednisolone 5mg 
59229 Dilacort 5mg gastro-resistant tablets  Prednisolone 5mg 
59283 Dilacort 2.5mg gastro-resistant tablets  Prednisolone 2.5mg 
59338 Prednisolone 1mg/5ml oral solution Prednisolone 200mcg/ml 
59912 Prednisolone 5mg gastro-resistant tablets  Prednisolone 5mg 
60120 Dexamethasone 2mg tablets  Dexamethasone 2mg 
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Product 
code 
Name Active 
ingredient 
Dose 
60421 Prednisolone 5mg tablets  Prednisolone 5mg 
61132 Prednisolone 1mg tablets  Prednisolone 1mg 
61162 Prednisolone 5mg tablets  Prednisolone 5mg 
62909 Dexamethasone 2mg tablets  Dexamethasone 2mg 
63066 Prednisolone 2.5mg tablets Prednisolone 2.5mg 
63549 Prednisolone 1mg/ml oral solution  Prednisolone 1mg/1ml 
64007 Pevanti 10mg tablets  Prednisolone 10mg 
64008 Pevanti 2.5mg tablets  Prednisolone 2.5mg 
64059 Hydrocortisone 2.5mg/5ml oral suspension Hydrocortisone 500mcg/ml 
64128 Pevanti 5mg tablets  Prednisolone 5mg 
64221 Prednisolone 5mg/5ml oral suspension Prednisolone 1mg/1ml 
64787 Hydrocortisone 10mg tablets  Hydrocortisone 10mg 
65626 Prednisolone 10mg/5ml oral suspension Prednisolone 2mg/1ml 
65984 Hydrocortisone 10mg tablets  Hydrocortisone 10mg 
66327 Hydrocortisone 20mg tablets  Hydrocortisone 20mg 
66550 Prednisolone 5mg gastro-resistant tablets  Prednisolone 5mg 
66666 Hydrocortisone 10mg tablets  Hydrocortisone 10mg 
67107 Prednisolone 5mg gastro-resistant tablets  Prednisolone 5mg 
67559 Prednisolone 5mg/5ml oral solution unit 
dose  
Prednisolone 1mg/1ml 
68182 Dexamethasone 2mg tablets  Dexamethasone 2mg 
68489 Dexamethasone 4mg tablets Dexamethasone 4mg 
68497 Prednisolone 2.5mg gastro-resistant tablets Prednisolone 2.5mg 
68593 Dexamethasone 5mg/5ml oral suspension Dexamethasone 1mg/1ml 
69568 Dilacort 5mg gastro-resistant tablets  Prednisolone 5mg 
69572 Dexamethasone 4mg/5ml oral suspension Dexamethasone 800mcg/ml 
69686 Pevanti 25mg tablets  Prednisolone 25mg 
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APPENDIX 5: Data collection form for systematic review 
  
Study ID  
Author  
Title  
Journal  
Year  
Volume  
Issue  
Page numbers  
Language of publication  
Continent where data collection occurred   
Sample size PMR: Controls: 
Average Age PMR:  Controls: 
Sex distribution PMR: Controls: 
 
PMR Clinical Criteria Used  Study design  
Chuang  Cohort  
Bird  Case control  
Jones  Cross sectional  
Nobunaga  Population  
Healey  Systematic Review  
Hunder    
EULAR-ACR    
Not referenced    
 
Name of comorbidity(s) Retrospective Prospective 
   
   
   
   
   
 
 N  N 
Cases  Controls  
Comorbid condition  Comorbid condition  
Proportion affected / Case rate  Proportion affected / Case rate  
Person years follow up  Person years follow up  
Incidence rate / Odds  Incidence rate / Odds  
Incidence rate or Odds ratio    
Effect Measures from paper    
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APPENDIX 7: ICD-10 codes for hospital admissions study 
ICD-10 
code 
Category ICD-10 
code 
Category ICD-10 
code 
Category 
C18 Colorectal 
cancer 
 
I21 MI 
 
J69 Pulmonary 
fibrosis C19 I22 J70 
C20 I23 J84 
C21 I24 J85 LRTI 
LRTI C34 Lung cancer I50 CCF 
 
J86 
C43 Melanoma I51 K20 Peptic ulcer 
C50 Breast cancer I60 CVA 
 
K21 
C61 Prostate cancer I61 K22 
C81 Leukaemia, 
lymphoma 
I62 K23 
C82 I63 K25 
C83 I64 K26 
C84 I65 K27 
C85 I66 K28 
C86 I67 K29 
C88 I68 K30 
C90 I69 K50 Crohn’s 
disease 
C91 I70 PVD 
 
K51 UC 
C92 I71 K70 Liver disease 
C93 I72 K71 
C94 I74 K72 
C95 I77 K73 
C96 I78 K74 
E03 Hypothyroid I79 K75 
E05 Hyperthyroid J00 URTI 
 
K76 
E10 T1DM J01 K77 
E11 T2DM J02 L00 Skin infections 
F00 Dementia J03 L01 
F01 J04 L02 
F02 J05 L03 
F03 J06 L04 
F20 Schizophrenia J09 LRTI 
 
L05 
F30 Bipolar disease J10 L08 
F31 J11 M05 RA 
F32 Depression J12 M06 
F33 J13 M07 Psoriatic 
arthritis 
F34 J14 M15 OA 
F40 Anxiety 
 
J15 M16 
F41 J16 M17 
F42 J17 M18 
F43 J18 M19 
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F44 J20 M32 SLE 
F45 J21 M34 Scleroderma 
F48 J22 M47 OA 
 G20 Parkison’s 
disease 
J43 COPD 
 
M50 
G30 Dementia J44 M51 
G35 MS J45 Asthma M53 
H25 Cataracts J46 M54 
H26 J60 Pulmonary 
fibrosis 
M80 Osteoporosis 
H27 J61 M81 
H28 J62 M82 
H40 Glauucoma J63 N10 UTI 
H42 J64 N18 CRF 
 I10 HTN 
 
J65 N19 
I11 J66 N30 UTI 
I12 J67 S52 Wrist fracture 
I13 J68 S72 Hip fracture 
I15 
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APPENDIX 8: Kaplan Meier estimates of time to admission with comorbidities 
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